text,chunk_id,title,publication_date,authors,disease
"Expression study of Krabbe Disease
<italic toggle=""yes"">GALC</italic>
missense variants – Insights from quantification profiles of residual enzyme activity, secretion and psychosine levels
 
Krabbe disease (KD) is an autosomal recessive lysosomal storage disorder caused by loss-of-function mutations in the
<italic toggle=""yes"">GALC</italic>",0_0,"
Expression study of Krabbe Disease
<italic toggle=""yes"">GALC</italic>
missense variants – Insights from quantification profiles of residual enzyme activity, secretion and psychosine levels
",17 10 2024,,Krabbe_Disease
"gene, which encodes for the enzyme galactosylceramidase (GALC). GALC is crucial for myelin metabolism. Functional deficiency of GALC leads to toxic accumulation of psychosine, dysfunction and death of oligodendrocytes, and eventual brain demyelination. To date, 46 clinically-relevant, pathogenic GALC missense mutations (MMs) have been identified in KD patients. These MMs are present in ∼70% of KD cases reported over 8 published studies between 1996 – 2019. However, the mechanisms by which these MMs lead to",0_1,"
Expression study of Krabbe Disease
<italic toggle=""yes"">GALC</italic>
missense variants – Insights from quantification profiles of residual enzyme activity, secretion and psychosine levels
",17 10 2024,,Krabbe_Disease
the mechanisms by which these MMs lead to GALC functional deficiency and their correlations with clinical phenotype remain poorly understood.,0_2,"
Expression study of Krabbe Disease
<italic toggle=""yes"">GALC</italic>
missense variants – Insights from quantification profiles of residual enzyme activity, secretion and psychosine levels
",17 10 2024,,Krabbe_Disease
"To address this, we generated a
<italic toggle=""yes"">GALC</italic>
-knockout human oligodendrocytic cell line (MO3.13/
<italic toggle=""yes"">GALC</italic>",0_3,"
Expression study of Krabbe Disease
<italic toggle=""yes"">GALC</italic>
missense variants – Insights from quantification profiles of residual enzyme activity, secretion and psychosine levels
",17 10 2024,,Krabbe_Disease
"-KO) using CRISPR-Cas9 method to assess GALC function and GALC secretion. We evaluated 5 polymorphic and 31 clinically-relevant MM variants (MMVs) using transient expression assays. Our results showed that 26 MMVs, including 10 co-variants with p.I562T, reduced GALC activity by 92% - 100% compared to wild-type GALC (WT-GALC). MMVs from infantile-onset KD patients produced < 2% of WT activity, whereas those associated with juvenile- and adult-onset cases retained up to 7% of WT activity. Residual GALC",0_4,"
Expression study of Krabbe Disease
<italic toggle=""yes"">GALC</italic>
missense variants – Insights from quantification profiles of residual enzyme activity, secretion and psychosine levels
",17 10 2024,,Krabbe_Disease
"retained up to 7% of WT activity. Residual GALC activity was correlated with mature, lysosomal GALC protein levels (Pearson r = 0.93, P<0.0001). Many low-activity MMVs did not correspondingly impair GALC secretion. Twenty-one of the 26 low-activity MMVs showed a 21% - 100% reduction in sec-GALC levels, indicating varying degrees of GALC mis-trafficking among these variants.",0_5,"
Expression study of Krabbe Disease
<italic toggle=""yes"">GALC</italic>
missense variants – Insights from quantification profiles of residual enzyme activity, secretion and psychosine levels
",17 10 2024,,Krabbe_Disease
"Importantly, GALC activity among MMVs strongly correlates with clinical disease severity, based on the age of symptom onset in patients with either homozygous MM (Pearson r = 0.98, P<0.0001, n = 7) or compound heterozygous (Pearson r = 0.94, P<0.0001, n = 12) MM-null mutation genotypes. Thus, our data suggests that GALC activity could serve as a prognostic disease indicator under specific experimental conditions. We further investigated the impact of pathogenic MMVs on psychosine accumulation, a key",0_6,"
Expression study of Krabbe Disease
<italic toggle=""yes"">GALC</italic>
missense variants – Insights from quantification profiles of residual enzyme activity, secretion and psychosine levels
",17 10 2024,,Krabbe_Disease
"pathogenic MMVs on psychosine accumulation, a key biomarker for KD. Psychosine levels were 21-fold higher in mock control cells compared to WT-GALC transfected cells (mock = 0.349 pmol/mg, WT-GALC = 0.016 pmol/mg), but negatively correlated with GALC activity among pathogenic MMVs (Pearson r = −0.63, P < 0.01, n = 15). Although psychosine levels were higher in most MMVs associated with infantile-onset KD, no significant correlations with clinical onset were detected.",0_7,"
Expression study of Krabbe Disease
<italic toggle=""yes"">GALC</italic>
missense variants – Insights from quantification profiles of residual enzyme activity, secretion and psychosine levels
",17 10 2024,,Krabbe_Disease
"Overall, our study provides a comprehensive quantitative analysis of the functional deficits and mis-trafficking associated with clinically-relevant GALC MMVs, enhancing our understanding of the molecular genetics and genotype-phenotype correlations of the
<italic toggle=""yes"">GALC</italic>
gene in Krabbe disease.
 Full text not available in PMC",0_8,"
Expression study of Krabbe Disease
<italic toggle=""yes"">GALC</italic>
missense variants – Insights from quantification profiles of residual enzyme activity, secretion and psychosine levels
",17 10 2024,,Krabbe_Disease
"The Effect of Donepezil Hydrochloride in the Twitcher Mouse Model of Krabbe Disease Krabbe disease (KD) is a rare demyelinating disorder characterized by demyelination caused by mutations in the <italic toggle=""yes"">GALC</italic> gene, resulting in toxic accumulation of psychosine. Psychosine has been identified as detrimental to oligodendrocytes, leading to demyelination through diverse hypothesized pathways. Reducing demyelination is essential to maintain neurological function in KD; however, therapeutic",1_0,The Effect of Donepezil Hydrochloride in the Twitcher Mouse Model of Krabbe Disease,1 4 2024,,Krabbe_Disease
"neurological function in KD; however, therapeutic interventions are currently limited. Acetylcholinesterase inhibitors (AChEi) are commonly used for symptomatic management of Alzheimer's Disease and are suggested to have potential disease-modifying effects, including regulating myelin state. In particular, donepezil, an AChEi, has demonstrated promising effects in cellular and animal models, including promotion of the expression of myelin-related genes and reduction of glial cell reactivity. This drug also",1_1,The Effect of Donepezil Hydrochloride in the Twitcher Mouse Model of Krabbe Disease,1 4 2024,,Krabbe_Disease
"of glial cell reactivity. This drug also acts as an agonist for sigma-1 receptors (Sig-1R), which are implicated in demyelination diseases. In the context of drug repurposing, here, we demonstrate that administration of donepezil has protective effects in the twitcher mouse model of KD. We provide data showing that donepezil preserves myelin and reduces glial cell reactivity in the brains of twitcher mice. Moreover, donepezil also improves behavioral phenotypes and increases lifespan in twitcher animals.",1_2,The Effect of Donepezil Hydrochloride in the Twitcher Mouse Model of Krabbe Disease,1 4 2024,,Krabbe_Disease
"and increases lifespan in twitcher animals. These findings suggest that donepezil, with its dual activity as an AChE inhibitor and Sig-1R agonist, may hold promise as a therapeutic candidate for demyelinating diseases, including KD. Krabbe disease (KD) is a demyelinating disease associated with oligodendrocyte cell death and aberrant myelin state. KD, also known as globoid cell leukodystrophy, is a rare autosomal recessive disease occurring in approximately 1:100,000 [<xref ref-type=""bibr""",1_3,The Effect of Donepezil Hydrochloride in the Twitcher Mouse Model of Krabbe Disease,1 4 2024,,Krabbe_Disease
"in approximately 1:100,000 [<xref ref-type=""bibr"" rid=""CR1"">1</xref>]. This disease is a lipid storage disorder caused by mutations in the <italic toggle=""yes"">GALC</italic> gene, which codes for the enzyme galactosylceramidase (GALC). Mutations in <italic toggle=""yes"">GALC</italic> result in a loss of function and the toxic build-up of metabolites galactosylceramide and galactosylsphingosine (psychosine) [<xref ref-type=""bibr"" rid=""CR2"">2</xref>]. Psychosine is known to be toxic to oligodendrocytes and",1_4,The Effect of Donepezil Hydrochloride in the Twitcher Mouse Model of Krabbe Disease,1 4 2024,,Krabbe_Disease
"is known to be toxic to oligodendrocytes and causes demyelination by various proposed mechanisms, where myelin loss and neuroinflammation are presumably triggered by consequences of absent GALC function not clearing psychosine [<xref ref-type=""bibr"" rid=""CR3"">3</xref>]. KD is also associated with a cluster of glial and immune cell dysfunctions including astrogliosis, microglia activation, as well as macrophage recruitment [<xref ref-type=""bibr"" rid=""CR4"">4</xref>]. Mitigating demyelination is essential for",1_5,The Effect of Donepezil Hydrochloride in the Twitcher Mouse Model of Krabbe Disease,1 4 2024,,Krabbe_Disease
"Mitigating demyelination is essential for preserving neurological function and quality of life in individuals with KD [<xref ref-type=""bibr"" rid=""CR5"">5</xref>]. By identifying drugs that can slow or halt the progression of demyelination, the onset of the symptoms can be delayed and improved outcomes observed in individuals. There is no approved treatment for KD, and the therapeutic approach focus on the symptomatic and supportive management of the disorder. Hematopoietic stem cell transplantation (HSCT)",1_6,The Effect of Donepezil Hydrochloride in the Twitcher Mouse Model of Krabbe Disease,1 4 2024,,Krabbe_Disease
"Hematopoietic stem cell transplantation (HSCT) is the only available treatment option that has been proven to slow down the progression of KD [<xref ref-type=""bibr"" rid=""CR6"">6</xref>]. Additionally, the Enzyme Replacement Therapy has been used successfully in other lysosomal storage disorders and is based on the intravenous administration of a synthetic form of the missing enzyme [<xref ref-type=""bibr"" rid=""CR7"">7</xref>]. However, its efficacy in KD is limited due to the difficulty of the enzyme crossing",1_7,The Effect of Donepezil Hydrochloride in the Twitcher Mouse Model of Krabbe Disease,1 4 2024,,Krabbe_Disease
"due to the difficulty of the enzyme crossing the BBB and reaching the affected brain regions [<xref ref-type=""bibr"" rid=""CR8"">8</xref>]. Additionally, experimental gene therapy approaches are under investigation, aiming to correct the genetic defect by introducing a functional copy of the GALC gene into the patient’s cells [<xref ref-type=""bibr"" rid=""CR9"">9</xref>], while the supportive and symptomatic treatment focuses on managing complications, such as controlling seizures and improving the quality of",1_8,The Effect of Donepezil Hydrochloride in the Twitcher Mouse Model of Krabbe Disease,1 4 2024,,Krabbe_Disease
"controlling seizures and improving the quality of life. Acetylcholinesterase inhibitors (AChEi) impede the hydrolysis of acetylcholine (ACh), increase the levels of this neurotransmitter in the synaptic cleft and thereby enhance cholinergic transmission [<xref ref-type=""bibr"" rid=""CR10"">10</xref>]. Cholinergic activation is considered critical for the maintenance of neuronal function and ensuring successful synaptic transmission in peripheral and central nervous systems. AChEi such as donepezil,",1_9,The Effect of Donepezil Hydrochloride in the Twitcher Mouse Model of Krabbe Disease,1 4 2024,,Krabbe_Disease
"central nervous systems. AChEi such as donepezil, rivastigmine, and tacrine improve cognitive function and are used for the symptomatic management of AD. Marketed AChEi drugs have been reported to have potential disease modifying targeting mechanisms. For example, these drugs appear to delay the deposition of amyloid plaques and attenuate microglia activation [<xref ref-type=""bibr"" rid=""CR11"">11</xref>]. AChE inhibition is also related to reduce lymphocyte proliferation [<xref ref-type=""bibr""",1_10,The Effect of Donepezil Hydrochloride in the Twitcher Mouse Model of Krabbe Disease,1 4 2024,,Krabbe_Disease
"lymphocyte proliferation [<xref ref-type=""bibr"" rid=""CR12"">12</xref>]. Cholinergic neurotransmission also plays a role in regulating the secretion of pro-inflammatory cytokines (such as TNF-α, IL-6, and IL-β). Drugs such as donepezil and rivastigmine are also suggested to play a role in regulating myelin state. The effect of donepezil on demyelination has been assessed in cellular studies such as on oligodendrocyte precursor cells (OPCs) seeded alone [<xref ref-type=""bibr"" rid=""CR13"">13</xref>] and in",1_11,The Effect of Donepezil Hydrochloride in the Twitcher Mouse Model of Krabbe Disease,1 4 2024,,Krabbe_Disease
"ref-type=""bibr"" rid=""CR13"">13</xref>] and in co-culture with dorsal root ganglion (OPC–DRG) neurons [<xref ref-type=""bibr"" rid=""CR14"">14</xref>]. The drug managed to increase the length of myelinated axons and promote OPC differentiation to OLs. Moreover, the number of myelinated axons, as well as the G-ratio of remyelinated axons in the corpus callosum region of mice was found to have increased in further in vivo experiments [<xref ref-type=""bibr"" rid=""CR15"">15</xref>]. Donepezil also upregulates the",1_12,The Effect of Donepezil Hydrochloride in the Twitcher Mouse Model of Krabbe Disease,1 4 2024,,Krabbe_Disease
"Donepezil also upregulates the expression of myelin-related genes in OPCs [<xref ref-type=""bibr"" rid=""CR13"">13</xref>]. AChEi drugs such as donepezil and rivastigmine are also agonists for sigma-1-receptors (Sig-1R) and bind to these receptors at a low nanomolar in range similar to AChE [<xref ref-type=""bibr"" rid=""CR15"">15</xref>–<xref ref-type=""bibr"" rid=""CR18"">18</xref>]. Sufficient evidence now exists to argue that efficacy of some AChEi drugs may be via a dual AChE inhibition and Sig-1R agonist",1_13,The Effect of Donepezil Hydrochloride in the Twitcher Mouse Model of Krabbe Disease,1 4 2024,,Krabbe_Disease
"be via a dual AChE inhibition and Sig-1R agonist mechanism. Notably, Sig-1R agonists have been suggested as potential use in demyelination diseases such as multiple sclerosis [<xref ref-type=""bibr"" rid=""CR19"">19</xref>] and vanishing white matter (VWM) disease [<xref ref-type=""bibr"" rid=""CR20"">20</xref>]. We have previously described a range of mechanisms that attenuate psychosine-induced cell toxicity and demyelination including (i) sphingosine 1-phosphate receptor functional antagonists [<xref",1_14,The Effect of Donepezil Hydrochloride in the Twitcher Mouse Model of Krabbe Disease,1 4 2024,,Krabbe_Disease
"receptor functional antagonists [<xref ref-type=""bibr"" rid=""CR21"">21</xref>–<xref ref-type=""bibr"" rid=""CR23"">23</xref>], (ii) phospholipase A2 inhibitors [<xref ref-type=""bibr"" rid=""CR24"">24</xref>], (iii) piezo 1 mechanosensitive ion channel antagonists [<xref ref-type=""bibr"" rid=""CR25"">25</xref>], (iv) hybrid nanoparticles [<xref ref-type=""bibr"" rid=""CR26"">26</xref>], and (v) more recently D2 receptor antagonist antipsychotics [<xref ref-type=""bibr"" rid=""CR27"">27</xref>]. In particular, we have described",1_15,The Effect of Donepezil Hydrochloride in the Twitcher Mouse Model of Krabbe Disease,1 4 2024,,Krabbe_Disease
"In particular, we have described that marketed drugs fingolimod [<xref ref-type=""bibr"" rid=""CR23"">23</xref>] and haloperidol [<xref ref-type=""bibr"" rid=""CR27"">27</xref>] promote lifespan in the twitcher mouse model of KD. In the context of drug repurposing, the myelin-promoting properties of donepezil, along with its dual inhibitory activity against AChE and activation of Sig-1R, render it as a promising candidate for the management of demyelinating diseases. Here, we aimed to assess the effect of an",1_16,The Effect of Donepezil Hydrochloride in the Twitcher Mouse Model of Krabbe Disease,1 4 2024,,Krabbe_Disease
"Here, we aimed to assess the effect of an archetypical AChEi drug, namely donepezil, in the twitcher mouse model, a demyelinating model translatable for KD. We report that donepezil protects against the loss of myelin, dampens glial cell reactivity, slows behavioral phenotypes, and increases lifespan in the twitcher mouse model of KD.    Below is the link to the electronic supplementary material.<supplementary-material content-type=""local-data"" id=""MOESM1""><media http://www.w3.org/1999/xlink",1_17,The Effect of Donepezil Hydrochloride in the Twitcher Mouse Model of Krabbe Disease,1 4 2024,,Krabbe_Disease
"id=""MOESM1""><media http://www.w3.org/1999/xlink href=""12035_2024_4137_MOESM1_ESM.pdf""><caption><p>Supplementary file1 (PDF 308 KB)</p></caption></media></supplementary-material>",1_18,The Effect of Donepezil Hydrochloride in the Twitcher Mouse Model of Krabbe Disease,1 4 2024,,Krabbe_Disease
Abstract 8: Facilitating Hematopoietic Cell Transplant for Patients with Infantile Krabbe Disease Identified by Newborn Screening Full text not available in PMC,2_0,Abstract 8: Facilitating Hematopoietic Cell Transplant for Patients with Infantile Krabbe Disease Identified by Newborn Screening,9 2024,,Krabbe_Disease
"Human iPSC-derived myelinating organoids and globoid cells to study Krabbe Disease Krabbe disease (Kd) is a lysosomal storage disorder (LSD) caused by the deficiency of the lysosomal galactosylceramidase (GALC) which cleaves the myelin enriched lipid galactosylceramide (GalCer). Accumulated GalCer is catabolized into the cytotoxic lipid psychosine that causes myelinating cells death and demyelination which recruits microglia/macrophages that fail to digest myelin debris and become globoid cells. Here, to",3_0,Human iPSC-derived myelinating organoids and globoid cells to study Krabbe Disease,23 7 2024,,Krabbe_Disease
"myelin debris and become globoid cells. Here, to understand the pathological mechanisms of Kd, we used induced pluripotent stem cells (iPSCs) from Kd patients to produce myelinating organoids and microglia. We show that Kd organoids have no obvious defects in neurogenesis, astrogenesis, and oligodendrogenesis but manifest early myelination defects. Specifically, Kd organoids showed shorter but a similar number of myelin internodes than Controls at the peak of myelination and a reduced number and shorter",3_1,Human iPSC-derived myelinating organoids and globoid cells to study Krabbe Disease,23 7 2024,,Krabbe_Disease
"of myelination and a reduced number and shorter internodes at a later time point. Interestingly, myelin is affected in the absence of autophagy and mTOR pathway dysregulation, suggesting lack of lysosomal dysfunction which makes this organoid model a very valuable tool to study the early events that drive demyelination in Kd. Kd iPSC-derived microglia show a marginal rate of globoid cell formation under normal culture conditions that is drastically increased upon GalCer feeding. Under normal culture",3_2,Human iPSC-derived myelinating organoids and globoid cells to study Krabbe Disease,23 7 2024,,Krabbe_Disease
"upon GalCer feeding. Under normal culture conditions, Kd microglia show a minor LAMP1 content decrease and a slight increase in the autophagy protein LC3B. Upon GalCer feeding, Kd cells show accumulation of autophagy proteins and strong LAMP1 reduction that at a later time point are reverted showing the compensatory capabilities of globoid cells. Altogether, this supports the value of our cultures as tools to study the mechanisms that drive globoid cell formation and the compensatory mechanism in play to",3_3,Human iPSC-derived myelinating organoids and globoid cells to study Krabbe Disease,23 7 2024,,Krabbe_Disease
"and the compensatory mechanism in play to overcome GalCer accumulation in Kd. Krabbe Disease (Kd), also known as globoid cell leukodystrophy, is a lysosomal storage disease (LSD) cause by mutations in the <italic toggle=""yes"">GALC</italic> gene which encodes the lysosomal hydrolase galactosyl ceramidase (GALC). The incidence of Kd in USA is estimated to be 1:100,000–1:250,000 (<xref rid=""R4"" ref-type=""bibr"">Barczykowski et al., 2012</xref>). Kd is classified on the basis of the age of symptoms onset as",3_4,Human iPSC-derived myelinating organoids and globoid cells to study Krabbe Disease,23 7 2024,,Krabbe_Disease
"on the basis of the age of symptoms onset as early infantile, late infantile, juvenile and adult (<xref rid=""R5"" ref-type=""bibr"">Bascou et al., 2018</xref>; <xref rid=""R11"" ref-type=""bibr"">Duffner et al., 2011</xref>; <xref rid=""R12"" ref-type=""bibr"">Duffner et al., 2012</xref>). Kd patients experience rapid and severe demyelination, neurodegeneration, and neuroinflammation in the central nervous system (CNS) and peripheral nervous system (PNS). Symptoms include: progressive neurologic deterioration with",3_5,Human iPSC-derived myelinating organoids and globoid cells to study Krabbe Disease,23 7 2024,,Krabbe_Disease
"progressive neurologic deterioration with decorticate posturing, blindness, deafness, peripheral neuropathy, autonomic instability, and death (<xref rid=""R11"" ref-type=""bibr"">Duffner et al., 2011</xref>; <xref rid=""R12"" ref-type=""bibr"">Duffner et al., 2012</xref>). White matter is mostly composed of axons that are ensheathed by myelin which is produced by mature oligodendrocytes (OLs) in the CNS. Myelin is a lipid-rich insulating multi-layer that protects and provides trophic support to axons, and allows",3_6,Human iPSC-derived myelinating organoids and globoid cells to study Krabbe Disease,23 7 2024,,Krabbe_Disease
"and provides trophic support to axons, and allows rapid impulse propagation through the saltatory propagation of action potentials between Nodes of Ranvier (<xref rid=""R47"" ref-type=""bibr"">Simons et al., 2024</xref>). Oligodendrocyte Progenitor Cells (OPCs) arise from neuroectoderm derived Neural Stem Cells (NSCs) which also produce neurons and astrocytes (<xref rid=""R14"" ref-type=""bibr"">El Waly et al., 2014</xref>). Microglia, the innate immune system surveillants of the CNS, originate from the mesoderm",3_7,Human iPSC-derived myelinating organoids and globoid cells to study Krabbe Disease,23 7 2024,,Krabbe_Disease
"of the CNS, originate from the mesoderm derived yolk sac which produces microglial progenitors capable of migrating towards and colonizing the CNS during embryonic development (<xref rid=""R46"" ref-type=""bibr"">Sierra et al., 2024</xref>). Animal models of Kd are available and in particular, the twitcher mouse (<xref rid=""R25"" ref-type=""bibr"">Kobayashi et al., 1980</xref>), a global <italic toggle=""yes"">GALC</italic> knock out model, and the recently developed <italic toggle=""yes"">GALC</italic> conditional",3_8,Human iPSC-derived myelinating organoids and globoid cells to study Krabbe Disease,23 7 2024,,Krabbe_Disease
"<italic toggle=""yes"">GALC</italic> conditional knock out mouse (<xref rid=""R49"" ref-type=""bibr"">Weinstock, Shin, et al., 2020</xref>) together with human biopsies had been used to study the physiopathology of Kd. In Kd, the lack of GalC function or the failure to dock GalC into lysosomes (<xref rid=""R45"" ref-type=""bibr"">Shin et al., 2016</xref>) causes the accumulation of GalC’s substrate galactosyl ceramide (GalCer) which is alternatively deacylated by the catabolic enzyme acid ceramidase (Asah1) to",3_9,Human iPSC-derived myelinating organoids and globoid cells to study Krabbe Disease,23 7 2024,,Krabbe_Disease
"the catabolic enzyme acid ceramidase (Asah1) to produce psychosine (<xref rid=""R29"" ref-type=""bibr"">Li et al., 2019</xref>), a very potent toxin. The myelinating cells, OLs in the CNS and Schwann Cells (SC) in the PNS, produce large amounts of GalCer and are particularly susceptible to cell death due to the accumulated psychosine. The subsequent demyelination triggers an inflammatory response that recruits microglia/macrophages (CNS/PNS) to demyelinating foci. Microglia/macrophages phagocytize and digest",3_10,Human iPSC-derived myelinating organoids and globoid cells to study Krabbe Disease,23 7 2024,,Krabbe_Disease
"Microglia/macrophages phagocytize and digest GalCer rich myelin debris however, the lack of GalC causes GalCer and psychosine accumulation, and the formation of multinucleated cells named globoid cells. Whereas animal models of Kd give us the opportunity to study the dynamics of the cellular and molecular events that drive the disease and to test different therapeutic interventions, the study of the human disease is limited to post mortem tissue. In the past few years, the utilization of iPSCs to replicate",3_11,Human iPSC-derived myelinating organoids and globoid cells to study Krabbe Disease,23 7 2024,,Krabbe_Disease
"few years, the utilization of iPSCs to replicate organogenesis <italic toggle=""yes"">in vitro</italic> has emerged and several diseases have been successfully modeled providing the tools to perform in-detail studies of the cellular and molecular mechanisms that drive different diseases (<xref rid=""R1"" ref-type=""bibr"">Adlakha, 2023</xref>; <xref rid=""R13"" ref-type=""bibr"">Eichmuller & Knoblich, 2022</xref>). Here, we show that Kd can be modeled by using myelinating organoids that show no obvious defects in",3_12,Human iPSC-derived myelinating organoids and globoid cells to study Krabbe Disease,23 7 2024,,Krabbe_Disease
"organoids that show no obvious defects in neurogenesis, astrogenesis and oligodendrogenesis but signs of demyelination and iPSC-derived microglia that when fed with GalCer give rise to globoid cells.   Currently, Kd patients receive supportive care and the only approved disease-modifying treatment is hematopoietic stem cell transplantation (HSCT) which is effective in asymptomatic patients (<xref rid=""R15"" ref-type=""bibr"">Escolar et al., 2005</xref>; <xref rid=""R27"" ref-type=""bibr"">Krivit et al.,",3_13,Human iPSC-derived myelinating organoids and globoid cells to study Krabbe Disease,23 7 2024,,Krabbe_Disease
"<xref rid=""R27"" ref-type=""bibr"">Krivit et al., 1998</xref>). Despite the immense success of HSCT in decreasing Kd’s progression, patients who receive HSCT experience variable levels of disability that are extensive in symptomatic patients (<xref rid=""R51"" ref-type=""bibr"">Wright et al., 2017</xref>; <xref rid=""R52"" ref-type=""bibr"">Yoon et al., 2021</xref>). In line with this, efforts have been made to explore additional treatments including substrate reduction therapy (SRT) (blocking catabolic pathways to",3_14,Human iPSC-derived myelinating organoids and globoid cells to study Krabbe Disease,23 7 2024,,Krabbe_Disease
"therapy (SRT) (blocking catabolic pathways to prevent GalCer accumulation), enzyme replacement therapy (ERT) (administration of recombinant GalC) or gene therapy (viral delivery of GalC’s construct) (<xref rid=""R18"" ref-type=""bibr"">Heller et al., 2023</xref>). Among the single treatments, adeno-associated virus (AAV) delivery of GalC’s construct shows the best outcomes in disease progression and survival of pre-symptomatic mice and dogs (<xref rid=""R20"" ref-type=""bibr"">Hordeaux et al., 2022</xref>; <xref",3_15,Human iPSC-derived myelinating organoids and globoid cells to study Krabbe Disease,23 7 2024,,Krabbe_Disease
"et al., 2022</xref>; <xref rid=""R41"" ref-type=""bibr"">Rafi et al., 2021</xref>). In addition, gene therapy combined with HSCT, shows superior disease outcomes in pre-symptomatic mice (<xref rid=""R41"" ref-type=""bibr"">Rafi et al., 2021</xref>; <xref rid=""R42"" ref-type=""bibr"">Rafi et al., 2015</xref>). Currently, there are two ongoing gene therapy-based clinical trials (<ext-link http://www.w3.org/1999/xlink href=""https://clinicaltrials.gov/ct2/show/NCT05739643"" ext-link-type=""uri"">NCT05739643</ext-link> and",3_16,Human iPSC-derived myelinating organoids and globoid cells to study Krabbe Disease,23 7 2024,,Krabbe_Disease
"ext-link-type=""uri"">NCT05739643</ext-link> and <ext-link http://www.w3.org/1999/xlink href=""https://clinicaltrials.gov/ct2/show/NCT04693598"" ext-link-type=""uri"">NCT04693598</ext-link>) (<ext-link http://www.w3.org/1999/xlink href=""https://clinicaltrials.gov/"" ext-link-type=""uri"">https://clinicaltrials.gov/</ext-link>). In addition, combining three different treatments including HSCT, gene therapy and SRT given to pre-symptomatic mice showed even better disease outcomes than dual HSCT/gene therapy treatment",3_17,Human iPSC-derived myelinating organoids and globoid cells to study Krabbe Disease,23 7 2024,,Krabbe_Disease
"outcomes than dual HSCT/gene therapy treatment (<xref rid=""R28"" ref-type=""bibr"">Li et al., 2021</xref>), but despite increasing the survival of the animals by 10-fold, motor dysfunction measured by rotarod and wire hanging tests, persists similarly to what happens in patients that received HSCT (<xref rid=""R51"" ref-type=""bibr"">Wright et al., 2017</xref>; <xref rid=""R52"" ref-type=""bibr"">Yoon et al., 2021</xref>) ultimately highlighting the importance of the need for a better understanding of the mechanisms",3_18,Human iPSC-derived myelinating organoids and globoid cells to study Krabbe Disease,23 7 2024,,Krabbe_Disease
"need for a better understanding of the mechanisms that drive demyelination, neurodegeneration and neuroinflammation. To identify the molecular mechanisms that underlay Kd pathology, iPSCs and iPSC-derived cultures were used. Liu and colleagues (<xref rid=""R33"" ref-type=""bibr"">Lv et al., 2023</xref>) performed bulk RNA sequencing of Kd iPSCs and NSC and found early dysregulated genes in Kd iPSCs and a significantly larger number of dysregulated genes in Kd NSC. Pathway analysis shows the involvement of",3_19,Human iPSC-derived myelinating organoids and globoid cells to study Krabbe Disease,23 7 2024,,Krabbe_Disease
"Kd NSC. Pathway analysis shows the involvement of novel pathways in Kd iPSCs, and the dysregulation of the MAPK, PI3K-Akt, cAMP, and RAS signaling pathways, as well as neuroactive ligand-receptor in Kd NSC. Interestingly, neither Kd iPSCs nor NSCs show dysregulation of the Kd associated Lysosome or Sphingolipid Metabolism KEGG pathways supporting the idea that the findings by Lv and colleagues are novel early events in Kd. Another work differentiated Kd iPSCs into astrocytes that show no gross development",3_20,Human iPSC-derived myelinating organoids and globoid cells to study Krabbe Disease,23 7 2024,,Krabbe_Disease
"into astrocytes that show no gross development defects, accumulate psychosine, have increased expression and levels of IL-6, and a lipid accumulation phenotype (<xref rid=""R30"" ref-type=""bibr"">Lieberman et al., 2022</xref>). Interestingly, Kd astrocytes negatively impact the survival of Ctrol neurons (both in a co-culture setting or by adding astrocyte conditioned media) but positively impact Ctrol microglia survival in co-culture. Mangiameli and colleagues (<xref rid=""R34"" ref-type=""bibr"">Mangiameli et",3_21,Human iPSC-derived myelinating organoids and globoid cells to study Krabbe Disease,23 7 2024,,Krabbe_Disease
"(<xref rid=""R34"" ref-type=""bibr"">Mangiameli et al., 2021</xref>) studied Kd patient-derived iPSCs and found that they retain normal stem cell properties, despite of accumulating psychosine, and show similar differentiation efficiency and comparable phenotype to Ctrol ones when differentiated into NSC. When Kd iPSCs were differentiated into neuronal/glial mixed cultures, the oligodendroglial and neuronal populations were negatively impacted. This phenomenon is explained by the activation of an early",3_22,Human iPSC-derived myelinating organoids and globoid cells to study Krabbe Disease,23 7 2024,,Krabbe_Disease
"is explained by the activation of an early senescence program that affects lineage commitment, and an altered lipidomic profile throughout the iPSC to NSC stage. Altogether, these studies show that Kd impacts neurodevelopment in iPSC-derived 2D cultures but none of them explored myelination, which is largely impacted in Kd. In line with this, we used a 3D culture method that produces robust myelination (<xref rid=""R23"" ref-type=""bibr"">James et al., 2021</xref>) among the several approaches to induce iPSC",3_23,Human iPSC-derived myelinating organoids and globoid cells to study Krabbe Disease,23 7 2024,,Krabbe_Disease
"among the several approaches to induce iPSC differentiation into oligodendrocyte and myelination (<xref rid=""R44"" ref-type=""bibr"">Shim et al., 2023</xref>) and were able to replicate, for the first time, the demyelinating phenotype observed in Kd using iPSC-derived cultures. Axonopathy in the spinal cord of pre-symptomatic Twitcher and Twitcher5J mice has been described before any detectable demyelination occurs suggesting a neuronal cell-autonomous phenotype (<xref rid=""R6"" ref-type=""bibr"">Castelvetri et",3_24,Human iPSC-derived myelinating organoids and globoid cells to study Krabbe Disease,23 7 2024,,Krabbe_Disease
"(<xref rid=""R6"" ref-type=""bibr"">Castelvetri et al., 2011</xref>; <xref rid=""R39"" ref-type=""bibr"">Potter et al., 2013</xref>). Interestingly, these findings do not manifest as a reduction in the number of NeuN<sup>+</sup> cells until the later stages of the disease. In support of a neuronal cell-autonomous mechanism of GALC ablation, early neuronal maturation defects together with a reduced number of Sox2<sup>+</sup>/Olig2<sup>+</sup> OPCs have been shown to occur in the brain stem of GALC null mice (<xref",3_25,Human iPSC-derived myelinating organoids and globoid cells to study Krabbe Disease,23 7 2024,,Krabbe_Disease
"occur in the brain stem of GALC null mice (<xref rid=""R48"" ref-type=""bibr"">Weinstock, Kreher, et al., 2020</xref>) and a follow up study using pan-neuronal GALC deficient mice showed morphological signs of neurodegeneration in the spinal cord of 6 month old animals confirming a neuronal cell-autonomous phenotype in Kd (<xref rid=""R26"" ref-type=""bibr"">Kreher et al., 2022</xref>). Because of all of these, we can expect that our Kd organoids are very likely to experience some extent of axonopathy, that is not",3_26,Human iPSC-derived myelinating organoids and globoid cells to study Krabbe Disease,23 7 2024,,Krabbe_Disease
"experience some extent of axonopathy, that is not detectable by NeuN staining during the early stages of the cultures but could be detected at later stages, and to not show any neurogenesis defects because of recapitulating spinal cord development instead of brain stem’s. In this context, the results reported by Mangiameli and colleagues (<xref rid=""R34"" ref-type=""bibr"">Mangiameli et al., 2021</xref>) showing neurodevelopmental defects, but not found in our study, could be caused by the limitations of 2D",3_27,Human iPSC-derived myelinating organoids and globoid cells to study Krabbe Disease,23 7 2024,,Krabbe_Disease
"study, could be caused by the limitations of 2D as compared to 3D cultures (<xref rid=""R24"" ref-type=""bibr"">Jensen & Teng, 2020</xref>), the use of a protocol that yields a modest number of astrocytes and oligodendrocytes (limiting potential compensatory mechanisms arising from these cell populations) or because of recapitulating forebrain development whereas our protocol recapitulates spinal cord development, shows abundant number of both cell populations and replicates the findings described in mice. In",3_28,Human iPSC-derived myelinating organoids and globoid cells to study Krabbe Disease,23 7 2024,,Krabbe_Disease
"and replicates the findings described in mice. In Kd, lysosomes fail to degrade GalCer resulting in the production and accumulation of psychosine which ultimately leads to lysosomal dysfunction (<xref rid=""R17"" ref-type=""bibr"">Folts et al., 2016</xref>). Lysosomes have multiple roles in several cellular processes including material recycling, metabolic signaling, autophagy, gene regulation, plasma membrane repair, and cell adhesion and migration (<xref rid=""R3"" ref-type=""bibr"">Ballabio & Bonifacino,",3_29,Human iPSC-derived myelinating organoids and globoid cells to study Krabbe Disease,23 7 2024,,Krabbe_Disease
"rid=""R3"" ref-type=""bibr"">Ballabio & Bonifacino, 2020</xref>). In line with this, Kd phenotype has been linked to: metabolic dysregulation as shown by mTOR pathway dysregulation (<xref rid=""R22"" ref-type=""bibr"">Inamura et al., 2018</xref>; <xref rid=""R31"" ref-type=""bibr"">Lin et al., 2023</xref>) and autophagy impairment (<xref rid=""R8"" ref-type=""bibr"">Del Grosso et al., 2019</xref>; <xref rid=""R9"" ref-type=""bibr"">Del Grosso et al., 2016</xref>; <xref rid=""R31"" ref-type=""bibr"">Lin et al., 2023</xref>; <xref",3_30,Human iPSC-derived myelinating organoids and globoid cells to study Krabbe Disease,23 7 2024,,Krabbe_Disease
"ref-type=""bibr"">Lin et al., 2023</xref>; <xref rid=""R38"" ref-type=""bibr"">Papini et al., 2023</xref>). Interestingly, our Kd organoids show signs of demyelination in the absence of any major autophagy dysregulation and the presence of a minor mTOR pathway dysregulation suggesting the absence of lysosomal dysfunction. Because of these, our Kd organoids are a valuable method to study the early events that drive demyelination in Kd in the absence of neuroinflammation, overcoming the limitations of using human",3_31,Human iPSC-derived myelinating organoids and globoid cells to study Krabbe Disease,23 7 2024,,Krabbe_Disease
"overcoming the limitations of using human biopsies. In regards to globoid cells. Kd microglia that weren’t fed with GalCer show small signs of what could be lysosomal impairment when compared to Ctrol microglia however, overloading microglia (both Ctrol and Kd) with GalCer shows an interesting phenomenon. In Ctrol microglia fed with GalCer, lysosomes can handle the overload as shown by the lack of accumulation of autophagic proteins and a modest mTOR pathway hyperactivation at an early time point. Later",3_32,Human iPSC-derived myelinating organoids and globoid cells to study Krabbe Disease,23 7 2024,,Krabbe_Disease
"hyperactivation at an early time point. Later on, a trend decrease in autophagic proteins together with an increased lysosomal biogenesis, suggested by a trend increase of LAMP1 content, is observed and we interpreted this as normal compensation to lysosome’s overload. In the case of Kd microglia fed with GalCer, a strong accumulation of autophagic proteins and reduction of LAMP1 is observed at an early time point but at later on, when most cells had become globoid cells, a similar compensatory mechanism",3_33,Human iPSC-derived myelinating organoids and globoid cells to study Krabbe Disease,23 7 2024,,Krabbe_Disease
"globoid cells, a similar compensatory mechanism takes place by increasing LAMP1 content, reducing autophagic proteins and increasing mTOR pathway activation. Altogether this suggests that Kd lysosomes could be damaged at early time points, but replaced later on, showing that globoid cells possess the capacity to promote lysosome biogenesis in an attempt to restore autophagic flow which could be explored in the future using our model of globoid cells. Globoid cells are pathognomonic of Kd, show a storage",3_34,Human iPSC-derived myelinating organoids and globoid cells to study Krabbe Disease,23 7 2024,,Krabbe_Disease
"cells are pathognomonic of Kd, show a storage phenotype, are PAS<sup>+</sup>, have a distended cytoplasm with enlarged lysosomes, lipid crystals (presumably GalCer), and partially digested myelin sheaths (<xref rid=""R36"" ref-type=""bibr"">Nelson et al., 1963</xref>; <xref rid=""R37"" ref-type=""bibr"">Norman et al., 1961</xref>). In regards to how globoid cells form, macrophages/microglia fed with psychosine (<xref rid=""R7"" ref-type=""bibr"">Claycomb et al., 2014</xref>; <xref rid=""R21"" ref-type=""bibr"">Ijichi et",3_35,Human iPSC-derived myelinating organoids and globoid cells to study Krabbe Disease,23 7 2024,,Krabbe_Disease
"<xref rid=""R21"" ref-type=""bibr"">Ijichi et al., 2013</xref>) or GalCer (<xref rid=""R49"" ref-type=""bibr"">Weinstock, Shin, et al., 2020</xref>) give rise to globoid cells. However, GalCer feeding induces globoid cells only in GALC deficient macrophages causing accumulation of both psychosine and GalCer whereas psychosine feeding induces globoid phenotype in wild type cell (wt) cultures. This indicates that psychosine is the driving force of globoid cell formation however, wt macrophages fed with GalCer (that",3_36,Human iPSC-derived myelinating organoids and globoid cells to study Krabbe Disease,23 7 2024,,Krabbe_Disease
"however, wt macrophages fed with GalCer (that do not become globoid cells) are very likely to resemble the foamy phagocytic cells observed in mice that received HSCT (<xref rid=""R19"" ref-type=""bibr"">Hoogerbrugge et al., 1988</xref>). These cells are a relevant cell population for treatment purposes like boosting the phagocytic capabilities of donor macrophages in LSDs (<xref rid=""R49"" ref-type=""bibr"">Weinstock, Shin, et al., 2020</xref>; <xref rid=""R50"" ref-type=""bibr"">Wolf et al., 2020</xref>). In this",3_37,Human iPSC-derived myelinating organoids and globoid cells to study Krabbe Disease,23 7 2024,,Krabbe_Disease
"et al., 2020</xref>). In this context, our model of globoid cells will allow us to study both globoid cells (Kd + GalCer) and overloaded donor-like cells (Ctrol + GalCer), in order to get a better understanding of the mechanisms that drive globoid cell formation and to identify novel mechanisms to promote donor cell’s beneficial effects.",3_38,Human iPSC-derived myelinating organoids and globoid cells to study Krabbe Disease,23 7 2024,,Krabbe_Disease
"Dietary Supplementation with n-3 Polyunsaturated Fatty Acids Delays the Phenotypic Manifestation of Krabbe Disease and Partially Restores Lipid Mediator Production in the Brain—Study in a Mouse Model of the Disease Lipid mediators from fatty acid oxidation have been shown to be associated with the severity of Krabbe disease (KD), a disorder linked to mutations in the galactosylceramidase (<italic toggle=""yes"">GALC</italic>) gene. This study aims to investigate the effects of n-3 polyunsaturated fatty acid",4_0,Dietary Supplementation with n-3 Polyunsaturated Fatty Acids Delays the Phenotypic Manifestation of Krabbe Disease and Partially Restores Lipid Mediator Production in the Brain—Study in a Mouse Model of the Disease,28 6 2024,,Krabbe_Disease
"the effects of n-3 polyunsaturated fatty acid (PUFA) supplementation on KD traits and fatty acid metabolism using Twitcher (Tw) animals as a natural model for KD. Wild-type (Wt), heterozygous (Ht), and affected Tw animals were treated orally with 36 mg n-3 PUFAs/kg body weight/day from 10 to 35 days of life. The end product of PUFA peroxidation (8-isoprostane), the lipid mediator involved in the resolution of inflammatory exudates (resolvin D1), and the total amount of n-3 PUFAs were analyzed in the brains",4_1,Dietary Supplementation with n-3 Polyunsaturated Fatty Acids Delays the Phenotypic Manifestation of Krabbe Disease and Partially Restores Lipid Mediator Production in the Brain—Study in a Mouse Model of the Disease,28 6 2024,,Krabbe_Disease
"amount of n-3 PUFAs were analyzed in the brains of mice. In Tw mice, supplementation with n-3 PUFAs delayed the manifestation of disease symptoms (<italic toggle=""yes"">p</italic> < 0.0001), and in the bran, decreased 8-isoprostane amounts (<italic toggle=""yes"">p</italic> < 0.0001), increased resolvin D1 levels (<italic toggle=""yes"">p</italic> < 0.005) and increased quantity of total n-3 PUFAs (<italic toggle=""yes"">p</italic> < 0.05). Furthermore, total brain n-3 PUFA levels were associated with disease",4_2,Dietary Supplementation with n-3 Polyunsaturated Fatty Acids Delays the Phenotypic Manifestation of Krabbe Disease and Partially Restores Lipid Mediator Production in the Brain—Study in a Mouse Model of the Disease,28 6 2024,,Krabbe_Disease
"n-3 PUFA levels were associated with disease severity (r = −0.562, <italic toggle=""yes"">p</italic> = 0.0001), resolvin D1 (r = 0.712, <italic toggle=""yes"">p</italic> < 0.0001), and 8-isoprostane brain levels (r = −0.690, <italic toggle=""yes"">p</italic> < 0.0001). For the first time in a natural model of KD, brain levels of n-3 PUFAs are shown to determine disease severity and to be involved in the peroxidation of brain PUFAs as well as in the production of pro-resolving lipid mediators. It is also shown",4_3,Dietary Supplementation with n-3 Polyunsaturated Fatty Acids Delays the Phenotypic Manifestation of Krabbe Disease and Partially Restores Lipid Mediator Production in the Brain—Study in a Mouse Model of the Disease,28 6 2024,,Krabbe_Disease
"pro-resolving lipid mediators. It is also shown that dietary supplementation with n-3 PUFAs leads to a slowing of the phenotypic presentation of the disease and restoration of lipid mediator production. In cell membranes, the lipid profile is mainly understood as the composition of fatty acids, e.g., polyunsaturated fatty acids (PUFAs), long- or short-chain PUFAs, omega-3 (n-3) or omega-6 (n-6) PUFAs, has been studied in neurological diseases [<xref rid=""B1-ijms-25-07149"" ref-type=""bibr"">1</xref>,<xref",4_4,Dietary Supplementation with n-3 Polyunsaturated Fatty Acids Delays the Phenotypic Manifestation of Krabbe Disease and Partially Restores Lipid Mediator Production in the Brain—Study in a Mouse Model of the Disease,28 6 2024,,Krabbe_Disease
"ref-type=""bibr"">1</xref>,<xref rid=""B2-ijms-25-07149"" ref-type=""bibr"">2</xref>]. In neurological disorders in particular, but not only [<xref rid=""B3-ijms-25-07149"" ref-type=""bibr"">3</xref>,<xref rid=""B4-ijms-25-07149"" ref-type=""bibr"">4</xref>], the relevance of n-3 PUFAs and n-6 PUFAs to the pathological condition has been investigated, and the effects of dietary interventions aimed at altering the ratio of n-6 PUFAs to n-3 PUFAs have been assessed [<xref rid=""B1-ijms-25-07149""",4_5,Dietary Supplementation with n-3 Polyunsaturated Fatty Acids Delays the Phenotypic Manifestation of Krabbe Disease and Partially Restores Lipid Mediator Production in the Brain—Study in a Mouse Model of the Disease,28 6 2024,,Krabbe_Disease
"have been assessed [<xref rid=""B1-ijms-25-07149"" ref-type=""bibr"">1</xref>,<xref rid=""B2-ijms-25-07149"" ref-type=""bibr"">2</xref>,<xref rid=""B5-ijms-25-07149"" ref-type=""bibr"">5</xref>]. The brain is enriched in lipids. Docosahexaenoic acid (DHA, 22:6n-3), one of the most abundant PUFAs in the brain, together with arachidonic acid (AA, 20:4n-6) [<xref rid=""B6-ijms-25-07149"" ref-type=""bibr"">6</xref>], has been evaluated as a beneficial molecule for reducing cell death, for recovering from damage and improving",4_6,Dietary Supplementation with n-3 Polyunsaturated Fatty Acids Delays the Phenotypic Manifestation of Krabbe Disease and Partially Restores Lipid Mediator Production in the Brain—Study in a Mouse Model of the Disease,28 6 2024,,Krabbe_Disease
"death, for recovering from damage and improving cognitive function [<xref rid=""B7-ijms-25-07149"" ref-type=""bibr"">7</xref>,<xref rid=""B8-ijms-25-07149"" ref-type=""bibr"">8</xref>,<xref rid=""B9-ijms-25-07149"" ref-type=""bibr"">9</xref>,<xref rid=""B10-ijms-25-07149"" ref-type=""bibr"">10</xref>,<xref rid=""B11-ijms-25-07149"" ref-type=""bibr"">11</xref>,<xref rid=""B12-ijms-25-07149"" ref-type=""bibr"">12</xref>,<xref rid=""B13-ijms-25-07149"" ref-type=""bibr"">13</xref>,<xref rid=""B14-ijms-25-07149"" ref-type=""bibr"">14</xref>],",4_7,Dietary Supplementation with n-3 Polyunsaturated Fatty Acids Delays the Phenotypic Manifestation of Krabbe Disease and Partially Restores Lipid Mediator Production in the Brain—Study in a Mouse Model of the Disease,28 6 2024,,Krabbe_Disease
"ref-type=""bibr"">14</xref>], and for assuring the physiological brain development [<xref rid=""B15-ijms-25-07149"" ref-type=""bibr"">15</xref>,<xref rid=""B16-ijms-25-07149"" ref-type=""bibr"">16</xref>,<xref rid=""B17-ijms-25-07149"" ref-type=""bibr"">17</xref>], although DHA effects are still debated and need to be explored in depth [<xref rid=""B18-ijms-25-07149"" ref-type=""bibr"">18</xref>,<xref rid=""B19-ijms-25-07149"" ref-type=""bibr"">19</xref>]. In addition, eicosapentaenoic acid (EPA, 20:5n-3), an n-3 PUFA, is",4_8,Dietary Supplementation with n-3 Polyunsaturated Fatty Acids Delays the Phenotypic Manifestation of Krabbe Disease and Partially Restores Lipid Mediator Production in the Brain—Study in a Mouse Model of the Disease,28 6 2024,,Krabbe_Disease
"acid (EPA, 20:5n-3), an n-3 PUFA, is thought to regulate brain function [<xref rid=""B14-ijms-25-07149"" ref-type=""bibr"">14</xref>], improve memory and attention [<xref rid=""B12-ijms-25-07149"" ref-type=""bibr"">12</xref>,<xref rid=""B13-ijms-25-07149"" ref-type=""bibr"">13</xref>], and maintain brain volume [<xref rid=""B13-ijms-25-07149"" ref-type=""bibr"">13</xref>]. Thus, EPA’s relevance in maintaining healthy brain function is emphasized. Moreover, n-3 PUFAs have been shown to reduce recurrent epilepsy seizures",4_9,Dietary Supplementation with n-3 Polyunsaturated Fatty Acids Delays the Phenotypic Manifestation of Krabbe Disease and Partially Restores Lipid Mediator Production in the Brain—Study in a Mouse Model of the Disease,28 6 2024,,Krabbe_Disease
"been shown to reduce recurrent epilepsy seizures [<xref rid=""B20-ijms-25-07149"" ref-type=""bibr"">20</xref>,<xref rid=""B21-ijms-25-07149"" ref-type=""bibr"">21</xref>,<xref rid=""B22-ijms-25-07149"" ref-type=""bibr"">22</xref>], even if the blood increase, on a genetic basis, of PUFAs was found to be associated with an increased risk of epilepsy [<xref rid=""B23-ijms-25-07149"" ref-type=""bibr"">23</xref>]. EPA and DHA are the long-chain PUFA derivatives of alpha-linolenic acid (ALA, 18:3n-3). Frequently, the more",4_10,Dietary Supplementation with n-3 Polyunsaturated Fatty Acids Delays the Phenotypic Manifestation of Krabbe Disease and Partially Restores Lipid Mediator Production in the Brain—Study in a Mouse Model of the Disease,28 6 2024,,Krabbe_Disease
"acid (ALA, 18:3n-3). Frequently, the more abundant PUFAs in the diet are linoleic acid (LA, 18:2n-6) and ALA. LA and ALA are not synthesized in animals and are regarded as essential fatty acids [<xref rid=""B4-ijms-25-07149"" ref-type=""bibr"">4</xref>,<xref rid=""B24-ijms-25-07149"" ref-type=""bibr"">24</xref>]. Overall, the ratio of n-3 to n-6 PUFAs is considered a critical factor for the regulation of neurophysiological and cognitive functions [<xref rid=""B6-ijms-25-07149"" ref-type=""bibr"">6</xref>]. In Krabbe",4_11,Dietary Supplementation with n-3 Polyunsaturated Fatty Acids Delays the Phenotypic Manifestation of Krabbe Disease and Partially Restores Lipid Mediator Production in the Brain—Study in a Mouse Model of the Disease,28 6 2024,,Krabbe_Disease
"ref-type=""bibr"">6</xref>]. In Krabbe disease (KD), because of mutations in the galactosylceramidase (<italic toggle=""yes"">GALC</italic>) gene, deposition of the toxic lipid D-glucosyl-beta1-1′-sphingosine (GluSph) in the brain occurs [<xref rid=""B25-ijms-25-07149"" ref-type=""bibr"">25</xref>]. The Twitcher mouse (Tw) is an enzymatically authentic model of human KD. It is deficient in GALC enzyme activity, shares many of the neuropathological and biochemical features of human KD, is the most commonly used",4_12,Dietary Supplementation with n-3 Polyunsaturated Fatty Acids Delays the Phenotypic Manifestation of Krabbe Disease and Partially Restores Lipid Mediator Production in the Brain—Study in a Mouse Model of the Disease,28 6 2024,,Krabbe_Disease
"features of human KD, is the most commonly used animal model to study KD pathogenesis and is used for experimental therapies [<xref rid=""B25-ijms-25-07149"" ref-type=""bibr"">25</xref>,<xref rid=""B26-ijms-25-07149"" ref-type=""bibr"">26</xref>,<xref rid=""B27-ijms-25-07149"" ref-type=""bibr"">27</xref>]. Heterozygous (Ht) mice carry one copy of a mutation that causes KD-like disease. As in human KD, the disease is rapidly progressive in the Tw mouse model, and interventional approaches have been tested to prevent",4_13,Dietary Supplementation with n-3 Polyunsaturated Fatty Acids Delays the Phenotypic Manifestation of Krabbe Disease and Partially Restores Lipid Mediator Production in the Brain—Study in a Mouse Model of the Disease,28 6 2024,,Krabbe_Disease
"approaches have been tested to prevent significant damage to myelinating cells [<xref rid=""B28-ijms-25-07149"" ref-type=""bibr"">28</xref>,<xref rid=""B29-ijms-25-07149"" ref-type=""bibr"">29</xref>]. In Tw mouse, neurological symptoms appear between 15 and 20 days after birth and include tremors, progressive paralysis of the hind limbs, and loss of coordination [<xref rid=""B30-ijms-25-07149"" ref-type=""bibr"">30</xref>,<xref rid=""B31-ijms-25-07149"" ref-type=""bibr"">31</xref>]. Interestingly, Ht mice have been",4_14,Dietary Supplementation with n-3 Polyunsaturated Fatty Acids Delays the Phenotypic Manifestation of Krabbe Disease and Partially Restores Lipid Mediator Production in the Brain—Study in a Mouse Model of the Disease,28 6 2024,,Krabbe_Disease
"Interestingly, Ht mice have been studied and compared to Tw animals [<xref rid=""B26-ijms-25-07149"" ref-type=""bibr"">26</xref>] to better understand the increased risk of developing a number of different diseases in Ht carriers. In the murine Tw model, brain levels of oxygenated PUFA metabolites (i.e., isoprostanes, IsoPs) and pro-resolving lipid mediators, in particular resolvin (Rv)D1 derived from DHA, have been found to be relevant for the severity of the disease [<xref rid=""B32-ijms-25-07149""",4_15,Dietary Supplementation with n-3 Polyunsaturated Fatty Acids Delays the Phenotypic Manifestation of Krabbe Disease and Partially Restores Lipid Mediator Production in the Brain—Study in a Mouse Model of the Disease,28 6 2024,,Krabbe_Disease
"of the disease [<xref rid=""B32-ijms-25-07149"" ref-type=""bibr"">32</xref>,<xref rid=""B33-ijms-25-07149"" ref-type=""bibr"">33</xref>]. Interestingly, a lipidomic approach to studying the nervous system was performed in homozygous Tw mice, and it was found that lipid classes differed significantly from those of wild-type mice [<xref rid=""B34-ijms-25-07149"" ref-type=""bibr"">34</xref>]. Moreover, a specific fatty acid profile was found in Tw mice compared to wild–type (Wt) mice [<xref rid=""B35-ijms-25-07149""",4_16,Dietary Supplementation with n-3 Polyunsaturated Fatty Acids Delays the Phenotypic Manifestation of Krabbe Disease and Partially Restores Lipid Mediator Production in the Brain—Study in a Mouse Model of the Disease,28 6 2024,,Krabbe_Disease
"(Wt) mice [<xref rid=""B35-ijms-25-07149"" ref-type=""bibr"">35</xref>], and a mechanism has been described in which psychosine toxicity in KD is associated with membrane lipid raft disruption and membrane microsimulation [<xref rid=""B36-ijms-25-07149"" ref-type=""bibr"">36</xref>]. In this study, we used the Tw mouse as a KD model to investigate whether dietary n-3 PUFAs can modulate brain n-3 PUFA content, brain PUFA oxidation, and KD severity. The study was performed in Wt control mice, Ht carriers of the",4_17,Dietary Supplementation with n-3 Polyunsaturated Fatty Acids Delays the Phenotypic Manifestation of Krabbe Disease and Partially Restores Lipid Mediator Production in the Brain—Study in a Mouse Model of the Disease,28 6 2024,,Krabbe_Disease
"performed in Wt control mice, Ht carriers of the <italic toggle=""yes"">GALC</italic> mutation, as unaffected mice, and affected Tw mice fed with or without dietary supplementation of n-3 PUFAs.  Oxidative stress and inflammation are known to contribute to the onset and progression of chronic degenerative diseases. PUFAs, which modulate both antioxidant signaling pathways and inflammatory processes, are widely implicated in the pathophysiology of chronic diseases. In addition, n-3 PUFAs, particularly EPA and",4_18,Dietary Supplementation with n-3 Polyunsaturated Fatty Acids Delays the Phenotypic Manifestation of Krabbe Disease and Partially Restores Lipid Mediator Production in the Brain—Study in a Mouse Model of the Disease,28 6 2024,,Krabbe_Disease
"In addition, n-3 PUFAs, particularly EPA and DHA, have been associated with a lower incidence of chronic inflammatory diseases [<xref rid=""B4-ijms-25-07149"" ref-type=""bibr"">4</xref>,<xref rid=""B37-ijms-25-07149"" ref-type=""bibr"">37</xref>,<xref rid=""B38-ijms-25-07149"" ref-type=""bibr"">38</xref>]. Here, these issues were investigated in KD, where free radical-triggered fatty acid oxidation and impairment of resolution of inflammation are considered relevant factors in KD brain pathology [<xref",4_19,Dietary Supplementation with n-3 Polyunsaturated Fatty Acids Delays the Phenotypic Manifestation of Krabbe Disease and Partially Restores Lipid Mediator Production in the Brain—Study in a Mouse Model of the Disease,28 6 2024,,Krabbe_Disease
"relevant factors in KD brain pathology [<xref rid=""B33-ijms-25-07149"" ref-type=""bibr"">33</xref>]. Supplementation with DHA and EPA slows the phenotypic manifestation of the disease and largely normalizes the biochemical processes involved in the enzymatic and free radical-triggered oxidation of PUFAs. In fact, 8-IsoP levels, although significantly reduced compared to the non-supplemented Tw, in supplemented Tw do not reach the levels found in the Wt control animals, whereas the RvD1 values in the",4_20,Dietary Supplementation with n-3 Polyunsaturated Fatty Acids Delays the Phenotypic Manifestation of Krabbe Disease and Partially Restores Lipid Mediator Production in the Brain—Study in a Mouse Model of the Disease,28 6 2024,,Krabbe_Disease
"control animals, whereas the RvD1 values in the supplemented Tw normalize to the values measured in the Wt control mice, both supplemented and non-supplemented animals. Considering this result, Tw mice probably benefit from supplementation with n-3 PUFAs because these stimulate the resolution of inflammation. Furthermore, it is necessary to consider that 8-IsoP derives from the oxidation of arachidonic acid, while RvD1 derives from the enzymatic metabolism of DHA. Therefore, multiple aspects of lipid",4_21,Dietary Supplementation with n-3 Polyunsaturated Fatty Acids Delays the Phenotypic Manifestation of Krabbe Disease and Partially Restores Lipid Mediator Production in the Brain—Study in a Mouse Model of the Disease,28 6 2024,,Krabbe_Disease
"of DHA. Therefore, multiple aspects of lipid oxidative metabolism are presumably implicated in the symptoms of KD and might be differently modulated by n-3 PUFA supplementation. Increases in pro-resolving mediators and beneficial changes in circulating pro-resolving mediators were found as results of a clinical trial after marine n-3 fatty acid supplementation [<xref rid=""B39-ijms-25-07149"" ref-type=""bibr"">39</xref>]. Moreover, nutritional supplementation with n-3 PUFAs and antioxidants was also associated",4_22,Dietary Supplementation with n-3 Polyunsaturated Fatty Acids Delays the Phenotypic Manifestation of Krabbe Disease and Partially Restores Lipid Mediator Production in the Brain—Study in a Mouse Model of the Disease,28 6 2024,,Krabbe_Disease
"n-3 PUFAs and antioxidants was also associated with good maintenance of cognitive status in patients with mild cognitive impairment [<xref rid=""B40-ijms-25-07149"" ref-type=""bibr"">40</xref>,<xref rid=""B41-ijms-25-07149"" ref-type=""bibr"">41</xref>]. The relevance of n-3 PUFA supplementation in the management of chronic inflammatory pathologies was documented in several different clinical conditions, even in conditions where the intake of fatty acids must be limited, such as, for example, in hepatic steatosis",4_23,Dietary Supplementation with n-3 Polyunsaturated Fatty Acids Delays the Phenotypic Manifestation of Krabbe Disease and Partially Restores Lipid Mediator Production in the Brain—Study in a Mouse Model of the Disease,28 6 2024,,Krabbe_Disease
"such as, for example, in hepatic steatosis [<xref rid=""B42-ijms-25-07149"" ref-type=""bibr"">42</xref>]. This reinforces the concept that the supplementation with n-3 PUFAs is to be considered as a supply of fatty acids able to support the resolution of inflammation, determining a resolvin up-regulation. Thus, also in the investigated Tw model, where a specific fatty acid profile was detected in the brain and serum of Tw mice [<xref rid=""B35-ijms-25-07149"" ref-type=""bibr"">35</xref>], the n-3 PUFA",4_24,Dietary Supplementation with n-3 Polyunsaturated Fatty Acids Delays the Phenotypic Manifestation of Krabbe Disease and Partially Restores Lipid Mediator Production in the Brain—Study in a Mouse Model of the Disease,28 6 2024,,Krabbe_Disease
"ref-type=""bibr"">35</xref>], the n-3 PUFA supplementation is here demonstrated to be useful in modulating the severity of the disease, the oxidative lipid damage and the production of a mediator for the resolution of inflammation. It is suggested that therapeutic approaches that promote the resolution of inflammation rather than block inflammation (anti-inflammatories) may be warranted [<xref rid=""B43-ijms-25-07149"" ref-type=""bibr"">43</xref>,<xref rid=""B44-ijms-25-07149"" ref-type=""bibr"">44</xref>], and in",4_25,Dietary Supplementation with n-3 Polyunsaturated Fatty Acids Delays the Phenotypic Manifestation of Krabbe Disease and Partially Restores Lipid Mediator Production in the Brain—Study in a Mouse Model of the Disease,28 6 2024,,Krabbe_Disease
"ref-type=""bibr"">44</xref>], and in this sense, there are numerous efforts to target production or receptors of the specialized pro-resolving mediators, among which RvD1 is included. RvD1 has also already been shown to resolve neuroinflammation after brain damage, and in hemicerebellectomy, a reduced ability to produce RvD1 has been reported [<xref rid=""B45-ijms-25-07149"" ref-type=""bibr"">45</xref>]. Moreover, RvD1 treatment was found to ameliorate neuroinflammation and improve neurological function",4_26,Dietary Supplementation with n-3 Polyunsaturated Fatty Acids Delays the Phenotypic Manifestation of Krabbe Disease and Partially Restores Lipid Mediator Production in the Brain—Study in a Mouse Model of the Disease,28 6 2024,,Krabbe_Disease
"and improve neurological function neuroinflammation in different conditions [<xref rid=""B46-ijms-25-07149"" ref-type=""bibr"">46</xref>,<xref rid=""B47-ijms-25-07149"" ref-type=""bibr"">47</xref>]. The relevance of specialized pro-resolving mediators from fatty acid oxidation in neurological and psychiatric disorders has been deeply investigated, beneficial effects have been reported, and therapeutic strategies have been suggested [<xref rid=""B48-ijms-25-07149"" ref-type=""bibr"">48</xref>]. In KD, neuroinflammation",4_27,Dietary Supplementation with n-3 Polyunsaturated Fatty Acids Delays the Phenotypic Manifestation of Krabbe Disease and Partially Restores Lipid Mediator Production in the Brain—Study in a Mouse Model of the Disease,28 6 2024,,Krabbe_Disease
"In KD, neuroinflammation is observed as in most leukodystrophies and coincides with white matter pathology [<xref rid=""B49-ijms-25-07149"" ref-type=""bibr"">49</xref>]. Thus, it is not surprising that there is an interest in the role of dietary PUFAs in ameliorating such diseases through the production of useful lipid mediators. Pharmacological combined protocols, including n-3 PUFAs and pro-resolving mediators, could be able to interact at multiple levels in the cross-talk of the pathophysiological",4_28,Dietary Supplementation with n-3 Polyunsaturated Fatty Acids Delays the Phenotypic Manifestation of Krabbe Disease and Partially Restores Lipid Mediator Production in the Brain—Study in a Mouse Model of the Disease,28 6 2024,,Krabbe_Disease
"in the cross-talk of the pathophysiological mechanisms. The ability of lipids to cross the blood-brain barrier, as well as the availability of a suitable vehicle to deliver drugs to treat neurological disorders [<xref rid=""B50-ijms-25-07149"" ref-type=""bibr"">50</xref>], can support the increase in total n-3 PUFA levels shown in the brain tissue of the experimental model investigated. The ability of n-3 PUFAs to cross the blood-brain barrier has been investigated, and it was shown that in aging, the",4_29,Dietary Supplementation with n-3 Polyunsaturated Fatty Acids Delays the Phenotypic Manifestation of Krabbe Disease and Partially Restores Lipid Mediator Production in the Brain—Study in a Mouse Model of the Disease,28 6 2024,,Krabbe_Disease
"investigated, and it was shown that in aging, the modification of the metabolism of peripheral plasma n-3 PUFAs modifies the amount of n-3 PUFAs available for uptake by the brain [<xref rid=""B51-ijms-25-07149"" ref-type=""bibr"">51</xref>]. To underline the possibility of using supplementation with n-3 PUFAs in neurological diseases, appear to be relevant the studies concerning the effects of n-3 PUFA supplementation in a further genetic neurological disease. In an early stage of Rett syndrome (OMIM#312750),",4_30,Dietary Supplementation with n-3 Polyunsaturated Fatty Acids Delays the Phenotypic Manifestation of Krabbe Disease and Partially Restores Lipid Mediator Production in the Brain—Study in a Mouse Model of the Disease,28 6 2024,,Krabbe_Disease
"In an early stage of Rett syndrome (OMIM#312750), oral supplementation with fish oil (containing DHA and EPA) of patients led to a significant reduction in clinical severity along with a significant decrease in oxidative damage of fatty acids and the reduction of fatty acid anomalies present in the erythrocyte membranes of subjects affected by Rett syndrome [<xref rid=""B1-ijms-25-07149"" ref-type=""bibr"">1</xref>,<xref rid=""B2-ijms-25-07149"" ref-type=""bibr"">2</xref>].  The total amount of n-3 PUFAs in the",4_31,Dietary Supplementation with n-3 Polyunsaturated Fatty Acids Delays the Phenotypic Manifestation of Krabbe Disease and Partially Restores Lipid Mediator Production in the Brain—Study in a Mouse Model of the Disease,28 6 2024,,Krabbe_Disease
"The total amount of n-3 PUFAs in the brain tissue of the KD mouse model is related to disease severity, PUFA peroxidation, and the production of pro-resolving lipid mediators (<xref rid=""ijms-25-07149-f006"" ref-type=""fig"">Figure 6</xref>). Dietary supplementation with n-3 PUFA slows the phenotypic manifestation of the disease and rebalances fatty acid oxidative processes by decreasing free radical-induced oxidation and increasing enzymatic oxidation, leading to the production of bioactive lipid mediators",4_32,Dietary Supplementation with n-3 Polyunsaturated Fatty Acids Delays the Phenotypic Manifestation of Krabbe Disease and Partially Restores Lipid Mediator Production in the Brain—Study in a Mouse Model of the Disease,28 6 2024,,Krabbe_Disease
to the production of bioactive lipid mediators that play an important role in regulating inflammatory processes.,4_33,Dietary Supplementation with n-3 Polyunsaturated Fatty Acids Delays the Phenotypic Manifestation of Krabbe Disease and Partially Restores Lipid Mediator Production in the Brain—Study in a Mouse Model of the Disease,28 6 2024,,Krabbe_Disease
"Late‐onset Krabbe disease presenting as spastic paraplegia – implications of <styled-content style=""fixed-case"" toggle=""no"">GCase</styled-content> and <styled-content style=""fixed-case"" toggle=""no"">CTSB</styled-content>/D Globoid cell leukodystrophy or Krabbe disease (KD) [MIM * 245200] is a rare autosomal recessive neurodegenerative disorder occurring in approx. 1 to 100,000–400,000 births.<xref rid=""acn352078-bib-0001"" ref-type=""bibr"">
<sup>1</sup>
</xref>, <xref rid=""acn352078-bib-0002"" ref-type=""bibr"">",5_0,"Late‐onset Krabbe disease presenting as spastic paraplegia – implications of <styled-content style=""fixed-case"" toggle=""no"">GCase</styled-content> and <styled-content style=""fixed-case"" toggle=""no"">CTSB</styled-content>/D",04 6 2024,,Krabbe_Disease
"<sup>2</sup>
</xref> The diagnosis of KD can be challenging due to the broad spectrum of clinical features and highly variable disease onset. To date, more than 340 variants in the <italic toggle=""yes"">GALC</italic> gene, encoding the lysosomal enzyme β‐galactocerebrosidase (GALC), have been identified for KD<xref rid=""acn352078-bib-0003"" ref-type=""bibr"">
<sup>3</sup>",5_1,"Late‐onset Krabbe disease presenting as spastic paraplegia – implications of <styled-content style=""fixed-case"" toggle=""no"">GCase</styled-content> and <styled-content style=""fixed-case"" toggle=""no"">CTSB</styled-content>/D",04 6 2024,,Krabbe_Disease
"<sup>3</sup>
</xref>. While the majority of cases is characterized by an onset before 6 months of age (early‐infantile KD) and a fatal outcome within 2 years, also later onset during infancy (late‐infantile KD) with a similarly rapid disease course are known.<xref rid=""acn352078-bib-0004"" ref-type=""bibr"">
<sup>4</sup>",5_2,"Late‐onset Krabbe disease presenting as spastic paraplegia – implications of <styled-content style=""fixed-case"" toggle=""no"">GCase</styled-content> and <styled-content style=""fixed-case"" toggle=""no"">CTSB</styled-content>/D",04 6 2024,,Krabbe_Disease
"<sup>4</sup>
</xref> Furthermore, with the availability of enzymatic and genetic testing, the phenotypic spectrum was widened, as the diagnosis of adolescent/adult onset cases remains undetected less often.<xref rid=""acn352078-bib-0005"" ref-type=""bibr"">
<sup>5</sup>
</xref> These late‐onset KD (LOKD) cases may present with only slight developmental regression and/or motor impairment including lower limb spasticity or reduced fine motor skills.<xref rid=""acn352078-bib-0006"" ref-type=""bibr"">
<sup>6</sup>",5_3,"Late‐onset Krabbe disease presenting as spastic paraplegia – implications of <styled-content style=""fixed-case"" toggle=""no"">GCase</styled-content> and <styled-content style=""fixed-case"" toggle=""no"">CTSB</styled-content>/D",04 6 2024,,Krabbe_Disease
"<sup>6</sup>
</xref> Some patients may present as late as within the fourth decade with initial clinical features resembling spastic paraparesis.<xref rid=""acn352078-bib-0007"" ref-type=""bibr"">
<sup>7</sup>",5_4,"Late‐onset Krabbe disease presenting as spastic paraplegia – implications of <styled-content style=""fixed-case"" toggle=""no"">GCase</styled-content> and <styled-content style=""fixed-case"" toggle=""no"">CTSB</styled-content>/D",04 6 2024,,Krabbe_Disease
"<sup>7</sup>
</xref> Interestingly, there is only a limited genotype–phenotype correlation. Early‐infantile cases are often caused by loss of function variants and consequently exhibit severely diminished GALC activity, leading to generalized neuronal demyelination and overall globoid cell pathology.<xref rid=""acn352078-bib-0008"" ref-type=""bibr"">
<sup>8</sup>",5_5,"Late‐onset Krabbe disease presenting as spastic paraplegia – implications of <styled-content style=""fixed-case"" toggle=""no"">GCase</styled-content> and <styled-content style=""fixed-case"" toggle=""no"">CTSB</styled-content>/D",04 6 2024,,Krabbe_Disease
"<sup>8</sup>
</xref> Adolescent/adult onset cases, in turn, were associated with a highly variable residual enzyme activity and a variable age at onset as late as in the seventh decade.<xref rid=""acn352078-bib-0006"" ref-type=""bibr"">
<sup>6</sup>
</xref> Hematopoietic stem cell transplantation is the only therapeutic option to date, but only performed in presymptomatic or early stages of the disease course.<xref rid=""acn352078-bib-0008"" ref-type=""bibr"">
<sup>8</sup>
</xref>",5_6,"Late‐onset Krabbe disease presenting as spastic paraplegia – implications of <styled-content style=""fixed-case"" toggle=""no"">GCase</styled-content> and <styled-content style=""fixed-case"" toggle=""no"">CTSB</styled-content>/D",04 6 2024,,Krabbe_Disease
"<sup>8</sup>
</xref>
 GALC is a glycoside hydrolase that catalyzes the hydrolysis of galactosylceramide to β‐galactose and ceramide, and of galactosylsphingosine (psychosine) to β‐galactose and sphingosine<xref rid=""acn352078-bib-0009"" ref-type=""bibr"">
<sup>9</sup>
</xref>, <xref rid=""acn352078-bib-0010"" ref-type=""bibr"">
<sup>10</sup>
</xref>, <xref rid=""acn352078-bib-0011"" ref-type=""bibr"">
<sup>11</sup>",5_7,"Late‐onset Krabbe disease presenting as spastic paraplegia – implications of <styled-content style=""fixed-case"" toggle=""no"">GCase</styled-content> and <styled-content style=""fixed-case"" toggle=""no"">CTSB</styled-content>/D",04 6 2024,,Krabbe_Disease
"<sup>11</sup>
</xref> (Fig. <xref rid=""acn352078-fig-0001"" ref-type=""fig"">1</xref>). Dysfunctional GALC or reduced enzymatic activity leads to accumulation of nondegraded galactosylceramide and cytotoxic psychosine within the lysosome.<xref rid=""acn352078-bib-0012"" ref-type=""bibr"">
<sup>12</sup>
</xref>, <xref rid=""acn352078-bib-0013"" ref-type=""bibr"">
<sup>13</sup>",5_8,"Late‐onset Krabbe disease presenting as spastic paraplegia – implications of <styled-content style=""fixed-case"" toggle=""no"">GCase</styled-content> and <styled-content style=""fixed-case"" toggle=""no"">CTSB</styled-content>/D",04 6 2024,,Krabbe_Disease
"</xref> Hence, KD belongs to the group of lysosomal storage disorders (LSDs). The lysosomal storage phenotype of KD is accompanied by demyelination in the central and peripheral nervous system, but also apoptotic and inflammatory responses contribute to KD development and progression. Common clinical hallmarks of a neuropathological KD diagnosis are gigantic polynuclear glia cells, also termed globoid cells, white matter demyelination, and signs of axonal and neuronal degeneration.<xref",5_9,"Late‐onset Krabbe disease presenting as spastic paraplegia – implications of <styled-content style=""fixed-case"" toggle=""no"">GCase</styled-content> and <styled-content style=""fixed-case"" toggle=""no"">CTSB</styled-content>/D",04 6 2024,,Krabbe_Disease
"signs of axonal and neuronal degeneration.<xref rid=""acn352078-bib-0014"" ref-type=""bibr"">",5_10,"Late‐onset Krabbe disease presenting as spastic paraplegia – implications of <styled-content style=""fixed-case"" toggle=""no"">GCase</styled-content> and <styled-content style=""fixed-case"" toggle=""no"">CTSB</styled-content>/D",04 6 2024,,Krabbe_Disease
"<sup>14</sup>
</xref>, <xref rid=""acn352078-bib-0015"" ref-type=""bibr"">
<sup>15</sup>
</xref>, <xref rid=""acn352078-bib-0016"" ref-type=""bibr"">
<sup>16</sup>
</xref>, <xref rid=""acn352078-bib-0017"" ref-type=""bibr"">
<sup>17</sup>
</xref>, <xref rid=""acn352078-bib-0018"" ref-type=""bibr"">
<sup>18</sup>
</xref>",5_11,"Late‐onset Krabbe disease presenting as spastic paraplegia – implications of <styled-content style=""fixed-case"" toggle=""no"">GCase</styled-content> and <styled-content style=""fixed-case"" toggle=""no"">CTSB</styled-content>/D",04 6 2024,,Krabbe_Disease
"<sup>18</sup>
</xref>
 Functional overlap of GALC is seen with the lysosomal enzymes β‐glucocerebrosidase (GCase) and acid sphingomyelinase (ASM), as they all metabolize their substrates (glucosylceramide as well as sphingomyelin) to ceramide (Fig. <xref rid=""acn352078-fig-0001"" ref-type=""fig"">1</xref>). Dysfunction of any of the three enzymes leads to a lack of ceramide and impairment of neuronal cell function.<xref rid=""acn352078-bib-0019"" ref-type=""bibr"">
<sup>19</sup>",5_12,"Late‐onset Krabbe disease presenting as spastic paraplegia – implications of <styled-content style=""fixed-case"" toggle=""no"">GCase</styled-content> and <styled-content style=""fixed-case"" toggle=""no"">CTSB</styled-content>/D",04 6 2024,,Krabbe_Disease
"<sup>19</sup>
</xref>, <xref rid=""acn352078-bib-0020"" ref-type=""bibr"">
<sup>20</sup>
</xref>, <xref rid=""acn352078-bib-0021"" ref-type=""bibr"">
<sup>21</sup>
</xref> Pathogenic variants of <italic toggle=""yes"">GBA1</italic> (encoding GCase) are known to cause Gaucher's disease, the most common LSD, and have also been described as one of the highest genetic risk factors for the development of the neurodegenerative disorder Parkinson's disease (PD).<xref rid=""acn352078-bib-0022"" ref-type=""bibr"">
<sup>22</sup>",5_13,"Late‐onset Krabbe disease presenting as spastic paraplegia – implications of <styled-content style=""fixed-case"" toggle=""no"">GCase</styled-content> and <styled-content style=""fixed-case"" toggle=""no"">CTSB</styled-content>/D",04 6 2024,,Krabbe_Disease
"<sup>22</sup>
</xref> Deficiency of ASM, caused by mutations in the <italic toggle=""yes"">SMPD1</italic> gene, leads to Niemann–Pick diseases types A or B (NPA/B), as sphingomyelin accumulates in the lysosomes of neurons, liver, spleen, and other organs.<xref rid=""acn352078-bib-0020"" ref-type=""bibr"">
<sup>20</sup>",5_14,"Late‐onset Krabbe disease presenting as spastic paraplegia – implications of <styled-content style=""fixed-case"" toggle=""no"">GCase</styled-content> and <styled-content style=""fixed-case"" toggle=""no"">CTSB</styled-content>/D",04 6 2024,,Krabbe_Disease
"<sup>20</sup>
</xref> Importantly, recent genome‐wide association studies also associated <italic toggle=""yes"">GALC</italic> with PD among other genes encoding lysosomal enzymes such as <italic toggle=""yes"">CTSB</italic> and <italic toggle=""yes"">CTSD</italic>.<xref rid=""acn352078-bib-0023"" ref-type=""bibr"">
<sup>23</sup>
</xref>, <xref rid=""acn352078-bib-0024"" ref-type=""bibr"">
<sup>24</sup>
</xref>, <xref rid=""acn352078-bib-0025"" ref-type=""bibr"">
<sup>25</sup>",5_15,"Late‐onset Krabbe disease presenting as spastic paraplegia – implications of <styled-content style=""fixed-case"" toggle=""no"">GCase</styled-content> and <styled-content style=""fixed-case"" toggle=""no"">CTSB</styled-content>/D",04 6 2024,,Krabbe_Disease
"<sup>25</sup>
</xref>, <xref rid=""acn352078-bib-0026"" ref-type=""bibr"">
<sup>26</sup>
</xref>, <xref rid=""acn352078-bib-0027"" ref-type=""bibr"">
<sup>27</sup>
</xref>",5_16,"Late‐onset Krabbe disease presenting as spastic paraplegia – implications of <styled-content style=""fixed-case"" toggle=""no"">GCase</styled-content> and <styled-content style=""fixed-case"" toggle=""no"">CTSB</styled-content>/D",04 6 2024,,Krabbe_Disease
"In this study, we clinically characterize a case of LOKD carrying a deletion and a missense <italic toggle=""yes"">GALC</italic> variant in compound heterozygous state. Additionally, we perform biochemical and cellular analyses to evaluate the interplay of GALC with other components of the lysosomal pathway in order to gain a better understanding of the molecular disease mechanisms.   In the present report, we demonstrate a comprehensive approach validating the pathogenicity of the genotype in a patient",5_17,"Late‐onset Krabbe disease presenting as spastic paraplegia – implications of <styled-content style=""fixed-case"" toggle=""no"">GCase</styled-content> and <styled-content style=""fixed-case"" toggle=""no"">CTSB</styled-content>/D",04 6 2024,,Krabbe_Disease
"the pathogenicity of the genotype in a patient with a late‐onset spastic paraplegia phenotype. Besides in‐depth clinical and neuroradiological phenotyping, we established functional evidence to confirm the pathogenicity based on <italic toggle=""yes"">in vitro</italic> GALC enzyme activity and a histopathological characterization of the lysosomal function. We uncovered the compromised lysosomal activity of GCase, CTSB, and CTSD in live cell fibroblast lysosomes (Fig. <xref rid=""acn352078-fig-0005""",5_18,"Late‐onset Krabbe disease presenting as spastic paraplegia – implications of <styled-content style=""fixed-case"" toggle=""no"">GCase</styled-content> and <styled-content style=""fixed-case"" toggle=""no"">CTSB</styled-content>/D",04 6 2024,,Krabbe_Disease
"lysosomes (Fig. <xref rid=""acn352078-fig-0005"" ref-type=""fig"">5‐DF</xref>) that may further contribute to a lysosomal dysregulation. Noteworthy, no decreased activity was observed in leukocyte homogenates, thus highlighting the importance of analyzing in particular the lysosomal activity of different enzymes besides GALC in live cell assays in KD studies. Determination of GALC activity levels from fibroblasts instead of leukocytes (Fig. <xref rid=""acn352078-fig-0005"" ref-type=""fig"">2H,J</xref>) showed",5_19,"Late‐onset Krabbe disease presenting as spastic paraplegia – implications of <styled-content style=""fixed-case"" toggle=""no"">GCase</styled-content> and <styled-content style=""fixed-case"" toggle=""no"">CTSB</styled-content>/D",04 6 2024,,Krabbe_Disease
"ref-type=""fig"">2H,J</xref>) showed promising, potentially more robust differentiation between KD and control cells, thus, these methods might be considered for future studies. As large C‐terminal deletions in the <italic toggle=""yes"">GALC</italic> gene cause a loss of enzyme activity,<xref rid=""acn352078-bib-0045"" ref-type=""bibr"">",5_20,"Late‐onset Krabbe disease presenting as spastic paraplegia – implications of <styled-content style=""fixed-case"" toggle=""no"">GCase</styled-content> and <styled-content style=""fixed-case"" toggle=""no"">CTSB</styled-content>/D",04 6 2024,,Krabbe_Disease
<sup>45</sup>,5_21,"Late‐onset Krabbe disease presenting as spastic paraplegia – implications of <styled-content style=""fixed-case"" toggle=""no"">GCase</styled-content> and <styled-content style=""fixed-case"" toggle=""no"">CTSB</styled-content>/D",04 6 2024,,Krabbe_Disease
"</xref> the reduced GALC activity shown in Figure <xref rid=""acn352078-fig-0002"" ref-type=""fig"">2G–J</xref> most likely represents residual activity of the c.334A>G missense allele. A previous functional GALC expression study conducted on this variant using COS1 cells observed reduced GALC activity compared to wt‐GALC, with GALC activity even more significantly reduced when an additional <italic toggle=""yes"">GALC</italic> missense variant was concurrently present.<xref rid=""acn352078-bib-0051""",5_22,"Late‐onset Krabbe disease presenting as spastic paraplegia – implications of <styled-content style=""fixed-case"" toggle=""no"">GCase</styled-content> and <styled-content style=""fixed-case"" toggle=""no"">CTSB</styled-content>/D",04 6 2024,,Krabbe_Disease
"present.<xref rid=""acn352078-bib-0051"" ref-type=""bibr"">",5_23,"Late‐onset Krabbe disease presenting as spastic paraplegia – implications of <styled-content style=""fixed-case"" toggle=""no"">GCase</styled-content> and <styled-content style=""fixed-case"" toggle=""no"">CTSB</styled-content>/D",04 6 2024,,Krabbe_Disease
"<sup>51</sup>
</xref> Noteworthy, a report of an early‐onset case carrying the homozygous c.334A>G variant led to the conclusion that this variant is sufficient for KD development.<xref rid=""acn352078-bib-0052"" ref-type=""bibr"">
<sup>52</sup>
</xref> All other cases describe the c.334A>G variant as insufficient in provoking KD alone and LOKD cases develop only in the presence of a second pathogenic variant.<xref rid=""acn352078-bib-0051"" ref-type=""bibr"">
<sup>51</sup>",5_24,"Late‐onset Krabbe disease presenting as spastic paraplegia – implications of <styled-content style=""fixed-case"" toggle=""no"">GCase</styled-content> and <styled-content style=""fixed-case"" toggle=""no"">CTSB</styled-content>/D",04 6 2024,,Krabbe_Disease
"<sup>51</sup>
</xref>, <xref rid=""acn352078-bib-0052"" ref-type=""bibr"">
<sup>52</sup>
</xref>, <xref rid=""acn352078-bib-0053"" ref-type=""bibr"">
<sup>53</sup>",5_25,"Late‐onset Krabbe disease presenting as spastic paraplegia – implications of <styled-content style=""fixed-case"" toggle=""no"">GCase</styled-content> and <styled-content style=""fixed-case"" toggle=""no"">CTSB</styled-content>/D",04 6 2024,,Krabbe_Disease
"</xref> Four homozygous carriers (0.25%) are present in GnomAD [14‐88452941‐T‐C, accessed 25Mar2024], but it is well possible that some of these were in the presymptomatic stage of KD. As described, we found reduced GALC activity in the presented patient who carried one loss of function variant, leaving the c.334A>G variant responsible for all residual GALC activity. The clinical constellation in the presented index patient with a relatively late and mild KD progression further supports the notion that",5_26,"Late‐onset Krabbe disease presenting as spastic paraplegia – implications of <styled-content style=""fixed-case"" toggle=""no"">GCase</styled-content> and <styled-content style=""fixed-case"" toggle=""no"">CTSB</styled-content>/D",04 6 2024,,Krabbe_Disease
"KD progression further supports the notion that homozygous c.334A>G variant causes mild GALC impairment, but is not sufficient to induce an early‐onset KD phenotype. The high conservation of Thr112 in GALC and nearby residues among different species suggests their importance for protein function. Consistently, missense variants c.331G>A (p.Gly111Ser), c.332G>A (p.Gly111Asp), and c.349A>G (p.Met117Val) close by are listed as (likely) pathogenic (VCV001163373.7, VCV000211058.17 and VCV000092504.13). The loss",5_27,"Late‐onset Krabbe disease presenting as spastic paraplegia – implications of <styled-content style=""fixed-case"" toggle=""no"">GCase</styled-content> and <styled-content style=""fixed-case"" toggle=""no"">CTSB</styled-content>/D",04 6 2024,,Krabbe_Disease
"VCV000211058.17 and VCV000092504.13). The loss of at least one hydrogen bond and potentially other interaction sites between Thr112 and its surrounding structure could impair protein stability and affect the interaction with substrates, that is, by increased flexibility or conformational changes in the substrate‐binding area. Furthermore, the surface charge of proteins is pH dependent, thus stability and flexibility of GALC depend on the environment. Amino acids such as aspartic acid, glutamic acid, and",5_28,"Late‐onset Krabbe disease presenting as spastic paraplegia – implications of <styled-content style=""fixed-case"" toggle=""no"">GCase</styled-content> and <styled-content style=""fixed-case"" toggle=""no"">CTSB</styled-content>/D",04 6 2024,,Krabbe_Disease
"acids such as aspartic acid, glutamic acid, and histidine may undergo changes in their protonation state depending on the pH level,<xref rid=""acn352078-bib-0054"" ref-type=""bibr"">",5_29,"Late‐onset Krabbe disease presenting as spastic paraplegia – implications of <styled-content style=""fixed-case"" toggle=""no"">GCase</styled-content> and <styled-content style=""fixed-case"" toggle=""no"">CTSB</styled-content>/D",04 6 2024,,Krabbe_Disease
<sup>54</sup>,5_30,"Late‐onset Krabbe disease presenting as spastic paraplegia – implications of <styled-content style=""fixed-case"" toggle=""no"">GCase</styled-content> and <styled-content style=""fixed-case"" toggle=""no"">CTSB</styled-content>/D",04 6 2024,,Krabbe_Disease
"</xref> which can also affect the glutamic acids involved in substrate binding (Glu198 and Glu274). The ConSurf estimation suggests several residues in close proximity to Thr112 as highly conserved and essential for the protein structure (Fig. <xref rid=""acn352078-supitem-0001"" ref-type=""supplementary-material"">S1</xref>). For lysosomal proteins with highest activities at low pH, alterations on the protein surface – especially near the substrate‐binding surface – can potentially cause stronger effects when",5_31,"Late‐onset Krabbe disease presenting as spastic paraplegia – implications of <styled-content style=""fixed-case"" toggle=""no"">GCase</styled-content> and <styled-content style=""fixed-case"" toggle=""no"">CTSB</styled-content>/D",04 6 2024,,Krabbe_Disease
"– can potentially cause stronger effects when translocated to the lysosome.<xref rid=""acn352078-bib-0039"" ref-type=""bibr"">",5_32,"Late‐onset Krabbe disease presenting as spastic paraplegia – implications of <styled-content style=""fixed-case"" toggle=""no"">GCase</styled-content> and <styled-content style=""fixed-case"" toggle=""no"">CTSB</styled-content>/D",04 6 2024,,Krabbe_Disease
"<sup>39</sup>
</xref>
 LOKD patients can lack the typical hallmarks in magnetic resonance imaging, like cortical atrophy and white matter changes,<xref rid=""acn352078-bib-0055"" ref-type=""bibr"">
<sup>55</sup>",5_33,"Late‐onset Krabbe disease presenting as spastic paraplegia – implications of <styled-content style=""fixed-case"" toggle=""no"">GCase</styled-content> and <styled-content style=""fixed-case"" toggle=""no"">CTSB</styled-content>/D",04 6 2024,,Krabbe_Disease
"</xref> which makes reliable tests of enzymatic activity more important in order to confirm pathogenicity of <italic toggle=""yes"">GALC</italic> variants. Albeit we did not perform a direct comparison of both methods of GALC enzyme determination, our findings support the notion that RIA assays (Fig. <xref rid=""acn352078-fig-0002"" ref-type=""fig"">2I,J</xref>) might have a superior sensitivity to test GALC enzymatic activity in comparison with artificial substrate testing,<xref rid=""acn352078-bib-0046""",5_34,"Late‐onset Krabbe disease presenting as spastic paraplegia – implications of <styled-content style=""fixed-case"" toggle=""no"">GCase</styled-content> and <styled-content style=""fixed-case"" toggle=""no"">CTSB</styled-content>/D",04 6 2024,,Krabbe_Disease
"substrate testing,<xref rid=""acn352078-bib-0046"" ref-type=""bibr"">",5_35,"Late‐onset Krabbe disease presenting as spastic paraplegia – implications of <styled-content style=""fixed-case"" toggle=""no"">GCase</styled-content> and <styled-content style=""fixed-case"" toggle=""no"">CTSB</styled-content>/D",04 6 2024,,Krabbe_Disease
"<sup>46</sup>
</xref> which had shown activity levels within the normal range (Fig. <xref rid=""acn352078-fig-0002"" ref-type=""fig"">2G</xref>). This is due to conventional fluorogenic substrates lacking specificity toward GALC and producing unspecific background signal via cleavage through β‐galactosidases.<xref rid=""acn352078-bib-0056"" ref-type=""bibr"">
<sup>56</sup>",5_36,"Late‐onset Krabbe disease presenting as spastic paraplegia – implications of <styled-content style=""fixed-case"" toggle=""no"">GCase</styled-content> and <styled-content style=""fixed-case"" toggle=""no"">CTSB</styled-content>/D",04 6 2024,,Krabbe_Disease
"</xref> Furthermore, fibroblasts might provide a more powerful resource when testing for enzymatic activity of lysosomal enzymes than leukocytes (Fig. <xref rid=""acn352078-fig-0002"" ref-type=""fig"">2H,J</xref>). Nevertheless, additional systematic analyses of KD patients and controls are necessary to evaluate both (fibroblast and leukocyte) assays' exact sensitivity and specificity. Additionally, determination of psychosine levels could be an additional way to test for pathogenicity of <italic",5_37,"Late‐onset Krabbe disease presenting as spastic paraplegia – implications of <styled-content style=""fixed-case"" toggle=""no"">GCase</styled-content> and <styled-content style=""fixed-case"" toggle=""no"">CTSB</styled-content>/D",04 6 2024,,Krabbe_Disease
"way to test for pathogenicity of <italic toggle=""yes"">GALC</italic> variants<xref rid=""acn352078-bib-0057"" ref-type=""bibr"">",5_38,"Late‐onset Krabbe disease presenting as spastic paraplegia – implications of <styled-content style=""fixed-case"" toggle=""no"">GCase</styled-content> and <styled-content style=""fixed-case"" toggle=""no"">CTSB</styled-content>/D",04 6 2024,,Krabbe_Disease
"<sup>57</sup>
</xref> for early‐onset Krabbe disease; however, data in late‐onset Krabbe cases are sparse. As disease severity has been shown to be linked to the cellular localization of the GALC enzyme,<xref rid=""acn352078-bib-0058"" ref-type=""bibr"">
<sup>58</sup>",5_39,"Late‐onset Krabbe disease presenting as spastic paraplegia – implications of <styled-content style=""fixed-case"" toggle=""no"">GCase</styled-content> and <styled-content style=""fixed-case"" toggle=""no"">CTSB</styled-content>/D",04 6 2024,,Krabbe_Disease
"</xref> analysis of GALC activity in lysosomes might deliver further information of disease state and progression. Preliminary measurements of GALC activity in lysosome‐enriched fractions of fibroblasts showed a decrease of the residual activity in LOKD comparable to the enzyme activity measured in leukocytes (data not shown). Beside reductions in the GALC activity, we also observed a decrease in lysosomal GCase, CTSB, and CTSD activity in patient fibroblasts. Impaired GALC function might affect protein",5_40,"Late‐onset Krabbe disease presenting as spastic paraplegia – implications of <styled-content style=""fixed-case"" toggle=""no"">GCase</styled-content> and <styled-content style=""fixed-case"" toggle=""no"">CTSB</styled-content>/D",04 6 2024,,Krabbe_Disease
"Impaired GALC function might affect protein expression, maturation, and/or activity of other enzymes as an alternative way to compensate the lack of degradation products (i.e., ceramides, see Fig. <xref rid=""acn352078-fig-0001"" ref-type=""fig"">1</xref>). Protein and activity levels do not necessarily correlate with each other, as GCase expression was increased in LOKD whole‐cell lysates, yet not in lysosome‐enriched fractions (Fig. <xref rid=""acn352078-fig-0004"" ref-type=""fig"">4C,D</xref>), although",5_41,"Late‐onset Krabbe disease presenting as spastic paraplegia – implications of <styled-content style=""fixed-case"" toggle=""no"">GCase</styled-content> and <styled-content style=""fixed-case"" toggle=""no"">CTSB</styled-content>/D",04 6 2024,,Krabbe_Disease
"ref-type=""fig"">4C,D</xref>), although activity levels were significantly reduced in lysosomes (Fig. <xref rid=""acn352078-fig-0005"" ref-type=""fig"">5D</xref>). Similarly, no altered protein levels of CTSB and CTSD could be found in whole‐cell or lysosome‐enriched lysates (Fig. <xref rid=""acn352078-fig-0004"" ref-type=""fig"">4E–H</xref>); however, both revealed significantly reduced activity levels in LOKD fibroblasts (Fig. <xref rid=""acn352078-fig-0005"" ref-type=""fig"">5E,F</xref>). We hypothesize that",5_42,"Late‐onset Krabbe disease presenting as spastic paraplegia – implications of <styled-content style=""fixed-case"" toggle=""no"">GCase</styled-content> and <styled-content style=""fixed-case"" toggle=""no"">CTSB</styled-content>/D",04 6 2024,,Krabbe_Disease
"ref-type=""fig"">5E,F</xref>). We hypothesize that alterations in GCase, CTSB, and CTSD activity might be caused via pathway interactions of the reduced GALC activity, in particular via reduced ceramide levels. While GCase and GALC are essential players in ceramide metabolism, CTSB and CTSD are interaction partners of ceramides, for example, being altered by ceramides in their maturation, biogenesis, transport, and activity.<xref rid=""acn352078-bib-0059"" ref-type=""bibr"">",5_43,"Late‐onset Krabbe disease presenting as spastic paraplegia – implications of <styled-content style=""fixed-case"" toggle=""no"">GCase</styled-content> and <styled-content style=""fixed-case"" toggle=""no"">CTSB</styled-content>/D",04 6 2024,,Krabbe_Disease
"<sup>59</sup>
</xref>, <xref rid=""acn352078-bib-0060"" ref-type=""bibr"">
<sup>60</sup>
</xref>, <xref rid=""acn352078-bib-0061"" ref-type=""bibr"">
<sup>61</sup>
</xref>, <xref rid=""acn352078-bib-0062"" ref-type=""bibr"">
<sup>62</sup>
</xref>, <xref rid=""acn352078-bib-0063"" ref-type=""bibr"">
<sup>63</sup>
</xref> A reduced CTSB activity has been seen in the LSD Niemann–Pick type C1 and C2<xref rid=""acn352078-bib-0064"" ref-type=""bibr"">
<sup>64</sup>",5_44,"Late‐onset Krabbe disease presenting as spastic paraplegia – implications of <styled-content style=""fixed-case"" toggle=""no"">GCase</styled-content> and <styled-content style=""fixed-case"" toggle=""no"">CTSB</styled-content>/D",04 6 2024,,Krabbe_Disease
"<sup>64</sup>
</xref> (NPC1 and 2), which is caused by dysfunction of cholesterol transporters 1 and 2, leading to an impairment in the metabolization of cholesterol and sphingomyelin<xref rid=""acn352078-bib-0065"" ref-type=""bibr"">
<sup>65</sup>
</xref>, <xref rid=""acn352078-bib-0066"" ref-type=""bibr"">
<sup>66</sup>",5_45,"Late‐onset Krabbe disease presenting as spastic paraplegia – implications of <styled-content style=""fixed-case"" toggle=""no"">GCase</styled-content> and <styled-content style=""fixed-case"" toggle=""no"">CTSB</styled-content>/D",04 6 2024,,Krabbe_Disease
"<sup>66</sup>
</xref> (Fig. <xref rid=""acn352078-fig-0001"" ref-type=""fig"">1</xref>). Interestingly, sphingomyelin has been reported to inhibit cholesterol transfer in NPC2, which points to an important role of acid sphingomyelinase (ASM) for cholesterol exit.<xref rid=""acn352078-bib-0067"" ref-type=""bibr"">
<sup>67</sup>",5_46,"Late‐onset Krabbe disease presenting as spastic paraplegia – implications of <styled-content style=""fixed-case"" toggle=""no"">GCase</styled-content> and <styled-content style=""fixed-case"" toggle=""no"">CTSB</styled-content>/D",04 6 2024,,Krabbe_Disease
"<sup>67</sup>
</xref> Deficiency in ASM activity, important for the processing of sphingomyelin to ceramide (Fig. <xref rid=""acn352078-fig-0001"" ref-type=""fig"">1</xref>), is related to Niemann–Pick type A and B (NPA and NPB),<xref rid=""acn352078-bib-0068"" ref-type=""bibr"">
<sup>68</sup>
</xref> and genetic variants have been associated with PD.<xref rid=""acn352078-bib-0026"" ref-type=""bibr"">
<sup>26</sup>
</xref>, <xref rid=""acn352078-bib-0069"" ref-type=""bibr"">
<sup>69</sup>",5_47,"Late‐onset Krabbe disease presenting as spastic paraplegia – implications of <styled-content style=""fixed-case"" toggle=""no"">GCase</styled-content> and <styled-content style=""fixed-case"" toggle=""no"">CTSB</styled-content>/D",04 6 2024,,Krabbe_Disease
"<sup>69</sup>
</xref>, <xref rid=""acn352078-bib-0070"" ref-type=""bibr"">
<sup>70</sup>
</xref> Further, CTSB and CTSL deficiency was shown to cause NPC‐like cholesterol sequestration.<xref rid=""acn352078-bib-0071"" ref-type=""bibr"">
<sup>71</sup>
</xref>
 The here observed changes in lysosomal GCase, CTSD, and CTSB activity might be consequence of a decreased maturation rate of pro‐saposin to saposin C, which an essential co‐activator of GCase,<xref rid=""acn352078-bib-0060"" ref-type=""bibr"">
<sup>60</sup>",5_48,"Late‐onset Krabbe disease presenting as spastic paraplegia – implications of <styled-content style=""fixed-case"" toggle=""no"">GCase</styled-content> and <styled-content style=""fixed-case"" toggle=""no"">CTSB</styled-content>/D",04 6 2024,,Krabbe_Disease
"<sup>60</sup>
</xref> as outlined in Figure <xref rid=""acn352078-fig-0006"" ref-type=""fig"">6</xref>. CTSB and CTSD are able to cleave pro‐saposin into the mature homologs including saposin C, potentially leading to the lack of saposin C‐mediated GCase co‐activation.<xref rid=""acn352078-bib-0060"" ref-type=""bibr"">
<sup>60</sup>
</xref>, <xref rid=""acn352078-bib-0072"" ref-type=""bibr"">
<sup>72</sup>",5_49,"Late‐onset Krabbe disease presenting as spastic paraplegia – implications of <styled-content style=""fixed-case"" toggle=""no"">GCase</styled-content> and <styled-content style=""fixed-case"" toggle=""no"">CTSB</styled-content>/D",04 6 2024,,Krabbe_Disease
"</xref> Overall, this may result into a vicious cycle: a GALC‐dependent decrease in ceramide results in less active CTSB and CTSD, which leads to a reduced cathepsin‐dependent maturation of saposin C. Consequently, a reduction of the saposin C level is accompanied by reduced GCase activity, feeding into diminished ceramide production, as already being present due to GALC deficiency (Fig. <xref rid=""acn352078-fig-0006"" ref-type=""fig"">6</xref>). Our study supports this hypothesis as we saw significantly",5_50,"Late‐onset Krabbe disease presenting as spastic paraplegia – implications of <styled-content style=""fixed-case"" toggle=""no"">GCase</styled-content> and <styled-content style=""fixed-case"" toggle=""no"">CTSB</styled-content>/D",04 6 2024,,Krabbe_Disease
"supports this hypothesis as we saw significantly reduced lysosomal activities of GCase, CTSB, and CTSD next to the present GALC deficiency, thus indicating a relevant interconnection of lysosomal enzymes and their substrates. Measurement of intermediates and substrates in future studies should corroborate here described interactions. Importantly, several variants in <italic toggle=""yes"">GBA1</italic>, <italic toggle=""yes"">CTSB</italic>, and <italic toggle=""yes"">CTSD</italic> are either causal for PD or",5_51,"Late‐onset Krabbe disease presenting as spastic paraplegia – implications of <styled-content style=""fixed-case"" toggle=""no"">GCase</styled-content> and <styled-content style=""fixed-case"" toggle=""no"">CTSB</styled-content>/D",04 6 2024,,Krabbe_Disease
"are either causal for PD or genetic risk factors for PD.<xref rid=""acn352078-bib-0021"" ref-type=""bibr"">",5_52,"Late‐onset Krabbe disease presenting as spastic paraplegia – implications of <styled-content style=""fixed-case"" toggle=""no"">GCase</styled-content> and <styled-content style=""fixed-case"" toggle=""no"">CTSB</styled-content>/D",04 6 2024,,Krabbe_Disease
"<sup>21</sup>
</xref>, <xref rid=""acn352078-bib-0023"" ref-type=""bibr"">
<sup>23</sup>
</xref>, <xref rid=""acn352078-bib-0073"" ref-type=""bibr"">
<sup>73</sup>
</xref> Remarkably, single nucleotide polymorphisms affecting <italic toggle=""yes"">GALC</italic> gene expression have also been associated with increased PD risk.<xref rid=""acn352078-bib-0023"" ref-type=""bibr"">
<sup>23</sup>
</xref>, <xref rid=""acn352078-bib-0026"" ref-type=""bibr"">
<sup>26</sup>
</xref>, <xref rid=""acn352078-bib-0074"" ref-type=""bibr"">",5_53,"Late‐onset Krabbe disease presenting as spastic paraplegia – implications of <styled-content style=""fixed-case"" toggle=""no"">GCase</styled-content> and <styled-content style=""fixed-case"" toggle=""no"">CTSB</styled-content>/D",04 6 2024,,Krabbe_Disease
"<sup>74</sup>
</xref> At least one <italic toggle=""yes"">GALC</italic> variant with enhanced protein expression levels and activity has been associated to PD<xref rid=""acn352078-bib-0027"" ref-type=""bibr"">
<sup>27</sup>",5_54,"Late‐onset Krabbe disease presenting as spastic paraplegia – implications of <styled-content style=""fixed-case"" toggle=""no"">GCase</styled-content> and <styled-content style=""fixed-case"" toggle=""no"">CTSB</styled-content>/D",04 6 2024,,Krabbe_Disease
"<sup>27</sup>
</xref>. In contrast, <italic toggle=""yes"">GALC</italic> knockout in human pluripotent stem cell derived neurons did neither affect GCase activity, nor induce accumulation of α‐synuclein. It has to be mentioned that in this case GCase activity was determined from whole‐cell lysate and not in the lysosomal compartment. Moreover, only soluble α‐synuclein was determined in this study,<xref rid=""acn352078-bib-0027"" ref-type=""bibr"">
<sup>27</sup>",5_55,"Late‐onset Krabbe disease presenting as spastic paraplegia – implications of <styled-content style=""fixed-case"" toggle=""no"">GCase</styled-content> and <styled-content style=""fixed-case"" toggle=""no"">CTSB</styled-content>/D",04 6 2024,,Krabbe_Disease
"<sup>27</sup>
</xref> lacking the analysis of insoluble, disease‐associated α‐synuclein conformers. Using the Twitcher mouse model, carrying a single mutation abrogating GALC activity, α‐synuclein inclusions could be detected in brain regions correlated with early symptoms of KD, as well as in the brain of three infantile KD cases.<xref rid=""acn352078-bib-0075"" ref-type=""bibr"">
<sup>75</sup>",5_56,"Late‐onset Krabbe disease presenting as spastic paraplegia – implications of <styled-content style=""fixed-case"" toggle=""no"">GCase</styled-content> and <styled-content style=""fixed-case"" toggle=""no"">CTSB</styled-content>/D",04 6 2024,,Krabbe_Disease
"</xref> The accumulation of α‐synuclein over longer time periods can potentially be linked to LOKD and PD, especially as the variety of symptoms cannot easily be correlated with one or the other. Hence, biochemical, functional, and genetic analyses of <italic toggle=""yes"">GALC</italic> in PD patients are needed, to validate potential correlations between the molecular mechanisms of PD and LOKD. Also, more in‐depth biochemical analyses of pathology‐associated α‐synuclein conformers, which are a hallmark of",5_57,"Late‐onset Krabbe disease presenting as spastic paraplegia – implications of <styled-content style=""fixed-case"" toggle=""no"">GCase</styled-content> and <styled-content style=""fixed-case"" toggle=""no"">CTSB</styled-content>/D",04 6 2024,,Krabbe_Disease
"α‐synuclein conformers, which are a hallmark of PD – either by structure‐specific antibodies or via the analysis of insoluble α‐synuclein fractions – should support a more complete picture. As α‐synuclein accumulation has been shown to mediate a negative effect on the lysosomal trafficking of GCase, CTSB, and CSTD,<xref rid=""acn352078-bib-0076"" ref-type=""bibr"">",5_58,"Late‐onset Krabbe disease presenting as spastic paraplegia – implications of <styled-content style=""fixed-case"" toggle=""no"">GCase</styled-content> and <styled-content style=""fixed-case"" toggle=""no"">CTSB</styled-content>/D",04 6 2024,,Krabbe_Disease
"<sup>76</sup>
</xref>, <xref rid=""acn352078-bib-0077"" ref-type=""bibr"">
<sup>77</sup>
</xref> further triggering α‐synuclein accumulation,<xref rid=""acn352078-bib-0077"" ref-type=""bibr"">
<sup>77</sup>
</xref>, <xref rid=""acn352078-bib-0078"" ref-type=""bibr"">
<sup>78</sup>
</xref>, <xref rid=""acn352078-bib-0079"" ref-type=""bibr"">
<sup>79</sup>",5_59,"Late‐onset Krabbe disease presenting as spastic paraplegia – implications of <styled-content style=""fixed-case"" toggle=""no"">GCase</styled-content> and <styled-content style=""fixed-case"" toggle=""no"">CTSB</styled-content>/D",04 6 2024,,Krabbe_Disease
"</xref> it would be interesting to study this reciprocal interaction also in a <italic toggle=""yes"">GALC</italic>‐deficient background. However, as fibroblasts do not express α‐synuclein, the precise interplay of α‐synuclein and GALC dysfunction needs to be established in another cell system than utilized in this study. Overall, the present report highlights the difficulties in diagnosing late‐onset KD and the importance of performing RIA analysis of GALC activity in leukocytes or even fibroblasts.",5_60,"Late‐onset Krabbe disease presenting as spastic paraplegia – implications of <styled-content style=""fixed-case"" toggle=""no"">GCase</styled-content> and <styled-content style=""fixed-case"" toggle=""no"">CTSB</styled-content>/D",04 6 2024,,Krabbe_Disease
"GALC activity in leukocytes or even fibroblasts. Moreover, our data identify alterations of additional lysosomal enzymes (GCase, CTSB, and CTSD) that may also be implicated in KD pathogenesis by reduced functionality within the ceramide cycle, where maturation of cathepsins and subsequent cofactors, like saposin C, are essential to keep the ceramide metabolism in a physiological state. We recommend to include protein expression and activity analyses of lysosomal enzymes in future KD/GALC studies to find",5_61,"Late‐onset Krabbe disease presenting as spastic paraplegia – implications of <styled-content style=""fixed-case"" toggle=""no"">GCase</styled-content> and <styled-content style=""fixed-case"" toggle=""no"">CTSB</styled-content>/D",04 6 2024,,Krabbe_Disease
"enzymes in future KD/GALC studies to find more evidence about cross‐interactions in lysosome metabolism. R.M., M.R., and F.Z. wrote the manuscript and provided figures. R.M. J.D., A.W., and M.K. performed experiments. R.M., J.D., M.K., S.G., and L.L. performed data analysis. M.S. performed magnetic resonance imaging and analysis. U.H. performed exome analysis. R.M. and P.A. performed homology/structure modeling. P.A. performed TEM analysis. M.R. and F.Z. supervised the study and provided funding. All",5_62,"Late‐onset Krabbe disease presenting as spastic paraplegia – implications of <styled-content style=""fixed-case"" toggle=""no"">GCase</styled-content> and <styled-content style=""fixed-case"" toggle=""no"">CTSB</styled-content>/D",04 6 2024,,Krabbe_Disease
supervised the study and provided funding. All authors were involved in proof reading and preparation of the final version of the manuscript. The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.,5_63,"Late‐onset Krabbe disease presenting as spastic paraplegia – implications of <styled-content style=""fixed-case"" toggle=""no"">GCase</styled-content> and <styled-content style=""fixed-case"" toggle=""no"">CTSB</styled-content>/D",04 6 2024,,Krabbe_Disease
"Experiences of patients with metachromatic leukodystrophy, adrenoleukodystrophy, or Krabbe disease and the experiences of their family members: a qualitative systematic review  Lysosomal storage and peroxisomal disorders are rare diseases that comprise over 50 disorders. These diseases are intractable inborn errors of metabolism caused by different genetic lesions and lead to impaired lysosomal and peroxisomal functions. Persons with these diseases present with symptoms throughout the body owing to the",6_0,"Experiences of patients with metachromatic leukodystrophy, adrenoleukodystrophy, or Krabbe disease and the experiences of their family members: a qualitative systematic review",7 2024,,Krabbe_Disease
"with symptoms throughout the body owing to the accumulation of metabolic substances; however, the diseases that present symptoms in the cranial nervous system have a significant impact on patients’ lives. Among these diseases, leukodystrophy of the central nervous system includes metachromatic leukodystrophy (MLD), adrenoleukodystrophy (ALD), and Krabbe disease (globoid cell leukodystrophy). These 3 conditions have a similar pathophysiology of leukodystrophy caused by demyelination in the central nervous",6_1,"Experiences of patients with metachromatic leukodystrophy, adrenoleukodystrophy, or Krabbe disease and the experiences of their family members: a qualitative systematic review",7 2024,,Krabbe_Disease
"caused by demyelination in the central nervous system and show a similar clinical phenotype, although the causative gene is different. The progression of leukodystrophy associated with demyelination causes cognitive and neurological dysfunction, which interferes with the daily life of patients and their families.<sup><xref rid=""R1"" ref-type=""bibr"">1</xref>–<xref rid=""R3"" ref-type=""bibr"">3</xref></sup>",6_2,"Experiences of patients with metachromatic leukodystrophy, adrenoleukodystrophy, or Krabbe disease and the experiences of their family members: a qualitative systematic review",7 2024,,Krabbe_Disease
"MLD is an autosomal recessive hereditary disease caused by a deficiency of arylsulfatase A.<sup><xref rid=""R1"" ref-type=""bibr"">1</xref></sup> The incidence of MLD is estimated to be 0.16–2.0 per 100,000 live births.<sup><xref rid=""R4"" ref-type=""bibr"">4</xref>,<xref rid=""R5"" ref-type=""bibr"">5</xref></sup> The disease is classified into 4 types according to age of onset and clinical course: i) late infantile, ii) early juvenile, iii) late juvenile, and iv) adult-onset.<sup><xref rid=""R6""",6_3,"Experiences of patients with metachromatic leukodystrophy, adrenoleukodystrophy, or Krabbe disease and the experiences of their family members: a qualitative systematic review",7 2024,,Krabbe_Disease
"juvenile, and iv) adult-onset.<sup><xref rid=""R6"" ref-type=""bibr"">6</xref></sup> The most common late infantile form develops before 2 years of age and presents with hypotonia, loss of deep tendon reflexes, and gait disturbance. The juvenile type develops between ages 2.5 and 16 years, and presents with optic nerve atrophy, intellectual disability, and spastic paraplegia. Patients with juvenile MLD become bedridden approximately 18 months after onset.<sup><xref rid=""R1"" ref-type=""bibr"">1</xref></sup>",6_4,"Experiences of patients with metachromatic leukodystrophy, adrenoleukodystrophy, or Krabbe disease and the experiences of their family members: a qualitative systematic review",7 2024,,Krabbe_Disease
"rid=""R1"" ref-type=""bibr"">1</xref></sup> Adult-onset type develops over 16 years of age, leading to motor and cognitive impairments.<sup><xref rid=""R6"" ref-type=""bibr"">6</xref></sup> Although enzyme replacement therapy, hematopoietic stem cell transplantation (HSCT), and gene therapy are promising treatment options, symptomatic therapies, such as antiepileptic drugs and muscle relaxants, are currently used.<sup><xref rid=""R1"" ref-type=""bibr"">1</xref></sup>",6_5,"Experiences of patients with metachromatic leukodystrophy, adrenoleukodystrophy, or Krabbe disease and the experiences of their family members: a qualitative systematic review",7 2024,,Krabbe_Disease
"ALD is an X-linked genetic disorder caused by <italic toggle=""yes"">ABCD1</italic> gene mutations. It involves demyelination in the central nervous system and adrenal glands.<sup><xref rid=""R2"" ref-type=""bibr"">2</xref></sup> The incidence of ALD in Asia is 0.2–0.7 patients per 100,000 live births.<sup><xref rid=""R4"" ref-type=""bibr"">4</xref>,<xref rid=""R7"" ref-type=""bibr"">7</xref></sup> However, incidence varies by race, with a reported 1.3/100,000 live births among non-Hispanic Blacks and 2.4/100,000 live",6_6,"Experiences of patients with metachromatic leukodystrophy, adrenoleukodystrophy, or Krabbe disease and the experiences of their family members: a qualitative systematic review",7 2024,,Krabbe_Disease
"among non-Hispanic Blacks and 2.4/100,000 live births among non-Hispanic Whites.<sup><xref rid=""R7"" ref-type=""bibr"">7</xref></sup> Childhood cerebral ALD is the most common type of ALD and occurs between the ages of 3 and 10 years. Patients may present with impaired academic performance, vision, and cognitive function, and progress quickly to a vegetative state.<sup><xref rid=""R2"" ref-type=""bibr"">2</xref></sup> In addition, there are various clinical types of ALD, including adrenomyeloneuropathy with",6_7,"Experiences of patients with metachromatic leukodystrophy, adrenoleukodystrophy, or Krabbe disease and the experiences of their family members: a qualitative systematic review",7 2024,,Krabbe_Disease
"of ALD, including adrenomyeloneuropathy with spastic gait after 20 years of age and Addison disease with only adrenal insufficiency symptoms. The treatments for cerebral ALD are HSCT and gene therapy by early detection.<sup><xref rid=""R2"" ref-type=""bibr"">2</xref>,<xref rid=""R8"" ref-type=""bibr"">8</xref></sup>",6_8,"Experiences of patients with metachromatic leukodystrophy, adrenoleukodystrophy, or Krabbe disease and the experiences of their family members: a qualitative systematic review",7 2024,,Krabbe_Disease
"Krabbe disease is an autosomal recessive genetic disorder caused by galactocerebrosidase deficiency. Patients with Krabbe disease present with central and peripheral neuropathies.<sup><xref rid=""R3"" ref-type=""bibr"">3</xref></sup> The disease can be classified into 4 types based on the age of onset: i) early infantile, ii) late infantile, iii) juvenile, and iv) adult. The incidence of early infantile type is 1 in 394,000 births.<sup><xref rid=""R9"" ref-type=""bibr"">9</xref></sup> Early infantile Krabbe",6_9,"Experiences of patients with metachromatic leukodystrophy, adrenoleukodystrophy, or Krabbe disease and the experiences of their family members: a qualitative systematic review",7 2024,,Krabbe_Disease
"Early infantile Krabbe disease develops around 6 months of age and progresses rapidly. Patients become bedridden by 1 year of age and die by 2 or 3 years of age.<sup><xref rid=""R3"" ref-type=""bibr"">3</xref></sup> Patients with the late infantile or juvenile types can live longer than patients with the early infantile type. Patients with adult Krabbe disease have gait changes, muscle weakness, and spastic paraplegia.<sup><xref rid=""R3"" ref-type=""bibr"">3</xref></sup> HSCT is an effective treatment for",6_10,"Experiences of patients with metachromatic leukodystrophy, adrenoleukodystrophy, or Krabbe disease and the experiences of their family members: a qualitative systematic review",7 2024,,Krabbe_Disease
"HSCT is an effective treatment for patients with infantile Krabbe disease.<sup><xref rid=""R10"" ref-type=""bibr"">10</xref></sup>",6_11,"Experiences of patients with metachromatic leukodystrophy, adrenoleukodystrophy, or Krabbe disease and the experiences of their family members: a qualitative systematic review",7 2024,,Krabbe_Disease
"Diagnosis of MLD and Krabbe disease is confirmed by a decrease in enzyme activity or presence of pathological mutations.<sup><xref rid=""R4"" ref-type=""bibr"">4</xref>,<xref rid=""R10"" ref-type=""bibr"">10</xref></sup> ALD is diagnosed by increasing levels of very long-chain fatty acids.<sup><xref rid=""R2"" ref-type=""bibr"">2</xref></sup> Early detection of Krabbe disease through newborn screening is being attempted.<sup><xref rid=""R10"" ref-type=""bibr"">10</xref>,<xref rid=""R11"" ref-type=""bibr"">11</xref></sup>",6_12,"Experiences of patients with metachromatic leukodystrophy, adrenoleukodystrophy, or Krabbe disease and the experiences of their family members: a qualitative systematic review",7 2024,,Krabbe_Disease
"rid=""R11"" ref-type=""bibr"">11</xref></sup> Because these diseases are hereditary, the diagnosis of one patient may lead to the discovery that a family member is a patient or carrier; therefore, it is important to provide genetic counseling for patients and their family members. Patients receive supportive therapy and HSCT for the treatment of these diseases.<sup><xref rid=""R1"" ref-type=""bibr"">1</xref>–<xref rid=""R3"" ref-type=""bibr"">3</xref></sup> Early HSCT can improve life expectancy,<sup><xref rid=""R2""",6_13,"Experiences of patients with metachromatic leukodystrophy, adrenoleukodystrophy, or Krabbe disease and the experiences of their family members: a qualitative systematic review",7 2024,,Krabbe_Disease
"can improve life expectancy,<sup><xref rid=""R2"" ref-type=""bibr"">2</xref>,<xref rid=""R10"" ref-type=""bibr"">10</xref>,<xref rid=""R12"" ref-type=""bibr"">12</xref></sup> whereas complications, such as graft-vs-host disease, may lead to increased suffering.<sup><xref rid=""R12"" ref-type=""bibr"">12</xref></sup>",6_14,"Experiences of patients with metachromatic leukodystrophy, adrenoleukodystrophy, or Krabbe disease and the experiences of their family members: a qualitative systematic review",7 2024,,Krabbe_Disease
"The progression of a patient’s symptoms places a heavy burden on the family as the level of care required increases.<sup><xref rid=""R4"" ref-type=""bibr"">4</xref></sup> The need for nighttime endotracheal suctioning and restrictions on activities, such as going out of the house, affect the lives of the family as well as the patient.<sup><xref rid=""R13"" ref-type=""bibr"">13</xref></sup> As symptoms progress, patients have difficulty speaking. When the disease progresses to the point the patient is in a",6_15,"Experiences of patients with metachromatic leukodystrophy, adrenoleukodystrophy, or Krabbe disease and the experiences of their family members: a qualitative systematic review",7 2024,,Krabbe_Disease
"progresses to the point the patient is in a vegetative state, end-of-life care is important.<sup><xref rid=""R3"" ref-type=""bibr"">3</xref></sup>",6_16,"Experiences of patients with metachromatic leukodystrophy, adrenoleukodystrophy, or Krabbe disease and the experiences of their family members: a qualitative systematic review",7 2024,,Krabbe_Disease
"Few quantitative studies have focused on the quality of life (QOL) of patients with MLD, ALD, or Krabbe disease and their family members. In a quantitative study that determined the impact of leukodystrophy on patients’ QOL, a disease-specific QOL scale for patients with Krabbe disease was developed.<sup><xref rid=""R14"" ref-type=""bibr"">14</xref></sup> Another study found that mothers of patients with MLD have a lower QOL than the general population.<sup><xref rid=""R15"" ref-type=""bibr"">15</xref></sup> It",6_17,"Experiences of patients with metachromatic leukodystrophy, adrenoleukodystrophy, or Krabbe disease and the experiences of their family members: a qualitative systematic review",7 2024,,Krabbe_Disease
"rid=""R15"" ref-type=""bibr"">15</xref></sup> It is important to interpret the experiences of patients and their families to identify the impact and challenges of the disease on their lives. Understanding the details of these experiences and accumulating information can allow health care providers to consider ways to assist patients and family members. Therefore, the synthesis of qualitative studies based on the experiences of patients and their family members is required. However, it was anticipated there",6_18,"Experiences of patients with metachromatic leukodystrophy, adrenoleukodystrophy, or Krabbe disease and the experiences of their family members: a qualitative systematic review",7 2024,,Krabbe_Disease
"is required. However, it was anticipated there would be limited studies on patients’ experiences because it would not be possible to interview patients after their symptoms had progressed to the point where conversation would be difficult. A preliminary search of PROSPERO, MEDLINE, the Cochrane Database of Systematic Reviews, and <italic toggle=""yes"">JBI Evidence Synthesis</italic> was conducted, and no current or in-progress systematic reviews on the topic were identified. In the preliminary search of",6_19,"Experiences of patients with metachromatic leukodystrophy, adrenoleukodystrophy, or Krabbe disease and the experiences of their family members: a qualitative systematic review",7 2024,,Krabbe_Disease
"were identified. In the preliminary search of MEDLINE, we identified 5 articles on the experiences of parents of patients with leukodystrophy.<sup><xref rid=""R15"" ref-type=""bibr"">15</xref>–<xref rid=""R19"" ref-type=""bibr"">19</xref></sup> Three papers on parents of children with ALD revealed families’ experiences with newborn screening, diagnosis, and long-term care.<sup><xref rid=""R17"" ref-type=""bibr"">17</xref>–<xref rid=""R19"" ref-type=""bibr"">19</xref></sup> Two papers on MLDs revealed findings on health",6_20,"Experiences of patients with metachromatic leukodystrophy, adrenoleukodystrophy, or Krabbe disease and the experiences of their family members: a qualitative systematic review",7 2024,,Krabbe_Disease
"Two papers on MLDs revealed findings on health care services and patients’ and family members’ QOL.<sup><xref rid=""R15"" ref-type=""bibr"">15</xref>,<xref rid=""R19"" ref-type=""bibr"">19</xref></sup> The articles obtained from the preliminary search showed that ALD and MLD affect the lives of patients and their families in several ways. Each study focused on different events, and the synthesis of such findings is necessary to clarify the overall experiences of patients and their families. This review aimed to",6_21,"Experiences of patients with metachromatic leukodystrophy, adrenoleukodystrophy, or Krabbe disease and the experiences of their family members: a qualitative systematic review",7 2024,,Krabbe_Disease
"patients and their families. This review aimed to synthesize the experiences of patients with MLD, ALD, or Krabbe disease and their families to reveal the impact of treatment and home care burden. The resulting synthesized findings show the challenges faced by patients and their family members, the support they seek, and factors that influence QOL, all of which may be used in diagnosis, treatment, and support at home. What are the experiences of patients with MLD, ALD, or Krabbe disease and the experiences",6_22,"Experiences of patients with metachromatic leukodystrophy, adrenoleukodystrophy, or Krabbe disease and the experiences of their family members: a qualitative systematic review",7 2024,,Krabbe_Disease
"MLD, ALD, or Krabbe disease and the experiences of their family members?  This systematic review was conducted in accordance with the JBI methodology for systematic reviews of qualitative evidence.<sup><xref rid=""R21"" ref-type=""bibr"">21</xref></sup> Selected studies were evaluated against the inclusion criteria, and then assessed for methodological quality. If judged to meet the criteria, the data were extracted and synthesized. The synthesized findings were graded according to the ConQual",6_23,"Experiences of patients with metachromatic leukodystrophy, adrenoleukodystrophy, or Krabbe disease and the experiences of their family members: a qualitative systematic review",7 2024,,Krabbe_Disease
"findings were graded according to the ConQual approach.<sup><xref rid=""R22"" ref-type=""bibr"">22</xref></sup> This review was conducted in accordance with an a priori protocol<sup><xref rid=""R23"" ref-type=""bibr"">23</xref></sup> and registered with PROSPERO (CRD42022318805).  The synthesized findings in this review revealed the experiences of parents and family members of patients with MLD and ALD. Although this review did not identify any articles in which the patients themselves were included, it is",6_24,"Experiences of patients with metachromatic leukodystrophy, adrenoleukodystrophy, or Krabbe disease and the experiences of their family members: a qualitative systematic review",7 2024,,Krabbe_Disease
"the patients themselves were included, it is possible that family members were also patients or carriers, due to the characteristics of the hereditary disease. Leukodystrophy is a progressive disease, and the importance of care for the progression of physical symptoms and severity of disability was evident in the review findings. A previous review of patients with similar rare diseases and their family members showed the burden of symptoms and treatment owing to disease progression.<sup><xref rid=""R35""",6_25,"Experiences of patients with metachromatic leukodystrophy, adrenoleukodystrophy, or Krabbe disease and the experiences of their family members: a qualitative systematic review",7 2024,,Krabbe_Disease
"owing to disease progression.<sup><xref rid=""R35"" ref-type=""bibr"">35</xref></sup> Another review noted the challenges of living as patient with a rare disease and the challenges in the health care system.<sup><xref rid=""R36"" ref-type=""bibr"">36</xref></sup>",6_26,"Experiences of patients with metachromatic leukodystrophy, adrenoleukodystrophy, or Krabbe disease and the experiences of their family members: a qualitative systematic review",7 2024,,Krabbe_Disease
"Other findings from the current review suggested that medical personnel responsible for providing support to patients and family members lacked knowledge and cooperation, and that there was a need to create a system to provide appropriate support. It was evident that family members were trying to adjust roles to provide care for patients and to manage challenges and conflicts. The synthesis of the studies in this review provided insight into the experiences of families who have a member with MLD or ALD.",6_27,"Experiences of patients with metachromatic leukodystrophy, adrenoleukodystrophy, or Krabbe disease and the experiences of their family members: a qualitative systematic review",7 2024,,Krabbe_Disease
"of families who have a member with MLD or ALD. In supporting patients and their families, this review suggests that it is necessary to provide appropriate care to patients, develop medical systems to make this possible, and provide support to families. The methodological quality of the studies included in the review and the description of the articles were lacking. As a result, the confidence of the synthesized findings is low or very low. Therefore, it is necessary to exercise caution when interpreting",6_28,"Experiences of patients with metachromatic leukodystrophy, adrenoleukodystrophy, or Krabbe disease and the experiences of their family members: a qualitative systematic review",7 2024,,Krabbe_Disease
"necessary to exercise caution when interpreting the recommendations that follow. Osaka University Library for assistance in developing the search strategy. This work was supported by Takeda Japan Medical Office Funded Research Grant 2021, which assisted with the collection of articles and language editing for this protocol, and by JSPS KAKENHI (Grant Number JP22K17513), which assisted with translation from other languages into English, English editing of manuscripts, and Open Access fees. YK conceptualized",6_29,"Experiences of patients with metachromatic leukodystrophy, adrenoleukodystrophy, or Krabbe disease and the experiences of their family members: a qualitative systematic review",7 2024,,Krabbe_Disease
"and Open Access fees. YK conceptualized the concept for the review and contributed to the methodology and writing of the original draft. SU conceptualized the concept for the review, contributed to the methodology, and reviewed the draft of the review. MY contributed to the methodology and reviewed the draft of the review. NS supervised the project and reviewed the draft of the review.",6_30,"Experiences of patients with metachromatic leukodystrophy, adrenoleukodystrophy, or Krabbe disease and the experiences of their family members: a qualitative systematic review",7 2024,,Krabbe_Disease
"Newborn Screening for Krabbe Disease: Status Quo and Recommendations for Improvements Krabbe disease (KD) is part of newborn screening (NBS) in 11 states with at least one additional state preparing to screen. In July 2021, KD was re-nominated for addition to the federal Recommended Uniform Screening Panel (RUSP) in the USA with a two-tiered strategy based on psychosine (PSY) as the determinant if an NBS result is positive or negative after a first-tier test revealed decreased galactocerebrosidase activity.",7_0,Newborn Screening for Krabbe Disease: Status Quo and Recommendations for Improvements,28 1 2024,,Krabbe_Disease
"revealed decreased galactocerebrosidase activity. Nine states currently screening for KD include PSY analysis in their screening strategy. However, the nomination was rejected in February 2023 because of perceived concerns about a high false positive rate, potential harm to newborns with an uncertain prognosis, and inadequate data on presymptomatic treatment benefit or harm. To address the concern about false positive NBS results, a survey was conducted of the eight NBS programs that use PSY and have been",7_1,Newborn Screening for Krabbe Disease: Status Quo and Recommendations for Improvements,28 1 2024,,Krabbe_Disease
"the eight NBS programs that use PSY and have been screening for KD for at least 1 year. Seven of eight states responded. We found that: (1) the use of PSY is variable; (2) when modeling the data based on the recommended screening strategy for KD, and applying different cutoffs for PSY, each state could virtually eliminate false positive results without major impact on sensitivity; (3) the reason for the diverse strategies appears to be primarily the difficulty of state programs to adjust screening",7_2,Newborn Screening for Krabbe Disease: Status Quo and Recommendations for Improvements,28 1 2024,,Krabbe_Disease
difficulty of state programs to adjust screening algorithms due to the concern of possibly missing even an adult-onset case following a change that focuses on infantile and early infantile KD. Contracts with outside vendors and the effort/cost of making changes to a program’s information systems can be additional obstacles. We recommend that programs review their historical NBS outcomes for KD with their advisory committees and make transparent decisions on whether to accept false positive results for such,7_3,Newborn Screening for Krabbe Disease: Status Quo and Recommendations for Improvements,28 1 2024,,Krabbe_Disease
"whether to accept false positive results for such a devastating condition or to adjust their procedures to ensure an efficient, effective, and manageable NBS program for KD. Krabbe disease (KD; OMIM #245200), also known as globoid cell leukodystrophy, is an autosomal recessive neurodegenerative disorder caused by deficient galactocerebrosidase (EC 3.2.1.46) activity, a lysosomal enzyme encoded by <italic toggle=""yes"">GALC</italic>. The disorder was first described clinically by Knud Krabbe in 1916 as an",7_4,Newborn Screening for Krabbe Disease: Status Quo and Recommendations for Improvements,28 1 2024,,Krabbe_Disease
"described clinically by Knud Krabbe in 1916 as an “infantile form of diffuse brain-sclerosis” [<xref rid=""B1-IJNS-10-00010"" ref-type=""bibr"">1</xref>]. In 1970, Kunihiko and Yoshiyuki Suzuki showed by analysis of brain and other solid tissues that deficient galactocerebrosidase activity was the cause of the disorder, and paved the way for the development of an enzyme assay in leukocytes for diagnostic purposes [<xref rid=""B2-IJNS-10-00010"" ref-type=""bibr"">2</xref>]. By 1995 David Wenger had identified the",7_5,Newborn Screening for Krabbe Disease: Status Quo and Recommendations for Improvements,28 1 2024,,Krabbe_Disease
"By 1995 David Wenger had identified the <italic toggle=""yes"">GALC</italic> gene, which enabled the molecular characterization and diagnosis of the disorder [<xref rid=""B3-IJNS-10-00010"" ref-type=""bibr"">3</xref>]. These developments led to an improved understanding of KD as a disorder of variable age of onset and milder phenotypes in patients with onset after infancy. The current categorization of KD is based on recent natural history studies [<xref rid=""B4-IJNS-10-00010"" ref-type=""bibr"">4</xref>] and",7_6,Newborn Screening for Krabbe Disease: Status Quo and Recommendations for Improvements,28 1 2024,,Krabbe_Disease
"ref-type=""bibr"">4</xref>] and includes:<list list-type=""simple""><list-item><label>−</label><p>Infantile Krabbe disease (IKD), which represents the phenotype described by Knud Krabbe, is characterized clinically by onset of irreversible and rapidly progressive symptoms (inconsolable crying, irritability, spasticity of lower extremities, fisting, vision loss, feeding difficulties) before 12 months of age leading to death before the age of 2 years;</p></list-item><list-item><label>−</label><p>Late Infantile",7_7,Newborn Screening for Krabbe Disease: Status Quo and Recommendations for Improvements,28 1 2024,,Krabbe_Disease
"Infantile Krabbe disease (LIKD) with onset of irreversible and progressive symptoms (loss of milestones, gait changes, hemi- or diplegia, vision loss, febrile seizures, tremors) between 1 to 3 years leading to death within several years;</p></list-item><list-item><label>−</label><p>Juvenile Krabbe disease (JKD) with onset of progressive symptoms between 4–17 years of age; and</p></list-item><list-item><label>−</label><p>Adult Krabbe disease (AKD) with onset of progressive symptoms at 18 or more years of",7_8,Newborn Screening for Krabbe Disease: Status Quo and Recommendations for Improvements,28 1 2024,,Krabbe_Disease
"of progressive symptoms at 18 or more years of age.</p></list-item></list> JKD and AKD have more variable phenotypes requiring careful evaluation of a patient’s history and more frequent inclusion of KD in the differential diagnosis of patients presenting with even subtle neurological symptoms, and inclusion of <italic toggle=""yes"">GALC</italic> in a broad spectrum of gene panel tests for neurological phenotypes [<xref rid=""B5-IJNS-10-00010"" ref-type=""bibr"">5</xref>]. The accumulation of psychosine (PSY)",7_9,Newborn Screening for Krabbe Disease: Status Quo and Recommendations for Improvements,28 1 2024,,Krabbe_Disease
"The accumulation of psychosine (PSY) in the brain and then additional organs of patients with galactocerebrosidase deficiency were first described in 1975 and 1994, respectively; however, it was not until 2012 that Ernesto Bongarzone’s group showed that PSY was elevated in serum and dried blood spots of the twitcher mouse, an animal model of KD [<xref rid=""B6-IJNS-10-00010"" ref-type=""bibr"">6</xref>,<xref rid=""B7-IJNS-10-00010"" ref-type=""bibr"">7</xref>,<xref rid=""B8-IJNS-10-00010"" ref-type=""bibr"">8</xref>].",7_10,Newborn Screening for Krabbe Disease: Status Quo and Recommendations for Improvements,28 1 2024,,Krabbe_Disease
"rid=""B8-IJNS-10-00010"" ref-type=""bibr"">8</xref>]. Through the collaborative effort of Joseph Orsini of the New York State (NY) newborn screening (NBS) program and colleagues at Genzyme, it was then shown that PSY is also elevated in dried blood spots of newborns with KD [<xref rid=""B9-IJNS-10-00010"" ref-type=""bibr"">9</xref>]. This discovery was highly relevant because the NY NBS program, through patient advocacy efforts, had begun NBS for KD in 2006. Based on the previous enzymatic and molecular",7_11,Newborn Screening for Krabbe Disease: Status Quo and Recommendations for Improvements,28 1 2024,,Krabbe_Disease
"Based on the previous enzymatic and molecular characterization of symptomatic patients with KD, the NY NBS program had chosen a screening strategy where GALC activity was determined as a first-tier test, and second-tier molecular genetic analysis of <italic toggle=""yes"">GALC</italic> was performed when enzyme activity was reduced. After 8 years of screening, the NY NBS program reported a positive predictive value of only 1.4% for IKD [<xref rid=""B10-IJNS-10-00010"" ref-type=""bibr"">10</xref>]. It was",7_12,Newborn Screening for Krabbe Disease: Status Quo and Recommendations for Improvements,28 1 2024,,Krabbe_Disease
"ref-type=""bibr"">10</xref>]. It was recognized that the cause of this poor screening performance was based on an incomplete understanding of the natural history of KD because an unexpectedly high number of cases were identified that had reduced GALC activity and <italic toggle=""yes"">GALC</italic> genotypes, including variants of uncertain significance with or without additional activity reducing but not disease-causing variants, typically referred to as pseudodeficiency alleles [<xref",7_13,Newborn Screening for Krabbe Disease: Status Quo and Recommendations for Improvements,28 1 2024,,Krabbe_Disease
"referred to as pseudodeficiency alleles [<xref rid=""B11-IJNS-10-00010"" ref-type=""bibr"">11</xref>]. Indeed, ClinVar currently lists more than 1200 variants in <italic toggle=""yes"">GALC</italic>, of which less than 30% are of known significance (<uri http://www.w3.org/1999/xlink href=""https://www.ncbi.nlm.nih.gov/clinvar/"">https://www.ncbi.nlm.nih.gov/clinvar/</uri>; last accessed 16 January 2024). The discovery of elevated PSY in blood spots of newborns affected with KD was therefore a significant",7_14,Newborn Screening for Krabbe Disease: Status Quo and Recommendations for Improvements,28 1 2024,,Krabbe_Disease
"affected with KD was therefore a significant advancement as it suggested that PSY could eliminate false positive and uncertain screening results. And indeed, when Kentucky (KY) began NBS for KD in 2016, PSY was used instead of molecular <italic toggle=""yes"">GALC</italic> analysis as a second-tier test. A cutoff of 2 nM prevented the identification of unaffected cases (false positive results) and facilitated the timely treatment of two newborns with KD [<xref rid=""B12-IJNS-10-00010""",7_15,Newborn Screening for Krabbe Disease: Status Quo and Recommendations for Improvements,28 1 2024,,Krabbe_Disease
"newborns with KD [<xref rid=""B12-IJNS-10-00010"" ref-type=""bibr"">12</xref>]. Moreover, PSY concentrations appear to differentiate patients with the most severe from late-onset forms of the disease [<xref rid=""B13-IJNS-10-00010"" ref-type=""bibr"">13</xref>]. Current standard of care is the administration of a hematopoietic stem cell transplant (HSCT) before the presence of severe, irreversible signs and symptoms. Accordingly, patients with IKD must be treated within the first 30 to 45 days of life, which is",7_16,Newborn Screening for Krabbe Disease: Status Quo and Recommendations for Improvements,28 1 2024,,Krabbe_Disease
"within the first 30 to 45 days of life, which is only achievable by identification through prenatal diagnosis or NBS [<xref rid=""B14-IJNS-10-00010"" ref-type=""bibr"">14</xref>,<xref rid=""B15-IJNS-10-00010"" ref-type=""bibr"">15</xref>]. While patients with LIKD do not require treatment in the neonatal period, a diagnosis based on clinical signs and symptoms is also usually only made when the disease has advanced too far for HSCT to be of benefit. Since initial data indicated that PSY is markedly elevated (≥10",7_17,Newborn Screening for Krabbe Disease: Status Quo and Recommendations for Improvements,28 1 2024,,Krabbe_Disease
"data indicated that PSY is markedly elevated (≥10 nM) in newborn dried blood spots in patients with IKD and moderately elevated (2–10 nM) in newborns with LIKD, reliance on PSY as the determinator of a normal or abnormal NBS result for KD is reasonable to minimize false positive results while accepting that not all patients with JKD and AKD would be identified as newborns [<xref rid=""B13-IJNS-10-00010"" ref-type=""bibr"">13</xref>,<xref rid=""B16-IJNS-10-00010"" ref-type=""bibr"">16</xref>]. Based on these data,",7_18,Newborn Screening for Krabbe Disease: Status Quo and Recommendations for Improvements,28 1 2024,,Krabbe_Disease
"ref-type=""bibr"">16</xref>]. Based on these data, in July 2021, KD was re-nominated for addition to the Recommended Uniform Screening Panel (RUSP) of the US Department of Health and Human Services (DHHS) with an NBS strategy based on that first used in KY. However, the DHHS’ Advisory Committee on Heritable Disorders in Newborns and Children (ACHDNC) with a tied vote rejected the addition of KD because of concerns about the perceived large number of false positive results generated by the 10 states",7_19,Newborn Screening for Krabbe Disease: Status Quo and Recommendations for Improvements,28 1 2024,,Krabbe_Disease
"false positive results generated by the 10 states performing NBS for KD at the time and inadequate data on presymptomatic treatment benefit (<uri http://www.w3.org/1999/xlink href=""https://www.hrsa.gov/sites/default/files/hrsa/advisory-committees/heritable-disorders/resources/chair-letterkrabbe-nominators.pdf"">https://www.hrsa.gov/sites/default/files/hrsa/advisory-committees/heritable-disorders/resources/chair-letterkrabbe-nominators.pdf</uri>; last accessed 16 January 2024). Of 11 states currently",7_20,Newborn Screening for Krabbe Disease: Status Quo and Recommendations for Improvements,28 1 2024,,Krabbe_Disease
"accessed 16 January 2024). Of 11 states currently screening for KD, 9 include PSY analysis in their screening strategy; however, it is unclear how PSY is actually used in determining normal or abnormal screening results. Considering these uncertainties and to address the ACHDNC’s first concern, we queried these states’ NBS programs about their practices and attempted to model each program’s outcomes based on various PSY cutoffs. Of the 11 states currently screening for KD, only 2 do not (yet) use PSY",7_21,Newborn Screening for Krabbe Disease: Status Quo and Recommendations for Improvements,28 1 2024,,Krabbe_Disease
"screening for KD, only 2 do not (yet) use PSY (Ohio, New Jersey) and 1 (South Carolina) that uses PSY only started NBS for KD on 15 May 2023. A questionnaire (<xref rid=""app1-IJNS-10-00010"" ref-type=""app"">Supplementary Table S1</xref>) was sent to 5 of the remaining 8 state NBS programs: Illinois (IL), Indiana, Missouri (MO), Pennsylvania (PA), and Tennessee (TN). Relevant outcome data were accessible to the authors for the programs of NY (J.J.O.), KY (D.M.), and Georgia (GA) (P.H.). The first part of the",7_22,Newborn Screening for Krabbe Disease: Status Quo and Recommendations for Improvements,28 1 2024,,Krabbe_Disease
"and Georgia (GA) (P.H.). The first part of the questionnaire tried to ascertain the screening strategy regarding tiered testing, result interpretation, and reporting. For example, is any state reporting preliminary results when GALC activity is below a particular threshold and before any additional 2nd or 3rd tier testing has been completed? The 2nd part asked about the number of true and false positive cases for three different PSY concentration cutoffs (≥2, ≥5, and ≥10 nM) to determine if any of those",7_23,Newborn Screening for Krabbe Disease: Status Quo and Recommendations for Improvements,28 1 2024,,Krabbe_Disease
"(≥2, ≥5, and ≥10 nM) to determine if any of those cutoffs could eliminate false positive results and which forms of KD may be missed if such a cutoff was applied. Performance metrics for the various screening approaches were calculated based on common practice in medical research and epidemiology [<xref rid=""B17-IJNS-10-00010"" ref-type=""bibr"">17</xref>,<xref rid=""B18-IJNS-10-00010"" ref-type=""bibr"">18</xref>]. The questionnaire was returned by all but one state and revealed significant differences in the",7_24,Newborn Screening for Krabbe Disease: Status Quo and Recommendations for Improvements,28 1 2024,,Krabbe_Disease
"state and revealed significant differences in the use of PSY and in reporting procedures. Only two states (GA, KY) currently use PSY to determine if a screening result is normal or abnormal. The other programs that do not use PSY to adjudicate a screen as normal or abnormal have varying strategies, including “panic values” to report very low GALC activities while second-tier PSY testing is pending at an outside laboratory (MO, TN), or include molecular genetic <italic toggle=""yes"">GALC</italic> analysis",7_25,Newborn Screening for Krabbe Disease: Status Quo and Recommendations for Improvements,28 1 2024,,Krabbe_Disease
"<italic toggle=""yes"">GALC</italic> analysis and then report any case with reduced GALC activity, any PSY result, and genotypes with at least one variant not considered benign or likely benign (IL, NY). At this point, the issued report has been added to the baby’s medical record and the primary care physician or a specialist is expected to decide if contacting the family and further follow up are warranted. Any newborn that is approached but ultimately determined to not be affected by KD (incl. carriers of",7_26,Newborn Screening for Krabbe Disease: Status Quo and Recommendations for Improvements,28 1 2024,,Krabbe_Disease
"to not be affected by KD (incl. carriers of pathogenic <italic toggle=""yes"">GALC</italic> variants as well as those with “pseudodeficiency” due to <italic toggle=""yes"">GALC</italic> genotypes conferring reduced GALC activity but not causing disease) meets the definition of a false positive case [<xref rid=""B19-IJNS-10-00010"" ref-type=""bibr"">19</xref>]. In <xref rid=""IJNS-10-00010-t001"" ref-type=""table"">Table 1</xref> are summarized the outcomes and performance metrics of NBS for KD as currently performed",7_27,Newborn Screening for Krabbe Disease: Status Quo and Recommendations for Improvements,28 1 2024,,Krabbe_Disease
"metrics of NBS for KD as currently performed in the seven of eight states that provided data. Sensitivity is 100% given that a false negative case has not been reported. The false positive rates appear to be low (<0.1%) for all screening programs; however, the positive predictive value (PPV) is also low in states that do not rely on PSY to determine if a screen is negative or presumptive positive for KD. Including the observed prevalence of KD in the calculation of the PPV did not increase the PPV, as is",7_28,Newborn Screening for Krabbe Disease: Status Quo and Recommendations for Improvements,28 1 2024,,Krabbe_Disease
"of the PPV did not increase the PPV, as is expected for rare conditions. However, as shown in <xref rid=""IJNS-10-00010-t002"" ref-type=""table"">Table 2</xref>, a strategy that only leads to abnormal reports when GALC activity is reduced and PSY is elevated can dramatically improve the PPV irrespective of prevalence and, more importantly, eliminate false positive results. Moreover, <xref rid=""IJNS-10-00010-t002"" ref-type=""table"">Table 2</xref> shows possible outcomes based on recalculated data for three",7_29,Newborn Screening for Krabbe Disease: Status Quo and Recommendations for Improvements,28 1 2024,,Krabbe_Disease
"outcomes based on recalculated data for three different cutoffs for PSY: ≥2, ≥5, and ≥10 nM. A cutoff of either ≥5 or ≥10 nM would eliminate all false positive results and identify all cases with IKD. However, patients with LIKD and later onset forms of KD would be missed when applying a cutoff of ≥10 nM, and one of two cases with LIKD would have been missed with a PSY cutoff of ≥5 nM. A cutoff of ≥2 nM would eliminate false positive cases in all but one state (IL) but identify all cases with IKD and LIKD,",7_30,Newborn Screening for Krabbe Disease: Status Quo and Recommendations for Improvements,28 1 2024,,Krabbe_Disease
"(IL) but identify all cases with IKD and LIKD, and at minimum some cases with LOKD. Newborn screening for KD began in NY in 2006, and in 2007, the Hunter’s Hope Foundation (HHF) nominated KD for addition to the RUSP. Following a formal review of the available evidence, the nomination did not pass in 2009 [<xref rid=""B20-IJNS-10-00010"" ref-type=""bibr"">20</xref>]. Three knowledge gaps regarding KD presenting during infancy (at the time referred to as Early Infantile Krabbe Disease, EIKD) were identified as",7_31,Newborn Screening for Krabbe Disease: Status Quo and Recommendations for Improvements,28 1 2024,,Krabbe_Disease
"Krabbe Disease, EIKD) were identified as needing to be addressed before a new nomination would be considered: 1. an agreed upon definition of early onset KD; 2. the approach to screening and diagnosis of KD and its cost implications; and 3. evidence about the benefits of HSCT and if specific <italic toggle=""yes"">GALC</italic> genotypes would be predictive of benefit (<uri http://www.w3.org/1999/xlink",7_32,Newborn Screening for Krabbe Disease: Status Quo and Recommendations for Improvements,28 1 2024,,Krabbe_Disease
"of benefit (<uri http://www.w3.org/1999/xlink href=""https://www.hrsa.gov/sites/default/files/hrsa/advisory-committees/heritable-disorders/krabbe-letter-committee.pdf"">https://www.hrsa.gov/sites/default/files/hrsa/advisory-committees/heritable-disorders/krabbe-letter-committee.pdf</uri>; last accessed 16 January 2024). Since then, the HHF has continued to engage and work with stakeholders, including KD and NBS experts. Through the organization of an annual research symposium and creation of a taskforce, the",7_33,Newborn Screening for Krabbe Disease: Status Quo and Recommendations for Improvements,28 1 2024,,Krabbe_Disease
"symposium and creation of a taskforce, the HHF promoted both the growth and sharing of knowledge with the goal to continually improve NBS and the outcomes of affected patients, and to fill the knowledge gaps as requested by the ACHDNC. During the same time, NBS for KD continued in NY and through advocacy efforts has expanded to another 10 states with at least one additional state (Minnesota, <uri http://www.w3.org/1999/xlink",7_34,Newborn Screening for Krabbe Disease: Status Quo and Recommendations for Improvements,28 1 2024,,Krabbe_Disease
"(Minnesota, <uri http://www.w3.org/1999/xlink href=""https://www.health.state.mn.us/news/pressrel/2023/newborn082823.html"">https://www.health.state.mn.us/news/pressrel/2023/newborn082823.html</uri>; last accessed 16 January 2024) preparing to start screening in 2024. In July 2021, KD was re-nominated for addition to the RUSP with a screening strategy based on PSY as the determinant if an NBS result is positive or negative. This recommended NBS strategy was first implemented by the NBS program of KY where it",7_35,Newborn Screening for Krabbe Disease: Status Quo and Recommendations for Improvements,28 1 2024,,Krabbe_Disease
"implemented by the NBS program of KY where it has been shown to virtually eliminate false positive results while identifying patients with IKD and LIKD but potentially missing some cases with JKD or AKD [<xref rid=""B12-IJNS-10-00010"" ref-type=""bibr"">12</xref>,<xref rid=""B13-IJNS-10-00010"" ref-type=""bibr"">13</xref>]. This strategy along with the experience of NY [<xref rid=""B10-IJNS-10-00010"" ref-type=""bibr"">10</xref>,<xref rid=""B11-IJNS-10-00010"" ref-type=""bibr"">11</xref>] and additional data on the",7_36,Newborn Screening for Krabbe Disease: Status Quo and Recommendations for Improvements,28 1 2024,,Krabbe_Disease
"and additional data on the clinical utility of PSY [<xref rid=""B13-IJNS-10-00010"" ref-type=""bibr"">13</xref>] also provided the basis for the development of follow-up guidelines of screen positive cases [<xref rid=""B16-IJNS-10-00010"" ref-type=""bibr"">16</xref>]. In addition, the National Coordinating Center for the Regional Genetics Networks (NCC) developed the ACMG ACT Sheets and a follow-up algorithm for presumptive positive NBS results for KD (<uri http://www.w3.org/1999/xlink",7_37,Newborn Screening for Krabbe Disease: Status Quo and Recommendations for Improvements,28 1 2024,,Krabbe_Disease
"results for KD (<uri http://www.w3.org/1999/xlink href=""https://www.acmg.net/act"">https://www.acmg.net/act</uri>; last accessed 16 January 2024). Nevertheless, the nomination was narrowly (tied vote) rejected by the ACHDNC in February 2023 following a discussion marked by suggestions, not backed by evidence, that patients may be harmed by early identification and subsequent treatment, possibly even treatment of unaffected infants, and that the false positive rate was too high. In his letter to the",7_38,Newborn Screening for Krabbe Disease: Status Quo and Recommendations for Improvements,28 1 2024,,Krabbe_Disease
"positive rate was too high. In his letter to the nominators of 22 March 2023, the committee chair summarized the perceived concerns as lacking data on presymptomatic treatment benefit and adequate case classification, requested data on potential harms of early HSCT and the possibility of HSCT occurring when not indicated, data about outcomes of cases with LIKD, and about the “number lost to follow-up and potential burden on families and infants of intensive follow-up visits and consequences of",7_39,Newborn Screening for Krabbe Disease: Status Quo and Recommendations for Improvements,28 1 2024,,Krabbe_Disease
"of intensive follow-up visits and consequences of indeterminate diagnostic testing” (<uri http://www.w3.org/1999/xlink href=""https://www.hrsa.gov/advisory-committees/heritable-disorders/rusp/previous-nominations"">https://www.hrsa.gov/advisory-committees/heritable-disorders/rusp/previous-nominations</uri>; last accessed 16 January 2024). The written communication exchange between the ACHDNC and the HHF is publicly available (see “<xref rid=""app1-IJNS-10-00010"" ref-type=""app"">Supporting Information</xref>”",7_40,Newborn Screening for Krabbe Disease: Status Quo and Recommendations for Improvements,28 1 2024,,Krabbe_Disease
"ref-type=""app"">Supporting Information</xref>” at: <uri http://www.w3.org/1999/xlink href=""https://www.huntershope.org/newborn-screening/achdnc/"">https://www.huntershope.org/newborn-screening/achdnc/</uri>; last accessed 16 January 2024), and following additional discussions with the ACHDNC’s leadership, KD was nominated for a third time for addition to the RUSP with IKD as the Core Condition and all other forms of KD as secondary targets by recommending that PSY be used as a second-tier test and suggesting",7_41,Newborn Screening for Krabbe Disease: Status Quo and Recommendations for Improvements,28 1 2024,,Krabbe_Disease
PSY be used as a second-tier test and suggesting that only cases with PSY ≥10 nM should be reported as abnormal. The goal of the study presented here was to investigate the concern about false positive NBS results by collecting data on the performance and short-term outcomes of current screening strategies that include PSY and then determine if the screening strategy recommended as part of the nomination of KD to the RUSP could improve screening performance. Our findings confirmed that the use of PSY is,7_42,Newborn Screening for Krabbe Disease: Status Quo and Recommendations for Improvements,28 1 2024,,Krabbe_Disease
"Our findings confirmed that the use of PSY is variable among the seven states that responded to the survey. Only two states (GA, KY) follow the strategy nominated in 2021, identified newborns with IKD, and experienced no false positive results with a cutoff of ≥2 nM for PSY. Modeling the outcomes for all seven states based on the recommended screening strategy and applying three different cutoffs for PSY, we found that the false positive rate can be markedly improved with any of the three cutoffs for PSY",7_43,Newborn Screening for Krabbe Disease: Status Quo and Recommendations for Improvements,28 1 2024,,Krabbe_Disease
"improved with any of the three cutoffs for PSY and reach 0% when using a PSY cutoff of ≥5 nM. Only MO would not eliminate their two false positive cases; however, those were caused by an unusual laboratory error, since remedied (see <xref rid=""app2-IJNS-10-00010"" ref-type=""app"">Appendix A</xref>). At the same time, a cutoff of ≥5 nM could miss some cases with LIKD and most with LOKD, and a cutoff of ≥10 nM could limit NBS to IKD. There are several reasons why there are various NBS strategies for KD among",7_44,Newborn Screening for Krabbe Disease: Status Quo and Recommendations for Improvements,28 1 2024,,Krabbe_Disease
"why there are various NBS strategies for KD among states. PSY analysis was not clinically available until 2015 [<xref rid=""B21-IJNS-10-00010"" ref-type=""bibr"">21</xref>] when NY and MO had already been screening for 9 and 3 years, respectively. Accordingly, molecular genetic analysis of <italic toggle=""yes"">GALC</italic> had become the de facto second-tier test after reduced GALC activity was determined. In Ohio and New Jersey, laws were passed to begin NBS for KD in 2016 and 2019, respectively, but the",7_45,Newborn Screening for Krabbe Disease: Status Quo and Recommendations for Improvements,28 1 2024,,Krabbe_Disease
"for KD in 2016 and 2019, respectively, but the relevant law in Ohio did not allow for testing beyond GALC activity measurement (<uri http://www.w3.org/1999/xlink href=""https://www.registerofohio.state.oh.us/servlet/RooBusinessPDF?ruleActionId=493752&docTypeId=14"">https://www.registerofohio.state.oh.us/servlet/RooBusinessPDF?ruleActionId=493752&docTypeId=14</uri>; last accessed 16 January 2024). New Jersey chose to pursue molecular <italic toggle=""yes"">GALC</italic> analysis, but uses only GALC activity to",7_46,Newborn Screening for Krabbe Disease: Status Quo and Recommendations for Improvements,28 1 2024,,Krabbe_Disease
"analysis, but uses only GALC activity to determine a result as screen positive or negative. Moreover, molecular genetic testing had to be stopped when the health department had to reallocate the relevant resources during the SARS-CoV-2 pandemic [<xref rid=""B22-IJNS-10-00010"" ref-type=""bibr"">22</xref>]. While IL and TN began screening in 2017, published data supporting PSY as the better screening test were still limited, which is why PSY and molecular <italic toggle=""yes"">GALC</italic> analysis became part",7_47,Newborn Screening for Krabbe Disease: Status Quo and Recommendations for Improvements,28 1 2024,,Krabbe_Disease
"toggle=""yes"">GALC</italic> analysis became part of these states’ screening approach, but PSY was not used to ultimately decide a screen as positive or negative [<xref rid=""B23-IJNS-10-00010"" ref-type=""bibr"">23</xref>]. Both states adjusted their algorithms in 2020 (TN) and in 2021 (IL), when molecular testing was only performed when PSY was above 1.5 nM (cutoff set by these states’ contracted laboratory), which improved the false positive rate and positive predictive values four-fold as documented for IL",7_48,Newborn Screening for Krabbe Disease: Status Quo and Recommendations for Improvements,28 1 2024,,Krabbe_Disease
"predictive values four-fold as documented for IL (<xref rid=""IJNS-10-00010-t001"" ref-type=""table"">Table 1</xref>). Of the next two states that began NBS for KD in 2021, GA decided to pilot the KY approach while PA adopted both molecular <italic toggle=""yes"">GALC</italic> analysis and PSY measurement. One state (MO) replaced molecular genetic analysis with PSY analysis as a second-tier test in 2020 but is still reporting as presumptive positive markedly reduced GALC activities even when PSY is not elevated.",7_49,Newborn Screening for Krabbe Disease: Status Quo and Recommendations for Improvements,28 1 2024,,Krabbe_Disease
"GALC activities even when PSY is not elevated. The states that provided data for this study and use molecular <italic toggle=""yes"">GALC</italic> analysis and PSY measurement continue to report cases with reduced GALC activity, normal PSY, and a genotype not normal or not consistent with “pseudodeficiency”. Although the screening strategy included in the nomination of KD to the RUSP had been recommended in previous publications [<xref rid=""B12-IJNS-10-00010"" ref-type=""bibr"">12</xref>,<xref",7_50,Newborn Screening for Krabbe Disease: Status Quo and Recommendations for Improvements,28 1 2024,,Krabbe_Disease
"ref-type=""bibr"">12</xref>,<xref rid=""B13-IJNS-10-00010"" ref-type=""bibr"">13</xref>], discussion among the authors identified several reasons for the lack of adoption by all NBS programs. One is the difficulty of state programs to adjust existing screening algorithms due to the concern, only supported by anecdotal reports [<xref rid=""B24-IJNS-10-00010"" ref-type=""bibr"">24</xref>], of possibly missing patients with IKD or even an AKD case following a change that focuses on IKD and LIKD as the primary targets",7_51,Newborn Screening for Krabbe Disease: Status Quo and Recommendations for Improvements,28 1 2024,,Krabbe_Disease
"focuses on IKD and LIKD as the primary targets of screening. Several programs rely on their advisory committees to determine screening algorithms, some even to set cutoffs. However, it is possible that change could be facilitated by the addition of IKD and LIKD to the RUSP as core conditions and with emphasis on the nominated screening strategy following the precedent of screening for spinal muscular atrophy by only testing for deletion of exon 7 in <italic toggle=""yes"">SMN1</italic>. (<uri",7_52,Newborn Screening for Krabbe Disease: Status Quo and Recommendations for Improvements,28 1 2024,,Krabbe_Disease
"7 in <italic toggle=""yes"">SMN1</italic>. (<uri http://www.w3.org/1999/xlink href=""https://www.hrsa.gov/advisory-committees/heritable-disorders/recommendations-reports"">https://www.hrsa.gov/advisory-committees/heritable-disorders/recommendations-reports</uri>; last accessed 16 January 2024). Finally, contracts with outside vendors and the necessary effort and cost of making changes to a program’s information systems can be obstacles to state programs adjusting their processes. A total of 11 cases with IKD",7_53,Newborn Screening for Krabbe Disease: Status Quo and Recommendations for Improvements,28 1 2024,,Krabbe_Disease
"their processes. A total of 11 cases with IKD were identified among a combined number of more than 2.7 million newborns screened in the seven states that shared data. PSY values ranged from 10 to 61 nM (median 42 nM). Short-term outcomes of screen positive cases in these states are shown in <xref rid=""IJNS-10-00010-t003"" ref-type=""table"">Table 3</xref>. Nine patients with IKD received an HSCT. Ages at HSCT are available for seven of these, ranging from 24 to 49 days of life (median: 31 days). The families",7_54,Newborn Screening for Krabbe Disease: Status Quo and Recommendations for Improvements,28 1 2024,,Krabbe_Disease
"49 days of life (median: 31 days). The families of the two remaining IKD cases decided against the invasive procedure after extensive counseling. Both patients developed the expected progressive symptoms of IKD; one already passed away and the other continues to receive supportive, palliative care. Two cases with LIKD have undergone HSCT within 4 months of life. Ten of eleven transplanted patients are alive, and detailed clinical information about six patients are currently being summarized for a separate",7_55,Newborn Screening for Krabbe Disease: Status Quo and Recommendations for Improvements,28 1 2024,,Krabbe_Disease
"are currently being summarized for a separate publication [<xref rid=""B25-IJNS-10-00010"" ref-type=""bibr"">25</xref>]. This study documents the currently variable approach to NBS for KD and the impact on false positive rates and case identification. This variability appears to have contributed to a delay in KD’s addition to the RUSP. Moreover, we showed that employing PSY as a second-tier test to determine if a case with reduced GALC activity should be reported as presumptive positive or negative for KD can",7_56,Newborn Screening for Krabbe Disease: Status Quo and Recommendations for Improvements,28 1 2024,,Krabbe_Disease
"as presumptive positive or negative for KD can virtually eliminate false positive results while identifying cases with IKD and LIKD with high sensitivity. Going forward, we recommend that state programs currently screening for KD review their historical outcomes with their advisory committees and make transparent decisions on whether to accept false positive results for such a devastating condition, or to adjust their procedures to ensure an efficient, effective, and manageable NBS program for KD. States",7_57,Newborn Screening for Krabbe Disease: Status Quo and Recommendations for Improvements,28 1 2024,,Krabbe_Disease
"and manageable NBS program for KD. States that plan to add KD to their NBS programs should also review the evidence and then make informed, explicit, and transparent decisions about their individual program’s goals (core conditions vs. secondary targets) in order to prevent false expectations regarding the chosen NBS strategy’s sensitivity and specificity towards the various forms of KD.",7_58,Newborn Screening for Krabbe Disease: Status Quo and Recommendations for Improvements,28 1 2024,,Krabbe_Disease
"Globoid Cell Leukodystrophy (Krabbe Disease): An Update Globoid cell leukodystrophy or Krabbe is a disease that affects children as well as adults who have mutations in the gene encoding the enzyme galactosylceramidase/galctocerebrosidase (GALC), resulting in the deposition of the toxic lipid D-galactosyl-beta1-1’ sphingosine (GalSph or psychosine). Several therapeutic modalities were used to treat patients with Krabbe disease, including hematopoietic stem cell transplantation, enzyme replacement therapy,",8_0,Globoid Cell Leukodystrophy (Krabbe Disease): An Update,31 10 2023,,Krabbe_Disease
"cell transplantation, enzyme replacement therapy, autophagy activators, intravenous immunoglobulin, and inhibitors of the Pyroptosis process, among many other approaches. In this article, I will briefly discuss the disease in both human and animal model, describe recent clinical observations as well as methods utilizing genetic analysis for diagnosis, and finally review recent advances in treating this rare and devastating disease. About 20 years ago, we reported that D-galactosyl-beta1-1’ sphingosine",8_1,Globoid Cell Leukodystrophy (Krabbe Disease): An Update,31 10 2023,,Krabbe_Disease
"reported that D-galactosyl-beta1-1’ sphingosine (GalSph, also known as psychosine), and D-glucosyl-beta1-1’ sphingosine (GluSph) induced the in vitro apoptosis of human natural killer (NK) cells.<xref rid=""cit0001"" ref-type=""bibr"">1</xref> NK cells are part of innate lymphoid cells 1 (ILC 1), which play major roles in fighting cancer but are also involved in inflammation.<xref rid=""cit0002"" ref-type=""bibr"">2</xref> Globoid cell leukodystrophy (GLD) or Krabbe disease (KD), is an autosomal recessive disease",8_2,Globoid Cell Leukodystrophy (Krabbe Disease): An Update,31 10 2023,,Krabbe_Disease
"disease (KD), is an autosomal recessive disease that affects infants.<xref rid=""cit0003"" ref-type=""bibr"">3–5</xref> The disease is caused by the destruction of oligodendrocytes, reduced myelin formation, and leading to the accumulation of globoid cells.<xref rid=""cit0006"" ref-type=""bibr"">6</xref>,<xref rid=""cit0007"" ref-type=""bibr"">7</xref> The toxic lipid GalSph, which is not present in normal brain or other tissues,<xref rid=""cit0008"" ref-type=""bibr"">8</xref> accumulates at high concentrations in the",8_3,Globoid Cell Leukodystrophy (Krabbe Disease): An Update,31 10 2023,,Krabbe_Disease
"accumulates at high concentrations in the brain of Krabbe patients, due to the deficiency of the enzyme galactosylceramidase/galctocerebrosidase (GALC). Although children are affected by the disease, adult-onset GLD is also prevalent but is usually neglected by clinicians.<xref rid=""cit0009"" ref-type=""bibr"">9</xref> GALC physiology, GLD pathophysiology, and therapeutic strategies for KD were recently reviewed.<xref rid=""cit0010"" ref-type=""bibr"">10</xref> Demyelination was observed in infantile KD patients",8_4,Globoid Cell Leukodystrophy (Krabbe Disease): An Update,31 10 2023,,Krabbe_Disease
"was observed in infantile KD patients suffering from GALC deficiency. In addition, an increase of pathological CD8<sup>+</sup> T lymphocytes was observed, suggesting a linkage between clinical severity and neuroimmunology. Taken together, these findings support the interplay among proteins in KD brain white matter.<xref rid=""cit0011"" ref-type=""bibr"">11</xref> Microscopic analyses show profound neuro-axonal degeneration with a mild effect on myelin structure, indicating that GALC accumulating in the neurons",8_5,Globoid Cell Leukodystrophy (Krabbe Disease): An Update,31 10 2023,,Krabbe_Disease
"indicating that GALC accumulating in the neurons is essential to protect the function of neurons regardless of myelin, which contributes to the pathogenesis of KD.<xref rid=""cit0012"" ref-type=""bibr"">12</xref> However, it must be noted that although the pathology of the infantile type of Krabbe disease exhibits atrophy of the brain and extensive loss of myelin in the white matter with massive gliosis and multiple globoid cells, in the few cases reporting adult-onset Krabbe disease, a focal and mild",8_6,Globoid Cell Leukodystrophy (Krabbe Disease): An Update,31 10 2023,,Krabbe_Disease
"adult-onset Krabbe disease, a focal and mild demyelination and a few globoid-like cells were observed.  Heterozygous missense mutation: c.1658G>A (p.G553E) and c.1901T>C (p.L634S) were identified in the GALC gene by whole-exome sequencing. In this study, a certain novel mutation, namely c.1658G>A (p.G553E) was observed, which broadened the mutation spectrum in KD patients.<xref rid=""cit0030"" ref-type=""bibr"">30</xref> Using CRISPR-Cas9 gene editing, point mutations T513M observed in infants introduced in",8_7,Globoid Cell Leukodystrophy (Krabbe Disease): An Update,31 10 2023,,Krabbe_Disease
"mutations T513M observed in infants introduced in the murine GALC, resulting in GALC T513M/T513M mice. These animals suffer from a decrease in GALC activity, increased psychosine levels, leading to progress towards lethal neurological phenotype. In contrast, another variant, ie, GALC G41S/G41S mice have normal lifespan, modest decreases of GALC, and minimal psychosine accumulation.<xref rid=""cit0022"" ref-type=""bibr"">22</xref> Changes in the gene expression of iPSCs and iPSC-derived neural stem cells (NSCs)",8_8,Globoid Cell Leukodystrophy (Krabbe Disease): An Update,31 10 2023,,Krabbe_Disease
"iPSCs and iPSC-derived neural stem cells (NSCs) from a patient with GLD designated as K-iPSCs/NSCs and normal control designated as AF-iPSCs/NSCs were investigated in order to determine the potential mechanism underlying GLD pathogenesis.<xref rid=""cit0031"" ref-type=""bibr"">31</xref> It was observed that mutations in the GALC gene affected the signaling pathways during neural development, suggesting that alterations in signaling pathways may contribute to GLD pathogenesis. These results also demonstrate",8_9,Globoid Cell Leukodystrophy (Krabbe Disease): An Update,31 10 2023,,Krabbe_Disease
"GLD pathogenesis. These results also demonstrate that the model based on K-iPSCs may represent a novel tool that can be used to study the underlying molecular basis of GLD.<xref rid=""cit0031"" ref-type=""bibr"">31</xref> Further, astrocytes collected from KD patients contain high levels of glucosylceramide and ceramide, suggesting that in certain cases the disease may not be always associated with the galactosylceramide and psychosine pathways.<xref rid=""cit0032"" ref-type=""bibr"">32</xref> Other",8_10,Globoid Cell Leukodystrophy (Krabbe Disease): An Update,31 10 2023,,Krabbe_Disease
"rid=""cit0032"" ref-type=""bibr"">32</xref> Other neuroinflammatory genes were explored to understand their correlation with disease severity in the twitcher mouse. It was observed that kinases such as Ripk1 kinase does not play a role in KD.<xref rid=""cit0033"" ref-type=""bibr"">33</xref> Collectively, these data suggest that although measuring the levels of GALC and psychosine is essential, other parameters must also be considered in order to reach a conclusive diagnosis therapy before is initiated. It is",8_11,Globoid Cell Leukodystrophy (Krabbe Disease): An Update,31 10 2023,,Krabbe_Disease
"diagnosis therapy before is initiated. It is imperative for pediatricians to identify patients with the disease as soon as possible. However, this might be difficult due to misunderstanding of the disease symptoms.<xref rid=""cit0034"" ref-type=""bibr"">34</xref> Doctors may rely on genetic studies to diagnose the disease. For example, in patients who had a leukodystrophy associated with hypomyelination or delayed myelination on MRI, it was suggested that exome genome sequencing would be used to identify KD",8_12,Globoid Cell Leukodystrophy (Krabbe Disease): An Update,31 10 2023,,Krabbe_Disease
"genome sequencing would be used to identify KD patients.<xref rid=""cit0035"" ref-type=""bibr"">35</xref> Further, KD patients with mitochondrial gene NDUFAF1 mutations were observed, suggesting that gene panel examination must be expanded in order not to miss pathogenic mutations.<xref rid=""cit0036"" ref-type=""bibr"">36</xref> In one study, two siblings with atypical clinical and neuroimaging phenotypes of KD were examined, and it was reported that they carry biallelic loss-of-function GALC variants, including",8_13,Globoid Cell Leukodystrophy (Krabbe Disease): An Update,31 10 2023,,Krabbe_Disease
"loss-of-function GALC variants, including a recurrent 30 kb deletion.<xref rid=""cit0037"" ref-type=""bibr"">37</xref> In an infant boy with KD, the pathogenic variants of the disease were screened by whole-exome sequencing. These variants expressed different outcomes. For example, c.328+5G>T variant was predicted to alter splicing, whereas the variant c.658C>T indicates truncation of the protein.<xref rid=""cit0038"" ref-type=""bibr"">38</xref> A whole-exome sequencing identified a pathogenic homozygous missense",8_14,Globoid Cell Leukodystrophy (Krabbe Disease): An Update,31 10 2023,,Krabbe_Disease
"identified a pathogenic homozygous missense mutation of the GALC gene in a young woman with an onset KD who was presented with generalized seizures, progressive cognitive decline, psychiatric symptoms, gait ataxia, and action-induced myoclonus.<xref rid=""cit0039"" ref-type=""bibr"">39</xref> Another polymorphic variant known as p.Ile562Thr over-represented in the KD population, was associated with reduced mature GALC protein and activity.<xref rid=""cit0011"" ref-type=""bibr"">11</xref> A patient who developed KD",8_15,Globoid Cell Leukodystrophy (Krabbe Disease): An Update,31 10 2023,,Krabbe_Disease
"A patient who developed KD in late infancy had a pathogenic genotype, showed reduced enzyme activity but surprisingly low psychosine levels, suggesting that measuring psychosine levels should be combined with other measurements, such as enzyme levels, as well as genotyping and correlation with the patient’s clinical presentations.<xref rid=""cit0040"" ref-type=""bibr"">40</xref> Therefore, magnetic resonance (MR) images showing abnormal signals, as well as the presence of globoid cells must be done before",8_16,Globoid Cell Leukodystrophy (Krabbe Disease): An Update,31 10 2023,,Krabbe_Disease
"the presence of globoid cells must be done before final diagnosis of the disease.<xref rid=""cit0041"" ref-type=""bibr"">41</xref> For instance, MR imaging diagnosed A 32-year-old woman with headache as adult onset KB with two pathogenic variants in GALC.<xref rid=""cit0042"" ref-type=""bibr"">42</xref> There was a high increase in psychosine levels in infants diagnosed with KD. This was corroborated with increased levels of acid ceramidase, a key enzyme for psychosine production, and hyperglycosylated",8_17,Globoid Cell Leukodystrophy (Krabbe Disease): An Update,31 10 2023,,Krabbe_Disease
"for psychosine production, and hyperglycosylated lysosomal-associated membrane protein 1, a marker for lysosomal activation in periventricular white matter.<xref rid=""cit0011"" ref-type=""bibr"">11</xref> This patient suffered from neuropathological changes. It should be stressed that diagnosis of KB is highly important as the disease carries a tremendous financial burden. A study estimated that KD patients had over $51 million in health care charges and hundreds of hospitalizations, demonstrating the health",8_18,Globoid Cell Leukodystrophy (Krabbe Disease): An Update,31 10 2023,,Krabbe_Disease
"of hospitalizations, demonstrating the health impacts of KD on the society.<xref rid=""cit0043"" ref-type=""bibr"">43</xref> Lysophospholipids play major roles in tumor microenvironment.<xref rid=""cit0044"" ref-type=""bibr"">44</xref> In this regard, GALC also plays a role in cancer.<xref rid=""cit0045"" ref-type=""bibr"">45</xref> Removal of β-galactose from β-galactosylceramide, leads to the formation of the oncosuppressor metabolite ceramide,<xref rid=""cit0046"" ref-type=""bibr"">46</xref> which may play a role in",8_19,Globoid Cell Leukodystrophy (Krabbe Disease): An Update,31 10 2023,,Krabbe_Disease
"which may play a role in tumor growth and differentiation.<xref rid=""cit0047"" ref-type=""bibr"">47</xref> GalSph and GlcSph, lipids that disrupt the lysosomes, play definitive roles in cancer therapy.<xref rid=""cit0048"" ref-type=""bibr"">48</xref> Consequently, they may contribute to the development of multidrug-resistance by cancer cells. It was shown that GlcCer may provoke immune reaction and acts as a self-antigen in KD. On the other hand, GalCer was recognized as an important cellular receptor for",8_20,Globoid Cell Leukodystrophy (Krabbe Disease): An Update,31 10 2023,,Krabbe_Disease
"recognized as an important cellular receptor for HIV-1.<xref rid=""cit0049"" ref-type=""bibr"">49</xref> Early studies showed that transplantation of hematopoietic stem cells from normal mice into syngeneic twitcher mice resulted in increased survival, but in these studies the success of the transplantation procedures did not go beyond 100 days.<xref rid=""cit0050"" ref-type=""bibr"">50</xref>,<xref rid=""cit0051"" ref-type=""bibr"">51</xref> In five patients with late-onset GLD, a high successful rate of recovery",8_21,Globoid Cell Leukodystrophy (Krabbe Disease): An Update,31 10 2023,,Krabbe_Disease
"GLD, a high successful rate of recovery after hematopoietic stem cell transplantation was reported.<xref rid=""cit0052"" ref-type=""bibr"">52</xref> A comprehensive study examining the impact of hematopoietic stem cell transplantation (HSCT), demonstrated that this therapeutic regimen is associated with reduced mortality in KD patients.<xref rid=""cit0053"" ref-type=""bibr"">53</xref> In a case study of KD patient showing progressive spastic paraparesis who underwent HSCT, it was observed that GALC activity",8_22,Globoid Cell Leukodystrophy (Krabbe Disease): An Update,31 10 2023,,Krabbe_Disease
"HSCT, it was observed that GALC activity returned to a normal level and the lesions in the brain and spinal cord became faint on images.<xref rid=""cit0054"" ref-type=""bibr"">54</xref> Among patients between 24 and 40 days of age, HSCT therapy was successful and the patients were alive 30 to 58 months later.<xref rid=""cit0013"" ref-type=""bibr"">13</xref> However, HSCT must be done during the first weeks of life before symptoms develop. Another regimen of therapy utilized recombinant adeno-associated virus",8_23,Globoid Cell Leukodystrophy (Krabbe Disease): An Update,31 10 2023,,Krabbe_Disease
"utilized recombinant adeno-associated virus (rAAV) vectors to infect Krabbe patient-derived neural stem cells (K-NSCs). Using several infected K-NSCs, this therapeutic regimen rescued GALC enzymatic activity in infected cells.<xref rid=""cit0055"" ref-type=""bibr"">55</xref> Another study successfully showed that human KD patients can be treated with high-dose AAVrh10 without blood stem cell transplantation.<xref rid=""cit0056"" ref-type=""bibr"">56</xref> The efficacy and safety of a single cisterna magna AAVhu68",8_24,Globoid Cell Leukodystrophy (Krabbe Disease): An Update,31 10 2023,,Krabbe_Disease
"and safety of a single cisterna magna AAVhu68 administration to treat KD was also reported.<xref rid=""cit0057"" ref-type=""bibr"">57</xref> In twitcher mice, adenovirus gene therapy of the lysosomal enzyme GALC significantly ameliorated central and peripheral neuropathology, prolonged survival, and largely normalized motor deficits. These observations indicate that AAV-gene therapy may be considered an alternative mode of effective intervention.<xref rid=""cit0058"" ref-type=""bibr"">58</xref> Rapamycin, an",8_25,Globoid Cell Leukodystrophy (Krabbe Disease): An Update,31 10 2023,,Krabbe_Disease
"ref-type=""bibr"">58</xref> Rapamycin, an inhibitor of mTOR but autophagy activator, was used in twitcher mice in order to reduce the deposition of insoluble ubiquitinated protein, corroborated with the attenuation of astrogliosis and microgliosis.<xref rid=""cit0059"" ref-type=""bibr"">59</xref> This therapeutic modality was critical in inducing cortical myelination, neurite density, and rescued the neurological abnormalities of twitcher mice. Further, it induced cell migration and improved the clearance of",8_26,Globoid Cell Leukodystrophy (Krabbe Disease): An Update,31 10 2023,,Krabbe_Disease
"cell migration and improved the clearance of focal adhesion in GALC-deficient fibroblasts.<xref rid=""cit0060"" ref-type=""bibr"">60</xref> Another therapeutic approach utilized lecithin/chitosan nanoparticles to prevent the cytotoxicity caused by psychosine in cultured human astrocytes in vitro suggesting a direct interaction between psychosine and the nanoparticles.<xref rid=""cit0061"" ref-type=""bibr"">61</xref> Enzyme replacement therapy is one of the initial approaches used to treat KD patients. However, it",8_27,Globoid Cell Leukodystrophy (Krabbe Disease): An Update,31 10 2023,,Krabbe_Disease
"approaches used to treat KD patients. However, it exerted limitations in relieving CNS lesions due to difficulties in passing the blood–brain barrier.<xref rid=""cit0062"" ref-type=""bibr"">62</xref> Administration of the enzyme GALC inserted into adeno-virus to twitcher mice resulted in the accumulation of this enzyme in the brains of these mice which consequently, led to prolong the mice lives.<xref rid=""cit0063"" ref-type=""bibr"">63</xref> Treating twitcher mouse with S202 amide, a galactosyltransferase",8_28,Globoid Cell Leukodystrophy (Krabbe Disease): An Update,31 10 2023,,Krabbe_Disease
"mouse with S202 amide, a galactosyltransferase inhibitor reduced GalCer and psychosine concentrations in the central and peripheral nervous systems, which significantly increased lifespan, although further studies are needed to understand the full therapeutic potential of such an inhibitor.<xref rid=""cit0064"" ref-type=""bibr"">64</xref> Substrate reduction therapy was also investigated utilizing RA 5557, a brain-penetrant inhibitor of GALC biosynthesis, in twitcher mice that lack GALC activity. This modality",8_29,Globoid Cell Leukodystrophy (Krabbe Disease): An Update,31 10 2023,,Krabbe_Disease
"mice that lack GALC activity. This modality was effective and has an acceptable safety in vivo profile.<xref rid=""cit0065"" ref-type=""bibr"">65</xref> Intriguingly, a novel approach for therapy was developed. Here, a young girl who was diagnosed with KD, received intravenous immunoglobulin (IVIg), and upon which her limb weakness improved. This was repeated when she reached 16 years old, and again her symptoms gradually improved. It was suggested that in certain KB cases, IVIg may be considered as a form of",8_30,Globoid Cell Leukodystrophy (Krabbe Disease): An Update,31 10 2023,,Krabbe_Disease
"KB cases, IVIg may be considered as a form of therapy.<xref rid=""cit0066"" ref-type=""bibr"">66</xref> Pentraxin-3 (PTX3), a soluble pattern recognition receptor and a regulator of innate immunity,<xref rid=""cit0067"" ref-type=""bibr"">67</xref> was seen in the CNS of GALC-deficient Krabbe patients and twitcher mice. PTX3 may exert a protective role by reducing the neuroinflammatory response that occurs in the spinal cord of GALC-deficient animals. Regarding the role of innate immune system, in situ",8_31,Globoid Cell Leukodystrophy (Krabbe Disease): An Update,31 10 2023,,Krabbe_Disease
"the role of innate immune system, in situ hybridization and immunohistochemical staining revealed that the expression of pro-inflammatory non-canonical caspase-11, canonical caspase-1, gasdermin D and cognate genes are induced in the nervous tissues. Caspase-11 was also found in reactive microglia/macrophages as well as in astrocytes, but caspase-1 and gasdermin D were restricted to reactive microglia/macrophages.<xref rid=""cit0068"" ref-type=""bibr"">68</xref> These results suggest that innate immune system",8_32,Globoid Cell Leukodystrophy (Krabbe Disease): An Update,31 10 2023,,Krabbe_Disease
"These results suggest that innate immune system might be involved in the inflammatory reactions associated with KB and twitcher mice. The role of the Pyroptosis process which utilizes gasdermin D and inflammasomes, in linking innate and adaptive immunity has been described.<xref rid=""cit0069"" ref-type=""bibr"">69</xref>,<xref rid=""cit0070"" ref-type=""bibr"">70</xref> It is therefore suggested that inhibitors of Pyroptosis such as those that inhibit inflammasomes, caspases, gasdermins, among others,<xref",8_33,Globoid Cell Leukodystrophy (Krabbe Disease): An Update,31 10 2023,,Krabbe_Disease
"caspases, gasdermins, among others,<xref rid=""cit0071"" ref-type=""bibr"">71</xref>,<xref rid=""cit0072"" ref-type=""bibr"">72</xref> should be evaluated for effective intervention in Krabbe disease. Although Krabbe disease was discovered by Dr Krabbe in the first twenty years of the last century, advances in understanding and treating this disease have been slow. When patients are presented in the clinic with a suspicious of disease occurring, neurologists and physicians rely on genetic studies in addition to",8_34,Globoid Cell Leukodystrophy (Krabbe Disease): An Update,31 10 2023,,Krabbe_Disease
"physicians rely on genetic studies in addition to the clinical observations in order to confirm the disease occurrence. Once this is validated, treatment can be started. Albeit early therapeutic modalities utilized hematopoietic stem cells transplantation and GALC enzyme replacement which are costly, recently several new therapeutic regimens have been successfully used to treat the disease, as shown in <xref rid=""f0001"" ref-type=""fig"">Figure 1</xref>. This figure also describes the algorithm of human",8_35,Globoid Cell Leukodystrophy (Krabbe Disease): An Update,31 10 2023,,Krabbe_Disease
"This figure also describes the algorithm of human disease from the time the patients enter the clinic until the time of therapy. The choice of the therapeutic modality should be agreed upon between the physicians and the parents of the patients diagnosed with the disease. Finally, the discovery of twitcher mice which resemble globoid cell leukodystrophy in humans, aided to some extent in certain aspects, particularly in generating novel therapeutic modalities. In this short review, I briefly touched on the",8_36,Globoid Cell Leukodystrophy (Krabbe Disease): An Update,31 10 2023,,Krabbe_Disease
"In this short review, I briefly touched on the nature of the disease and discussed novel approaches using genetic methods. I also discussed recent advances in treating KD.",8_37,Globoid Cell Leukodystrophy (Krabbe Disease): An Update,31 10 2023,,Krabbe_Disease
"<fig position=""float"" id=""f0001"" fig-type=""figure""><label>Figure 1</label><caption><p>Algorithm of human Krabbe disease.</p></caption><graphic http://www.w3.org/1999/xlink href=""ITT-12-105-g0001"" content-type=""print-only"" position=""float""></graphic></fig>",8_38,Globoid Cell Leukodystrophy (Krabbe Disease): An Update,31 10 2023,,Krabbe_Disease
"Untargeted Lipidomic Approach for Studying Different Nervous System Tissues of the Murine Model of Krabbe Disease Krabbe disease is a rare neurodegenerative disease with an autosomal recessive character caused by a mutation in the <italic toggle=""yes"">GALC</italic> gene. The mutation leads to an accumulation of psychosine and a subsequent degeneration of oligodendrocytes and Schwann cells. Psychosine is the main biomarker of the disease. The Twitcher mouse is the most commonly used animal model to study",9_0,Untargeted Lipidomic Approach for Studying Different Nervous System Tissues of the Murine Model of Krabbe Disease,23 10 2023,,Krabbe_Disease
"is the most commonly used animal model to study Krabbe disease. Although there are many references to this model in the literature, the lipidomic study of nervous system tissues in the Twitcher model has received little attention. This study focuses on the comparison of the lipid profiles of four nervous system tissues (brain, cerebellum, spinal cord, and sciatic nerve) in the Twitcher mouse compared to the wild-type mouse. Altogether, approximately 230 molecular species belonging to 19 lipid classes were",9_1,Untargeted Lipidomic Approach for Studying Different Nervous System Tissues of the Murine Model of Krabbe Disease,23 10 2023,,Krabbe_Disease
"species belonging to 19 lipid classes were annotated and quantified. A comparison at the levels of class, molecular species, and lipid building blocks showed significant differences between the two groups, particularly in the sciatic nerve. The in-depth study of the lipid phenotype made it possible to hypothesize the genes and enzymes involved in the changes. The integration of metabolic data with genetic data may be useful from a systems biology perspective to gain a better understanding of the molecular",9_2,Untargeted Lipidomic Approach for Studying Different Nervous System Tissues of the Murine Model of Krabbe Disease,23 10 2023,,Krabbe_Disease
"to gain a better understanding of the molecular basis of the disease. Globoid cell leukodystrophy, also called Krabbe disease (KD; OMIM #245200), is an autosomal recessive sphingolipidosis belonging to the larger class of lysosomal storage disorders (LSDs). It is characterized by decreased or abolished GALC enzymatic activity within cell lysosomes due to homozygous or compound heterozygous mutations in the galactosyl ceramidase gene (<italic toggle=""yes"">GALC</italic>, OMIM #606890; chromosome 14q31).",9_3,Untargeted Lipidomic Approach for Studying Different Nervous System Tissues of the Murine Model of Krabbe Disease,23 10 2023,,Krabbe_Disease
"OMIM #606890; chromosome 14q31). Different subtypes of KD, including infantile, late infantile, juvenile, and adult, are recognized based on specific mutations [<xref rid=""B1-biomolecules-13-01562"" ref-type=""bibr"">1</xref>]. GALC enzyme deficiency leads to an accumulation of the cytotoxic galactosyl sphingosine (psychosine, PSY) in the myelin sheath. This causes degeneration of oligodendrocytes and Schwann cells and the formation of macrophage-derived, psychosine-rich globoid cells [<xref",9_4,Untargeted Lipidomic Approach for Studying Different Nervous System Tissues of the Murine Model of Krabbe Disease,23 10 2023,,Krabbe_Disease
"psychosine-rich globoid cells [<xref rid=""B2-biomolecules-13-01562"" ref-type=""bibr"">2</xref>]. Enzyme replacement in vivo seems to be insufficient to completely restore homeostasis and can only partially eliminate PSY [<xref rid=""B3-biomolecules-13-01562"" ref-type=""bibr"">3</xref>]. Furthermore, a number of findings are appearing in the literature involving new aspects of KD’s progression that cannot be explained by PSY accumulation alone. One of the latest aspects highlighted is that PSY is released in",9_5,Untargeted Lipidomic Approach for Studying Different Nervous System Tissues of the Murine Model of Krabbe Disease,23 10 2023,,Krabbe_Disease
"aspects highlighted is that PSY is released in extracellular vesicles in the brain of the Twitcher (TWI) mouse (the natural KD murine model). Changes were found in the structure and function of the brain endothelium of KD patients and TWI mice, in vivo and in vitro, demonstrating an increased permeability of the vessels [<xref rid=""B4-biomolecules-13-01562"" ref-type=""bibr"">4</xref>]. In addition, KD seems to be characterized by autophagy dysregulation, neuronal degeneration, and calcium signaling defects.",9_6,Untargeted Lipidomic Approach for Studying Different Nervous System Tissues of the Murine Model of Krabbe Disease,23 10 2023,,Krabbe_Disease
"degeneration, and calcium signaling defects. The only available clinical treatment is hematopoietic stem cell transplantation (HSCT) for presymptomatic patients. Experimental treatments are currently under pre-clinical study, such as gene therapy (GT), chaperone-mediated therapy, or nanovector-mediated enzyme replacement therapy (ERT) [<xref rid=""B1-biomolecules-13-01562"" ref-type=""bibr"">1</xref>]. Lipids are an important class of biomolecules characterized by hundreds or thousands of molecules with a",9_7,Untargeted Lipidomic Approach for Studying Different Nervous System Tissues of the Murine Model of Krabbe Disease,23 10 2023,,Krabbe_Disease
"by hundreds or thousands of molecules with a considerable structural diversity that is reflected in the variety and complexity of the physiological processes in which they are involved (signaling membrane, reserve energy, endocrine action) [<xref rid=""B5-biomolecules-13-01562"" ref-type=""bibr"">5</xref>]. Since 2005, the International Lipid Classification and Nomenclature Committee under the sponsorship of the Lipid Metabolites and Pathways Strategy (LIPID MAPS) consortium established the “Comprehensive",9_8,Untargeted Lipidomic Approach for Studying Different Nervous System Tissues of the Murine Model of Krabbe Disease,23 10 2023,,Krabbe_Disease
"MAPS) consortium established the “Comprehensive Classification System for Lipids” that divided all lipids into eight lipid categories: fatty acyls, glycerolipids, glycerophospholipids, sphingolipids, sterol lipids, prenol lipids, saccharolipids, and polyketides. The complete set of lipid species in a cell, tissue, organism, or biological system is referred to by researchers as the “lipidome” and the broad-scale analytic study of pathways and networks of the lipidome as “lipidomics” [<xref",9_9,Untargeted Lipidomic Approach for Studying Different Nervous System Tissues of the Murine Model of Krabbe Disease,23 10 2023,,Krabbe_Disease
"networks of the lipidome as “lipidomics” [<xref rid=""B6-biomolecules-13-01562"" ref-type=""bibr"">6</xref>]. Lipidomics is a relatively young field of science that employs a variety of techniques to quantify the hundreds of chemically distinct lipids in cells and to spot changes in lipid metabolism and lipid-mediated signaling pathways that control cellular homeostasis in both health and sickness [<xref rid=""B7-biomolecules-13-01562"" ref-type=""bibr"">7</xref>]. Thanks to technological advances over the last",9_10,Untargeted Lipidomic Approach for Studying Different Nervous System Tissues of the Murine Model of Krabbe Disease,23 10 2023,,Krabbe_Disease
"Thanks to technological advances over the last decade, which have made it possible to carry out sensitive and accurate lipidomic research, there has been a recent increase in interest in the study of lipid molecules, as is well shown by the increase in the number of research articles published over the past few years [<xref rid=""B6-biomolecules-13-01562"" ref-type=""bibr"">6</xref>], and lipidomics is now seen as one of the most important and fundamental “omics”. The characterization of lipid profiles is",9_11,Untargeted Lipidomic Approach for Studying Different Nervous System Tissues of the Murine Model of Krabbe Disease,23 10 2023,,Krabbe_Disease
"The characterization of lipid profiles is increasingly conducted through LC/MS (liquid chromatography/mass spectrometry) analyses. Bioinformatics tools like LipidOne [<xref rid=""B8-biomolecules-13-01562"" ref-type=""bibr"">8</xref>], Biopan [<xref rid=""B9-biomolecules-13-01562"" ref-type=""bibr"">9</xref>], the MetaboAnalist 5.0 web platform [<xref rid=""B10-biomolecules-13-01562"" ref-type=""bibr"">10</xref>], and OmicsNet [<xref rid=""B11-biomolecules-13-01562"" ref-type=""bibr"">11</xref>] prove to be indispensable",9_12,Untargeted Lipidomic Approach for Studying Different Nervous System Tissues of the Murine Model of Krabbe Disease,23 10 2023,,Krabbe_Disease
"prove to be indispensable for processing data matrices, enabling comparisons between samples and variables. These tools facilitate the study of variations in molecular species and building blocks, as well as the prediction of the biochemical pathways involved [<xref rid=""B12-biomolecules-13-01562"" ref-type=""bibr"">12</xref>]. As metabolic diseases can develop long before they become clinically visible, it is particularly important to identify potential biomarkers in order to find suitable treatments or",9_13,Untargeted Lipidomic Approach for Studying Different Nervous System Tissues of the Murine Model of Krabbe Disease,23 10 2023,,Krabbe_Disease
"in order to find suitable treatments or preventive measures for the right patients. Nowadays, lipidomics is becoming a key tool for biomarker research, as thanks to the lipid profiling of potential biomarkers for disease, diagnosis and prognosis can be identified [<xref rid=""B13-biomolecules-13-01562"" ref-type=""bibr"">13</xref>]. Indeed, recent research has revealed that any disruption in a biological system is likely to affect its lipid pool’s abundance and/or composition. Furthermore, it has been shown",9_14,Untargeted Lipidomic Approach for Studying Different Nervous System Tissues of the Murine Model of Krabbe Disease,23 10 2023,,Krabbe_Disease
"composition. Furthermore, it has been shown that alterations in the blood lipid profile may be connected to the development of several serious human disorders, including cardiovascular disease [<xref rid=""B14-biomolecules-13-01562"" ref-type=""bibr"">14</xref>], hypertensive diseases [<xref rid=""B15-biomolecules-13-01562"" ref-type=""bibr"">15</xref>], Alzheimer’s disease [<xref rid=""B16-biomolecules-13-01562"" ref-type=""bibr"">16</xref>], and cancer [<xref rid=""B17-biomolecules-13-01562""",9_15,Untargeted Lipidomic Approach for Studying Different Nervous System Tissues of the Murine Model of Krabbe Disease,23 10 2023,,Krabbe_Disease
"and cancer [<xref rid=""B17-biomolecules-13-01562"" ref-type=""bibr"">17</xref>]. Despite this, the lipid composition of human or animal models of KD in central and in peripheral nervous system tissues or cells has received no attention in the literature. To the best of our knowledge, no works have been carried out using a lipidomics approach, although it is known that the molecular trigger and biomarker of KD is PSY, a lipid belonging to the class of lysosphingolipid, and lipid metabolism is critical in",9_16,Untargeted Lipidomic Approach for Studying Different Nervous System Tissues of the Murine Model of Krabbe Disease,23 10 2023,,Krabbe_Disease
"and lipid metabolism is critical in diseases belong to the class of LSDs, like KD. Only a few works concern the study of PSY, without a lipidomics approach but with biochemical approaches [<xref rid=""B18-biomolecules-13-01562"" ref-type=""bibr"">18</xref>,<xref rid=""B19-biomolecules-13-01562"" ref-type=""bibr"">19</xref>,<xref rid=""B20-biomolecules-13-01562"" ref-type=""bibr"">20</xref>,<xref rid=""B21-biomolecules-13-01562"" ref-type=""bibr"">21</xref>,<xref rid=""B22-biomolecules-13-01562"" ref-type=""bibr"">22</xref>].",9_17,Untargeted Lipidomic Approach for Studying Different Nervous System Tissues of the Murine Model of Krabbe Disease,23 10 2023,,Krabbe_Disease
"ref-type=""bibr"">22</xref>]. Therefore, the aim of this work is to investigate further lipidomic analyses of nervous system tissues, including sciatic nerve tissue (SN), spinal cord tissue (SC), and brain (B) and cerebellum (C) tissue in both a mouse model of KD (HOM) and healthy wild-type mice (WT), especially to highlight differences between the lipid profiles of healthy and sick subjects. In fact, in the context of systems biology, any alteration in the lipid profile may be linked to alterations in the",9_18,Untargeted Lipidomic Approach for Studying Different Nervous System Tissues of the Murine Model of Krabbe Disease,23 10 2023,,Krabbe_Disease
"lipid profile may be linked to alterations in the proteome and modifications in the genome [<xref rid=""B12-biomolecules-13-01562"" ref-type=""bibr"">12</xref>]. To carry out our research, we performed an untargeted lipidomic analysis on nervous system tissues of a mouse model of KD using LC/MS Q-TOF and then we proceeded with an analysis of the complex dataset obtained. Any differences will also relate to PSY levels. For this purpose, in addition to the lipid profile, the work proposes the quantification of",9_19,Untargeted Lipidomic Approach for Studying Different Nervous System Tissues of the Murine Model of Krabbe Disease,23 10 2023,,Krabbe_Disease
"profile, the work proposes the quantification of PSY by means of a targeted approach based on LC/MS Q-TOF.  The Lipidomic dataset of each tissue obtained from the lipidomic analysis contains qualitative and semi-quantitative information on all detected and annotated lipid molecular species. To evaluate the variations in the lipid profiles in the four tissues, multivariate statistical data analysis was performed at the levels of lipid class, lipid molecular species, and lipid building blocks. It must be",9_20,Untargeted Lipidomic Approach for Studying Different Nervous System Tissues of the Murine Model of Krabbe Disease,23 10 2023,,Krabbe_Disease
"species, and lipid building blocks. It must be considered that this study has limitations. Firstly, its exploratory nature results in a limited number of samples, due to the difficulty in obtaining tissues from the animal model. In fact, obtaining tissues from Twitcher mice is challenging due to maintenance issues. Often the homozygous mutant dies shortly after birth or is sacrificed directly by the mother. Thus, obtaining homozygous mutants that can survive for use in experiments is not easy.",9_21,Untargeted Lipidomic Approach for Studying Different Nervous System Tissues of the Murine Model of Krabbe Disease,23 10 2023,,Krabbe_Disease
"can survive for use in experiments is not easy. Additionally, there are approximately 10% dropouts due to disease complications. Moreover, they are considered a suffering model under Italian law, limiting the number of animals for experiments. Furthermore, the scarcity of samples did not allow us to consider additional parameters that could influence the lipid profile of nervous system tissues, such as the sex, dietary behavior, and body mass index of both healthy and diseased mice. A further limitation is",9_22,Untargeted Lipidomic Approach for Studying Different Nervous System Tissues of the Murine Model of Krabbe Disease,23 10 2023,,Krabbe_Disease
"and diseased mice. A further limitation is that the untargeted lipidomic approach detected the presence of lipid classes and subclasses, which are not present as marked species in the internal standard used for annotation (Splash Lipidomix). This may have resulted in an over- or under-estimation of these classes (such as PE-O, Hex-Cer, SHex-Cer). In this work, we analyzed four different tissues belonging to the nervous system (brain, cerebellum, spinal cord and sciatic nerve) of healthy (WT) and Krabbe",9_23,Untargeted Lipidomic Approach for Studying Different Nervous System Tissues of the Murine Model of Krabbe Disease,23 10 2023,,Krabbe_Disease
"and sciatic nerve) of healthy (WT) and Krabbe disease (HOM) mouse models to highlight any changes in the lipid profile attributable to the disease. The results of the lipid profile analysis revealed 219 to 246 molecular species belonging to up to 19 lipid classes in the different tissues. The data show that the total lipid concentration decreases in all tissues in the HOM group compared to the corresponding tissues in the WT group; however, this decrease is statistically significant only in the sciatic",9_24,Untargeted Lipidomic Approach for Studying Different Nervous System Tissues of the Murine Model of Krabbe Disease,23 10 2023,,Krabbe_Disease
"is statistically significant only in the sciatic nerve tissue, where the total lipid concentration is almost halved in the HOM group compared to the WT. Regarding the lipid class analysis, the brain demonstrated less differences between the two groups, with just 1 class differing between the two groups; on the other hand, SN demonstrated differences between the two groups in 13 different lipid classes.  At the level of lipid molecular species, the PCA carried out on all four tissues demonstrated the same",9_25,Untargeted Lipidomic Approach for Studying Different Nervous System Tissues of the Murine Model of Krabbe Disease,23 10 2023,,Krabbe_Disease
"out on all four tissues demonstrated the same result with the most separation between the two groups observed in the SN and SC tissues. In addition, the concentration of psychosine in the four tissues increases in HOM compared to WT and correlates with the magnitude of the change in lipid profile in the four HOM tissues. The differences in the lipid profile are particularly pronounced in SN tissue. The lack of a reference for the lipid profile of the sciatic nerve does not allow a comparison of the data we",9_26,Untargeted Lipidomic Approach for Studying Different Nervous System Tissues of the Murine Model of Krabbe Disease,23 10 2023,,Krabbe_Disease
"nerve does not allow a comparison of the data we obtained. However, using the typical myelin lipid profile as a reference, it can be seen that the lipid classes most decreased in HOM are those characteristic of the myelin sheath (such as HexCer, SHexCer, PC, and PE-O). In contrast, no major differences in SM levels were found. The concentrations of HexCer and SHexCer were lower than expected in both HOM and WT. It is also important to mention that the decrease in the concentration of PC within the HOM",9_27,Untargeted Lipidomic Approach for Studying Different Nervous System Tissues of the Murine Model of Krabbe Disease,23 10 2023,,Krabbe_Disease
"in the concentration of PC within the HOM could be the result of oxidation processes affecting these species. This process produces a specific oxidized PC, which, in turn, could contribute to increased neurodegeneration within nerve tissues. In addition, CE levels were increased in the HOM group compared to the WT, which could be a compensating system to reduce cholesterol accumulation caused by the degradation of the myelin. These results not only demonstrate that these changes could be the consequence of",9_28,Untargeted Lipidomic Approach for Studying Different Nervous System Tissues of the Murine Model of Krabbe Disease,23 10 2023,,Krabbe_Disease
"that these changes could be the consequence of neurodegeneration but also could be its cause. Focusing on the SN tissue, the heatmap shows a number of molecular species which differ between the two groups, most of them of the PE-O and PC classes, such as PE O-16:1_18:1, PE O-18:1_18:1, PE O-18:2_18:1, PE O-16:1_18:1, PC 16:0_18:1, and PC 18:0_18:1. The analyses of lipid class interactions showed that the transformation of Pas and PCs into PG, PI, and PS is favored. This allows the assumption that there is",9_29,Untargeted Lipidomic Approach for Studying Different Nervous System Tissues of the Murine Model of Krabbe Disease,23 10 2023,,Krabbe_Disease
"favored. This allows the assumption that there is an altered regulation of genes such as CDS, PLD, and PSS. At the level of the buildings blocks analysis, a general inhibition of the elongation of carbon chains can be seen, while the activity of desaturase enzymes increased, mainly involving chains with 18 and 22 carbon atoms. These results could indicate alterations in specific enzymes involved with the elongation and desaturation of fatty acids such as elongase 1, elongase 3, elongase 6, Δ6 desaturase,",9_30,Untargeted Lipidomic Approach for Studying Different Nervous System Tissues of the Murine Model of Krabbe Disease,23 10 2023,,Krabbe_Disease
"1, elongase 3, elongase 6, Δ6 desaturase, Δ5 desaturase, and Stearoyl-CoA desaturase. These changes confirm the presence of significant changes and differences in the lipid profile of specific tissues inside the HOM mice compared to WT. These changes can be helpful to increase knowledge of the molecular causes of Krabbe disease. In fact, in a systems biology scenario, the changes in the lipidic phenotype highlighted in this study could allow us to hypothesize and predict the alterations in the enzymatic",9_31,Untargeted Lipidomic Approach for Studying Different Nervous System Tissues of the Murine Model of Krabbe Disease,23 10 2023,,Krabbe_Disease
"and predict the alterations in the enzymatic activity and genetic expression that could be caused by the disease. Regarding the possible clinical significance of the differences in the lipid profile in KD patients, it may help, first of all, in the identification of early biomarkers for KD, which are currently missing at the moment in clinical practice. Additionally, some lipid biomarkers could help to identify the degree of progression of the disease, and thus the more appropriate approach to treat",9_32,Untargeted Lipidomic Approach for Studying Different Nervous System Tissues of the Murine Model of Krabbe Disease,23 10 2023,,Krabbe_Disease
"and thus the more appropriate approach to treat specific patients. Also very appealing is the possible usage of lipid biomarkers as a readout of the effect of a therapeutic approach. Classic biomarkers of the disease, such as GALC enzymatic activity and PSY levels, are not enough to study KD. Indeed, Twitcher mice treated with experimental therapies (as gene therapy approaches) that present GALC enzymatic activity and PSY levels in normal ranges are not cured from KD [<xref rid=""B47-biomolecules-13-01562""",9_33,Untargeted Lipidomic Approach for Studying Different Nervous System Tissues of the Murine Model of Krabbe Disease,23 10 2023,,Krabbe_Disease
"from KD [<xref rid=""B47-biomolecules-13-01562"" ref-type=""bibr"">47</xref>,<xref rid=""B50-biomolecules-13-01562"" ref-type=""bibr"">50</xref>], but die from multiple and still-unclear complications.",9_34,Untargeted Lipidomic Approach for Studying Different Nervous System Tissues of the Murine Model of Krabbe Disease,23 10 2023,,Krabbe_Disease
"HDAC-6 inhibition ameliorates the early neuropathology in a mouse model of Krabbe disease Krabbe disease (KD), or globoid cell leukodystrophy, is a lysosomal storage disorder caused by mutations in the <italic toggle=""yes"">galc</italic> gene that result in impaired activity of the lysosomal hydrolase galactosylceramidase (GALC). As a consequence of GALC deficiency, the metabolism of several galactosphingolipids is impaired and GALC substrates - galactosylceramide and galactosylsphingosine (also known as",10_0,HDAC-6 inhibition ameliorates the early neuropathology in a mouse model of Krabbe disease,27 7 2023,,Krabbe_Disease
"and galactosylsphingosine (also known as psychosine), accumulate (<xref rid=""ref44"" ref-type=""bibr"">Wenger et al., 1997</xref>). Whereas galactocerebroside builds up inside macrophages and microglia giving rise to globoid cells, psychosine is highly toxic to myelin-forming cells (oligodendrocytes in the central nervous system - CNS - and Schwann cells in the peripheral nervous system - PNS). Psychosine disrupts the architecture and composition of lipid rafts (<xref rid=""ref45"" ref-type=""bibr"">White et al.,",10_1,HDAC-6 inhibition ameliorates the early neuropathology in a mouse model of Krabbe disease,27 7 2023,,Krabbe_Disease
"(<xref rid=""ref45"" ref-type=""bibr"">White et al., 2009</xref>) and leads to the activation of apoptosis pathways that result in progressive demyelination (<xref rid=""ref23"" ref-type=""bibr"">Krabbe, 1916</xref>; <xref rid=""ref29"" ref-type=""bibr"">Miyatake and Suzuki, 1972</xref>; <xref rid=""ref18"" ref-type=""bibr"">Igisu and Suzuki, 1984</xref>; <xref rid=""ref48"" ref-type=""bibr"">Zaka and Wenger, 2004</xref>). Consequently, KD patients present severe irritability, limb stiffness, motor function impairment, mental",10_2,HDAC-6 inhibition ameliorates the early neuropathology in a mouse model of Krabbe disease,27 7 2023,,Krabbe_Disease
"limb stiffness, motor function impairment, mental development arrest, epileptic seizures, hypertonicity and dystonia (<xref rid=""ref23"" ref-type=""bibr"">Krabbe, 1916</xref>; <xref rid=""ref2"" ref-type=""bibr"">Bradbury et al., 2021</xref>). Among the KD onsets based on the age of presentation of symptoms, the infantile onset is the most prevalent and severe subtype, as patients usually do not survive past 2 years of age (<xref rid=""ref14"" ref-type=""bibr"">Hagberg et al., 1969</xref>; <xref rid=""ref2""",10_3,HDAC-6 inhibition ameliorates the early neuropathology in a mouse model of Krabbe disease,27 7 2023,,Krabbe_Disease
"et al., 1969</xref>; <xref rid=""ref2"" ref-type=""bibr"">Bradbury et al., 2021</xref>). The Twitcher mouse, a naturally occurring mutant with a premature stop codon in the <italic toggle=""yes"">galc</italic> gene that results in lack of functional GALC (<xref rid=""ref40"" ref-type=""bibr"">Suzuki and Suzuki, 1995</xref>), mimics the infantile form of KD (<xref rid=""ref25"" ref-type=""bibr"">Lee et al., 2006</xref>). Similarly to human patients, Twitcher mice present demyelination both in the CNS and PNS that can be",10_4,HDAC-6 inhibition ameliorates the early neuropathology in a mouse model of Krabbe disease,27 7 2023,,Krabbe_Disease
"demyelination both in the CNS and PNS that can be clearly detected at post-natal day 15 (P15) (<xref rid=""ref41"" ref-type=""bibr"">Tanaka et al., 1988</xref>). Hematopoietic stem cell transplantation (HSCT) emerged as one of the most valuable treatments for KD, delaying disease progression and extending life time of KD patients if transplantation is performed before the onset of symptoms (<xref rid=""ref12"" ref-type=""bibr"">Escolar et al., 2005</xref>; <xref rid=""ref24"" ref-type=""bibr"">Kreher et al.,",10_5,HDAC-6 inhibition ameliorates the early neuropathology in a mouse model of Krabbe disease,27 7 2023,,Krabbe_Disease
"<xref rid=""ref24"" ref-type=""bibr"">Kreher et al., 2022</xref>). In spite of co-morbidities, HSCT slows down disease progression and improves pathology in the CNS, while a less significant effect is observed in the PNS, possibly given the lower ability of Schwann cells to uptake exogenous GALC (<xref rid=""ref46"" ref-type=""bibr"">Wright et al., 2017</xref>; <xref rid=""ref43"" ref-type=""bibr"">Weinstock et al., 2020</xref>; <xref rid=""ref22"" ref-type=""bibr"">Kofler et al., 2022</xref>). Two AAV-based clinical",10_6,HDAC-6 inhibition ameliorates the early neuropathology in a mouse model of Krabbe disease,27 7 2023,,Krabbe_Disease
"et al., 2022</xref>). Two AAV-based clinical trials for KD (NCT04693598 and NCT04771416) are currently underway (<xref rid=""ref15"" ref-type=""bibr"">Heller et al., 2023</xref>) but, it is likely that future therapeutic approaches for KD will rely on combinatorial strategies aimed at providing the missing enzyme and simultaneously counteract neuroinflammation and promote neuroprotection. With respect to neuroprotection, it is important to note that in addition to demyelination, neuronal-autonomous defects are",10_7,HDAC-6 inhibition ameliorates the early neuropathology in a mouse model of Krabbe disease,27 7 2023,,Krabbe_Disease
"to demyelination, neuronal-autonomous defects are also central players in KD progression (<xref rid=""ref30"" ref-type=""bibr"">Nogueira-Rodrigues et al., 2016</xref>; <xref rid=""ref4"" ref-type=""bibr"">Brites and Sousa, 2022</xref>; <xref rid=""ref24"" ref-type=""bibr"">Kreher et al., 2022</xref>). In fact, a myelin-independent axonopathy contributes to the severe neuropathology in Twitcher mice (<xref rid=""ref7"" ref-type=""bibr"">Castelvetri et al., 2011</xref>; <xref rid=""ref37"" ref-type=""bibr"">Smith et al.,",10_8,HDAC-6 inhibition ameliorates the early neuropathology in a mouse model of Krabbe disease,27 7 2023,,Krabbe_Disease
"<xref rid=""ref37"" ref-type=""bibr"">Smith et al., 2011</xref>; <xref rid=""ref42"" ref-type=""bibr"">Teixeira et al., 2014</xref>; <xref rid=""ref24"" ref-type=""bibr"">Kreher et al., 2022</xref>), correlating with reports of loss of unmyelinated axons in human KD nerves (<xref rid=""ref38"" ref-type=""bibr"">Sourander and Olsson, 1968</xref>). Our group has shown that before the onset of demyelination, Twitcher mice already exhibit a decreased number of axons in the CNS and PNS, and of sensory neurons in dorsal root",10_9,HDAC-6 inhibition ameliorates the early neuropathology in a mouse model of Krabbe disease,27 7 2023,,Krabbe_Disease
"and PNS, and of sensory neurons in dorsal root ganglia (<xref rid=""ref42"" ref-type=""bibr"">Teixeira et al., 2014</xref>). In fact, Twitcher neurons have a generalized impairment in axonal transport including mitochondria (<xref rid=""ref6"" ref-type=""bibr"">Cantuti Castelvetri et al., 2013</xref>), lysosomes (<xref rid=""ref42"" ref-type=""bibr"">Teixeira et al., 2014</xref>) and synaptic vesicles (<xref rid=""ref42"" ref-type=""bibr"">Teixeira et al., 2014</xref>), possibly associated with abnormal levels of",10_10,HDAC-6 inhibition ameliorates the early neuropathology in a mouse model of Krabbe disease,27 7 2023,,Krabbe_Disease
"possibly associated with abnormal levels of post-translational modifications of tubulin and with a decreased microtubule stability (<xref rid=""ref42"" ref-type=""bibr"">Teixeira et al., 2014</xref>). Of note, in Twitcher mice, microtubules have decreased levels of polyglutamylated and acetylated tubulin (<xref rid=""ref42"" ref-type=""bibr"">Teixeira et al., 2014</xref>), which may be directly linked with the defective axonal transport. α-Tubulin acetylation is tightly regulated by α-tubulin-acetyltransferases",10_11,HDAC-6 inhibition ameliorates the early neuropathology in a mouse model of Krabbe disease,27 7 2023,,Krabbe_Disease
"tightly regulated by α-tubulin-acetyltransferases (αTATs) and a specific histone deacetylase, HDAC6, that has a cytoplasmic location and thereby does not interfere with histone acetylation (<xref rid=""ref17"" ref-type=""bibr"">Hubbert et al., 2002</xref>). Studies using HDAC6 inhibitors highlighted their neuroprotective role as they facilitate axonal transport by promoting microtubule acetylation (<xref rid=""ref11"" ref-type=""bibr"">Dompierre et al., 2007</xref>; <xref rid=""ref33"" ref-type=""bibr"">Rivieccio et",10_12,HDAC-6 inhibition ameliorates the early neuropathology in a mouse model of Krabbe disease,27 7 2023,,Krabbe_Disease
"<xref rid=""ref33"" ref-type=""bibr"">Rivieccio et al., 2009</xref>; <xref rid=""ref49"" ref-type=""bibr"">Zilberman et al., 2009</xref>; <xref rid=""ref9"" ref-type=""bibr"">Chen et al., 2010</xref>). This is especially relevant in KD, as Twitcher mice have impaired axonal transport and diminished levels of acetylated tubulin (<xref rid=""ref42"" ref-type=""bibr"">Teixeira et al., 2014</xref>). Several HDAC6 inhibitors have been used in various models of neurodegeneration such as tubastatin A (<xref rid=""ref19""",10_13,HDAC-6 inhibition ameliorates the early neuropathology in a mouse model of Krabbe disease,27 7 2023,,Krabbe_Disease
"such as tubastatin A (<xref rid=""ref19"" ref-type=""bibr"">Jian et al., 2017</xref>), trichostatin A (<xref rid=""ref39"" ref-type=""bibr"">Su et al., 2021</xref>), ACY-775 (<xref rid=""ref1"" ref-type=""bibr"">Benoy et al., 2017</xref>) and ACY-738 (<xref rid=""ref34"" ref-type=""bibr"">Rossaert et al., 2019</xref>). ACY-738 (N-hydroxy-2-(1-phenylcycloproylamino)pyrimidine-5-carboxamide) inhibits the C- terminal catalytic domain of HDAC6, increasing α-tubulin acetylation without altering histone acetylation (<xref",10_14,HDAC-6 inhibition ameliorates the early neuropathology in a mouse model of Krabbe disease,27 7 2023,,Krabbe_Disease
"without altering histone acetylation (<xref rid=""ref20"" ref-type=""bibr"">Jochems et al., 2014</xref>). ACY-738 has low nanomolar potency (IC<sub>50</sub>–1,7 nM) with a high selectivity of 60-1,500-fold over class I HDACs. Although this compound has a rapid elimination from plasma (T<sub>1/2</sub>–0.2 h), upon systemic administration, it leads to a ratio brain-plasma exposure of 1.22:1, demonstrating a higher capacity to cross the blood–brain barrier than other HDAC6 inhibitors such as tubastatin A (<xref",10_15,HDAC-6 inhibition ameliorates the early neuropathology in a mouse model of Krabbe disease,27 7 2023,,Krabbe_Disease
"HDAC6 inhibitors such as tubastatin A (<xref rid=""ref20"" ref-type=""bibr"">Jochems et al., 2014</xref>; <xref rid=""ref28"" ref-type=""bibr"">Majid et al., 2015</xref>). As stable microtubules are the railroads for axonal cargos, ACY-738 is also associated with increased efficiency of axonal transport (<xref rid=""ref28"" ref-type=""bibr"">Majid et al., 2015</xref>; <xref rid=""ref13"" ref-type=""bibr"">Guo et al., 2017</xref>). Current data indicates that ACY-738 promotes axon growth <italic toggle=""yes"">in",10_16,HDAC-6 inhibition ameliorates the early neuropathology in a mouse model of Krabbe disease,27 7 2023,,Krabbe_Disease
"promotes axon growth <italic toggle=""yes"">in vitro</italic> in inhibitory conditions (<xref rid=""ref33"" ref-type=""bibr"">Rivieccio et al., 2009</xref>), and <italic toggle=""yes"">in vivo</italic> improves the outcome of animal models of several neurodegenerative conditions, including Alzheimer’s disease, multiple sclerosis, Charcot–Marie-Tooth and amyotrophic lateral sclerosis. In mouse models of demyelinating disorders, such as multiple sclerosis, ACY-738 treatment increases short-term memory and",10_17,HDAC-6 inhibition ameliorates the early neuropathology in a mouse model of Krabbe disease,27 7 2023,,Krabbe_Disease
"ACY-738 treatment increases short-term memory and decelerates disease progression (<xref rid=""ref27"" ref-type=""bibr"">LoPresti, 2019</xref>), whereas in a model of Charcot–Marie–Tooth disease (a demyelinating neuropathy), ACY-738 improves sensory and motor nerve conduction (<xref rid=""ref1"" ref-type=""bibr"">Benoy et al., 2017</xref>). In the case of Amyotrophic Lateral Sclerosis, treating the TgFUS<sup>+/+</sup> mouse model with ACY-738 leads to improved axonal transport, motor phenotypes and lifespan (<xref",10_18,HDAC-6 inhibition ameliorates the early neuropathology in a mouse model of Krabbe disease,27 7 2023,,Krabbe_Disease
"transport, motor phenotypes and lifespan (<xref rid=""ref34"" ref-type=""bibr"">Rossaert et al., 2019</xref>; <xref rid=""ref5"" ref-type=""bibr"">Burg et al., 2021</xref>). ACY-738 has been shown to ameliorate Alzheimer disease’ related-impairments such as short term memory and hyperactivity, by acting on tau and tubulin modifications leading to normalization of axonal transport (<xref rid=""ref28"" ref-type=""bibr"">Majid et al., 2015</xref>). In view of the therapeutic properties of ACY-738 in conditions that share",10_19,HDAC-6 inhibition ameliorates the early neuropathology in a mouse model of Krabbe disease,27 7 2023,,Krabbe_Disease
"properties of ACY-738 in conditions that share similar pathological features to Krabbe disease, including demyelination and axonal transport defects, it emerged as a promising candidate to test in this leukodystrophy. Given the impairment caused by the defect in tubulin acetylation in Twitcher nerves, we tested whether ACY-738 delivery could counteract the early neuropathology of this KD model. Here, we show that the early systemic delivery of ACY-738 robustly increases tubulin acetylation, stabilizes",10_20,HDAC-6 inhibition ameliorates the early neuropathology in a mouse model of Krabbe disease,27 7 2023,,Krabbe_Disease
"increases tubulin acetylation, stabilizes microtubule dynamics, increases axonal transport, and rescues the early loss of myelinated axons in the optic and sciatic nerves of Twitcher mice. Our results thus support that ACY-738 has neuroprotective effect in KD and should be considered as an add-on therapy in KD.   KD is a severe neurological condition for which therapeutic options are still limited and mainly focused on managing symptomatology. Even in successful cases, following the current standard",10_21,HDAC-6 inhibition ameliorates the early neuropathology in a mouse model of Krabbe disease,27 7 2023,,Krabbe_Disease
"successful cases, following the current standard therapy, HSCT, some patients still develop severe peripheral neuropathy years after transplantation (<xref rid=""ref36"" ref-type=""bibr"">Siddiqi et al., 2006</xref>; <xref rid=""ref46"" ref-type=""bibr"">Wright et al., 2017</xref>). In the case of AAV-mediated delivery of <italic toggle=""yes"">Galc</italic>, in long-term surviving AAV-treated Twitcher mice, multiple demyelinating areas are still detected in the brain, suggesting a possible late onset reduction of",10_22,HDAC-6 inhibition ameliorates the early neuropathology in a mouse model of Krabbe disease,27 7 2023,,Krabbe_Disease
"suggesting a possible late onset reduction of AAV efficacy (<xref rid=""ref31"" ref-type=""bibr"">Rafi et al., 2012</xref>, <xref rid=""ref32"" ref-type=""bibr"">2015</xref>; <xref rid=""ref16"" ref-type=""bibr"">Heller et al., 2021</xref>). As such, the current data on KD strongly points towards the possibility that long-term effective therapies targeting different aspects of the pathology and different groups of patients, will most probably rely on combinatorial approaches. The knowledge gained on the dysregulated",10_23,HDAC-6 inhibition ameliorates the early neuropathology in a mouse model of Krabbe disease,27 7 2023,,Krabbe_Disease
"The knowledge gained on the dysregulated molecular events in KD neurons, specifically on the defects in tubulin acetylation, microtubule dynamics and axonal transport, opens exciting new windows of action to counteract the associated neuropathology. In view of the therapeutic properties of ACY-738 in conditions that share similar pathological features to Krabbe disease, as is the case of demyelinating conditions such as Charcot–Marie Tooth disease and multiple sclerosis where it slows disease progression",10_24,HDAC-6 inhibition ameliorates the early neuropathology in a mouse model of Krabbe disease,27 7 2023,,Krabbe_Disease
"sclerosis where it slows disease progression (<xref rid=""ref27"" ref-type=""bibr"">LoPresti, 2019</xref>) and improves nerve conduction (<xref rid=""ref1"" ref-type=""bibr"">Benoy et al., 2017</xref>), ACY-738 emerged as a promising candidate to test in Krabbe. In fact, our data supports that the positive effects of ACY-738 extend to other conditions where myelin is affected, as is the case of leukodystrophies. Likewise, in the Krabbe disease mouse model, we observed similar outcomes on the improvement of axonal",10_25,HDAC-6 inhibition ameliorates the early neuropathology in a mouse model of Krabbe disease,27 7 2023,,Krabbe_Disease
"similar outcomes on the improvement of axonal transport, as those previously reported for mouse models of amyotrophic lateral sclerosis (<xref rid=""ref34"" ref-type=""bibr"">Rossaert et al., 2019</xref>; <xref rid=""ref5"" ref-type=""bibr"">Burg et al., 2021</xref>) and Alzheimer disease’ (<xref rid=""ref28"" ref-type=""bibr"">Majid et al., 2015</xref>). However, and given the genetic nature of Krabbe disease where toxic substrates of GALC continuously accumulate in the nervous system, ACY-738 did not provide on its",10_26,HDAC-6 inhibition ameliorates the early neuropathology in a mouse model of Krabbe disease,27 7 2023,,Krabbe_Disease
"nervous system, ACY-738 did not provide on its own for increased lifespan in this disorder, in contrast to what happens in models of other neurodegenerative diseases (<xref rid=""ref34"" ref-type=""bibr"">Rossaert et al., 2019</xref>; <xref rid=""ref5"" ref-type=""bibr"">Burg et al., 2021</xref>). Still, considering its properties and neuroprotective effects, ACY-738 is a compelling add-on therapeutic candidate for Krabbe disease as it is able to correct the defects on tubulin acetylation, microtubule dynamics and",10_27,HDAC-6 inhibition ameliorates the early neuropathology in a mouse model of Krabbe disease,27 7 2023,,Krabbe_Disease
"on tubulin acetylation, microtubule dynamics and axonal transport and to counteract the early axonal loss observed in Twitcher mice. The reason why these improvements failed to translate into increased lifespan is most likely due to the fact that ACY-738 does not act directly on the genetic cause of the disease, and therefore does not counteract the continuous deleterious accumulation of psychosine. Our data therefore supports that while ACY-738 cannot be considered as a single therapeutic candidate for",10_28,HDAC-6 inhibition ameliorates the early neuropathology in a mouse model of Krabbe disease,27 7 2023,,Krabbe_Disease
"considered as a single therapeutic candidate for KD, it could potentially be tested in combinatorial approaches where gene/enzyme replacement therapy targeting metabolic correction is done. The original contributions presented in the study are included in the article/<xref rid=""SM1"" ref-type=""supplementary-material"">Supplementary material</xref>, further inquiries can be directed to the corresponding authors. The animal study was reviewed and approved by i3S Ethical Committee, Instituto de Investigação e",10_29,HDAC-6 inhibition ameliorates the early neuropathology in a mouse model of Krabbe disease,27 7 2023,,Krabbe_Disease
"Ethical Committee, Instituto de Investigação e Inovação em Saúde (i3S), University of Porto, Porto, Portugal. MS and JN-R coordinated research. MJ, MS, and JN-R designed the study. SB, PB, MJ, MS, and JN-R analysed experiments. SB, MM, MP, AM, and JN-R performed the experiments. SB, MS, and JN-R wrote the manuscript. All authors contributed to the article and approved the submitted version. The Nerve Regeneration group was supported by a Sponsored Research Agreement with Acetylon Pharmaceuticals Inc. that",10_30,HDAC-6 inhibition ameliorates the early neuropathology in a mouse model of Krabbe disease,27 7 2023,,Krabbe_Disease
"Agreement with Acetylon Pharmaceuticals Inc. that provided ACY-738. The work was also supported by Portuguese funds through FCT - Fundação para a Ciência e a Tecnologia/Ministério da Ciência, Tecnologia e Ensino Superior in the framework of the project EJPRD/0002/2019. The funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article, or the decision to submit it for publication. OG and MJ were employed by Acetylon Pharmaceuticals Inc. The remaining",10_31,HDAC-6 inhibition ameliorates the early neuropathology in a mouse model of Krabbe disease,27 7 2023,,Krabbe_Disease
"by Acetylon Pharmaceuticals Inc. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its",10_32,HDAC-6 inhibition ameliorates the early neuropathology in a mouse model of Krabbe disease,27 7 2023,,Krabbe_Disease
"in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.",10_33,HDAC-6 inhibition ameliorates the early neuropathology in a mouse model of Krabbe disease,27 7 2023,,Krabbe_Disease
"Brain Targeted AAV1-GALC Gene Therapy Reduces Psychosine and Extends Lifespan in a Mouse Model of Krabbe Disease Krabbe disease (KD) is a progressive and devasting neurological disorder that leads to the toxic accumulation of psychosine in the white matter of the central nervous system (CNS). The condition is inherited via biallelic, loss-of-function mutations in the galactosylceramidase (<italic toggle=""yes"">GALC</italic>) gene. To rescue <italic toggle=""yes"">GALC</italic> gene function in the CNS of the",11_0,Brain Targeted AAV1-GALC Gene Therapy Reduces Psychosine and Extends Lifespan in a Mouse Model of Krabbe Disease,25 7 2023,,Krabbe_Disease
"gene function in the CNS of the twitcher mouse model of KD, an adeno-associated virus serotype 1 vector expressing murine <italic toggle=""yes"">GALC</italic> under control of a chicken β-actin promoter (AAV1-GALC) was administered to newborn mice by unilateral intracerebroventricular injection. AAV1-GALC treatment significantly improved body weight gain and survival of the twitcher mice (<italic toggle=""yes"">n</italic> = 8) when compared with untreated controls (<italic toggle=""yes"">n</italic> = 5). The",11_1,Brain Targeted AAV1-GALC Gene Therapy Reduces Psychosine and Extends Lifespan in a Mouse Model of Krabbe Disease,25 7 2023,,Krabbe_Disease
"(<italic toggle=""yes"">n</italic> = 5). The maximum weight gain after postnatal day 10 was significantly increased from 81% to 217%. The median lifespan was extended from 43 days to 78 days (range: 74–88 days) in the AAV1-GALC-treated group. Widespread expression of GALC protein and alleviation of KD neuropathology were detected in the CNS of the treated mice when examined at the moribund stage. Functionally, elevated levels of psychosine were completely normalized in the forebrain region of the treated",11_2,Brain Targeted AAV1-GALC Gene Therapy Reduces Psychosine and Extends Lifespan in a Mouse Model of Krabbe Disease,25 7 2023,,Krabbe_Disease
"normalized in the forebrain region of the treated mice. In the posterior region, which includes the mid- and the hindbrain, psychosine was reduced by an average of 77% (range: 53–93%) compared to the controls. Notably, psychosine levels in this region were inversely correlated with body weight and lifespan of AAV1-GALC-treated mice, suggesting that the degree of viral transduction of posterior brain regions following ventricular injection determined treatment efficacy on growth and survivability,",11_3,Brain Targeted AAV1-GALC Gene Therapy Reduces Psychosine and Extends Lifespan in a Mouse Model of Krabbe Disease,25 7 2023,,Krabbe_Disease
"treatment efficacy on growth and survivability, respectively. Overall, our results suggest that viral vector delivery via the cerebroventricular system can partially correct psychosine accumulation in brain that leads to slower disease progression in KD. Krabbe disease (KD) (OMIM 245200) is a lysosomal storage disorder (LSD) characterized by demyelination of the central nervous system (CNS) [<xref rid=""B1-genes-14-01517"" ref-type=""bibr"">1</xref>]. It is a monogenetic, autosomal recessive disease caused by",11_4,Brain Targeted AAV1-GALC Gene Therapy Reduces Psychosine and Extends Lifespan in a Mouse Model of Krabbe Disease,25 7 2023,,Krabbe_Disease
"autosomal recessive disease caused by deficiency in galactosylceramidase (GALC, EC 3.2.1.46) enzymatic activity [<xref rid=""B2-genes-14-01517"" ref-type=""bibr"">2</xref>]. GALC activity is predominantly localized in lysosomes, where it is essential for normal catabolism of galactolipids, including psychosine and a major myelin component, galactosylceramide. GALC deficiency results in progressive accumulation of psychosine, which is cytotoxic to oligodendrocytes and Schwann cells [<xref",11_5,Brain Targeted AAV1-GALC Gene Therapy Reduces Psychosine and Extends Lifespan in a Mouse Model of Krabbe Disease,25 7 2023,,Krabbe_Disease
"to oligodendrocytes and Schwann cells [<xref rid=""B3-genes-14-01517"" ref-type=""bibr"">3</xref>,<xref rid=""B4-genes-14-01517"" ref-type=""bibr"">4</xref>]. Loss of these myelin-forming cells causes demyelination and neurodegeneration in both the CNS and the peripheral nervous system (PNS) during early developmental stages [<xref rid=""B5-genes-14-01517"" ref-type=""bibr"">5</xref>]. Clinically, the onset of infantile KD occurs between three and six months of age. Initial symptoms include spasticity, irritability,",11_6,Brain Targeted AAV1-GALC Gene Therapy Reduces Psychosine and Extends Lifespan in a Mouse Model of Krabbe Disease,25 7 2023,,Krabbe_Disease
"symptoms include spasticity, irritability, and hypersensitivity to external stimuli, followed by opisthotonic posturing, visual failure, hypertonic fits, and loss of tendon reflexes; death typically occurs before two years of age. Treatment options for KD are mainly palliative, with the exception of hematopoietic stem cell transplantation (HSCT) which can slow disease progression in infantile KD patients when treated at a pre-symptomatic stage [<xref rid=""B6-genes-14-01517"" ref-type=""bibr"">6</xref>,<xref",11_7,Brain Targeted AAV1-GALC Gene Therapy Reduces Psychosine and Extends Lifespan in a Mouse Model of Krabbe Disease,25 7 2023,,Krabbe_Disease
"ref-type=""bibr"">6</xref>,<xref rid=""B7-genes-14-01517"" ref-type=""bibr"">7</xref>] or in late-onset KD patients treated during an early clinical stage [<xref rid=""B8-genes-14-01517"" ref-type=""bibr"">8</xref>].  The twitcher mouse is the most widely used animal model to study pathology and experimental therapeutics in KD [<xref rid=""B9-genes-14-01517"" ref-type=""bibr"">9</xref>,<xref rid=""B10-genes-14-01517"" ref-type=""bibr"">10</xref>]. It carries a homozygous, nonsense mutation (p.W339X) on the <italic",11_8,Brain Targeted AAV1-GALC Gene Therapy Reduces Psychosine and Extends Lifespan in a Mouse Model of Krabbe Disease,25 7 2023,,Krabbe_Disease
"nonsense mutation (p.W339X) on the <italic toggle=""yes"">GALC</italic> gene that abolishes GALC protein expression through a nonsense-mediated mRNA decay mechanism [<xref rid=""B11-genes-14-01517"" ref-type=""bibr"">11</xref>]. Complete loss of GALC function leads to abnormal accumulation of psychosine, particularly in nervous tissues [<xref rid=""B12-genes-14-01517"" ref-type=""bibr"">12</xref>,<xref rid=""B13-genes-14-01517"" ref-type=""bibr"">13</xref>]. The most common variant observed in human infantile KD is a 30",11_9,Brain Targeted AAV1-GALC Gene Therapy Reduces Psychosine and Extends Lifespan in a Mouse Model of Krabbe Disease,25 7 2023,,Krabbe_Disease
"variant observed in human infantile KD is a 30 kb deletion from exon 11 through exon 17, which also causes a complete loss of GALC protein [<xref rid=""B14-genes-14-01517"" ref-type=""bibr"">14</xref>]. Thus, the twitcher mouse presents an authentic genetic and biochemical disease model for infantile KD. Clinically, twitcher mice have a failure to thrive phenotype, characterized by slow weight gain through postnatal day (PND) 32, followed by precipitous weight loss until death around PND 40 [<xref",11_10,Brain Targeted AAV1-GALC Gene Therapy Reduces Psychosine and Extends Lifespan in a Mouse Model of Krabbe Disease,25 7 2023,,Krabbe_Disease
"weight loss until death around PND 40 [<xref rid=""B15-genes-14-01517"" ref-type=""bibr"">15</xref>]. A decrease in motor function becomes apparent at PND 15, and the motor function rapidly declines after PND 20 [<xref rid=""B16-genes-14-01517"" ref-type=""bibr"">16</xref>]. Pathologically, globoid cells are present in twitcher mice and increase in number in the white matter of the CNS and the PNS beginning at PNDs 10−15 [<xref rid=""B17-genes-14-01517"" ref-type=""bibr"">17</xref>]. Neuroinflammation including",11_11,Brain Targeted AAV1-GALC Gene Therapy Reduces Psychosine and Extends Lifespan in a Mouse Model of Krabbe Disease,25 7 2023,,Krabbe_Disease
"Neuroinflammation including microglial activation and astrogliosis are also prominent and can be detected at two to three weeks [<xref rid=""B18-genes-14-01517"" ref-type=""bibr"">18</xref>]. Demyelination in the CNS and the PNS can be detected after PND 21, and its progression is associated with neurological symptoms such as tremor and spasticity [<xref rid=""B19-genes-14-01517"" ref-type=""bibr"">19</xref>,<xref rid=""B20-genes-14-01517"" ref-type=""bibr"">20</xref>]. Recently, CD8-positive cytotoxic T lymphocytes",11_12,Brain Targeted AAV1-GALC Gene Therapy Reduces Psychosine and Extends Lifespan in a Mouse Model of Krabbe Disease,25 7 2023,,Krabbe_Disease
"Recently, CD8-positive cytotoxic T lymphocytes were also found in the CNS of twitcher mice and implicated to play a role in initiation of clinical symptoms in the model [<xref rid=""B21-genes-14-01517"" ref-type=""bibr"">21</xref>]. The use of adeno-associated viral (AAV) vectors has emerged as a strategy to achieve widespread in vivo gene replacement in the CNS and the PNS. A growing number of gene therapy studies using AAV vectors have yielded promising results in preclinical applications, paving the way for",11_13,Brain Targeted AAV1-GALC Gene Therapy Reduces Psychosine and Extends Lifespan in a Mouse Model of Krabbe Disease,25 7 2023,,Krabbe_Disease
"in preclinical applications, paving the way for phase I and II clinical trials using AAV to treat the CNS-affecting LSDs (reviewed in [<xref rid=""B22-genes-14-01517"" ref-type=""bibr"">22</xref>,<xref rid=""B23-genes-14-01517"" ref-type=""bibr"">23</xref>]). One clinical trial to treat KD patients combines hematopoietic stem cell transplantation and intravenous AAV serotype rh10-<italic toggle=""yes"">GALC</italic> gene therapy (ID: NCT04693598). The nonblinded, non-randomized trial is ongoing with plans to enroll",11_14,Brain Targeted AAV1-GALC Gene Therapy Reduces Psychosine and Extends Lifespan in a Mouse Model of Krabbe Disease,25 7 2023,,Krabbe_Disease
"trial is ongoing with plans to enroll six KD infants. Another trial was planned to study AAV serotype hu68-GALC administered into cisterna magna (NCT04771416). Unfortunately, the clinical trial was halted by the sponsor in early 2023 due to product prioritization. Several different AAV serotypes have been considered for gene therapy studies; while AAV serotype 1 (AAV1) is one of the most common viral vectors tested, not much information is available on its application in KD. Here, we report on the results",11_15,Brain Targeted AAV1-GALC Gene Therapy Reduces Psychosine and Extends Lifespan in a Mouse Model of Krabbe Disease,25 7 2023,,Krabbe_Disease
"application in KD. Here, we report on the results of a preclinical gene replacement study with AAV1-GALC in the twitcher mouse model of KD, including a description of GALC protein distribution and psychosine levels in different brain regions, which may provide useful information regarding treatment efficacy following AAV treatment.  The twitcher mouse is a naturally occurring model of infantile KD that exhibits a complete loss of GALC function [<xref rid=""B9-genes-14-01517"" ref-type=""bibr"">9</xref>].",11_16,Brain Targeted AAV1-GALC Gene Therapy Reduces Psychosine and Extends Lifespan in a Mouse Model of Krabbe Disease,25 7 2023,,Krabbe_Disease
"ref-type=""bibr"">9</xref>]. Therefore, substrate accumulation in the CNS of this model happens early, and animals are onset with disease symptoms around PND 10. We hypothesized that performing AAV1-GALC gene replacement at neonatal stage would induce global CNS expression of GALC leading to substrate reduction. Given that psychosine levels are only mildly elevated on PND 1 in twitcher mice compared to wildtype controls [<xref rid=""B29-genes-14-01517"" ref-type=""bibr"">29</xref>], GALC expression at an early",11_17,Brain Targeted AAV1-GALC Gene Therapy Reduces Psychosine and Extends Lifespan in a Mouse Model of Krabbe Disease,25 7 2023,,Krabbe_Disease
"GALC expression at an early age could slow psychosine accumulation and alleviate disease progression. To replace the function of endogenous GALC, we constructed a murine <italic toggle=""yes"">GALC</italic> cDNA expression vector under the control of a chicken β-actin promoter on the AAV2 genomic DNA backbone, packaged in the AAV1 capsid. Gene replacement was achieved by injecting 6.5 × 10<sup>10</sup> genomes of AAV1-GALC particles into the right ventricle of neonatal twitcher pups (<italic",11_18,Brain Targeted AAV1-GALC Gene Therapy Reduces Psychosine and Extends Lifespan in a Mouse Model of Krabbe Disease,25 7 2023,,Krabbe_Disease
"ventricle of neonatal twitcher pups (<italic toggle=""yes"">n</italic> = 8) on or before PND 3. Control animals, including untreated twitcher mice (<italic toggle=""yes"">n</italic> = 5) and wildtypes, were housed, handled and studied alongside the treated mice until the moribund stage (<xref rid=""genes-14-01517-t001"" ref-type=""table"">Table 1</xref>).  To examine the brain expression of GALC protein from transgene, we performed immunohistochemistry (IHC) on sagittal brain sections of AAV1-GALC-treated mice. In",11_19,Brain Targeted AAV1-GALC Gene Therapy Reduces Psychosine and Extends Lifespan in a Mouse Model of Krabbe Disease,25 7 2023,,Krabbe_Disease
"brain sections of AAV1-GALC-treated mice. In our study, all the treated mice had a similar spatial distribution of GALC protein; therefore, GALC signals from a representative mouse (A02) were illustrated in <xref rid=""genes-14-01517-f001"" ref-type=""fig"">Figure 1</xref>. We detected a widespread CNS distribution of GALC in the AAV1-GALC treated mice at PND 88 (<xref rid=""genes-14-01517-f001"" ref-type=""fig"">Figure 1</xref>A), compared to an undetectable IHC-GALC signal in a control twitcher mouse (C02) at",11_20,Brain Targeted AAV1-GALC Gene Therapy Reduces Psychosine and Extends Lifespan in a Mouse Model of Krabbe Disease,25 7 2023,,Krabbe_Disease
"signal in a control twitcher mouse (C02) at PND 42 (<xref rid=""genes-14-01517-f001"" ref-type=""fig"">Figure 1</xref>B). GALC protein was predominantly expressed in the forebrain (<xref rid=""genes-14-01517-f001"" ref-type=""fig"">Figure 1</xref>A), including the cerebral cortex (ctx), the corpus collosum (cc), the hippocampus (hpc), the thalamus (th), the hypothalamus (hth), and the caudate putamen (cp). At lower levels, GALC was also expressed in the midbrain (mbr) (<xref rid=""genes-14-01517-f001""",11_21,Brain Targeted AAV1-GALC Gene Therapy Reduces Psychosine and Extends Lifespan in a Mouse Model of Krabbe Disease,25 7 2023,,Krabbe_Disease
"midbrain (mbr) (<xref rid=""genes-14-01517-f001"" ref-type=""fig"">Figure 1</xref>C), the cerebellum (<xref rid=""genes-14-01517-f001"" ref-type=""fig"">Figure 1</xref>D), and the pons (<xref rid=""genes-14-01517-f001"" ref-type=""fig"">Figure 1</xref>E). Distinctive patterns of neuronal expression were detected in hpc (<xref rid=""genes-14-01517-f001"" ref-type=""fig"">Figure 1</xref>A), dentate gyrus (<xref rid=""genes-14-01517-f001"" ref-type=""fig"">Figure 1</xref>A), and Purkinje cells (<xref rid=""genes-14-01517-f001""",11_22,Brain Targeted AAV1-GALC Gene Therapy Reduces Psychosine and Extends Lifespan in a Mouse Model of Krabbe Disease,25 7 2023,,Krabbe_Disease
"Purkinje cells (<xref rid=""genes-14-01517-f001"" ref-type=""fig"">Figure 1</xref>D), which were less apparent in the medulla (mdl) (<xref rid=""genes-14-01517-f001"" ref-type=""fig"">Figure 1</xref>A).  To determine whether AAV1-GALC injected directly into brain ventricle was transduced into peripheral tissues, we examined GALC levels in liver tissue of the treated mice. No significant increase of GALC was detected in the treated mice compared with that in the control. Additionally, we tried examining GALC levels",11_23,Brain Targeted AAV1-GALC Gene Therapy Reduces Psychosine and Extends Lifespan in a Mouse Model of Krabbe Disease,25 7 2023,,Krabbe_Disease
"Additionally, we tried examining GALC levels in the plasma of treated mice. However, we were not able to sample clear plasma from the twitcher mice at the moribund stage due to their severe dehydration state. Our results suggest that there was not significant, or at least detectable, leakage of AAV1-GALC into the peripheral tissues of animals in our study.  Pathological analysis of postmortem KD brains reveals extensive neuroinflammation, prominent astrogliosis (in white matter), and the presence of",11_24,Brain Targeted AAV1-GALC Gene Therapy Reduces Psychosine and Extends Lifespan in a Mouse Model of Krabbe Disease,25 7 2023,,Krabbe_Disease
"(in white matter), and the presence of globoid cells, multinucleated macrophages characterized by the accumulation of lipids [<xref rid=""B30-genes-14-01517"" ref-type=""bibr"">30</xref>,<xref rid=""B31-genes-14-01517"" ref-type=""bibr"">31</xref>,<xref rid=""B32-genes-14-01517"" ref-type=""bibr"">32</xref>]. Looking at these pathologies in our AAV1-GALC-treated mice, which had widespread GALC expression, we observed that the number of globoid cells was dramatically reduced in the cerebellum white matter (cbwm).",11_25,Brain Targeted AAV1-GALC Gene Therapy Reduces Psychosine and Extends Lifespan in a Mouse Model of Krabbe Disease,25 7 2023,,Krabbe_Disease
"reduced in the cerebellum white matter (cbwm). Additionally, the appearance of vacuoles detected in the cbwm, which is an indication of intramyelinic oedema, was also lowered in the AAV1-GALC-treated mice, as analyzed by LFB/PAS staining (<xref rid=""genes-14-01517-f002"" ref-type=""fig"">Figure 2</xref>A vs. <xref rid=""genes-14-01517-f002"" ref-type=""fig"">Figure 2</xref>B). Activated reactive astrocytes had elevated glial fibrillary acidic protein (GFAP) levels that were positively correlated with the extent",11_26,Brain Targeted AAV1-GALC Gene Therapy Reduces Psychosine and Extends Lifespan in a Mouse Model of Krabbe Disease,25 7 2023,,Krabbe_Disease
"that were positively correlated with the extent of astrogliosis. An apparent reduction of GFAP signal was detected in the AAV1-GALC-treated mouse, which suggests an alleviation of astrogliosis compared to that in the control animals at the moribund stage (<xref rid=""genes-14-01517-f002"" ref-type=""fig"">Figure 2</xref>C vs. <xref rid=""genes-14-01517-f002"" ref-type=""fig"">Figure 2</xref>D). In the current study, untreated twitcher mice gained weight until PND 31, followed by sharp deterioration over the next",11_27,Brain Targeted AAV1-GALC Gene Therapy Reduces Psychosine and Extends Lifespan in a Mouse Model of Krabbe Disease,25 7 2023,,Krabbe_Disease
"31, followed by sharp deterioration over the next 10 to 12 days. The average maximal body weight attained was 181% of weight on PND 10, demonstrating a failure-to-thrive phenotype. In contrast, the body weights of twitcher mice treated with AAV1-GALC were partially rescued; the treated mice gained 205% of their body weight (**** <italic toggle=""yes"">p</italic> < 0.0001 vs. controls) from PND 10 to PND 38, compared to unaffected wildtype mice that gained 281% of their body weight over the same period.",11_28,Brain Targeted AAV1-GALC Gene Therapy Reduces Psychosine and Extends Lifespan in a Mouse Model of Krabbe Disease,25 7 2023,,Krabbe_Disease
"281% of their body weight over the same period. Moreover, the treated mice maintained their weights longer, up to PND 59, and then gradually deteriorated over the last three–four weeks of their lifespans (<xref rid=""genes-14-01517-f003"" ref-type=""fig"">Figure 3</xref>A). The median lifespan of the AAV1-GALC treated mice was 78 days compared with that of the untreated controls of 43 days—an 81% increase (<xref rid=""genes-14-01517-f003"" ref-type=""fig"">Figure 3</xref>B; **** <italic toggle=""yes"">p</italic> <",11_29,Brain Targeted AAV1-GALC Gene Therapy Reduces Psychosine and Extends Lifespan in a Mouse Model of Krabbe Disease,25 7 2023,,Krabbe_Disease
"3</xref>B; **** <italic toggle=""yes"">p</italic> < 0.0001). Next, we analyzed the effect of <italic toggle=""yes"">GALC</italic> gene replacement on substrate clearance. Hemibrain divided into anterior- and posterior-brain portions was analyzed for the distribution of psychosine levels (<xref rid=""genes-14-01517-f004"" ref-type=""fig"">Figure 4</xref>A). The anterior portion contained forebrain regions closest to the viral particle injection site (i.e., lateral ventricle); while the posterior portion contained",11_30,Brain Targeted AAV1-GALC Gene Therapy Reduces Psychosine and Extends Lifespan in a Mouse Model of Krabbe Disease,25 7 2023,,Krabbe_Disease
"ventricle); while the posterior portion contained the midbrain, the cerebellum, and brain stem regions, which were further away from the injection site. Psychosine is enriched in myelin, and a higher content of white matter is present in the posterior portion; thus, more psychosine accumulation takes place in these regions. Accordingly, psychosine levels were two times higher in the posterior brain compared to in the anterior brain in untreated animals (blue bars in <xref rid=""genes-14-01517-f004""",11_31,Brain Targeted AAV1-GALC Gene Therapy Reduces Psychosine and Extends Lifespan in a Mouse Model of Krabbe Disease,25 7 2023,,Krabbe_Disease
"(blue bars in <xref rid=""genes-14-01517-f004"" ref-type=""fig"">Figure 4</xref>B; 11.8 vs. 5.8 ng/mg). AAV1-GALC treatment normalized psychosine levels in twitcher mice to a level indistinguishable from the wildtype in the anterior brain. Psychosine levels were reduced by 89% in the treated group compared to in the untreated group at the moribund stage (<xref rid=""genes-14-01517-f004"" ref-type=""fig"">Figure 4</xref>B (left); **** <italic toggle=""yes"">p</italic> < 0.0001), which suggests that <italic",11_32,Brain Targeted AAV1-GALC Gene Therapy Reduces Psychosine and Extends Lifespan in a Mouse Model of Krabbe Disease,25 7 2023,,Krabbe_Disease
"< 0.0001), which suggests that <italic toggle=""yes"">GALC</italic> gene delivery was highly efficient in regions proximal to the injection site. By comparison, AAV1-GALC administration resulted in a 77% (range: 53–92%) reduction of psychosine accumulation in the posterior brain of treated mice compared to in the posterior brain of the untreated mice at the moribund stage (<xref rid=""genes-14-01517-f004"" ref-type=""fig"">Figure 4</xref>B (right); **** <italic toggle=""yes"">p</italic> < 0.0001). Given that",11_33,Brain Targeted AAV1-GALC Gene Therapy Reduces Psychosine and Extends Lifespan in a Mouse Model of Krabbe Disease,25 7 2023,,Krabbe_Disease
"toggle=""yes"">p</italic> < 0.0001). Given that cerebellum and brain stem are major pathological sites in KD and incomplete psychosine clearance was observed in these brain regions, we hypothesized that the degree of substrate clearance in the posterior brain may be associated with the severity of disease phenotype. Therefore, we performed a correlation analysis to determine whether psychosine levels in the posterior brain correlated to treatment efficacy. Interestingly, psychosine levels in the posterior",11_34,Brain Targeted AAV1-GALC Gene Therapy Reduces Psychosine and Extends Lifespan in a Mouse Model of Krabbe Disease,25 7 2023,,Krabbe_Disease
"Interestingly, psychosine levels in the posterior brain, but not the anterior brain, were significantly and inversely correlated with the lifespan (Pearson r = −0.72, * <italic toggle=""yes"">p</italic> < 0.05; <xref rid=""genes-14-01517-f004"" ref-type=""fig"">Figure 4</xref>C) and the maximum body weight (Pearson r = −0.75, * <italic toggle=""yes"">p</italic> < 0.05; <xref rid=""genes-14-01517-f004"" ref-type=""fig"">Figure 4</xref>D) of the AAV1-GALC-treated mice. Our results suggest that following viral particle",11_35,Brain Targeted AAV1-GALC Gene Therapy Reduces Psychosine and Extends Lifespan in a Mouse Model of Krabbe Disease,25 7 2023,,Krabbe_Disease
"Our results suggest that following viral particle injection to the lateral ventricle, the level of GALC activity achieved in remote brain regions is not sufficient to attain complete substrate clearance and thereby the maximum treatment efficacy. AAV1 vector-mediated gene therapy has been used in several human clinical studies, including the treatment of lipoprotein lipase deficiency [<xref rid=""B33-genes-14-01517"" ref-type=""bibr"">33</xref>], antitrypsin deficiency [<xref rid=""B34-genes-14-01517""",11_36,Brain Targeted AAV1-GALC Gene Therapy Reduces Psychosine and Extends Lifespan in a Mouse Model of Krabbe Disease,25 7 2023,,Krabbe_Disease
"deficiency [<xref rid=""B34-genes-14-01517"" ref-type=""bibr"">34</xref>], and muscular dystrophy [<xref rid=""B35-genes-14-01517"" ref-type=""bibr"">35</xref>]. It has also been shown to yield robust transgene expression in the CNS of several animal models [<xref rid=""B36-genes-14-01517"" ref-type=""bibr"">36</xref>,<xref rid=""B37-genes-14-01517"" ref-type=""bibr"">37</xref>,<xref rid=""B38-genes-14-01517"" ref-type=""bibr"">38</xref>,<xref rid=""B39-genes-14-01517"" ref-type=""bibr"">39</xref>]. In light of these recent",11_37,Brain Targeted AAV1-GALC Gene Therapy Reduces Psychosine and Extends Lifespan in a Mouse Model of Krabbe Disease,25 7 2023,,Krabbe_Disease
"In light of these recent studies, we chose the AAV serotype 1 vector for our study. To maximize the CNS distribution of viral vector infection, we administered AAV1-GALC via injection directly into the lateral ventricle during the neonatal period. Our intent was that the viral vector would enter the cerebrospinal fluid (CSF) flow and be delivered globally in the CNS through the ventricular system [<xref rid=""B40-genes-14-01517"" ref-type=""bibr"">40</xref>]. Compared to one previous study using the same AAV1",11_38,Brain Targeted AAV1-GALC Gene Therapy Reduces Psychosine and Extends Lifespan in a Mouse Model of Krabbe Disease,25 7 2023,,Krabbe_Disease
"to one previous study using the same AAV1 serotype [<xref rid=""B41-genes-14-01517"" ref-type=""bibr"">41</xref>], we achieved more widespread expression of GALC in the CNS and, therefore, observed a more significant correction to lifespan extension (i.e., medians of 78 vs. 55 days). Since both studies used strong constitutive promoters and murine <italic toggle=""yes"">GALC</italic> cDNA, the difference in efficacy may likely be a result of the higher AAV1-GALC dose administered in the current study (i.e., 6.5",11_39,Brain Targeted AAV1-GALC Gene Therapy Reduces Psychosine and Extends Lifespan in a Mouse Model of Krabbe Disease,25 7 2023,,Krabbe_Disease
"dose administered in the current study (i.e., 6.5 × 10<sup>10</sup> vs. 3 × 10<sup>10</sup> genomes). A more recent study that injected 1 × 10<sup>11</sup> genomes of AAVhu68-human GALC to the lateral ventricle of twitcher mice achieved an improvement in the median lifespan of 130 days [<xref rid=""B42-genes-14-01517"" ref-type=""bibr"">42</xref>]. Differences in AAV serotype and dosage likely account for observed differences in survivability. To our knowledge, our work represents one of the few preclinical",11_40,Brain Targeted AAV1-GALC Gene Therapy Reduces Psychosine and Extends Lifespan in a Mouse Model of Krabbe Disease,25 7 2023,,Krabbe_Disease
"our work represents one of the few preclinical studies with AAV-GALC gene therapy that highlights the correlations between psychosine clearance and treatment efficacy. Among existing studies in twitcher mouse-related models [<xref rid=""B41-genes-14-01517"" ref-type=""bibr"">41</xref>,<xref rid=""B42-genes-14-01517"" ref-type=""bibr"">42</xref>,<xref rid=""B43-genes-14-01517"" ref-type=""bibr"">43</xref>,<xref rid=""B44-genes-14-01517"" ref-type=""bibr"">44</xref>,<xref rid=""B45-genes-14-01517""",11_41,Brain Targeted AAV1-GALC Gene Therapy Reduces Psychosine and Extends Lifespan in a Mouse Model of Krabbe Disease,25 7 2023,,Krabbe_Disease
"rid=""B45-genes-14-01517"" ref-type=""bibr"">45</xref>,<xref rid=""B46-genes-14-01517"" ref-type=""bibr"">46</xref>,<xref rid=""B47-genes-14-01517"" ref-type=""bibr"">47</xref>], murine GALC expressed by AAV was used to evaluate treatment efficacy in all, but one study that used human GALC, as mentioned above [<xref rid=""B42-genes-14-01517"" ref-type=""bibr"">42</xref>]. While there are no dramatic structural differences between murine and human GALC, the protein sequence identity between the two species is determined at",11_42,Brain Targeted AAV1-GALC Gene Therapy Reduces Psychosine and Extends Lifespan in a Mouse Model of Krabbe Disease,25 7 2023,,Krabbe_Disease
"identity between the two species is determined at only 83% (based on NCBI blastp suite-2sequences alignment; NP_000144 vs. EDL18937). Therefore, key residues known to mediate interactions for transportation through trafficking machinery [<xref rid=""B48-genes-14-01517"" ref-type=""bibr"">48</xref>,<xref rid=""B49-genes-14-01517"" ref-type=""bibr"">49</xref>] and for co-activation through saposin A [<xref rid=""B50-genes-14-01517"" ref-type=""bibr"">50</xref>] may be varied between species and may therefore impact",11_43,Brain Targeted AAV1-GALC Gene Therapy Reduces Psychosine and Extends Lifespan in a Mouse Model of Krabbe Disease,25 7 2023,,Krabbe_Disease
"varied between species and may therefore impact human GALC function in animal models. For example, murine residue serine-146 forms a hydrogen bond with residue lysine-19 on murine saposin A [<xref rid=""B50-genes-14-01517"" ref-type=""bibr"">50</xref>]. However, the same position on human GALC is an aspartic acid, which has a longer carbon chain backbone, and therefore may alter the hydrogen bond formation, the GALC−saposin A interaction, and GALC activity. Additionally, expression of human GALC may trigger a",11_44,Brain Targeted AAV1-GALC Gene Therapy Reduces Psychosine and Extends Lifespan in a Mouse Model of Krabbe Disease,25 7 2023,,Krabbe_Disease
"expression of human GALC may trigger a host immune response that neutralizes the function of therapeutic protein in mouse models with endogenous mutant GALC expression such as the Twi-5J mouse [<xref rid=""B51-genes-14-01517"" ref-type=""bibr"">51</xref>] and the CRISPR-Cas9 human mutation knock-in models [<xref rid=""B52-genes-14-01517"" ref-type=""bibr"">52</xref>]. Taken together, these examples explain the tendency toward using murine GALC for AAV gene therapy studies in mouse models.  AAV-GALC gene",11_45,Brain Targeted AAV1-GALC Gene Therapy Reduces Psychosine and Extends Lifespan in a Mouse Model of Krabbe Disease,25 7 2023,,Krabbe_Disease
"therapy studies in mouse models.  AAV-GALC gene replacement studies in twitcher mice have also yielded mixed results with varied efficacy. Interestingly, a strategy for AAV-GALC delivery targeted to the cerebellum led to only minor clinical improvements, which suggests that GALC replacement in forebrain is crucial for increased efficacy [<xref rid=""B53-genes-14-01517"" ref-type=""bibr"">53</xref>]. To date, the AAV-GALC study that achieved the highest level of efficacy utilized AAV serotype rh10 that combined",11_46,Brain Targeted AAV1-GALC Gene Therapy Reduces Psychosine and Extends Lifespan in a Mouse Model of Krabbe Disease,25 7 2023,,Krabbe_Disease
"efficacy utilized AAV serotype rh10 that combined intracerebroventricular and intracerebellar administrations together with repeated intravenous injections to target peripheral tissues. That strategy allowed 25% of treated twitcher mice to live up to eight months [<xref rid=""B45-genes-14-01517"" ref-type=""bibr"">45</xref>] and highlights the importance of GALC replacement into peripheral tissues. Numerous AAV-GALC gene therapy studies using various administration routes, AAV serotypes, and animal models have",11_47,Brain Targeted AAV1-GALC Gene Therapy Reduces Psychosine and Extends Lifespan in a Mouse Model of Krabbe Disease,25 7 2023,,Krabbe_Disease
"routes, AAV serotypes, and animal models have been well reviewed recently [<xref rid=""B54-genes-14-01517"" ref-type=""bibr"">54</xref>,<xref rid=""B55-genes-14-01517"" ref-type=""bibr"">55</xref>,<xref rid=""B56-genes-14-01517"" ref-type=""bibr"">56</xref>]. Overall, AAV1-GALC gene replacement by unilateral intracerebroventricular administration at the neonatal age led to widespread expression of functional GALC protein in the CNS, which was associated with alleviation in neuropathology, psychosine clearance, and",11_48,Brain Targeted AAV1-GALC Gene Therapy Reduces Psychosine and Extends Lifespan in a Mouse Model of Krabbe Disease,25 7 2023,,Krabbe_Disease
"in neuropathology, psychosine clearance, and slower disease progression in the twitcher mouse model of KD.",11_49,Brain Targeted AAV1-GALC Gene Therapy Reduces Psychosine and Extends Lifespan in a Mouse Model of Krabbe Disease,25 7 2023,,Krabbe_Disease
"The Effects of Antipsychotics in Experimental Models of Krabbe Disease The role of altered myelin in the onset and development of schizophrenia and changes in myelin due to antipsychotics remains unclear. Antipsychotics are D<sub>2</sub> receptor antagonists, yet D<sub>2</sub> receptor agonists increase oligodendrocyte progenitor numbers and limit oligodendrocyte injury. Conflicting studies suggest these drugs promote the differentiation of neural progenitors to oligodendrocyte lineage, while others report",12_0,The Effects of Antipsychotics in Experimental Models of Krabbe Disease,28 4 2023,,Krabbe_Disease
"to oligodendrocyte lineage, while others report antipsychotics inhibit the proliferation and differentiation of oligodendrocyte precursors. Here, we utilised in-vitro (human astrocytes), ex-vivo (organotypic slice cultures) and in-vivo (twitcher mouse model) experimental study designs of psychosine-induced demyelination, a toxin that accumulates in Krabbe disease (KD), to investigate direct effects of antipsychotics on glial cell dysfunction and demyelination. Typical and atypical antipsychotics, and",12_1,The Effects of Antipsychotics in Experimental Models of Krabbe Disease,28 4 2023,,Krabbe_Disease
"Typical and atypical antipsychotics, and selective D<sub>2</sub> and 5HT<sub>2A</sub> receptor antagonists, attenuated psychosine-induced cell viability, toxicity, and morphological aberrations in human astrocyte cultures. Haloperidol and clozapine reduced psychosine-induced demyelination in mouse organotypic cerebellar slices. These drugs also attenuated the effects of psychosine on astrocytes and microglia and restored non-phosphorylated neurofilament levels, indicating neuroprotective effects. In the",12_2,The Effects of Antipsychotics in Experimental Models of Krabbe Disease,28 4 2023,,Krabbe_Disease
"indicating neuroprotective effects. In the demyelinating twitcher mouse model of KD, haloperidol improved mobility and significantly increased the survival of these animals. Overall, this study suggests that antipsychotics directly regulate glial cell dysfunction and exert a protective effect on myelin loss. This work also points toward the potential use of these pharmacological agents in KD. Schizophrenia is a chronic condition involving the complex interplay between genetic and environmental factors and",12_3,The Effects of Antipsychotics in Experimental Models of Krabbe Disease,28 4 2023,,Krabbe_Disease
"between genetic and environmental factors and is thought to be associated with aberrant neurodevelopment [<xref rid=""B1-biomedicines-11-01313"" ref-type=""bibr"">1</xref>,<xref rid=""B2-biomedicines-11-01313"" ref-type=""bibr"">2</xref>]. Schizophrenia is associated with abnormalities in grey and white matter, as well as loss of cerebral volume and anatomical pathology [<xref rid=""B3-biomedicines-11-01313"" ref-type=""bibr"">3</xref>]. While neuronal dysfunction has been well studied in schizophrenia, the role of",12_4,The Effects of Antipsychotics in Experimental Models of Krabbe Disease,28 4 2023,,Krabbe_Disease
"been well studied in schizophrenia, the role of glial cells in the pathophysiology of this disease is still emerging, and, in particular, the role of altered oligodendrocyte biology is less clear [<xref rid=""B4-biomedicines-11-01313"" ref-type=""bibr"">4</xref>]. Differing theories exist, although there is no consensus as to whether altered levels of myelin are linked with the onset of this illness, if altered myelination is a cause or consequence associated with the development of the condition, and/or how",12_5,The Effects of Antipsychotics in Experimental Models of Krabbe Disease,28 4 2023,,Krabbe_Disease
"with the development of the condition, and/or how levels of myelin change during short and long-term use of antipsychotic treatment. There is an agreement, however, that patients with schizophrenia have decreased white matter volume and integrity, where post-mortem studies demonstrate white matter pathology linked to deficits in myelin, axons and mature oligodendrocytes [<xref rid=""B5-biomedicines-11-01313"" ref-type=""bibr"">5</xref>,<xref rid=""B6-biomedicines-11-01313"" ref-type=""bibr"">6</xref>]. In",12_6,The Effects of Antipsychotics in Experimental Models of Krabbe Disease,28 4 2023,,Krabbe_Disease
"ref-type=""bibr"">6</xref>]. In addition, altered expression and risk variants of several genes playing a role in oligodendrocyte maturation and myelination have also been associated with this illness, where variants in myelin-related genes increase schizophrenia susceptibility [<xref rid=""B7-biomedicines-11-01313"" ref-type=""bibr"">7</xref>,<xref rid=""B8-biomedicines-11-01313"" ref-type=""bibr"">8</xref>,<xref rid=""B9-biomedicines-11-01313"" ref-type=""bibr"">9</xref>]. Antipsychotic treatment of patients with",12_7,The Effects of Antipsychotics in Experimental Models of Krabbe Disease,28 4 2023,,Krabbe_Disease
"Antipsychotic treatment of patients with schizophrenia has also been suggested to directly regulate the expression of genes associated with oligodendrocyte maturation and myelination, thus influencing white matter integrity [<xref rid=""B5-biomedicines-11-01313"" ref-type=""bibr"">5</xref>,<xref rid=""B6-biomedicines-11-01313"" ref-type=""bibr"">6</xref>]. The effects of antipsychotics are, however, somewhat controversial, where studies suggest these drugs either promote proliferation and differentiation of neural",12_8,The Effects of Antipsychotics in Experimental Models of Krabbe Disease,28 4 2023,,Krabbe_Disease
"proliferation and differentiation of neural progenitors to oligodendrocyte lineage or instead can inhibit differentiation of oligodendrocyte precursor cells [<xref rid=""B6-biomedicines-11-01313"" ref-type=""bibr"">6</xref>,<xref rid=""B9-biomedicines-11-01313"" ref-type=""bibr"">9</xref>]. Antipsychotics, such as clozapine, have been demonstrated to reduce neuroinflammation and demyelination in the experimental autoimmune encephalomyelitis (EAE) model of multiple sclerosis (MS) and enhance the rate of functional",12_9,The Effects of Antipsychotics in Experimental Models of Krabbe Disease,28 4 2023,,Krabbe_Disease
"sclerosis (MS) and enhance the rate of functional recovery in the cuprizone non-immune model of demyelination [<xref rid=""B10-biomedicines-11-01313"" ref-type=""bibr"">10</xref>,<xref rid=""B11-biomedicines-11-01313"" ref-type=""bibr"">11</xref>]. When considering the pharmacology of antipsychotics regulating levels of myelin, it is known that hyper-dopaminergia in the basal ganglia is linked with schizophrenia, where typical antipsychotics have dopamine D<sub>2</sub> receptor subtype antagonism and atypical",12_10,The Effects of Antipsychotics in Experimental Models of Krabbe Disease,28 4 2023,,Krabbe_Disease
"receptor subtype antagonism and atypical antipsychotics have additional serotonin (e.g., 5HT<sub>2A</sub>) receptor antagonism [<xref rid=""B12-biomedicines-11-01313"" ref-type=""bibr"">12</xref>]. It has been reported that oligodendrocytes express dopamine D<sub>2</sub> receptors, of which expression levels increase following combined oxygen and glucose deprivation [<xref rid=""B13-biomedicines-11-01313"" ref-type=""bibr"">13</xref>]. Dopamine action on D<sub>2</sub> receptors can affect myelin formation by",12_11,The Effects of Antipsychotics in Experimental Models of Krabbe Disease,28 4 2023,,Krabbe_Disease
"receptors can affect myelin formation by regulating the development and function of oligodendrocytes [<xref rid=""B14-biomedicines-11-01313"" ref-type=""bibr"">14</xref>,<xref rid=""B15-biomedicines-11-01313"" ref-type=""bibr"">15</xref>]. In addition, dopamine receptors have been shown to play a role in the development of EAE and MS [<xref rid=""B16-biomedicines-11-01313"" ref-type=""bibr"">16</xref>]. Paradoxically to typical antipsychotics being D<sub>2</sub> receptor antagonists, studies show that D<sub>2</sub>",12_12,The Effects of Antipsychotics in Experimental Models of Krabbe Disease,28 4 2023,,Krabbe_Disease
"antagonists, studies show that D<sub>2</sub> agonists increase the number of oligodendrocyte progenitor cells and protect oligodendrocytes against oxidative injury [<xref rid=""B13-biomedicines-11-01313"" ref-type=""bibr"">13</xref>], which may explain the therapeutic effects of some antipsychotics that are partial D<sub>2</sub> receptor agonists. Moreover, studies suggest the protective effect of D<sub>2</sub> agonists can be diminished by D<sub>2</sub> antagonists, suggesting that D<sub>2</sub> receptor",12_13,The Effects of Antipsychotics in Experimental Models of Krabbe Disease,28 4 2023,,Krabbe_Disease
"suggesting that D<sub>2</sub> receptor activation may play an important role in oligodendrocyte protection against injury, whereas typical antipsychotics may restrict oligodendrocyte recovery from injury. Contradictory, haloperidol and clozapine prevented apoptotic cell death in oligodendrocytes that were cultured under glucose-deprived conditions, highlighting their potential protective effects [<xref rid=""B17-biomedicines-11-01313"" ref-type=""bibr"">17</xref>]. Krabbe disease (KD), also known as globoid",12_14,The Effects of Antipsychotics in Experimental Models of Krabbe Disease,28 4 2023,,Krabbe_Disease
"Krabbe disease (KD), also known as globoid cell leukodystrophy, is a rare autosomal recessive disease caused by mutations in the <italic toggle=""yes"">galc</italic> gene, which codes for the enzyme galactosylceramidase (GALC). Psychosine (galactosylsphingosine) is a toxic lipid that accumulates abnormally in those with KD. It has been shown to be toxic to oligodendrocytes and cause demyelination by various proposed mechanisms [<xref rid=""B18-biomedicines-11-01313"" ref-type=""bibr"">18</xref>]. Given the",12_15,The Effects of Antipsychotics in Experimental Models of Krabbe Disease,28 4 2023,,Krabbe_Disease
"ref-type=""bibr"">18</xref>]. Given the uncertainty of the effects of antipsychotics on glial cells and myelin state, this study examined the direct effects of multiple typical and atypical antipsychotics on human astrocyte cell toxicity, tested the archetypical drugs haloperidol and clozapine on levels of myelin in mouse organotypic cerebellar slices, and lastly demonstrated effects of haloperidol in a demyelinating mouse model, specifically the twitcher mouse model of KD. The aims of this study were to",12_16,The Effects of Antipsychotics in Experimental Models of Krabbe Disease,28 4 2023,,Krabbe_Disease
"mouse model of KD. The aims of this study were to investigate if antipsychotics prevented psychosine-induced toxicity in human astrocytes, psychosine-mediated demyelination in organotypic slices, and improve survival, twitching scores, immobility scores and subtle behavioural metrics on open field testing in a murine model of psychosine toxicity, namely the twitcher mouse model of KD.",12_17,The Effects of Antipsychotics in Experimental Models of Krabbe Disease,28 4 2023,,Krabbe_Disease
A novel variant of GALC in a familial case of Krabbe disease: Insights from structural bioinformatics and molecular dynamics simulation The authors declare that there are no competing interests. This work was funded by the Higher Education Comission of Pakistan (No. NRPU-20–17341).,13_0,A novel variant of GALC in a familial case of Krabbe disease: Insights from structural bioinformatics and molecular dynamics simulation,23 4 2023,,Krabbe_Disease
"Impaired Autophagy in Krabbe Disease: The Role of BCL2 and Beclin-1 Phosphorylation Autophagic impairment was identified in many lysosomal storage diseases and adult neurodegenerative diseases. It seems that this defect could be directly related to the appearance of a neurodegenerative phenotype and could contribute to worsen metabolite accumulation and lysosomal distress. Thus, autophagy is becoming a promising target for supportive therapies. Autophagy alterations were recently identified also in Krabbe",14_0,Impaired Autophagy in Krabbe Disease: The Role of BCL2 and Beclin-1 Phosphorylation,22 3 2023,,Krabbe_Disease
"were recently identified also in Krabbe disease. Krabbe disease is characterized by extensive demyelination and dysmyelination and it is due to the genetic loss of function of the lysosomal enzyme galactocerebrosidase (GALC). This enzyme leads to the accumulation of galactosylceramide, psychosine, and secondary substrates such as lactosylceramide. In this paper, we induced autophagy through starvation and examined the cellular response occurring in fibroblasts isolated from patients. We demonstrated that",14_1,Impaired Autophagy in Krabbe Disease: The Role of BCL2 and Beclin-1 Phosphorylation,22 3 2023,,Krabbe_Disease
"isolated from patients. We demonstrated that the inhibitory AKT-mediated phosphorylation of beclin-1 and the BCL2-beclin-1 complex concur to reduce autophagosomes formation in response to starvation. These events were not dependent on the accumulation of psychosine, which was previously identified as a possible player in autophagic impairment in Krabbe disease. We believe that these data could better elucidate the capability of response to autophagic stimuli in Krabbe disease, in order to identify possible",14_2,Impaired Autophagy in Krabbe Disease: The Role of BCL2 and Beclin-1 Phosphorylation,22 3 2023,,Krabbe_Disease
"in Krabbe disease, in order to identify possible molecules able to stimulate the process. In all its forms (macroautophagy, selective autophagy, chaperone-mediated autophagy, and microautophagy), autophagy is deeply involved in nervous system development and functioning. Many processes strictly depend on autophagy, namely the removal of proteins that could form aggregates if present in excess and the preservation of axons. Furthermore, the engagement of Schwann cells in myelination, remyelination, myelin",14_3,Impaired Autophagy in Krabbe Disease: The Role of BCL2 and Beclin-1 Phosphorylation,22 3 2023,,Krabbe_Disease
"cells in myelination, remyelination, myelin debris clearance after damage, neurogenesis, and the maintenance of adult neural stem cells, as extensively reviewed by Menzies et al. [<xref rid=""B1-ijms-24-05984"" ref-type=""bibr"">1</xref>], are also linked to autophagy. Accordingly, autophagy dysfunctions were recognized in many neurodegenerative diseases, including Alzheimer’s and Parkinson’s diseases, amyotrophic lateral sclerosis, and polyglutamine disorders [<xref rid=""B1-ijms-24-05984""",14_4,Impaired Autophagy in Krabbe Disease: The Role of BCL2 and Beclin-1 Phosphorylation,22 3 2023,,Krabbe_Disease
"disorders [<xref rid=""B1-ijms-24-05984"" ref-type=""bibr"">1</xref>]. Autophagy impairment was also identified in many lysosomal storage diseases which most frequently are associated with neurodegeneration in children [<xref rid=""B2-ijms-24-05984"" ref-type=""bibr"">2</xref>]. In these diseases, autophagy dysfunctions were usually linked to lysosomal damage. The damage consists of alterations of membrane lipids which, in turn, modify autophagosome-lysosome fusion, in the inadequate lysosomal acidification and in",14_5,Impaired Autophagy in Krabbe Disease: The Role of BCL2 and Beclin-1 Phosphorylation,22 3 2023,,Krabbe_Disease
"in the inadequate lysosomal acidification and in the altered trafficking of hydrolytic enzymes. Eventually, lysosomal damage alters the functionality of the transcription factor EB (TFEB), which controls lysosomal biogenesis [<xref rid=""B1-ijms-24-05984"" ref-type=""bibr"">1</xref>,<xref rid=""B2-ijms-24-05984"" ref-type=""bibr"">2</xref>,<xref rid=""B3-ijms-24-05984"" ref-type=""bibr"">3</xref>]. By now, in Krabbe disease (KD), also known as globoid cell leukodystrophy (OMIM #245200), several proofs of autophagy",14_6,Impaired Autophagy in Krabbe Disease: The Role of BCL2 and Beclin-1 Phosphorylation,22 3 2023,,Krabbe_Disease
"(OMIM #245200), several proofs of autophagy impairment were reported and mostly explained by the accumulation of psychosine (PSY) (galactosylsphingosine) that is characteristic of the disease and caused by the deficiency of the lysosomal enzyme galactocerebrosidase (GALC). Firstly, after adding PSY, Ribbens et al. identified increased cleavage levels of microtubule-associated protein light chain (LC3) 1B in the immortalized neuroglial cell line, 145M-Twi, established from twitcher mouse brain [<xref",14_7,Impaired Autophagy in Krabbe Disease: The Role of BCL2 and Beclin-1 Phosphorylation,22 3 2023,,Krabbe_Disease
"established from twitcher mouse brain [<xref rid=""B4-ijms-24-05984"" ref-type=""bibr"">4</xref>]. Then, PSY was demonstrated to enhance autophagic flux in the human oligodendrocyte cell line MO3.13 [<xref rid=""B5-ijms-24-05984"" ref-type=""bibr"">5</xref>]. p62/sequestome 1 (SQSTM1) levels increased, if compared with wild-type (WT) murine strains, in brain sections, sciatic nerve, and fibroblasts isolated from twitcher mouse, suggesting autophagy impairment [<xref rid=""B6-ijms-24-05984""",14_8,Impaired Autophagy in Krabbe Disease: The Role of BCL2 and Beclin-1 Phosphorylation,22 3 2023,,Krabbe_Disease
"impairment [<xref rid=""B6-ijms-24-05984"" ref-type=""bibr"">6</xref>]. It was proved that while brief administration of PSY induced autophagy, a long exposure to high doses of this molecule caused the impairment of autophagy and of the ubiquitin-proteasome system (UPS), leading to the accumulation of cytoplasmic aggregates composed of ubiquitin and p62/SQSTM1 and visible in white matter and spinal cord of twitcher mice [<xref rid=""B7-ijms-24-05984"" ref-type=""bibr"">7</xref>]. In agreement with the evidence of",14_9,Impaired Autophagy in Krabbe Disease: The Role of BCL2 and Beclin-1 Phosphorylation,22 3 2023,,Krabbe_Disease
"In agreement with the evidence of alterations in autophagy, aggregates of alpha-synuclein, a typical autophagic target, were recognized in twitcher mice and KD patients [<xref rid=""B8-ijms-24-05984"" ref-type=""bibr"">8</xref>,<xref rid=""B9-ijms-24-05984"" ref-type=""bibr"">9</xref>,<xref rid=""B10-ijms-24-05984"" ref-type=""bibr"">10</xref>]. In this view, several studies tested the autophagic response induced by lithium and demonstrated that lithium increased the survival of MO3.13 oligodendrocytes treated with",14_10,Impaired Autophagy in Krabbe Disease: The Role of BCL2 and Beclin-1 Phosphorylation,22 3 2023,,Krabbe_Disease
"survival of MO3.13 oligodendrocytes treated with PSY [<xref rid=""B5-ijms-24-05984"" ref-type=""bibr"">5</xref>] and transiently ameliorated muscle strength in twitcher mice. On the contrary, in vivo, autophagy was not differently induced, at least at the doses and timing used for lithium administration by the authors [<xref rid=""B11-ijms-24-05984"" ref-type=""bibr"">11</xref>]. Autophagy is a promising topic to be better explored in KD to find novel therapeutic tools to improve patients’ survival and well-being.",14_11,Impaired Autophagy in Krabbe Disease: The Role of BCL2 and Beclin-1 Phosphorylation,22 3 2023,,Krabbe_Disease
"to improve patients’ survival and well-being. Nevertheless, the molecular mechanisms that cause autophagy dysfunction in KD disease should be still fully elucidated before they can be used as therapeutic targets. Although PSY accumulation plays a key role in this process, some evidence suggests that this molecule by itself cannot account for all defects detected in autophagy. In particular, it emerged that fibroblasts isolated from twitcher mice showed signs of autophagy dysfunction even if endogenous PSY",14_12,Impaired Autophagy in Krabbe Disease: The Role of BCL2 and Beclin-1 Phosphorylation,22 3 2023,,Krabbe_Disease
"of autophagy dysfunction even if endogenous PSY was present at levels comparable to the ones present in WT fibroblasts, without PSY added exogenously [<xref rid=""B6-ijms-24-05984"" ref-type=""bibr"">6</xref>]. Recently, we demonstrated that human KD fibroblasts are characterized by increased levels of lactosylceramide (LacCer), a substrate of GALC. In turn, LacCer is responsible for the altered activation of several signalling molecules, among which the most relevant are AKT and B-cell lymphoma 2 (BCL2),",14_13,Impaired Autophagy in Krabbe Disease: The Role of BCL2 and Beclin-1 Phosphorylation,22 3 2023,,Krabbe_Disease
"relevant are AKT and B-cell lymphoma 2 (BCL2), which are both upregulated [<xref rid=""B12-ijms-24-05984"" ref-type=""bibr"">12</xref>]. Since the AKT pathway and BCL2 were shown to interact with the autophagic machinery [<xref rid=""B13-ijms-24-05984"" ref-type=""bibr"">13</xref>,<xref rid=""B14-ijms-24-05984"" ref-type=""bibr"">14</xref>,<xref rid=""B15-ijms-24-05984"" ref-type=""bibr"">15</xref>], we investigated the effects of starvation to trigger autophagy in KD human fibroblasts which, as we previously reported,",14_14,Impaired Autophagy in Krabbe Disease: The Role of BCL2 and Beclin-1 Phosphorylation,22 3 2023,,Krabbe_Disease
"fibroblasts which, as we previously reported, did not accumulate PSY [<xref rid=""B12-ijms-24-05984"" ref-type=""bibr"">12</xref>]. Our results demonstrated that, independently from PSY, KD fibroblasts showed several defects in the autophagic response and that they can be associated with AKT upregulation.  A large consensus was established to consider substrate accumulation as a pivotal step of lysosomal storage disorders’ pathogenesis but, possibly, it is not the unique alteration responsible for the multiple",14_15,Impaired Autophagy in Krabbe Disease: The Role of BCL2 and Beclin-1 Phosphorylation,22 3 2023,,Krabbe_Disease
"unique alteration responsible for the multiple facets of these diseases. The appearance of secondary anomalous metabolites, perturbations of signalling pathways, trafficking, metabolism, organelles functionality, and cellular processes, such as autophagy, have a great pathogenic drive [<xref rid=""B2-ijms-24-05984"" ref-type=""bibr"">2</xref>,<xref rid=""B36-ijms-24-05984"" ref-type=""bibr"">36</xref>]. Impaired autophagy was identified as a common dysfunction in many lysosomal storage diseases characterized by",14_16,Impaired Autophagy in Krabbe Disease: The Role of BCL2 and Beclin-1 Phosphorylation,22 3 2023,,Krabbe_Disease
"many lysosomal storage diseases characterized by neurodegeneration. Autophagy dysfunction is deeply related to the appearance of neurodegenerative symptoms, as demonstrated by studies performed in Atg5 or Atg7 deficient mice. In addition, autophagy alterations could be involved in substrate accumulation because many molecules such as cholesterol and lipids are removed by this pathway, when functioning. Furthermore, aged or damaged mitochondria are renewed through autophagy and, for this reason, autophagic",14_17,Impaired Autophagy in Krabbe Disease: The Role of BCL2 and Beclin-1 Phosphorylation,22 3 2023,,Krabbe_Disease
"autophagy and, for this reason, autophagic defect could increase oxidative stress [<xref rid=""B37-ijms-24-05984"" ref-type=""bibr"">37</xref>]. In this perspective, some small molecules able to rescue autophagic pathways such as rapamycin, carbamazepine, and lithium are under investigation [<xref rid=""B37-ijms-24-05984"" ref-type=""bibr"">37</xref>]. Autophagy inducers appear to be particularly promising if combined with other therapeutic options such as enzyme replacement therapy (ERT) [<xref",14_18,Impaired Autophagy in Krabbe Disease: The Role of BCL2 and Beclin-1 Phosphorylation,22 3 2023,,Krabbe_Disease
"such as enzyme replacement therapy (ERT) [<xref rid=""B37-ijms-24-05984"" ref-type=""bibr"">37</xref>]. Along this line, lithium administration was tested to improve the survival of PSY-treated MO3.13 oligodendrocytes [<xref rid=""B5-ijms-24-05984"" ref-type=""bibr"">5</xref>]. We previously identified an increase in the nuclear fraction of the nuclear factor erythroid 2-related factor 2 (NRF2), which could be indicative of autophagic dysfunction, in human KD fibroblasts [<xref rid=""B12-ijms-24-05984""",14_19,Impaired Autophagy in Krabbe Disease: The Role of BCL2 and Beclin-1 Phosphorylation,22 3 2023,,Krabbe_Disease
"KD fibroblasts [<xref rid=""B12-ijms-24-05984"" ref-type=""bibr"">12</xref>]. In fact, the increase in p62/Keap1 complexes could induce a prolonged activation of NRF2 [<xref rid=""B38-ijms-24-05984"" ref-type=""bibr"">38</xref>,<xref rid=""B39-ijms-24-05984"" ref-type=""bibr"">39</xref>]. Moreover, we demonstrated that in KD fibroblasts some signalling perturbations coexist; in particular, AKT activation and BCL2 expression are upregulated due to LacCer increase [<xref rid=""B12-ijms-24-05984""",14_20,Impaired Autophagy in Krabbe Disease: The Role of BCL2 and Beclin-1 Phosphorylation,22 3 2023,,Krabbe_Disease
"to LacCer increase [<xref rid=""B12-ijms-24-05984"" ref-type=""bibr"">12</xref>]. It is well-known that both AKT and BCL2 can act as autophagy modulators [<xref rid=""B40-ijms-24-05984"" ref-type=""bibr"">40</xref>]. However, in normal growing conditions, we were not able to identify marked alterations in autophagosomes formation or in autophagic markers in human KD fibroblasts. Thus, we decided to better investigate the autophagic machinery by inducing autophagy through starvation. This paper demonstrated an",14_21,Impaired Autophagy in Krabbe Disease: The Role of BCL2 and Beclin-1 Phosphorylation,22 3 2023,,Krabbe_Disease
"through starvation. This paper demonstrated an impaired autophagic response to starvation in KD fibroblasts. We first observed that the overall formation of autophagosomes appeared to be reduced. Since we excluded that this finding could be caused by the presence of PSY in KD fibroblasts [<xref rid=""B12-ijms-24-05984"" ref-type=""bibr"">12</xref>], we investigated the molecular machinery involved in autophagy. AMPK is a cellular energy sensor, and it is activated by starvation. It induces autophagy by",14_22,Impaired Autophagy in Krabbe Disease: The Role of BCL2 and Beclin-1 Phosphorylation,22 3 2023,,Krabbe_Disease
"activated by starvation. It induces autophagy by phosphorylating ULK1, which is a promoter of autophagosomes formation [<xref rid=""B41-ijms-24-05984"" ref-type=""bibr"">41</xref>] and which is involved in autophagosome maturation and lysosomal degradation [<xref rid=""B42-ijms-24-05984"" ref-type=""bibr"">42</xref>]. During starvation, AMPK increased only in control cells, not in KD fibroblasts. Previously, it was reported that PSY reduced AMPK activity in oligodendrocytes and the investigation of AMPK activators",14_23,Impaired Autophagy in Krabbe Disease: The Role of BCL2 and Beclin-1 Phosphorylation,22 3 2023,,Krabbe_Disease
"and the investigation of AMPK activators in KD was proposed [<xref rid=""B43-ijms-24-05984"" ref-type=""bibr"">43</xref>]. Overall, AMPK is activated in conditions that cause a reduction in ATP levels, such as starvation. Lysosome constitutes a critical compartment in AMPK activation signalling [<xref rid=""B44-ijms-24-05984"" ref-type=""bibr"">44</xref>]; thus, it can be hypothesized that alterations in lysosomal functionality could have consequences on AMPK signalling. Our data demonstrated a defect in the",14_24,Impaired Autophagy in Krabbe Disease: The Role of BCL2 and Beclin-1 Phosphorylation,22 3 2023,,Krabbe_Disease
"signalling. Our data demonstrated a defect in the response to energetic stress. This alteration consists of the increase in AMPK expression rather than in the activation/phosphorylation of AMPK. Thus, it is difficult to argue if the phosphorylating regulation of AMPK is impaired in KD fibroblasts. We supposed that AKT upregulation could influence the response to energetic stress induced by starvation in KD fibroblasts. The increase in AMPK expression that appeared to occur in starved control fibroblasts",14_25,Impaired Autophagy in Krabbe Disease: The Role of BCL2 and Beclin-1 Phosphorylation,22 3 2023,,Krabbe_Disease
"appeared to occur in starved control fibroblasts and that, on the contrary, was impaired in KD fibroblasts could be a consequence of this upregulation. Nevertheless, we can conclude that the AMPK response to starvation in KD fibroblasts was altered. Beclin-1 is a key player during the early autophagic steps (initiation) and it is crucial for autophagosomes formation [<xref rid=""B45-ijms-24-05984"" ref-type=""bibr"">45</xref>]. Beclin-1 can associate with different proteins such as Atg14L to activate the",14_26,Impaired Autophagy in Krabbe Disease: The Role of BCL2 and Beclin-1 Phosphorylation,22 3 2023,,Krabbe_Disease
"different proteins such as Atg14L to activate the kinase Vps34 and Ambra1. It can also induce the aggregation of beclin-1-Vps34-Vps15 complexes that trigger autophagosomes formation [<xref rid=""B20-ijms-24-05984"" ref-type=""bibr"">20</xref>]. During starvation, the increase in beclin-1 was significantly lower in KD fibroblasts than in control fibroblasts. LC3B protein processing is a common method used to monitor the autophagic flux. LC3B is cleaved by Atg4 to form LC3B-I, which is in turn associated with",14_27,Impaired Autophagy in Krabbe Disease: The Role of BCL2 and Beclin-1 Phosphorylation,22 3 2023,,Krabbe_Disease
"to form LC3B-I, which is in turn associated with phosphatidylethanolamine to constitute LC3B-II. LC3B-II is crucial for autophagosomes formation; in fact, it is a key component of their membrane, and it is degraded when autophagosomes merge with lysosomes [<xref rid=""B22-ijms-24-05984"" ref-type=""bibr"">22</xref>]. Using CQ as a lysosomal inhibitor, we showed that LC3B-II levels decreased in KD fibroblasts, demonstrating that autophagic flux was reduced. Finally, we investigated p62/SQSTM1 levels and",14_28,Impaired Autophagy in Krabbe Disease: The Role of BCL2 and Beclin-1 Phosphorylation,22 3 2023,,Krabbe_Disease
"Finally, we investigated p62/SQSTM1 levels and observed an increased expression during starvation in both control and KD fibroblasts. Among other functions, p62/SQSTM1 is known to be enclosed in autophagosomes and then, to be destined for degradation. Thus, an inverse correlation between p62/SQSTM1 levels and autophagic flux should emerge in this model. However, the employment of p62/SQSTM1 as an indicator of autophagic flux is not universally accepted because of other variables affecting its expression.",14_29,Impaired Autophagy in Krabbe Disease: The Role of BCL2 and Beclin-1 Phosphorylation,22 3 2023,,Krabbe_Disease
"of other variables affecting its expression. In particular, it was demonstrated that in starved cells autophagic flux, transcriptional upregulation and availability of lysosomal-derived amino acids concur to define p62/SQSTM1 levels [<xref rid=""B46-ijms-24-05984"" ref-type=""bibr"">46</xref>]. Moreover, p62/SQSTM1 acts as a scaffold for proteins involved in UPS, signalling, autophagy, and apoptosis [<xref rid=""B47-ijms-24-05984"" ref-type=""bibr"">47</xref>]. Based on our data, it can be hypothesized that the",14_30,Impaired Autophagy in Krabbe Disease: The Role of BCL2 and Beclin-1 Phosphorylation,22 3 2023,,Krabbe_Disease
"on our data, it can be hypothesized that the increase in p62/SQSTM1 transcription could occur in parallel to autophagy in both control and KD fibroblasts during starvation. When CQ was added to block the autophagic flux and autophagosomes degradation, we observed that p62/SQSTM1 accumulation was higher in controls than in KD fibroblasts. Significantly, it was demonstrated that p62/SQSTM1 reduction decreased the recruitment of LC3 to autophagosome during starvation [<xref rid=""B48-ijms-24-05984""",14_31,Impaired Autophagy in Krabbe Disease: The Role of BCL2 and Beclin-1 Phosphorylation,22 3 2023,,Krabbe_Disease
"during starvation [<xref rid=""B48-ijms-24-05984"" ref-type=""bibr"">48</xref>]. Summing up, all these data concur to identify impairment in autophagosomes formation and maturation in KD fibroblasts. To assess the involvement of lysosomes during the final steps of autophagy, we employed the probe Lysotracker red DND-99 and observed the appearance of dilated lysosomes in KD fibroblasts. This finding could be related to lysosomal dysfunction [<xref rid=""B49-ijms-24-05984"" ref-type=""bibr"">49</xref>]. However, the",14_32,Impaired Autophagy in Krabbe Disease: The Role of BCL2 and Beclin-1 Phosphorylation,22 3 2023,,Krabbe_Disease
"ref-type=""bibr"">49</xref>]. However, the measurement of lysosomal enzymatic activities, i.e., beta-galactosidase and beta-hexosaminidase, and lysosomal proteins, i.e., LAMP1 and cathepsin D, did not reveal dysfunctions in lysosomal functionality. GALC is a lysosomal enzyme; therefore, its deficiency leads to the impaired metabolism of other lysosomal substrates with increased levels of secondary metabolites [<xref rid=""B12-ijms-24-05984"" ref-type=""bibr"">12</xref>] in addition to PSY. It is possible to",14_33,Impaired Autophagy in Krabbe Disease: The Role of BCL2 and Beclin-1 Phosphorylation,22 3 2023,,Krabbe_Disease
"in addition to PSY. It is possible to suppose that secondary metabolites could induce lysosomal distress, in particular when autophagy was stimulated. However, we did not observe p62/SQSTM1 or LC3B-II accumulation specifically in KD fibroblasts when CQ was not added to the cells; therefore, we can suppose that the autophagosome degradation step was functioning. Thus, all data collected proved that autophagic flux was reduced in starved KD fibroblasts and that the steps of autophagosome formation were",14_34,Impaired Autophagy in Krabbe Disease: The Role of BCL2 and Beclin-1 Phosphorylation,22 3 2023,,Krabbe_Disease
"that the steps of autophagosome formation were impaired in KD fibroblasts. We can exclude that these effects could be related to PSY accumulation because we did not observe its presence in KD fibroblasts before and after starvation with CQ addition. However, glycosphingolipid synthesis inhibition through D-PDMP was able to induce LC3B-II increase in KD fibroblasts. We demonstrated that LacCer increase in KD fibroblasts persists also during autophagy induction. This could be particularly relevant because of",14_35,Impaired Autophagy in Krabbe Disease: The Role of BCL2 and Beclin-1 Phosphorylation,22 3 2023,,Krabbe_Disease
"This could be particularly relevant because of the association between LacCer increase and AKT/BCL2 upregulation in KD fibroblasts [<xref rid=""B12-ijms-24-05984"" ref-type=""bibr"">12</xref>]. AKT was demonstrated to be able to inhibit autophagy through different paths including the activation of mTOR and the direct phosphorylation of beclin-1. AKT-phosphorylated beclin-1 strongly interacts with intermediate proteins of the cytoskeleton and shows a reduced capability to trigger autophagy [<xref",14_36,Impaired Autophagy in Krabbe Disease: The Role of BCL2 and Beclin-1 Phosphorylation,22 3 2023,,Krabbe_Disease
"a reduced capability to trigger autophagy [<xref rid=""B32-ijms-24-05984"" ref-type=""bibr"">32</xref>]. To demonstrate that AKT upregulation could be responsible for autophagic impairment in KD fibroblasts, we proved that phosphorylation of beclin-1 on Ser295 was enhanced. Furthermore, BCL2 reduces the pro-autophagic action of beclin-1 [<xref rid=""B50-ijms-24-05984"" ref-type=""bibr"">50</xref>]. In KD fibroblasts, we showed that a higher amount of beclin-1 was associated with BCL2. To confirm these results and",14_37,Impaired Autophagy in Krabbe Disease: The Role of BCL2 and Beclin-1 Phosphorylation,22 3 2023,,Krabbe_Disease
"with BCL2. To confirm these results and the involvement of AKT, the employment of the PI3K inhibitor, LY294002, which in turn reduces also AKT activity and BCL2 expression, was able to reduce Ser295 phosphorylation on beclin-1. In conclusion, this paper demonstrated that several mechanisms that above all concerning beclin-1 are deregulated in KD fibroblasts. First of all, the induction in beclin-1 increase upon autophagic stimuli is impaired even if basal levels of beclin-1 appear to be the same between",14_38,Impaired Autophagy in Krabbe Disease: The Role of BCL2 and Beclin-1 Phosphorylation,22 3 2023,,Krabbe_Disease
"levels of beclin-1 appear to be the same between control and KD fibroblasts. This evidence is in line with a previous report demonstrating that beclin-1 expression is not altered in several lysosomal storage diseases with normal sphingolipid traffic [<xref rid=""B51-ijms-24-05984"" ref-type=""bibr"">51</xref>]. Then, inhibitory phosphorylation of beclin-1 and the formation of the complex with BCL2 concur to the impairment of autophagy activation. These findings underline the importance of altered signalling",14_39,Impaired Autophagy in Krabbe Disease: The Role of BCL2 and Beclin-1 Phosphorylation,22 3 2023,,Krabbe_Disease
underline the importance of altered signalling pathways induced by changed levels of secondary substrates in the interpretation of KD pathogenesis. They permit to understand dysfunctions in tissues and cells which are not significantly affected by PSY accumulation or during the early phases of the disease when PSY levels are not so high.,14_40,Impaired Autophagy in Krabbe Disease: The Role of BCL2 and Beclin-1 Phosphorylation,22 3 2023,,Krabbe_Disease
"Mechanotransduction Impairment in Primary Fibroblast Model of Krabbe Disease Krabbe disease (KD) is a genetic disorder caused by the absence of the galactosylceramidase (GALC) functional enzyme. No cure is currently available. Here, we investigate the mechanotransduction process in primary fibroblasts collected from the twitcher mouse, a natural KD murine model. Thanks to mechanotransduction, cells can sense their environment and convert external mechanical stimuli into biochemical signals that result in",15_0,Mechanotransduction Impairment in Primary Fibroblast Model of Krabbe Disease,16 3 2023,,Krabbe_Disease
"stimuli into biochemical signals that result in intracellular changes. In GALC-deficient fibroblasts, we show that focal adhesions (FAs), the protein clusters necessary to adhere and migrate, are increased, and that single-cell migration and wound healing are impaired. We also investigate the involvement of the autophagic process in this framework. We show a dysregulation in the FA turnover: here, the treatment with the autophagy activator rapamycin boosts cell migration and improves the clearance of FAs",15_1,Mechanotransduction Impairment in Primary Fibroblast Model of Krabbe Disease,16 3 2023,,Krabbe_Disease
"cell migration and improves the clearance of FAs in GALC-deficient fibroblasts. We propose mechanosensing impairment as a novel potential pathological mechanism in twitcher fibroblasts, and more in general in Krabbe disease. Krabbe disease (KD) is a rare genetic lysosomal storage disorder caused by the mutation of the galactosylceramidase (GALC) gene. The GALC enzyme is widely expressed in the mammalian body and its absence determines a severe disease, involving myelin loss, neurodegeneration, and death in",15_2,Mechanotransduction Impairment in Primary Fibroblast Model of Krabbe Disease,16 3 2023,,Krabbe_Disease
"myelin loss, neurodegeneration, and death in a few years. The main pathological features are linked to the accumulation of the cytotoxic sphingolipid psychosine (PSY), based on the so-called “psychosine hypothesis” [<xref rid=""B1-biomedicines-11-00927"" ref-type=""bibr"">1</xref>]. PSY acts as a detergent and alters the biological membrane architecture [<xref rid=""B2-biomedicines-11-00927"" ref-type=""bibr"">2</xref>,<xref rid=""B3-biomedicines-11-00927"" ref-type=""bibr"">3</xref>]. Various effects are attributed",15_3,Mechanotransduction Impairment in Primary Fibroblast Model of Krabbe Disease,16 3 2023,,Krabbe_Disease
"Various effects are attributed to its accumulation in the nervous system: from demyelination and gliosis to membrane shedding enhancement [<xref rid=""B4-biomedicines-11-00927"" ref-type=""bibr"">4</xref>] and endocytosis inhibition in neural cells. Enzyme replacement in vivo appears to be insufficient to reconstitute the homeostasis and remove PSY [<xref rid=""B5-biomedicines-11-00927"" ref-type=""bibr"">5</xref>]. This could be presumably attributed to the involvement of several molecular pathways and organelles",15_4,Mechanotransduction Impairment in Primary Fibroblast Model of Krabbe Disease,16 3 2023,,Krabbe_Disease
"of several molecular pathways and organelles in PSY accumulation [<xref rid=""B6-biomedicines-11-00927"" ref-type=""bibr"">6</xref>], such as PLA2 [<xref rid=""B7-biomedicines-11-00927"" ref-type=""bibr"">7</xref>], mitochondria, Akt signalling [<xref rid=""B8-biomedicines-11-00927"" ref-type=""bibr"">8</xref>], proapoptotic factor [<xref rid=""B9-biomedicines-11-00927"" ref-type=""bibr"">9</xref>], inflammation and immune response [<xref rid=""B10-biomedicines-11-00927"" ref-type=""bibr"">10</xref>,<xref",15_5,Mechanotransduction Impairment in Primary Fibroblast Model of Krabbe Disease,16 3 2023,,Krabbe_Disease
"ref-type=""bibr"">10</xref>,<xref rid=""B11-biomedicines-11-00927"" ref-type=""bibr"">11</xref>], calcium signalling [<xref rid=""B12-biomedicines-11-00927"" ref-type=""bibr"">12</xref>], and much more. Moreover, several findings are emerging in the literature concerning new aspects of KD’s pathogenesis that cannot be explained by PSY accumulation alone. This theory is evolving, and one of the latest aspects pointed out is that PSY is secreted in extracellular vesicles in the brain of the twitcher mouse (the natural",15_6,Mechanotransduction Impairment in Primary Fibroblast Model of Krabbe Disease,16 3 2023,,Krabbe_Disease
"in the brain of the twitcher mouse (the natural KD murine model); however, substrate reduction therapy can increase lifespan but not rescue the phenotype [<xref rid=""B13-biomedicines-11-00927"" ref-type=""bibr"">13</xref>]. Alterations were found in the structure and function of the brain endothelium of KD patients and twitcher mice, in vivo and in vitro, revealing an increased permeability of the vessels [<xref rid=""B14-biomedicines-11-00927"" ref-type=""bibr"">14</xref>]; importantly, studies on zebrafish",15_7,Mechanotransduction Impairment in Primary Fibroblast Model of Krabbe Disease,16 3 2023,,Krabbe_Disease
"importantly, studies on zebrafish embryos [<xref rid=""B15-biomedicines-11-00927"" ref-type=""bibr"">15</xref>] and on human endothelial cells [<xref rid=""B16-biomedicines-11-00927"" ref-type=""bibr"">16</xref>] suggested that these effects were not PSY-dependent. Teixeira and colleagues [<xref rid=""B17-biomedicines-11-00927"" ref-type=""bibr"">17</xref>] showed that in the twitcher mouse, there are fewer axons in the central and peripheral nervous system before the onset of demyelination, with impairment in the",15_8,Mechanotransduction Impairment in Primary Fibroblast Model of Krabbe Disease,16 3 2023,,Krabbe_Disease
"onset of demyelination, with impairment in the retrograde component of axonal transport and microtubule stability. Moreover, in KD patients-derived fibroblasts [<xref rid=""B18-biomedicines-11-00927"" ref-type=""bibr"">18</xref>], lactosylceramide (another GALC substrate) metabolism is impaired, even in the absence of PSY accumulation. Thus, a clear picture of KD-related intracellular signalling is still far from being achieved. We recently demonstrated for the first time that [<xref",15_9,Mechanotransduction Impairment in Primary Fibroblast Model of Krabbe Disease,16 3 2023,,Krabbe_Disease
"demonstrated for the first time that [<xref rid=""B19-biomedicines-11-00927"" ref-type=""bibr"">19</xref>] autophagy is dysregulated in the twitcher mouse (GALC<sup>−/−</sup>), the spontaneous KD murine model. We found dysregulation of the autophagy markers p62 and LC3-II in the brain, sciatic nerve, and primary fibroblasts of GALC<sup>−/−</sup> mice. This effect is not completely driven by PSY, because from the literature we know that GALC<sup>−/−</sup> fibroblasts, either murine [<xref",15_10,Mechanotransduction Impairment in Primary Fibroblast Model of Krabbe Disease,16 3 2023,,Krabbe_Disease
"fibroblasts, either murine [<xref rid=""B19-biomedicines-11-00927"" ref-type=""bibr"">19</xref>] or human [<xref rid=""B20-biomedicines-11-00927"" ref-type=""bibr"">20</xref>], do not present significant PSY accumulation. Rapamycin (RAPA, an autophagy activator that acts via inhibiting the mTORC1 pathway) [<xref rid=""B19-biomedicines-11-00927"" ref-type=""bibr"">19</xref>,<xref rid=""B21-biomedicines-11-00927"" ref-type=""bibr"">21</xref>,<xref rid=""B22-biomedicines-11-00927"" ref-type=""bibr"">22</xref>,<xref",15_11,Mechanotransduction Impairment in Primary Fibroblast Model of Krabbe Disease,16 3 2023,,Krabbe_Disease
"ref-type=""bibr"">22</xref>,<xref rid=""B23-biomedicines-11-00927"" ref-type=""bibr"">23</xref>] administration, moreover, was able to partially restore the autophagy marker levels. Clearly, in KD, restoring the presence of the functioning enzyme in the brain is mandatory. However, brain targeting in enzyme replacement therapy did not lead to a long-lasting result either in mice [<xref rid=""B24-biomedicines-11-00927"" ref-type=""bibr"">24</xref>,<xref rid=""B25-biomedicines-11-00927"" ref-type=""bibr"">25</xref>] or",15_12,Mechanotransduction Impairment in Primary Fibroblast Model of Krabbe Disease,16 3 2023,,Krabbe_Disease
"ref-type=""bibr"">25</xref>] or human patients [<xref rid=""B26-biomedicines-11-00927"" ref-type=""bibr"">26</xref>,<xref rid=""B27-biomedicines-11-00927"" ref-type=""bibr"">27</xref>], who died from further complications. It is therefore essential to discover and understand all the molecular mechanisms that lead to the pathological imbalances in KD, to treat this pathology with multiple approaches by acting on the affected pathways, rescuing the KD phenotype. In specialized cells (e.g., fibroblasts), cell sensing",15_13,Mechanotransduction Impairment in Primary Fibroblast Model of Krabbe Disease,16 3 2023,,Krabbe_Disease
"cells (e.g., fibroblasts), cell sensing and migration are achieved through focal adhesions (FAs) [<xref rid=""B28-biomedicines-11-00927"" ref-type=""bibr"">28</xref>]. FAs are protein clusters, and their components assemble on the transmembrane integrins adhered to the substrate [<xref rid=""B29-biomedicines-11-00927"" ref-type=""bibr"">29</xref>]. Later, FAs’ maturation and protein recruitment are guided by actomyosin tensile stress [<xref rid=""B30-biomedicines-11-00927"" ref-type=""bibr"">30</xref>]. At the",15_14,Mechanotransduction Impairment in Primary Fibroblast Model of Krabbe Disease,16 3 2023,,Krabbe_Disease
"ref-type=""bibr"">30</xref>]. At the trailing edge, old and larger FAs are targeted by microtubules, dynamins and FAK that interact; FAs are hence disassembled and destined to an autophagic fate, and their components are recycled [<xref rid=""B31-biomedicines-11-00927"" ref-type=""bibr"">31</xref>]. At this point, the cell has left the anchor at the trailing edge, represented by the old FAs, and can pull itself to the leading edge. The training movement is transmitted through cells thanks to the actin",15_15,Mechanotransduction Impairment in Primary Fibroblast Model of Krabbe Disease,16 3 2023,,Krabbe_Disease
"is transmitted through cells thanks to the actin cytoskeleton via cell–cell junctions [<xref rid=""B32-biomedicines-11-00927"" ref-type=""bibr"">32</xref>]. These junctions are mainly represented by cadherins, which are a family of transmembrane proteins mediating adhesion and movement transmission between two neighbouring cells. N-cadherin in particular have a role in migration [<xref rid=""B33-biomedicines-11-00927"" ref-type=""bibr"">33</xref>]. Fibroblasts are a simple and accessible cell model easily",15_16,Mechanotransduction Impairment in Primary Fibroblast Model of Krabbe Disease,16 3 2023,,Krabbe_Disease
"are a simple and accessible cell model easily collectable from both patients [<xref rid=""B34-biomedicines-11-00927"" ref-type=""bibr"">34</xref>] and mice [<xref rid=""B35-biomedicines-11-00927"" ref-type=""bibr"">35</xref>], and they represent the most common cells in the connective tissue. We can find them in the interstitial spaces of the tissues, where they synthesize and produce extracellular matrix (ECM) components. They can migrate and remodel the environment and signal to other cells their fate and",15_17,Mechanotransduction Impairment in Primary Fibroblast Model of Krabbe Disease,16 3 2023,,Krabbe_Disease
"and signal to other cells their fate and directions [<xref rid=""B36-biomedicines-11-00927"" ref-type=""bibr"">36</xref>]. They have a role in injury healing and inflammation regulation, thanks to their ability to produce and release chemokines [<xref rid=""B37-biomedicines-11-00927"" ref-type=""bibr"">37</xref>]. Therefore, migration and interaction with matrices and other cells are fundamental for fibroblasts’ activities. Here, we studied mechanotransduction and migration processes in primary fibroblasts",15_18,Mechanotransduction Impairment in Primary Fibroblast Model of Krabbe Disease,16 3 2023,,Krabbe_Disease
"and migration processes in primary fibroblasts collected from twitcher mice. Via time-lapse microscopy, we investigated single-cell migration and wound healing in cell monolayers. We evaluated the development and the expression of FA intracellular components, and also that of N-cadherin junctions, via immunocytochemistry and Western blot. We investigated the cross-talk between the mechanotransduction and autophagy processes by looking for the presence and localization of the neighbour of BRCA1 gene 1",15_19,Mechanotransduction Impairment in Primary Fibroblast Model of Krabbe Disease,16 3 2023,,Krabbe_Disease
"and localization of the neighbour of BRCA1 gene 1 protein (NBR1) [<xref rid=""B38-biomedicines-11-00927"" ref-type=""bibr"">38</xref>,<xref rid=""B39-biomedicines-11-00927"" ref-type=""bibr"">39</xref>], the protein needed for the selective autophagy, recycling, and turnover of FAs. Furthermore, we tested whether RAPA treatment would rescue the impaired twitcher fibroblasts’ responses.   Here, we investigated the migration and adhesion processes in primary fibroblasts extracted from the twitcher mouse, a",15_20,Mechanotransduction Impairment in Primary Fibroblast Model of Krabbe Disease,16 3 2023,,Krabbe_Disease
"fibroblasts extracted from the twitcher mouse, a spontaneous KD model. We show that mechanotransduction is impaired in HOM fibroblasts, which lack the functional GALC enzyme and do not accumulate PSY. Both in single-cell migration and wound healing, we observed reduced motility in HOM cells compared to WT cells. In line with this, the number of FAs per cell was higher in HOM fibroblasts, while the number of N-CAD cell junctions was reduced at the cell periphery and YAP showed diminished nuclear",15_21,Mechanotransduction Impairment in Primary Fibroblast Model of Krabbe Disease,16 3 2023,,Krabbe_Disease
"cell periphery and YAP showed diminished nuclear translocation (i.e., activation). We also investigated the involvement of the autophagic process in this framework. We found an accumulation of NBR1 aggregates in HOM cells. Here, the treatment with the autophagy activator RAPA rescued the cell migration behaviour in HOM fibroblasts and slightly reduced the number of FA and NBR1 aggregates in HOM cells. Overall, we propose that GALC deficiency impacts HOM fibroblast cell mechanotransduction processes (i.e.,",15_22,Mechanotransduction Impairment in Primary Fibroblast Model of Krabbe Disease,16 3 2023,,Krabbe_Disease
"cell mechanotransduction processes (i.e., FAs accumulation, impaired migration behaviour) via the impairment of the autophagic process. Fibroblasts are an optimal cell model for studying how cells migrate and interact with the extracellular environment, and they do not accumulate PSY. We know that the migration process is regulated through FAs [<xref rid=""B51-biomedicines-11-00927"" ref-type=""bibr"">51</xref>]. We found an increase in the number of FAs together with a slower migration rate in HOM fibroblasts",15_23,Mechanotransduction Impairment in Primary Fibroblast Model of Krabbe Disease,16 3 2023,,Krabbe_Disease
"with a slower migration rate in HOM fibroblasts compared with WT fibroblasts. However, FA morphology and maturation, together with FA intracellular pathway activation (at the level of FAK and PAX), were similar between WT and HOM cells. In agreement with our findings, there are several reports in the literature wherein an increased number of FAs is linked to a reduced cell migration rate [<xref rid=""B28-biomedicines-11-00927"" ref-type=""bibr"">28</xref>,<xref rid=""B52-biomedicines-11-00927""",15_24,Mechanotransduction Impairment in Primary Fibroblast Model of Krabbe Disease,16 3 2023,,Krabbe_Disease
"rid=""B52-biomedicines-11-00927"" ref-type=""bibr"">52</xref>,<xref rid=""B53-biomedicines-11-00927"" ref-type=""bibr"">53</xref>,<xref rid=""B54-biomedicines-11-00927"" ref-type=""bibr"">54</xref>]. FAs and N-CAD junctions are both mechanotransduction effectors and transducers, which mediate migration and can influence each other. In line with the increase in FAs in HOM cells, we observed a reduced presence of N-CAD-positive cell–cell junctions at the cell periphery, suggesting a molecular explanation for the reduced",15_25,Mechanotransduction Impairment in Primary Fibroblast Model of Krabbe Disease,16 3 2023,,Krabbe_Disease
"a molecular explanation for the reduced wound healing response [<xref rid=""B33-biomedicines-11-00927"" ref-type=""bibr"">33</xref>,<xref rid=""B55-biomedicines-11-00927"" ref-type=""bibr"">55</xref>]. YAP and YAP/TAZ signalling represent good molecular connectors, influencing cell migration [<xref rid=""B54-biomedicines-11-00927"" ref-type=""bibr"">54</xref>,<xref rid=""B56-biomedicines-11-00927"" ref-type=""bibr"">56</xref>]. It has been reported that YAP activation (i.e., translocation into the nucleus) determines an",15_26,Mechanotransduction Impairment in Primary Fibroblast Model of Krabbe Disease,16 3 2023,,Krabbe_Disease
"translocation into the nucleus) determines an increase in the N-CAD protein level and FA formation and stabilization in primary glioma cell lines [<xref rid=""B50-biomedicines-11-00927"" ref-type=""bibr"">50</xref>]. In line with this, YAP downregulation was linked to an increased number of FAs and delayed motility [<xref rid=""B54-biomedicines-11-00927"" ref-type=""bibr"">54</xref>]. Here, we also show that HOM fibroblasts have reduced YAP nuclear translocation compared to WT fibroblasts. In our view, the reduced",15_27,Mechanotransduction Impairment in Primary Fibroblast Model of Krabbe Disease,16 3 2023,,Krabbe_Disease
"to WT fibroblasts. In our view, the reduced YAP activation could be linked to the increase in FAs, even if the contribution of other molecular pathways cannot be excluded and the direction of the reciprocal influence is not given [<xref rid=""B56-biomedicines-11-00927"" ref-type=""bibr"">56</xref>]. In conclusion, HOM fibroblasts show several defects in mechanotransduction effectors. Our previous work assessed the presence of dysregulations in the autophagy process in HOM models: we found an accumulation of",15_28,Mechanotransduction Impairment in Primary Fibroblast Model of Krabbe Disease,16 3 2023,,Krabbe_Disease
"in HOM models: we found an accumulation of LC3 puncta and increased LC3-II protein levels in MO3.13 cells treated with PSY [<xref rid=""B57-biomedicines-11-00927"" ref-type=""bibr"">57</xref>], together with increased p62 levels in HOM fibroblasts in vitro, and in twitcher mouse brain in vivo [<xref rid=""B19-biomedicines-11-00927"" ref-type=""bibr"">19</xref>]. Moreover, we showed that the treatment with the autophagy activator RAPA partially restores the autophagy markers levels and, in particular, the number of",15_29,Mechanotransduction Impairment in Primary Fibroblast Model of Krabbe Disease,16 3 2023,,Krabbe_Disease
"markers levels and, in particular, the number of p62 aggregates in twitcher fibroblasts [<xref rid=""B19-biomedicines-11-00927"" ref-type=""bibr"">19</xref>]. Our present results confirm the presence of dysregulations in the autophagy process in HOM fibroblasts. The rate of cell migration is regulated by the turnover of FAs [<xref rid=""B51-biomedicines-11-00927"" ref-type=""bibr"">51</xref>,<xref rid=""B58-biomedicines-11-00927"" ref-type=""bibr"">58</xref>], and their disassembly is dynamically tuned by autophagy.",15_30,Mechanotransduction Impairment in Primary Fibroblast Model of Krabbe Disease,16 3 2023,,Krabbe_Disease
"disassembly is dynamically tuned by autophagy. The selective autophagy mediator for FAs is the autophagy cargo receptor NBR1 [<xref rid=""B39-biomedicines-11-00927"" ref-type=""bibr"">39</xref>], which is analogous to the most famous p62 [<xref rid=""B59-biomedicines-11-00927"" ref-type=""bibr"">59</xref>]. Kenific et al. showed that NBR1 depletion significantly inhibits cell migration [<xref rid=""B60-biomedicines-11-00927"" ref-type=""bibr"">60</xref>,<xref rid=""B61-biomedicines-11-00927"" ref-type=""bibr"">61</xref>].",15_31,Mechanotransduction Impairment in Primary Fibroblast Model of Krabbe Disease,16 3 2023,,Krabbe_Disease
"ref-type=""bibr"">61</xref>]. We found an increase in the number of NBR1 aggregates in HOM cells, in accordance with what we found for p62 [<xref rid=""B19-biomedicines-11-00927"" ref-type=""bibr"">19</xref>]. The treatment with RAPA (i.e., autophagy activation) led to a slight decrease in the accumulation of NBR1 aggregates, rescued the FA levels in HOM fibroblasts by reducing their number at the WT level, and fully rescued their migration behaviour. In line with these results, BAF treatment, which inhibits",15_32,Mechanotransduction Impairment in Primary Fibroblast Model of Krabbe Disease,16 3 2023,,Krabbe_Disease
"with these results, BAF treatment, which inhibits autophagosome–lysosome fusion and induces the block of autophagy [<xref rid=""B62-biomedicines-11-00927"" ref-type=""bibr"">62</xref>,<xref rid=""B63-biomedicines-11-00927"" ref-type=""bibr"">63</xref>], had an opposite effect, thus increasing NBR1 accumulation in WT cells and the number of FAs in both WT and HOM fibroblasts [<xref rid=""B64-biomedicines-11-00927"" ref-type=""bibr"">64</xref>]. Unfortunately, BAF itself completely blocked the cell motion, both in WT",15_33,Mechanotransduction Impairment in Primary Fibroblast Model of Krabbe Disease,16 3 2023,,Krabbe_Disease
"completely blocked the cell motion, both in WT and HOM, and we could not evaluate the migration after this treatment. Altogether, our results indicate that in HOM fibroblasts, RAPA treatment restores migration and induces the reduction in FA and NBR1 aggregates. Previous studies showed that autophagy is important for the migratory phenotype [<xref rid=""B64-biomedicines-11-00927"" ref-type=""bibr"">64</xref>,<xref rid=""B65-biomedicines-11-00927"" ref-type=""bibr"">65</xref>]. We showed that autophagy congestion",15_34,Mechanotransduction Impairment in Primary Fibroblast Model of Krabbe Disease,16 3 2023,,Krabbe_Disease
"We showed that autophagy congestion in HOM cells causes an increase in NBR1 and FA aggregates. This can cause a slowdown in cell migration. Recently, Weinstock et al. [<xref rid=""B66-biomedicines-11-00927"" ref-type=""bibr"">66</xref>] showed that the ablation of GALC before P4 induced severe neurodevelopmental defects in the brainstem, demonstrating that temporal GALC expression is a major contributor to brainstem development. Cell migration is particularly important during neurodevelopment (e.g., in the",15_35,Mechanotransduction Impairment in Primary Fibroblast Model of Krabbe Disease,16 3 2023,,Krabbe_Disease
"important during neurodevelopment (e.g., in the cortical layers) [<xref rid=""B67-biomedicines-11-00927"" ref-type=""bibr"">67</xref>], and here slight delays in migration can lead to important deficits. Therefore, our results indicate that: (i) the mechanotransduction and migration defects due to GALC deficiency and demonstrated in HOM fibroblasts can have a relevant role in neural cells; (ii) a boost to the autophagy process can help to counteract the cell migration deficits due to GALC deficiency and maybe",15_36,Mechanotransduction Impairment in Primary Fibroblast Model of Krabbe Disease,16 3 2023,,Krabbe_Disease
"deficits due to GALC deficiency and maybe other KD pathological features also. Although additional studies are required to fully characterize the autophagy machinery in TWI mice, we suggest autophagy dysregulation as a new aspect involved in the molecular pathogenesis of KD: our data suggest that autophagy is dysregulated (but not impaired) in the TWI models [<xref rid=""B19-biomedicines-11-00927"" ref-type=""bibr"">19</xref>,<xref rid=""B57-biomedicines-11-00927"" ref-type=""bibr"">57</xref>]. Data overall",15_37,Mechanotransduction Impairment in Primary Fibroblast Model of Krabbe Disease,16 3 2023,,Krabbe_Disease
"ref-type=""bibr"">57</xref>]. Data overall suggest a higher basal level of autophagy activation in the missing GALC condition that is further stimulated in the presence of PSY. Specifically, GALC deficiency could lead to lysosomal dysfunction, partial blocking, and, consequently, saturating the autophagy flux. In line with this, altered autophagy and accumulation of lipids, especially cholesterol and glycosphingolipids, have been reported for a wide range of lysosomal storage disorders, including those",15_38,Mechanotransduction Impairment in Primary Fibroblast Model of Krabbe Disease,16 3 2023,,Krabbe_Disease
"of lysosomal storage disorders, including those without primary defects in glycosphingolipid or cholesterol degradation [<xref rid=""B68-biomedicines-11-00927"" ref-type=""bibr"">68</xref>]. Recently, several findings have emerged in the literature concerning new aspects of KD pathogenesis that cannot be explained by PSY accumulation alone. Therefore, we studied mechanotransduction signalling in twitcher fibroblasts, which are a cell model that does not accumulate PSY and allows us to observe phenotypes",15_39,Mechanotransduction Impairment in Primary Fibroblast Model of Krabbe Disease,16 3 2023,,Krabbe_Disease
"PSY and allows us to observe phenotypes related to PSY-independent pathological mechanisms. The measurement of this toxic lipid was addressed both in primary twitcher-mouse-derived fibroblasts [<xref rid=""B19-biomedicines-11-00927"" ref-type=""bibr"">19</xref>] and in primary fibroblasts derived from KD patients [<xref rid=""B20-biomedicines-11-00927"" ref-type=""bibr"">20</xref>], and both WT and HOM cells presented a similar level of PSY. To the best of our knowledge, only Li et al. [<xref",15_40,Mechanotransduction Impairment in Primary Fibroblast Model of Krabbe Disease,16 3 2023,,Krabbe_Disease
"the best of our knowledge, only Li et al. [<xref rid=""B69-biomedicines-11-00927"" ref-type=""bibr"">69</xref>] have reported a very modest accumulation of PSY levels in twitcher fibroblasts (i.e., PSY is 0.0010 arbitrary units in HOM mouse fibroblasts compared to 0.15–0.25 a.u. in the sciatic nerve and brain of HOM mice). We also addressed this problem and measured PSY in our WT and HOM fibroblasts, as in [<xref rid=""B19-biomedicines-11-00927"" ref-type=""bibr"">19</xref>]: PSY levels were really low and almost",15_41,Mechanotransduction Impairment in Primary Fibroblast Model of Krabbe Disease,16 3 2023,,Krabbe_Disease
"PSY levels were really low and almost undetectable (i.e., under the detection limit of the instrument, which is 18.2 pg/µg protein) in both our WT and HOM fibroblast samples (<xref rid=""app1-biomedicines-11-00927"" ref-type=""app"">Figure S4</xref>). For this reason, we suggest that PSY is not primarily responsible for the adhesion and migration deficits that we observed in twitcher HOM fibroblasts. To better understand the role of GALC, further examinations have to be performed. Until now, research has",15_42,Mechanotransduction Impairment in Primary Fibroblast Model of Krabbe Disease,16 3 2023,,Krabbe_Disease
"have to be performed. Until now, research has focused mainly on PSY’s effects, due to its devastative impact on cells, but it is now emerging that GALC deficiency is pathological itself. Being able to discriminate the role of PSY from other GALC deficiency effects in this pathology is the first step to improve and design efficacy treatments. To conclude, we propose that the mechanosensing impairment in HOM twitcher fibroblasts is due to the dysregulation of autophagy, which is primarily caused by GALC",15_43,Mechanotransduction Impairment in Primary Fibroblast Model of Krabbe Disease,16 3 2023,,Krabbe_Disease
"of autophagy, which is primarily caused by GALC deficiency and leads to cell migration deficits. Our results suggest that a boost to the autophagy process can help to counteract some KD pathological features, laying the foundation for rapamycin preclinical testing.",15_44,Mechanotransduction Impairment in Primary Fibroblast Model of Krabbe Disease,16 3 2023,,Krabbe_Disease
"Upregulation of non-canonical and canonical inflammasome genes associates with pathological features in Krabbe disease and related disorders Infantile Krabbe disease is a rapidly progressive and fatal disorder of myelin, caused by inherited deficiency of the lysosomal enzyme β-galactocerebrosidase. Affected children lose their motor skills and other faculties; uncontrolled seizures are a frequent terminal event. Overexpression of the sphingolipid metabolite psychosine is a pathogenic factor, but does not",16_0,Upregulation of non-canonical and canonical inflammasome genes associates with pathological features in Krabbe disease and related disorders,15 4 2023,,Krabbe_Disease
"psychosine is a pathogenic factor, but does not fully account for the pleiotropic manifestations and there is a clear need to investigate additional pathological mechanisms. We examined innate immunity, caspase-11 and associated inflammatory pathways in twitcher mice, an authentic model of Krabbe disease. Combined use of molecular tools, RNAscope <italic toggle=""yes"">in situ</italic> hybridization and immunohistochemical staining established that the expression of pro-inflammatory non-canonical caspase-11,",16_1,Upregulation of non-canonical and canonical inflammasome genes associates with pathological features in Krabbe disease and related disorders,15 4 2023,,Krabbe_Disease
"of pro-inflammatory non-canonical caspase-11, canonical caspase-1, gasdermin D and cognate genes is induced in nervous tissue. Early onset and progressive upregulation of these genes accompany demyelination and gliosis and although the molecules are scant in healthy tissue, abundance of the respective translation products is greatly increased in diseased animals. Caspase-11 is found in reactive microglia/macrophages as well as astrocytes but caspase-1 and gasdermin D are restricted to reactive",16_2,Upregulation of non-canonical and canonical inflammasome genes associates with pathological features in Krabbe disease and related disorders,15 4 2023,,Krabbe_Disease
"and gasdermin D are restricted to reactive microglia/macrophages. The inflammasome signature is not unique to Krabbe disease; to varying degrees, this signature is also prominent in other lysosomal diseases, Sandhoff and Niemann-Pick Type-C1, and the lysolecithin toxin model of focal demyelination. Given the potent inflammatory response here identified in Krabbe disease and the other neurodegenerative disorders studied, a broad induction of inflammasomes is likely to be a dominant factor in the",16_3,Upregulation of non-canonical and canonical inflammasome genes associates with pathological features in Krabbe disease and related disorders,15 4 2023,,Krabbe_Disease
"is likely to be a dominant factor in the pathogenesis, and thus represents a platform for therapeutic exploration.",16_4,Upregulation of non-canonical and canonical inflammasome genes associates with pathological features in Krabbe disease and related disorders,15 4 2023,,Krabbe_Disease
"<fig position=""float"" id=""ga1""><graphic http://www.w3.org/1999/xlink href=""ddac299ga1"" position=""float""></graphic></fig>",16_5,Upregulation of non-canonical and canonical inflammasome genes associates with pathological features in Krabbe disease and related disorders,15 4 2023,,Krabbe_Disease
"Krabbe disease (OMIM 245200), also known as globoid cell leukodystrophy (<xref rid=""ref1"" ref-type=""bibr"">1</xref>), is an inborn error of metabolism caused by deficiency of the lysosomal enzyme β-galactocerebrosidase (GALC) (EC 3.2.1.46) (<xref rid=""ref2"" ref-type=""bibr"">2</xref>), essential for the hydrolysis of the sphingolipid β-galactosylceramide (GalCer). Myelin, the insulating sheath of nerve fibres, produced by oligodendrocytes and Schwann cells, is highly enriched in GalCer (<xref rid=""ref3""",16_6,Upregulation of non-canonical and canonical inflammasome genes associates with pathological features in Krabbe disease and related disorders,15 4 2023,,Krabbe_Disease
"is highly enriched in GalCer (<xref rid=""ref3"" ref-type=""bibr"">3</xref>). A consequence of GALC deficiency is that the turnover of myelin is compromised, which ultimately leads to its degeneration and loss of myelin-producing cells (<xref rid=""ref4"" ref-type=""bibr"">4</xref>,<xref rid=""ref5"" ref-type=""bibr"">5</xref>). Many lysosomal diseases are characterized by the cellular accumulation of the target compound of the relevant defective enzyme, but in Krabbe disease, GalCer does not accumulate in",16_7,Upregulation of non-canonical and canonical inflammasome genes associates with pathological features in Krabbe disease and related disorders,15 4 2023,,Krabbe_Disease
"in Krabbe disease, GalCer does not accumulate in myelin-producing cells. Rather, the cognate cytotoxic lipid metabolite galactosylsphingosine (psychosine), itself a substrate of GALC, increases progressively with disease severity (<xref rid=""ref6"" ref-type=""bibr"">6</xref>,<xref rid=""ref7"" ref-type=""bibr"">7</xref>). Psychosine is generated catabolically through deacylation of GalCer by acid ceramidase (N-acylsphingosine deacylase, EC 3.5.1.23) in the lysosome, partly explaining the lack of GalCer increases",16_8,Upregulation of non-canonical and canonical inflammasome genes associates with pathological features in Krabbe disease and related disorders,15 4 2023,,Krabbe_Disease
"partly explaining the lack of GalCer increases in diseased tissue (<xref rid=""ref8"" ref-type=""bibr"">8</xref>). The incidence of Krabbe disease is estimated at 1 in 100 000–250 000 births (<xref rid=""ref9"" ref-type=""bibr"">9</xref>), and on the basis of the age of onset, infantile, juvenile and adult forms are recognized. In the most frequent and acute form, the infant appears normal at birth, but the disease declares itself within a few months: characteristic manifestations include extreme irritability,",16_9,Upregulation of non-canonical and canonical inflammasome genes associates with pathological features in Krabbe disease and related disorders,15 4 2023,,Krabbe_Disease
"manifestations include extreme irritability, feeding difficulties, recurrent fevers, psychomotor regression and generalized seizures. Most of these children succumb before the age of 2 years (<xref rid=""ref10"" ref-type=""bibr"">10</xref>). Juvenile and adult cases develop neurodegenerative signs but with later onset and an attenuated course (<xref rid=""ref11"" ref-type=""bibr"">11</xref>). Hematopoietic stem cell transplantation, although not curative, is the only effective treatment for Krabbe disease, and",16_10,Upregulation of non-canonical and canonical inflammasome genes associates with pathological features in Krabbe disease and related disorders,15 4 2023,,Krabbe_Disease
"only effective treatment for Krabbe disease, and long-term clinical benefit is restricted to those patients who undergo this procedure before symptomatic disease becomes apparent (<xref rid=""ref12"" ref-type=""bibr"">12</xref>). GALC is expressed by different cell-types in neural tissue (<xref rid=""ref13"" ref-type=""bibr"">13</xref>), and infiltrating macrophages respond to demyelination by increasing GALC production, an indication of regulated expression (<xref rid=""ref14"" ref-type=""bibr"">14</xref>). After a",16_11,Upregulation of non-canonical and canonical inflammasome genes associates with pathological features in Krabbe disease and related disorders,15 4 2023,,Krabbe_Disease
"rid=""ref14"" ref-type=""bibr"">14</xref>). After a demyelinating event, owing to its inhibitory effect on remyelination and strong pro-inflammatory effects, myelin debris must be removed (<xref rid=""ref15"" ref-type=""bibr"">15</xref>). Microglia/macrophages principally undertake this clearance; for receptor-mediated phagocytic removal, myelin binds to surface receptors either directly or after opsonization (<xref rid=""ref16"" ref-type=""bibr"">16</xref>), but clearance of degenerated myelin cannot proceed",16_12,Upregulation of non-canonical and canonical inflammasome genes associates with pathological features in Krabbe disease and related disorders,15 4 2023,,Krabbe_Disease
"clearance of degenerated myelin cannot proceed effectively in Krabbe disease because of GALC deficiency in these cells. Danger-associated molecular patterns are sensed by cytosolic innate immune receptors which, together with the adaptor molecule ASC (apoptotic speck-containing protein with a card) and pro-caspase-1 assemble into a canonical inflammasome complex ensuing pro-caspase-1 activation (<xref rid=""ref17"" ref-type=""bibr"">17</xref>). Mature caspase-1 cleaves and activates many substrates, including",16_13,Upregulation of non-canonical and canonical inflammasome genes associates with pathological features in Krabbe disease and related disorders,15 4 2023,,Krabbe_Disease
"cleaves and activates many substrates, including interleukin-1β (IL-1β); a major mediator of pathogenesis that induces local inflammation, fever and interferon responses (<xref rid=""ref18"" ref-type=""bibr"">18</xref>,<xref rid=""ref19"" ref-type=""bibr"">19</xref>). The more recently discovered non-canonical inflammasomes, consisting of mouse caspase-11 and its human orthologues caspase-4 and -5, are best known as endogenous receptors for endotoxin lipopolysaccharide (LPS), derived from the outer membrane of",16_14,Upregulation of non-canonical and canonical inflammasome genes associates with pathological features in Krabbe disease and related disorders,15 4 2023,,Krabbe_Disease
"(LPS), derived from the outer membrane of Gram-negative bacteria. LPS through its lipid A tail moiety binds caspase-11, and leads to its oligomerization and proximity-induced activation by auto-proteolysis (<xref rid=""ref20"" ref-type=""bibr"">20–23</xref>). In common with canonical inflammasomes, non-canonical inflammasomes can cause cytokine release and pyroptosis mediated by gasdermin D (GSDMD). The C-terminal domain of the full size GSDMD auto-inhibits its function, but cleavage by either caspase-1 or -11",16_15,Upregulation of non-canonical and canonical inflammasome genes associates with pathological features in Krabbe disease and related disorders,15 4 2023,,Krabbe_Disease
"function, but cleavage by either caspase-1 or -11 releases this inhibition. The GSDMD-N-containing fragment can travel to the plasma membrane to form membrane-permeable pores. Pore formation can result in loss of ionic gradient, cell membrane rupture and extravasation of cellular contents (<xref rid=""ref24"" ref-type=""bibr"">24–26</xref>). Autophagosomes and lysosomes are important mediators of innate immunity (<xref rid=""ref27"" ref-type=""bibr"">27–29</xref>) and inborn errors that undermine the function of",16_16,Upregulation of non-canonical and canonical inflammasome genes associates with pathological features in Krabbe disease and related disorders,15 4 2023,,Krabbe_Disease
"and inborn errors that undermine the function of these organelles together with unhydrolyzed compounds as a result of an impaired autophagosomal/lysosomal system likely influence immune responses. An idea supported by the recent discovery that the canonical inflammasome Nlrp3 (nucleotide-binding leucine-rich repeat receptor family member pyrin-domain containing) is activated in diverse lysosomal disorders, Gaucher disease (<xref rid=""ref30"" ref-type=""bibr"">30</xref>) and mucopolysaccharidosis type IIIA",16_17,Upregulation of non-canonical and canonical inflammasome genes associates with pathological features in Krabbe disease and related disorders,15 4 2023,,Krabbe_Disease
"and mucopolysaccharidosis type IIIA (MPSIIIA) (<xref rid=""ref31"" ref-type=""bibr"">31</xref>), caused by defects in glucosylceramide and heparan sulphate degradation, respectively. On the basis of these and findings by others, we hypothesized that inflammasome activation and GSDMD-mediated pyroptosis might occur in Krabbe disease and contribute substantially to pathogenesis and neurological disability. Accordingly, we designed the current study with two specific goals: to elucidate the involvement of the",16_18,Upregulation of non-canonical and canonical inflammasome genes associates with pathological features in Krabbe disease and related disorders,15 4 2023,,Krabbe_Disease
"goals: to elucidate the involvement of the inflammasome in Krabbe disease, and to understand whether there is an inflammasome signature characteristic of the disease. To assess the specificity of the inflammasome response in Krabbe disease, we used comparative analysis, against lysosomal disorders Sandhoff (SD) and Niemann–Pick Type C1 (NPC1) disease that preferentially target neurons, and a distinct model of focal demyelination caused by injection of the toxin lysolecithin (Lys) into the spinal cord of",16_19,Upregulation of non-canonical and canonical inflammasome genes associates with pathological features in Krabbe disease and related disorders,15 4 2023,,Krabbe_Disease
"toxin lysolecithin (Lys) into the spinal cord of wild-type animals.  Krabbe disease, an inborn error of sphingolipid metabolism, is characterized by florid demyelination and neuroinflammation. The deficiency of GALC activity in this disorder leads to the overproduction of the neurotoxic lysosphingolipid galactosylsphingosine, which is derived by deacylation of galactosylceramide as a consequence of activation of acid ceramidase (N-acylsphingosine deacylase, ASAH1) in the pathological lysosome (<xref",16_20,Upregulation of non-canonical and canonical inflammasome genes associates with pathological features in Krabbe disease and related disorders,15 4 2023,,Krabbe_Disease
"ASAH1) in the pathological lysosome (<xref rid=""ref8"" ref-type=""bibr"">8</xref>). Although this metabolite, commonly known as psychosine, contributes to the neuropathology of Krabbe disease (<xref rid=""ref6"" ref-type=""bibr"">6</xref>,<xref rid=""ref7"" ref-type=""bibr"">7</xref>,<xref rid=""ref61"" ref-type=""bibr"">61</xref>), as demonstrated by interbreeding twi mice with a strain genetically engineered with Asah1 deficiency, or by administration of carmofur (an inhibitor of psychosine biosynthesis), these",16_21,Upregulation of non-canonical and canonical inflammasome genes associates with pathological features in Krabbe disease and related disorders,15 4 2023,,Krabbe_Disease
"(an inhibitor of psychosine biosynthesis), these measures did not completely correct the neurological phenotype, nor did they fully restore survival in mutant animals (<xref rid=""ref8"" ref-type=""bibr"">8</xref>). Although psychosine is clearly toxic, its accumulation cannot account for all the manifestations of this disease—a view supported by experimental data (<xref rid=""ref62"" ref-type=""bibr"">62–67</xref>). Results from these and other studies suggest that the pathological features of the disease are the",16_22,Upregulation of non-canonical and canonical inflammasome genes associates with pathological features in Krabbe disease and related disorders,15 4 2023,,Krabbe_Disease
"the pathological features of the disease are the consequence of several cellular and molecular pathways, induced at least in part by psychosine and other, largely unrelated inflammatory events. We speculated that exposure to myelin/cell debris, whether extra- or/and intracellularly, might engage innate sensors of damage-associated molecular patterns and drive inflammasome activation, thus contributing to pathogenesis. Expression of caspase-1 and caspase-11 increases progressively with age and disease",16_23,Upregulation of non-canonical and canonical inflammasome genes associates with pathological features in Krabbe disease and related disorders,15 4 2023,,Krabbe_Disease
"increases progressively with age and disease severity in twi mice, and both pro-forms and cleaved species are conspicuous in nervous tissue, suggesting inflammasome activation. Pro-inflammatory caspases cleave Gsdmd and can lead to pyroptosis and cytokine release. <italic toggle=""yes"">Gsdmd</italic> is upregulated in neural tissue in twi mice and parallels the expression pattern of pro-inflammatory caspases. The cleaved Gsdmd form is presumably able to form pores in the plasma membrane, but even if pores",16_24,Upregulation of non-canonical and canonical inflammasome genes associates with pathological features in Krabbe disease and related disorders,15 4 2023,,Krabbe_Disease
"pores in the plasma membrane, but even if pores are formed, this might not inevitably provoke cell death. Exposure of phagocytes to sublytic amounts of inflammasome activation can cause pore formation and release of cytokines without committing the cell to die (<xref rid=""ref68"" ref-type=""bibr"">68</xref>). Although canonical inflammasomes and Gsdmd have been implicated in other neurodegenerative conditions (<xref rid=""ref69"" ref-type=""bibr"">69</xref>,<xref rid=""ref70"" ref-type=""bibr"">70</xref>), the",16_25,Upregulation of non-canonical and canonical inflammasome genes associates with pathological features in Krabbe disease and related disorders,15 4 2023,,Krabbe_Disease
"rid=""ref70"" ref-type=""bibr"">70</xref>), the finding of caspase-11 induction, particularly strong in the Krabbe disease model was unexpected, as its activation is best known in response to bacterial infections. Only a small number of studies have examined caspase-11 induction in brain under sterile conditions (<xref rid=""ref71"" ref-type=""bibr"">71</xref>,<xref rid=""ref72"" ref-type=""bibr"">72</xref>). Our data show that remarkably, pathological events in Krabbe disease induce the expression of caspase-11 and",16_26,Upregulation of non-canonical and canonical inflammasome genes associates with pathological features in Krabbe disease and related disorders,15 4 2023,,Krabbe_Disease
"disease induce the expression of caspase-11 and associated molecules <italic toggle=""yes"">Gbps</italic> and <italic toggle=""yes"">Irgm</italic>, known as the most highly expressed and important genes in combating infection (<xref rid=""ref43"" ref-type=""bibr"">43</xref>,<xref rid=""ref73"" ref-type=""bibr"">73–75</xref>). To stablish the unique nature, or otherwise, of the inflammasome signature in Krabbe disease, we performed comparative studies with mouse models of the lysosomal storage diseases Sandhoff and",16_27,Upregulation of non-canonical and canonical inflammasome genes associates with pathological features in Krabbe disease and related disorders,15 4 2023,,Krabbe_Disease
"of the lysosomal storage diseases Sandhoff and NPC1. The expression of inflammasome and associated genes is significantly upregulated in all three disorders, albeit showing different degrees of activation. This would suggest that exposure of innate immune cells to degenerated/dead oligodendrocytes/Schwann cells and myelin debris in Krabbe disease is, in all likelihood, the driver of the identified strong inflammasome response. Because inflammasome activation is not limited to professional innate immune",16_28,Upregulation of non-canonical and canonical inflammasome genes associates with pathological features in Krabbe disease and related disorders,15 4 2023,,Krabbe_Disease
"is not limited to professional innate immune cells, we combined mRNA ISH with IHC staining to establish tissue and cellular distribution of key components. Expression of <italic toggle=""yes"">Casp1</italic>, <italic toggle=""yes"">Casp11</italic> and <italic toggle=""yes"">Gsdmd</italic> is extremely low in wild-type animals, and whereas <italic toggle=""yes"">Casp1</italic> and <italic toggle=""yes"">Gsdmd</italic> are mostly confined to reactive microglia/macrophages, <italic toggle=""yes"">Casp11</italic> is also",16_29,Upregulation of non-canonical and canonical inflammasome genes associates with pathological features in Krabbe disease and related disorders,15 4 2023,,Krabbe_Disease
"<italic toggle=""yes"">Casp11</italic> is also highly induced in reactive astrocytes. However, the <italic toggle=""yes"">Casp11</italic> signal congregates almost exclusively in the nucleus of astrocytes, while appearing evenly distributed in microglia/macrophages. Whether the nucleus-retained RNA is unspliced or mature and what the biological significance might be is currently unknown, but genome-wide studies have reported that many mRNAs are retained in the nucleus at high levels (<xref rid=""ref76""",16_30,Upregulation of non-canonical and canonical inflammasome genes associates with pathological features in Krabbe disease and related disorders,15 4 2023,,Krabbe_Disease
"in the nucleus at high levels (<xref rid=""ref76"" ref-type=""bibr"">76</xref>,<xref rid=""ref77"" ref-type=""bibr"">77</xref>), and can be released into the cytoplasm upon stimulation, suggesting a novel control mechanism of gene expression (<xref rid=""ref78"" ref-type=""bibr"">78</xref>). A study on the Experimental Autoimmune Encephalomyelitis murine model of demyelination demonstrated increased expression of inflammasome-associated genes, and importantly, many of the findings were corroborated in autopsied",16_31,Upregulation of non-canonical and canonical inflammasome genes associates with pathological features in Krabbe disease and related disorders,15 4 2023,,Krabbe_Disease
"of the findings were corroborated in autopsied samples from patients with multiple sclerosis (<xref rid=""ref70"" ref-type=""bibr"">70</xref>). Caspase-1 and Gsdmd were identified in cells immunoreactive for Iba1 and glutathione S-transferase pi, an oligodendrocyte marker. Although not discussed directly, the report showed <italic toggle=""yes"">Casp11</italic> upregulation in these mice, and attenuated expression following exposure to the inhibitor VX-765. Improvement in tissue injury and behaviour were",16_32,Upregulation of non-canonical and canonical inflammasome genes associates with pathological features in Krabbe disease and related disorders,15 4 2023,,Krabbe_Disease
"Improvement in tissue injury and behaviour were attributed to caspase-1 inhibition. However, it can be argued that the beneficial outcome might be due, at least in part, to inhibition of caspase-11, because VX-765 also hinders the function of this proteinase (<xref rid=""ref79"" ref-type=""bibr"">79</xref>). Functionally active interleukin-1, IL-1α and IL-1β, are produced after inflammasome activation. Il-1α is specifically cleaved and activated by caspase-11 in macrophages (<xref rid=""ref80""",16_33,Upregulation of non-canonical and canonical inflammasome genes associates with pathological features in Krabbe disease and related disorders,15 4 2023,,Krabbe_Disease
"by caspase-11 in macrophages (<xref rid=""ref80"" ref-type=""bibr"">80</xref>), and we speculate also in microglia. These powerful apical cytokines bind and signal through type 1 IL-1 receptor (IL-1R), which can be blocked by the competitive action of the IL-1 receptor antagonist (IL-1Ra), inhibiting all signal transduction (<xref rid=""ref81"" ref-type=""bibr"">81</xref>). The interleukin-1 system, mediated by microglia/macrophage, contributes to neurodegeneration and its inhibition improves disease outcome",16_34,Upregulation of non-canonical and canonical inflammasome genes associates with pathological features in Krabbe disease and related disorders,15 4 2023,,Krabbe_Disease
"and its inhibition improves disease outcome (<xref rid=""ref82"" ref-type=""bibr"">82</xref>,<xref rid=""ref83"" ref-type=""bibr"">83</xref>). Notably, within the context of a lysosomal disease, overexpression of IL-1Ra or abrogation of Il-1R1 in a mouse model of MPSIIIA halted the development of pathological hallmarks, including a striking reduction in reactive astrocytes (<xref rid=""ref31"" ref-type=""bibr"">31</xref>), which is evidence of interleukin-1 being a driver of astrogliosis (<xref rid=""ref84""",16_35,Upregulation of non-canonical and canonical inflammasome genes associates with pathological features in Krabbe disease and related disorders,15 4 2023,,Krabbe_Disease
"being a driver of astrogliosis (<xref rid=""ref84"" ref-type=""bibr"">84</xref>). Importantly, the salutary effects occurred without a reduction in the accumulation of storage substrates. The results from the MPSIIIA study are well aligned with those of Liddelow <italic toggle=""yes"">et al</italic>. on the activation of astrocytes by microglia (<xref rid=""ref58"" ref-type=""bibr"">58</xref>). The expression profile of astrocytes, particularly in the Krabbe disease model, reveals an extremely acute phenotype at the",16_36,Upregulation of non-canonical and canonical inflammasome genes associates with pathological features in Krabbe disease and related disorders,15 4 2023,,Krabbe_Disease
"reveals an extremely acute phenotype at the HEP, a response more severe than that to an ischemic insult or infection at peak disease time (<xref rid=""ref55"" ref-type=""bibr"">55</xref>). We conclude that in common with other neurodegenerative disorders (<xref rid=""ref58"" ref-type=""bibr"">58</xref>), reactive astrocytes are a prominent feature of Krabbe, NPC1 and SD. We examined psychosine as a possible inducer of <italic toggle=""yes"">Casp11</italic> expression in primary cultures of astrocytes isolated from",16_37,Upregulation of non-canonical and canonical inflammasome genes associates with pathological features in Krabbe disease and related disorders,15 4 2023,,Krabbe_Disease
"in primary cultures of astrocytes isolated from the brains of twi and their wild-type counterparts, and used LPS as a control, a known inducer of its expression. LPS-treated astrocytes of both genotypes robustly induced <italic toggle=""yes"">Casp11</italic> expression, but exposure to toxic amounts of psychosine did not induce <italic toggle=""yes"">Casp11</italic>. Of note, in a study by O’Sullivan and Dev, exposure of astrocytes to psychosine caused cell death, but had no effect on the expression of",16_38,Upregulation of non-canonical and canonical inflammasome genes associates with pathological features in Krabbe disease and related disorders,15 4 2023,,Krabbe_Disease
"death, but had no effect on the expression of pro-inflammatory cytokines IL6, TNFα, and IL1β. However, psychosine potentiated LPS induction of these cytokines (<xref rid=""ref61"" ref-type=""bibr"">61</xref>). They also found that pre-treatment of these cultures with fingolimod pFTY720, a sphingosine 1-phosphate (S1P) receptor agonist that resembles S1P, attenuated the effects of psychosine and LPS by reducing cell death and cytokine production. Moreover, pFTY720-treated organotypic cerebellar slices resulted",16_39,Upregulation of non-canonical and canonical inflammasome genes associates with pathological features in Krabbe disease and related disorders,15 4 2023,,Krabbe_Disease
"organotypic cerebellar slices resulted in similar findings and inhibition of demyelination. Recently, the same group tested the effects of pFTY20 on twi (<xref rid=""ref85"" ref-type=""bibr"">85</xref>), and described rescue of myelin levels, reduction of reactive microglia and astrocytes concomitant with a modest increase in life span. Given that fingolimod has been shown to have powerful anti-inflammatory effects in different animal models of neurodegeneration (<xref rid=""ref86""",16_40,Upregulation of non-canonical and canonical inflammasome genes associates with pathological features in Krabbe disease and related disorders,15 4 2023,,Krabbe_Disease
"models of neurodegeneration (<xref rid=""ref86"" ref-type=""bibr"">86</xref>,<xref rid=""ref87"" ref-type=""bibr"">87</xref>), and that S1P receptors influence expression of cytokines in immune and glial cells (<xref rid=""ref88"" ref-type=""bibr"">88</xref>), it appears likely that inflammasome activation might be mediated, at least in part, by S1P signalling. To summarize, our investigations identified a profound inflammatory response in Krabbe disease, characterized by a heightened expression and activation of",16_41,Upregulation of non-canonical and canonical inflammasome genes associates with pathological features in Krabbe disease and related disorders,15 4 2023,,Krabbe_Disease
"by a heightened expression and activation of non-canonical and canonical inflammasomes and associated molecules. The reaction starts early in life and intensifies with advancing age and progression of the neuropathological injury. Taken together, the data suggest that this inflammatory response is likely to contribute to the neuropathogenesis of Krabbe disease. Similar findings, however, were identified in NPC1, SD and the Lys toxin model of demyelination, thus pointing to a shared innate immune response",16_42,Upregulation of non-canonical and canonical inflammasome genes associates with pathological features in Krabbe disease and related disorders,15 4 2023,,Krabbe_Disease
"thus pointing to a shared innate immune response that is engaged in these neurodegenerative conditions and is a mechanism likely common to many such diseases. We hypothesize that activated caspase-11 in microglia/macrophages cleaves and activates Il-1α and Gsdmd, forming pores and allowing the release of Il-1α and other cytokines, which in turn activates astrocytes, cells that abundantly express IL-IR. Although we acknowledge that the understanding of these processes remains limited, and that the",16_43,Upregulation of non-canonical and canonical inflammasome genes associates with pathological features in Krabbe disease and related disorders,15 4 2023,,Krabbe_Disease
"of these processes remains limited, and that the conclusions are drawn from: (1) finding an association between inflammasome induction and disease pathology; and (2) prior research in related diseases that demonstrated the pathogenicity of activated inflammasomes in these disorders, defining the precise molecular triggers of inflammasome activation in the diseases studied here are of paramount importance, and further investigations are currently underway to identify the most plausible candidates.",16_44,Upregulation of non-canonical and canonical inflammasome genes associates with pathological features in Krabbe disease and related disorders,15 4 2023,,Krabbe_Disease
"to identify the most plausible candidates. Deciphering inflammatory mechanisms that underpin the pathogenesis of Krabbe disease, and indeed those of other neurodegenerative disorders, is essential to inform the design of future therapeutic stratagems. Our findings provide a tangible route to test whether modulation of the innate immune response, on its own or in combination with established approaches, can address some of the challenges encountered in the treatment of these devastating diseases.",16_45,Upregulation of non-canonical and canonical inflammasome genes associates with pathological features in Krabbe disease and related disorders,15 4 2023,,Krabbe_Disease
"A Roadmap for Potential Improvement of Newborn Screening for Inherited Metabolic Diseases Following Recent Developments and Successful Applications of Bivariate Normal Limits for Pre-Symptomatic Detection of MPS I, Pompe Disease, and Krabbe Disease The mucopolysaccharidoses (MPS), Pompe Disease (PD), and Krabbe disease (KD) are inherited conditions known as lysosomal storage disorders (LSDs) The resulting enzyme deficiencies give rise to progressive symptoms. The United States Department of Health and Human",17_0,"A Roadmap for Potential Improvement of Newborn Screening for Inherited Metabolic Diseases Following Recent Developments and Successful Applications of Bivariate Normal Limits for Pre-Symptomatic Detection of MPS I, Pompe Disease, and Krabbe Disease",15 11 2022,,Krabbe_Disease
"The United States Department of Health and Human Services’ Recommended Uniform Screening Panel (RUSP) suggests LSDs for inclusion in state universal newborn screening (NBS) programs and has identified screening deficiencies in MPS I, KD, and PD NBS programs. MPS I NBS programs utilize newborn dried blood spots and assay alpha L-iduronidase (IDUA) enzyme to screen for potential cases. Glycosaminoglycans (GAGs) offer potential as a confirmatory test. KD NBS programs utilize galactocerebrosidase (GaLC) as an",17_1,"A Roadmap for Potential Improvement of Newborn Screening for Inherited Metabolic Diseases Following Recent Developments and Successful Applications of Bivariate Normal Limits for Pre-Symptomatic Detection of MPS I, Pompe Disease, and Krabbe Disease",15 11 2022,,Krabbe_Disease
"utilize galactocerebrosidase (GaLC) as an initial test, with psychosine (PSY) activity increasingly used as a confirmatory test for predicting onset of Krabbe disease, though with an excessive false positive rate. PD is marked by a deficiency in acid α-glucosidase (GAA), causing increased glycogen, creatine (CRE), and other biomarkers. Bivariate normal limit (BVNL) methods have been applied to GaLC and PSY activity to produce a NBS tool for KD, and more recently, to IDUA and GAG activity to develop a NBS",17_2,"A Roadmap for Potential Improvement of Newborn Screening for Inherited Metabolic Diseases Following Recent Developments and Successful Applications of Bivariate Normal Limits for Pre-Symptomatic Detection of MPS I, Pompe Disease, and Krabbe Disease",15 11 2022,,Krabbe_Disease
"to IDUA and GAG activity to develop a NBS tool for MPS I. A BVNL tool based on GAA and CRE is in development for infantile PD diagnosis. Early infantile KD, MPS I, and PD cases were pre-symptomatically identified by BVNL-based NBS tools. This article reviews these developments, discusses how they address screening deficiencies identified by the RUSP and may improve NBS more generally. The mucopolysaccharidoses (MPS) are a group of lysosomal storage disorders (LSDs), a class of over forty conditions, which",17_3,"A Roadmap for Potential Improvement of Newborn Screening for Inherited Metabolic Diseases Following Recent Developments and Successful Applications of Bivariate Normal Limits for Pre-Symptomatic Detection of MPS I, Pompe Disease, and Krabbe Disease",15 11 2022,,Krabbe_Disease
"(LSDs), a class of over forty conditions, which are characterized by excessive accumulation of complex lipids, glycoproteins, glycosaminoglycans (GAGs), and other macromolecules within the lysosome [<xref rid=""B1-IJNS-08-00061"" ref-type=""bibr"">1</xref>,<xref rid=""B2-IJNS-08-00061"" ref-type=""bibr"">2</xref>]. The results of metabolic disturbances caused by enzymatic deficiencies in LSDs vary symptomatically but often present multi-systemic clinical symptoms, including neurological, organ, and skeletal",17_4,"A Roadmap for Potential Improvement of Newborn Screening for Inherited Metabolic Diseases Following Recent Developments and Successful Applications of Bivariate Normal Limits for Pre-Symptomatic Detection of MPS I, Pompe Disease, and Krabbe Disease",15 11 2022,,Krabbe_Disease
"including neurological, organ, and skeletal challenges [<xref rid=""B2-IJNS-08-00061"" ref-type=""bibr"">2</xref>]. Most LSDs comprise multiple phenotypic variants. The most severe phenotypes occur in the first months of life. For MPS, the unattenuated Hurler’s phenotype (MPS I) has the onset in the first year of life. In general, LSD phenotypes with earlier ages at onset are more severe, and these conditions can cause permanent dysfunction in affected systems [<xref rid=""B1-IJNS-08-00061""",17_5,"A Roadmap for Potential Improvement of Newborn Screening for Inherited Metabolic Diseases Following Recent Developments and Successful Applications of Bivariate Normal Limits for Pre-Symptomatic Detection of MPS I, Pompe Disease, and Krabbe Disease",15 11 2022,,Krabbe_Disease
"in affected systems [<xref rid=""B1-IJNS-08-00061"" ref-type=""bibr"">1</xref>,<xref rid=""B2-IJNS-08-00061"" ref-type=""bibr"">2</xref>]. Pompe disease (PD) and Krabbe disease (KD) are neurodegenerative disorders that more broadly are characterized by specific enzymatic deficiencies. PD causes glycogen storage in skeletal and cardiac muscle [<xref rid=""B3-IJNS-08-00061"" ref-type=""bibr"">3</xref>,<xref rid=""B4-IJNS-08-00061"" ref-type=""bibr"">4</xref>]. KD primarily affects the white matter in the brain and",17_6,"A Roadmap for Potential Improvement of Newborn Screening for Inherited Metabolic Diseases Following Recent Developments and Successful Applications of Bivariate Normal Limits for Pre-Symptomatic Detection of MPS I, Pompe Disease, and Krabbe Disease",15 11 2022,,Krabbe_Disease
"affects the white matter in the brain and peripheral nerves, with enzyme deficiency disrupting myelin production, degrading the protective myelin sheath around nerve endings and causing progressive symptoms [<xref rid=""B5-IJNS-08-00061"" ref-type=""bibr"">5</xref>,<xref rid=""B6-IJNS-08-00061"" ref-type=""bibr"">6</xref>,<xref rid=""B7-IJNS-08-00061"" ref-type=""bibr"">7</xref>]. Like LSDs generally, PD and KD phenotypes with earlier ages at onset of symptoms typically experience a more severe disease course, and",17_7,"A Roadmap for Potential Improvement of Newborn Screening for Inherited Metabolic Diseases Following Recent Developments and Successful Applications of Bivariate Normal Limits for Pre-Symptomatic Detection of MPS I, Pompe Disease, and Krabbe Disease",15 11 2022,,Krabbe_Disease
"experience a more severe disease course, and infant mortality rates are high. MPS, PD, and KD are generally progressive, and treatment has historically been limited to symptom management, with enzyme replacement therapy (ERT) being employed for only MPS and PD clinically in 1991 [<xref rid=""B4-IJNS-08-00061"" ref-type=""bibr"">4</xref>,<xref rid=""B8-IJNS-08-00061"" ref-type=""bibr"">8</xref>]. Hematopoietic stem cell transplantation (HSCT) offers the greatest improvement in clinical outcomes and attenuation of",17_8,"A Roadmap for Potential Improvement of Newborn Screening for Inherited Metabolic Diseases Following Recent Developments and Successful Applications of Bivariate Normal Limits for Pre-Symptomatic Detection of MPS I, Pompe Disease, and Krabbe Disease",15 11 2022,,Krabbe_Disease
"in clinical outcomes and attenuation of disease course for these three disorders, with several thousand transplants since the 1980s, but is reliant on the identification of diseased patients pre-symptomatically to maximize the efficacy of the treatment [<xref rid=""B9-IJNS-08-00061"" ref-type=""bibr"">9</xref>]. Considering the risks of infection and other complications associated with HSCT, and the difficulty with the reliable prediction of disease phenotypes, it is clear that improved pre-symptomatic",17_9,"A Roadmap for Potential Improvement of Newborn Screening for Inherited Metabolic Diseases Following Recent Developments and Successful Applications of Bivariate Normal Limits for Pre-Symptomatic Detection of MPS I, Pompe Disease, and Krabbe Disease",15 11 2022,,Krabbe_Disease
"it is clear that improved pre-symptomatic identification of LSD patients is one of the most critical challenges facing newborn screening (NBS) programs and the LSD research community [<xref rid=""B10-IJNS-08-00061"" ref-type=""bibr"">10</xref>]. While there is no United States federal body enforcing standardized NBS, the Advisory Committee on Heritable Disorders in Newborns and Children (ACHDNC) maintains a collection of diseases collectively known as the Recommended Uniform Newborn Screening Panel (RUSP)",17_10,"A Roadmap for Potential Improvement of Newborn Screening for Inherited Metabolic Diseases Following Recent Developments and Successful Applications of Bivariate Normal Limits for Pre-Symptomatic Detection of MPS I, Pompe Disease, and Krabbe Disease",15 11 2022,,Krabbe_Disease
"Uniform Newborn Screening Panel (RUSP) [<xref rid=""B11-IJNS-08-00061"" ref-type=""bibr"">11</xref>,<xref rid=""B12-IJNS-08-00061"" ref-type=""bibr"">12</xref>]. For many diseases, the anxiety placed upon families with children undergoing screening procedures is a significant risk associated with NBS programs [<xref rid=""B10-IJNS-08-00061"" ref-type=""bibr"">10</xref>]. This is the crux of the “false positive problem” that would benefit from improved pre-symptomatic identification of diseased patients. However, long",17_11,"A Roadmap for Potential Improvement of Newborn Screening for Inherited Metabolic Diseases Following Recent Developments and Successful Applications of Bivariate Normal Limits for Pre-Symptomatic Detection of MPS I, Pompe Disease, and Krabbe Disease",15 11 2022,,Krabbe_Disease
"of diseased patients. However, long term parental anxiety may not be a significant problem in all cases in which false positive results are given [<xref rid=""B13-IJNS-08-00061"" ref-type=""bibr"">13</xref>]. For example, anxiety seems to become minimal after six months after false positive results for cystic fibrosis [<xref rid=""B14-IJNS-08-00061"" ref-type=""bibr"">14</xref>]. It has also been suggested recently that improved second tier tests, third tier molecular tests, and analytical tools of the sort that",17_12,"A Roadmap for Potential Improvement of Newborn Screening for Inherited Metabolic Diseases Following Recent Developments and Successful Applications of Bivariate Normal Limits for Pre-Symptomatic Detection of MPS I, Pompe Disease, and Krabbe Disease",15 11 2022,,Krabbe_Disease
"tests, and analytical tools of the sort that we propose here can diminish parental anxiety [<xref rid=""B15-IJNS-08-00061"" ref-type=""bibr"">15</xref>]. Multivariate normal distribution theory allows for estimation of (1 − α)100% prediction regions [<xref rid=""B16-IJNS-08-00061"" ref-type=""bibr"">16</xref>]. Thus, we have developed (1 − fp)100% <italic toggle=""yes"">Bivariate Normal Limits</italic> (BVNL), where fp is a pre-specified tolerable false positive rate, as a post-analytical tool to test for early",17_13,"A Roadmap for Potential Improvement of Newborn Screening for Inherited Metabolic Diseases Following Recent Developments and Successful Applications of Bivariate Normal Limits for Pre-Symptomatic Detection of MPS I, Pompe Disease, and Krabbe Disease",15 11 2022,,Krabbe_Disease
"rate, as a post-analytical tool to test for early childhood KD [<xref rid=""B5-IJNS-08-00061"" ref-type=""bibr"">5</xref>]. The resulting NBS test was refined based on improved input data to produce a finalized NBS tool, based on GaLC enzyme activity and psychosine (PSY) concentration measures from newborn dried blood spots (DBS). The tool was retrospectively evaluated for pre-symptomatic identification of patients with early childhood KD who would most benefit from HSCT [<xref rid=""B6-IJNS-08-00061""",17_14,"A Roadmap for Potential Improvement of Newborn Screening for Inherited Metabolic Diseases Following Recent Developments and Successful Applications of Bivariate Normal Limits for Pre-Symptomatic Detection of MPS I, Pompe Disease, and Krabbe Disease",15 11 2022,,Krabbe_Disease
"benefit from HSCT [<xref rid=""B6-IJNS-08-00061"" ref-type=""bibr"">6</xref>]. The BVNL methodology was subsequently applied to MPS I with apparent success, with the resulting BVNL tests yet to be validated [<xref rid=""B7-IJNS-08-00061"" ref-type=""bibr"">7</xref>]. Applications of the BVNL tool can be performed on biomarkers already being collected during many newborn screening protocols, minimizing additional cost or effort and without need for proprietary software or submission of data to a third party. This",17_15,"A Roadmap for Potential Improvement of Newborn Screening for Inherited Metabolic Diseases Following Recent Developments and Successful Applications of Bivariate Normal Limits for Pre-Symptomatic Detection of MPS I, Pompe Disease, and Krabbe Disease",15 11 2022,,Krabbe_Disease
"or submission of data to a third party. This review article summarizes BVNL methodology and its applications to NBS for KD, PD, and MPS I to provide a roadmap for the development and application of BVNL-based NBS tests for inherited metabolic diseases more generally. The advent of tandem mass spectrometry (MS/MS) in the 1990s enabled laboratories to conduct more efficient newborn screening [<xref rid=""B17-IJNS-08-00061"" ref-type=""bibr"">17</xref>]. Coupled with the establishment of the RUSP, this has",17_16,"A Roadmap for Potential Improvement of Newborn Screening for Inherited Metabolic Diseases Following Recent Developments and Successful Applications of Bivariate Normal Limits for Pre-Symptomatic Detection of MPS I, Pompe Disease, and Krabbe Disease",15 11 2022,,Krabbe_Disease
"with the establishment of the RUSP, this has enabled several pilot NBS programs for MPS I, the first of which began in 2008 in Taiwan [<xref rid=""B18-IJNS-08-00061"" ref-type=""bibr"">18</xref>,<xref rid=""B19-IJNS-08-00061"" ref-type=""bibr"">19</xref>,<xref rid=""B20-IJNS-08-00061"" ref-type=""bibr"">20</xref>,<xref rid=""B21-IJNS-08-00061"" ref-type=""bibr"">21</xref>,<xref rid=""B22-IJNS-08-00061"" ref-type=""bibr"">22</xref>,<xref rid=""B23-IJNS-08-00061"" ref-type=""bibr"">23</xref>,<xref rid=""B24-IJNS-08-00061""",17_17,"A Roadmap for Potential Improvement of Newborn Screening for Inherited Metabolic Diseases Following Recent Developments and Successful Applications of Bivariate Normal Limits for Pre-Symptomatic Detection of MPS I, Pompe Disease, and Krabbe Disease",15 11 2022,,Krabbe_Disease
"rid=""B24-IJNS-08-00061"" ref-type=""bibr"">24</xref>,<xref rid=""B25-IJNS-08-00061"" ref-type=""bibr"">25</xref>,<xref rid=""B26-IJNS-08-00061"" ref-type=""bibr"">26</xref>,<xref rid=""B27-IJNS-08-00061"" ref-type=""bibr"">27</xref>]. GAG measurements, IDUA enzyme assays, and molecular diagnosis have all been implemented for MPS I screening [<xref rid=""B28-IJNS-08-00061"" ref-type=""bibr"">28</xref>]. Currently, universal NBS programs that screen for MPS I are conducted in several states, including Illinois, Washington,",17_18,"A Roadmap for Potential Improvement of Newborn Screening for Inherited Metabolic Diseases Following Recent Developments and Successful Applications of Bivariate Normal Limits for Pre-Symptomatic Detection of MPS I, Pompe Disease, and Krabbe Disease",15 11 2022,,Krabbe_Disease
"several states, including Illinois, Washington, Kentucky, and New York [<xref rid=""B21-IJNS-08-00061"" ref-type=""bibr"">21</xref>,<xref rid=""B23-IJNS-08-00061"" ref-type=""bibr"">23</xref>,<xref rid=""B26-IJNS-08-00061"" ref-type=""bibr"">26</xref>,<xref rid=""B29-IJNS-08-00061"" ref-type=""bibr"">29</xref>]. Globally, NBS programs screen for MPS I in countries including Italy, Taiwan, Japan, and Brazil [<xref rid=""B22-IJNS-08-00061"" ref-type=""bibr"">22</xref>,<xref rid=""B24-IJNS-08-00061""",17_19,"A Roadmap for Potential Improvement of Newborn Screening for Inherited Metabolic Diseases Following Recent Developments and Successful Applications of Bivariate Normal Limits for Pre-Symptomatic Detection of MPS I, Pompe Disease, and Krabbe Disease",15 11 2022,,Krabbe_Disease
"rid=""B24-IJNS-08-00061"" ref-type=""bibr"">24</xref>,<xref rid=""B30-IJNS-08-00061"" ref-type=""bibr"">30</xref>,<xref rid=""B31-IJNS-08-00061"" ref-type=""bibr"">31</xref>]. Modern NBS for PD began in 2005 in Taiwan and utilized fluorescence assays [<xref rid=""B32-IJNS-08-00061"" ref-type=""bibr"">32</xref>,<xref rid=""B33-IJNS-08-00061"" ref-type=""bibr"">33</xref>,<xref rid=""B34-IJNS-08-00061"" ref-type=""bibr"">34</xref>,<xref rid=""B35-IJNS-08-00061"" ref-type=""bibr"">35</xref>]. Further NBS programs in Japan, Italy,",17_20,"A Roadmap for Potential Improvement of Newborn Screening for Inherited Metabolic Diseases Following Recent Developments and Successful Applications of Bivariate Normal Limits for Pre-Symptomatic Detection of MPS I, Pompe Disease, and Krabbe Disease",15 11 2022,,Krabbe_Disease
"Further NBS programs in Japan, Italy, Hungary, Germany, Colombia, Austria relied on tandem MS/MS as well as fluorescence assays [<xref rid=""B32-IJNS-08-00061"" ref-type=""bibr"">32</xref>,<xref rid=""B33-IJNS-08-00061"" ref-type=""bibr"">33</xref>,<xref rid=""B36-IJNS-08-00061"" ref-type=""bibr"">36</xref>,<xref rid=""B37-IJNS-08-00061"" ref-type=""bibr"">37</xref>,<xref rid=""B38-IJNS-08-00061"" ref-type=""bibr"">38</xref>,<xref rid=""B39-IJNS-08-00061"" ref-type=""bibr"">39</xref>,<xref rid=""B40-IJNS-08-00061""",17_21,"A Roadmap for Potential Improvement of Newborn Screening for Inherited Metabolic Diseases Following Recent Developments and Successful Applications of Bivariate Normal Limits for Pre-Symptomatic Detection of MPS I, Pompe Disease, and Krabbe Disease",15 11 2022,,Krabbe_Disease
"rid=""B40-IJNS-08-00061"" ref-type=""bibr"">40</xref>,<xref rid=""B41-IJNS-08-00061"" ref-type=""bibr"">41</xref>]. In the United States, programs in Washington, New York, Illinois, Kentucky, Mississippi, and Pennsylvania utilized tandem MS/MS, with Missouri NBS programs implementing digital microfluidics screening method [<xref rid=""B23-IJNS-08-00061"" ref-type=""bibr"">23</xref>,<xref rid=""B32-IJNS-08-00061"" ref-type=""bibr"">32</xref>,<xref rid=""B33-IJNS-08-00061"" ref-type=""bibr"">33</xref>,<xref",17_22,"A Roadmap for Potential Improvement of Newborn Screening for Inherited Metabolic Diseases Following Recent Developments and Successful Applications of Bivariate Normal Limits for Pre-Symptomatic Detection of MPS I, Pompe Disease, and Krabbe Disease",15 11 2022,,Krabbe_Disease
"ref-type=""bibr"">33</xref>,<xref rid=""B42-IJNS-08-00061"" ref-type=""bibr"">42</xref>,<xref rid=""B43-IJNS-08-00061"" ref-type=""bibr"">43</xref>,<xref rid=""B44-IJNS-08-00061"" ref-type=""bibr"">44</xref>]. NBS efforts for KD have been ongoing in several US states [<xref rid=""B45-IJNS-08-00061"" ref-type=""bibr"">45</xref>,<xref rid=""B46-IJNS-08-00061"" ref-type=""bibr"">46</xref>,<xref rid=""B47-IJNS-08-00061"" ref-type=""bibr"">47</xref>]. The efficacy of these programs in the previous decade have been mixed at best. For MPS",17_23,"A Roadmap for Potential Improvement of Newborn Screening for Inherited Metabolic Diseases Following Recent Developments and Successful Applications of Bivariate Normal Limits for Pre-Symptomatic Detection of MPS I, Pompe Disease, and Krabbe Disease",15 11 2022,,Krabbe_Disease
"previous decade have been mixed at best. For MPS I, NBS programs in the United States, Italy, and Taiwan have seen PPV ranging from 0–50% [<xref rid=""B21-IJNS-08-00061"" ref-type=""bibr"">21</xref>,<xref rid=""B22-IJNS-08-00061"" ref-type=""bibr"">22</xref>,<xref rid=""B23-IJNS-08-00061"" ref-type=""bibr"">23</xref>,<xref rid=""B24-IJNS-08-00061"" ref-type=""bibr"">24</xref>,<xref rid=""B26-IJNS-08-00061"" ref-type=""bibr"">26</xref>]. For PD, NBS programs abroad in Taiwan and Austria achieved PPV of 63.4% and 80% but",17_24,"A Roadmap for Potential Improvement of Newborn Screening for Inherited Metabolic Diseases Following Recent Developments and Successful Applications of Bivariate Normal Limits for Pre-Symptomatic Detection of MPS I, Pompe Disease, and Krabbe Disease",15 11 2022,,Krabbe_Disease
"and Austria achieved PPV of 63.4% and 80% but subsequent Italian and Hungarian studies could only achieve 6%, while US efforts in Illinois, Missouri, Washington, and New York achieved PPV ranging from 3–21% [<xref rid=""B33-IJNS-08-00061"" ref-type=""bibr"">33</xref>,<xref rid=""B34-IJNS-08-00061"" ref-type=""bibr"">34</xref>,<xref rid=""B37-IJNS-08-00061"" ref-type=""bibr"">37</xref>,<xref rid=""B38-IJNS-08-00061"" ref-type=""bibr"">38</xref>,<xref rid=""B41-IJNS-08-00061"" ref-type=""bibr"">41</xref>]. KD programs likewise",17_25,"A Roadmap for Potential Improvement of Newborn Screening for Inherited Metabolic Diseases Following Recent Developments and Successful Applications of Bivariate Normal Limits for Pre-Symptomatic Detection of MPS I, Pompe Disease, and Krabbe Disease",15 11 2022,,Krabbe_Disease
"ref-type=""bibr"">41</xref>]. KD programs likewise have been insufficient; NBS programs in New York State could only achieve a PPV of 1.4% prompting reservations of proliferated NBS, while Illinois screening programs using PSY and post-analytical software (Collaborative Laboratory Interpretive Reports, <uri http://www.w3.org/1999/xlink href=""https://clir.mayo.edu"">https://clir.mayo.edu</uri> (accessed on 4 October 2022) could only achieve 40% PPV without genetic testing [<xref rid=""B29-IJNS-08-00061""",17_26,"A Roadmap for Potential Improvement of Newborn Screening for Inherited Metabolic Diseases Following Recent Developments and Successful Applications of Bivariate Normal Limits for Pre-Symptomatic Detection of MPS I, Pompe Disease, and Krabbe Disease",15 11 2022,,Krabbe_Disease
"genetic testing [<xref rid=""B29-IJNS-08-00061"" ref-type=""bibr"">29</xref>,<xref rid=""B45-IJNS-08-00061"" ref-type=""bibr"">45</xref>,<xref rid=""B46-IJNS-08-00061"" ref-type=""bibr"">46</xref>,<xref rid=""B47-IJNS-08-00061"" ref-type=""bibr"">47</xref>]. Latest efforts for MPS I and KD, however, have begun to show increasing promise. MPS I screening has shown improved PPV using a two-tier testing approach incorporating DS and HS, with PPV rates of 74% in the US and 100% in retrospective studies [<xref",17_27,"A Roadmap for Potential Improvement of Newborn Screening for Inherited Metabolic Diseases Following Recent Developments and Successful Applications of Bivariate Normal Limits for Pre-Symptomatic Detection of MPS I, Pompe Disease, and Krabbe Disease",15 11 2022,,Krabbe_Disease
"the US and 100% in retrospective studies [<xref rid=""B48-IJNS-08-00061"" ref-type=""bibr"">48</xref>,<xref rid=""B49-IJNS-08-00061"" ref-type=""bibr"">49</xref>]. While PPV rates in current KD studies remain lower, recent studies have highlighted the improvement that genetic testing can offer, with Illinois achieving 100% PPV when genetic testing is used [<xref rid=""B47-IJNS-08-00061"" ref-type=""bibr"">47</xref>]. Indeed, recent consensus recommendations suggest genetic testing may reduce follow-up testing by 88%",17_28,"A Roadmap for Potential Improvement of Newborn Screening for Inherited Metabolic Diseases Following Recent Developments and Successful Applications of Bivariate Normal Limits for Pre-Symptomatic Detection of MPS I, Pompe Disease, and Krabbe Disease",15 11 2022,,Krabbe_Disease
"testing may reduce follow-up testing by 88% [<xref rid=""B50-IJNS-08-00061"" ref-type=""bibr"">50</xref>]. Regarding PD, however, a 2020 review highlights the difficulty of discriminating IOPD from pseudodeficiency [<xref rid=""B51-IJNS-08-00061"" ref-type=""bibr"">51</xref>]. US NBS programs now screen for at least 30 core disorders and up to 26 secondary disorders [<xref rid=""B52-IJNS-08-00061"" ref-type=""bibr"">52</xref>]. In the cases of MPS I and PD, these conditions have been added to the RUSP despite the",17_29,"A Roadmap for Potential Improvement of Newborn Screening for Inherited Metabolic Diseases Following Recent Developments and Successful Applications of Bivariate Normal Limits for Pre-Symptomatic Detection of MPS I, Pompe Disease, and Krabbe Disease",15 11 2022,,Krabbe_Disease
"have been added to the RUSP despite the significant screening deficiencies. MPS I/II are the only MPS disorders included on the RUSP, having their nomination confirmed in 2016 and 2022 [<xref rid=""B53-IJNS-08-00061"" ref-type=""bibr"">53</xref>,<xref rid=""B54-IJNS-08-00061"" ref-type=""bibr"">54</xref>]. PD was recommended for addition to the RUSP in 2013 and added as a core disorder in 2015 [<xref rid=""B25-IJNS-08-00061"" ref-type=""bibr"">25</xref>]. The AHCDNC completed a review of EIKD in 2010 and declined its",17_30,"A Roadmap for Potential Improvement of Newborn Screening for Inherited Metabolic Diseases Following Recent Developments and Successful Applications of Bivariate Normal Limits for Pre-Symptomatic Detection of MPS I, Pompe Disease, and Krabbe Disease",15 11 2022,,Krabbe_Disease
"a review of EIKD in 2010 and declined its inclusion on the RUSP, noting that while EIKD would benefit from early diagnosis and intervention, the possibility of substantial harm from screening and/or treatment precluded addition to the panel [<xref rid=""B55-IJNS-08-00061"" ref-type=""bibr"">55</xref>]. Indeed, all three conditions discussed here would benefit from improved pre-symptomatic identification of diseased newborns.  The current article argues that BVNL NBS tests are appropriate for inherited",17_31,"A Roadmap for Potential Improvement of Newborn Screening for Inherited Metabolic Diseases Following Recent Developments and Successful Applications of Bivariate Normal Limits for Pre-Symptomatic Detection of MPS I, Pompe Disease, and Krabbe Disease",15 11 2022,,Krabbe_Disease
"that BVNL NBS tests are appropriate for inherited metabolic diseases in general and presents two examples of very successful applications of them in the context of KD and MPS I. It provides an overview of tolerance regions of univariate and bivariate normal distributions, their estimation by prediction regions, and a roadmap for using them to develop BVNL NBS tests for additional inherited metabolic diseases. The accuracy of BVNL tests to be developed for additional diseases, of course, will depend on",17_32,"A Roadmap for Potential Improvement of Newborn Screening for Inherited Metabolic Diseases Following Recent Developments and Successful Applications of Bivariate Normal Limits for Pre-Symptomatic Detection of MPS I, Pompe Disease, and Krabbe Disease",15 11 2022,,Krabbe_Disease
"additional diseases, of course, will depend on identifying suitable biomarkers, in addition to the enzymes whose deficiency is the primary cause of disease, that reflects well the buildup of toxic metabolites in cells that contribute to the pathogenesis of the diseases. In the case of KD and MPS I, PSY and HS worked extremely well as secondary biomarkers. The potential for similarly informative secondary biomarkers to improve NBS tests for at least some other inherited metabolic diseases seems to warrant",17_33,"A Roadmap for Potential Improvement of Newborn Screening for Inherited Metabolic Diseases Following Recent Developments and Successful Applications of Bivariate Normal Limits for Pre-Symptomatic Detection of MPS I, Pompe Disease, and Krabbe Disease",15 11 2022,,Krabbe_Disease
"inherited metabolic diseases seems to warrant continued research. One caveat with respect to MPS I is the observation that a more stringent univariate threshold for IDUA, corresponding to a value to the left of the left-most pseudo-deficient, but to the right of the MPS I cases would also discriminate the known cases from the normal observations without the need for a BVNL approach. However, given the small samples, it is possible that a true MPS I case may be missed using only a univariate approach if",17_34,"A Roadmap for Potential Improvement of Newborn Screening for Inherited Metabolic Diseases Following Recent Developments and Successful Applications of Bivariate Normal Limits for Pre-Symptomatic Detection of MPS I, Pompe Disease, and Krabbe Disease",15 11 2022,,Krabbe_Disease
"may be missed using only a univariate approach if that case has sufficiently elevated HS. Similarly with PD, a GAA threshold of −7.5 would eliminate all false positive cases. However, future PD cases may be missed. Given the high-risk for these newborns, a higher GAA threshold to allow more potential false positives coupled with genetic testing may be the optimal strategy. Continued development of the PD ellipse with other biomarkers or statistical transformations may improve efficiency, but in its current",17_35,"A Roadmap for Potential Improvement of Newborn Screening for Inherited Metabolic Diseases Following Recent Developments and Successful Applications of Bivariate Normal Limits for Pre-Symptomatic Detection of MPS I, Pompe Disease, and Krabbe Disease",15 11 2022,,Krabbe_Disease
"may improve efficiency, but in its current state would outperform the use of univariate thresholds for GAA and CRE. Additional variables such as birth weight, age, transfusion status, etc. may serve to improve accuracy as well. There remain open questions as to how the BVNL methodology would be integrated into NBS program workflow efficiently, as well as measurement differences between laboratories affecting the consistency of results. Regarding the former, one advantage this method has over other",17_36,"A Roadmap for Potential Improvement of Newborn Screening for Inherited Metabolic Diseases Following Recent Developments and Successful Applications of Bivariate Normal Limits for Pre-Symptomatic Detection of MPS I, Pompe Disease, and Krabbe Disease",15 11 2022,,Krabbe_Disease
"former, one advantage this method has over other post-analytical tools is that these methods are not proprietary and each NBS program can decide how best to integrate the BVNL within the program workflow. It is likely that different programs may have different implementation strategies, and should BVNL methods be widely adopted these implementations will need to be evaluated. As to the latter, while standardization of the biomarkers provides easily comparable values, laboratory differences may still exist",17_37,"A Roadmap for Potential Improvement of Newborn Screening for Inherited Metabolic Diseases Following Recent Developments and Successful Applications of Bivariate Normal Limits for Pre-Symptomatic Detection of MPS I, Pompe Disease, and Krabbe Disease",15 11 2022,,Krabbe_Disease
"values, laboratory differences may still exist [<xref rid=""B65-IJNS-08-00061"" ref-type=""bibr"">65</xref>]. Maintaining distinct BVNL tools for each laboratory is one potential solution, although a unified approach would be preferable. We propose BVNL methodology as an effective way to improve NBS programs and expect that the advantage of the BVNL test over a bivariate test that predicts disease if X < τ<sub>1</sub> and Y > τ<sub>2</sub> seen in our KD studies will prove to be a general phenomenon. Due to",17_38,"A Roadmap for Potential Improvement of Newborn Screening for Inherited Metabolic Diseases Following Recent Developments and Successful Applications of Bivariate Normal Limits for Pre-Symptomatic Detection of MPS I, Pompe Disease, and Krabbe Disease",15 11 2022,,Krabbe_Disease
"will prove to be a general phenomenon. Due to the additional information found in the bivariate relationship between the biomarkers, BVNL tests can be expected to have lower false positive rates than bivariate alternatives without notably increased false negative rates. This property of BVNL tests suggest that existing screening tools that utilize univariate thresholds may see improvement by implementing bivariate or multivariate normal tests wherever univariate tests are used. Prospective testing of BVNL",17_39,"A Roadmap for Potential Improvement of Newborn Screening for Inherited Metabolic Diseases Following Recent Developments and Successful Applications of Bivariate Normal Limits for Pre-Symptomatic Detection of MPS I, Pompe Disease, and Krabbe Disease",15 11 2022,,Krabbe_Disease
tests are used. Prospective testing of BVNL methodology would consequently appear to be warranted.,17_40,"A Roadmap for Potential Improvement of Newborn Screening for Inherited Metabolic Diseases Following Recent Developments and Successful Applications of Bivariate Normal Limits for Pre-Symptomatic Detection of MPS I, Pompe Disease, and Krabbe Disease",15 11 2022,,Krabbe_Disease
"Neurodegenerative Disorder Risk in Krabbe Disease Carriers Krabbe disease (KD) is a rare autosomal recessive disorder caused by mutations in the galactocerebrosidase gene (<italic toggle=""yes"">GALC</italic>). Defective GALC causes aberrant metabolism of galactolipids present almost exclusively in myelin, with consequent demyelinization and neurodegeneration of the central and peripheral nervous system (NS). KD shares some similar features with other neuropathies and heterozygous carriers of <italic",18_0,Neurodegenerative Disorder Risk in Krabbe Disease Carriers,04 11 2022,,Krabbe_Disease
"neuropathies and heterozygous carriers of <italic toggle=""yes"">GALC</italic> mutations are emerging with an increased risk in developing NS disorders. In this work, we set out to identify possible variations in the proteomic profile of KD-carrier brain to identify altered pathways that may imbalance its homeostasis and that may be associated with neurological disorders. The differential analysis performed on whole brains from 33-day-old twitcher (<italic toggle=""yes"">galc <sup>−/−</sup></italic>),",18_1,Neurodegenerative Disorder Risk in Krabbe Disease Carriers,04 11 2022,,Krabbe_Disease
"toggle=""yes"">galc <sup>−/−</sup></italic>), heterozygous (<italic toggle=""yes"">galc <sup>+/−</sup>),</italic> and wild-type mice highlighted the dysregulation of several multifunctional factors in both heterozygous and twitcher mice. Notably, the KD-carrier mouse, despite its normal phenotype, presents the deregulation of vimentin, receptor of activated protein C kinase 1 (RACK1), myelin basic protein (MBP), 2′,3′-cyclic-nucleotide 3′-phosphodiesterase (CNP), transitional endoplasmic reticulum ATPase",18_2,Neurodegenerative Disorder Risk in Krabbe Disease Carriers,04 11 2022,,Krabbe_Disease
"(CNP), transitional endoplasmic reticulum ATPase (VCP), and N-myc downstream regulated gene 1 protein (NDRG1) as well as changes in the ubiquitinated-protein pattern. Our findings suggest the carrier may be affected by dysfunctions classically associated with neurodegeneration: (i) alteration of (mechano) signaling and intracellular trafficking, (ii) a generalized affection of proteostasis and lipid metabolism, with possible defects in myelin composition and turnover, and (iii) mitochondrion and energy",18_3,Neurodegenerative Disorder Risk in Krabbe Disease Carriers,04 11 2022,,Krabbe_Disease
"and turnover, and (iii) mitochondrion and energy supply dysfunctions. Krabbe disease (KD) (OMIM #245200), also known as globoid cell leukodystrophy, is a neurological disorder presenting demyelination and impaired neuronal transmission. It is a rare autosomal recessive disease that affects the central and peripheral nervous system (CNS and PNS, respectively). Infantile, juvenile, and adult-onset forms of KD have been described, with the infantile form being the most common, rapidly progressive, and fatal",18_4,Neurodegenerative Disorder Risk in Krabbe Disease Carriers,04 11 2022,,Krabbe_Disease
"the most common, rapidly progressive, and fatal while the latter presenting less severity and slower progression [<xref rid=""B1-ijms-23-13537"" ref-type=""bibr"">1</xref>,<xref rid=""B2-ijms-23-13537"" ref-type=""bibr"">2</xref>]. KD is a lysosome storage disease (LSD) caused by the functional deficiency of galactocerebrosidase (GALC). This lysosomal enzyme is vital for the degradation of sphingolipids, for the recycling of sphingosine and ceramide, and, consequently, for myelin synthesis and homeostasis [<xref",18_5,Neurodegenerative Disorder Risk in Krabbe Disease Carriers,04 11 2022,,Krabbe_Disease
"for myelin synthesis and homeostasis [<xref rid=""B3-ijms-23-13537"" ref-type=""bibr"">3</xref>,<xref rid=""B4-ijms-23-13537"" ref-type=""bibr"">4</xref>,<xref rid=""B5-ijms-23-13537"" ref-type=""bibr"">5</xref>,<xref rid=""B6-ijms-23-13537"" ref-type=""bibr"">6</xref>]. Biochemical defects related to GALC aberrant functionality cause abnormal myelin turnover that leads to demyelination, neurodegeneration, and neuroinflammation, with white matter perivascular monocyte/macrophage infiltrates [<xref rid=""B7-ijms-23-13537""",18_6,Neurodegenerative Disorder Risk in Krabbe Disease Carriers,04 11 2022,,Krabbe_Disease
"infiltrates [<xref rid=""B7-ijms-23-13537"" ref-type=""bibr"">7</xref>]. Although it is not unique in catabolizing the myelin highly-abundant sphingolipid galactosylceramide (GalCer), GALC is the only known enzyme able to degrade galactosylsphingosine (psychosine, Psy), whose accumulation is highly toxic [<xref rid=""B8-ijms-23-13537"" ref-type=""bibr"">8</xref>]. Nonetheless, increasing evidence suggests that all the dysfunctions described in KD cannot be merely explained by psychosine accumulation and that",18_7,Neurodegenerative Disorder Risk in Krabbe Disease Carriers,04 11 2022,,Krabbe_Disease
"explained by psychosine accumulation and that additional mechanisms could be involved. In fibroblasts from KD patients, Papini et al. [<xref rid=""B9-ijms-23-13537"" ref-type=""bibr"">9</xref>] have recently correlated increased concentrations of lactosylceramide (LacCer), a bioactive lipid metabolized by GALC, to several signaling pathway alterations involved in neurodegeneration. Other studies have also reported axonal defects independent of Psy accumulation or demyelinization [<xref rid=""B10-ijms-23-13537""",18_8,Neurodegenerative Disorder Risk in Krabbe Disease Carriers,04 11 2022,,Krabbe_Disease
"or demyelinization [<xref rid=""B10-ijms-23-13537"" ref-type=""bibr"">10</xref>,<xref rid=""B11-ijms-23-13537"" ref-type=""bibr"">11</xref>]. In fact, Kreher et al. [<xref rid=""B11-ijms-23-13537"" ref-type=""bibr"">11</xref>] proved that GALC absence in neurons triggers neuro-axonal degeneration and related inflammatory demyelination. In addition, neuron-specific GALC ablation was described in attenuating neuron maturation during brain development [<xref rid=""B12-ijms-23-13537"" ref-type=""bibr"">12</xref>], and thus",18_9,Neurodegenerative Disorder Risk in Krabbe Disease Carriers,04 11 2022,,Krabbe_Disease
"ref-type=""bibr"">12</xref>], and thus intimately impacting the CNS properties. Phenotypically, KD shares similar traits with other neurodegenerative disorders that, in some cases, correlate to similar molecular defects. Notably, several papers report KD patients, prevalently with late onset KD, and misdiagnosed as affected by MS. Sahai et al. [<xref rid=""B13-ijms-23-13537"" ref-type=""bibr"">13</xref>] discussed the MS family history of a KD patient with infantile-onset KD. In addition, genome-wide association",18_10,Neurodegenerative Disorder Risk in Krabbe Disease Carriers,04 11 2022,,Krabbe_Disease
"KD. In addition, genome-wide association studies (GWAS) and expression analyses recognized, in the <italic toggle=""yes"">GALC</italic> SNPs and expression levels, highly significant patterns distinguishing a number of people with MS (PwMS) from healthy controls [<xref rid=""B14-ijms-23-13537"" ref-type=""bibr"">14</xref>,<xref rid=""B15-ijms-23-13537"" ref-type=""bibr"">15</xref>,<xref rid=""B16-ijms-23-13537"" ref-type=""bibr"">16</xref>]. Currently, the <italic toggle=""yes"">GALC</italic> gene (14q31) is actually",18_11,Neurodegenerative Disorder Risk in Krabbe Disease Carriers,04 11 2022,,Krabbe_Disease
"gene (14q31) is actually considered a susceptibility locus for MS [<xref rid=""B15-ijms-23-13537"" ref-type=""bibr"">15</xref>]. Furthermore, α-synuclein fibrillization and Lewy body (LB) formation, which are characteristic features of synucleinopathies, lipidoses, other LSDs, and mitochondrial diseases, were described in KD human and mouse brains [<xref rid=""B17-ijms-23-13537"" ref-type=""bibr"">17</xref>,<xref rid=""B18-ijms-23-13537"" ref-type=""bibr"">18</xref>]. Despite the very low incidence of KD [1:100,000",18_12,Neurodegenerative Disorder Risk in Krabbe Disease Carriers,04 11 2022,,Krabbe_Disease
"Despite the very low incidence of KD [1:100,000 live births in the United States and Europe, with a pick of incidence recorded in Sweden (1:39,000)] [<xref rid=""B19-ijms-23-13537"" ref-type=""bibr"">19</xref>,<xref rid=""B20-ijms-23-13537"" ref-type=""bibr"">20</xref>], heterozygous carriers are estimated to be frequent in Caucasians (1:150) [<xref rid=""B21-ijms-23-13537"" ref-type=""bibr"">21</xref>] and are suggested to carry a risk for neurological disorder onset [<xref rid=""B5-ijms-23-13537""",18_13,Neurodegenerative Disorder Risk in Krabbe Disease Carriers,04 11 2022,,Krabbe_Disease
"disorder onset [<xref rid=""B5-ijms-23-13537"" ref-type=""bibr"">5</xref>]. In fact, despite carriers of recessive disorders not being clinically ill, they may present non-physiological biochemical and molecular traits that may predispose them to develop a disease state [<xref rid=""B16-ijms-23-13537"" ref-type=""bibr"">16</xref>]. In fact, carriers of mutations causing KD are known for presenting an increased risk for developing open angle glaucoma and pulmonary artery enlargement in chronic obstructive pulmonary",18_14,Neurodegenerative Disorder Risk in Krabbe Disease Carriers,04 11 2022,,Krabbe_Disease
"enlargement in chronic obstructive pulmonary disease [<xref rid=""B22-ijms-23-13537"" ref-type=""bibr"">22</xref>,<xref rid=""B23-ijms-23-13537"" ref-type=""bibr"">23</xref>]. Furthermore, the <italic toggle=""yes"">galc <sup>+/−</sup></italic> mutation carrier mouse, from the twitcher (Twi) KD-model, seems to corroborate these hypotheses. After cuprizone administration, young adult heterozygous mice, despite being apparently healthy and identical, in physiological conditions, to wild-type (WT), present a reduced",18_15,Neurodegenerative Disorder Risk in Krabbe Disease Carriers,04 11 2022,,Krabbe_Disease
"conditions, to wild-type (WT), present a reduced remyelination response and an impaired microglial reaction to myelin damage when compared with similarly treated WT animals. These defects result in a reduced debris clearance and a more frequent inflammation occurrence, which may increase the possibility to develop auto-antibodies against components of myelin sheaths [<xref rid=""B16-ijms-23-13537"" ref-type=""bibr"">16</xref>]. In addition, a late onset manifestation of GALC deficiency in Twi mice underwent",18_16,Neurodegenerative Disorder Risk in Krabbe Disease Carriers,04 11 2022,,Krabbe_Disease
"of GALC deficiency in Twi mice underwent massive gene therapy (<italic toggle=""yes"">galc</italic> transgene) consisting of brain lesions associated with leakage of the blood–brain barrier and plasma fibrinogen extravasation (PFE), with consequent activation of the fibrinogen-bone morphogenic protein (BMP)-SMAD-glial fibrillary acidic protein (GFAP) glia response [<xref rid=""B24-ijms-23-13537"" ref-type=""bibr"">24</xref>]. In particular, PFE observed in late Twi treated-mice, where <italic",18_17,Neurodegenerative Disorder Risk in Krabbe Disease Carriers,04 11 2022,,Krabbe_Disease
"observed in late Twi treated-mice, where <italic toggle=""yes"">galc</italic> transgene decreased in expression, resembles microglial activation and brain damage observed in neurological disorders. Asymptomatic <italic toggle=""yes"">galc <sup>+/−</sup></italic> heterozygous mice also present, similarly to Twi animals, an increase in oxidative stress markers, i.e., F2-isoprostanes and F4-neuroprostanes, that were generated from polyunsaturated fatty acid oxidative damage. Their occurrence is retained impacting",18_18,Neurodegenerative Disorder Risk in Krabbe Disease Carriers,04 11 2022,,Krabbe_Disease
"damage. Their occurrence is retained impacting on the nervous system (NS) and associated with neurological diseases [<xref rid=""B25-ijms-23-13537"" ref-type=""bibr"">25</xref>]. Based on these premises, we performed a functional proteomic analysis on whole brain lysates from 33-day-old Twi, heterozygous <italic toggle=""yes"">galc</italic> <sup>+/−</sup> carrier (Het), and wild-type (WT) mice [<xref rid=""B26-ijms-23-13537"" ref-type=""bibr"">26</xref>] to identify molecular affections and related biomarkers that,",18_19,Neurodegenerative Disorder Risk in Krabbe Disease Carriers,04 11 2022,,Krabbe_Disease
"molecular affections and related biomarkers that, over time, may increase or report an increased risk for carriers to develop NS affections. As proteoform heterogeneity define protein properties and the functional profile of investigated systems, we applied a 2DE/mass spectrometry approach with the intent to capture and visualize, on a large scale, possible different proteoform presences that may differentially impact mutants’ physiology. According to our data, the Het proteome profile diverges from both",18_20,Neurodegenerative Disorder Risk in Krabbe Disease Carriers,04 11 2022,,Krabbe_Disease
"data, the Het proteome profile diverges from both WT and Twi ones. Hence, we provide an integrated overview on the identified protein differences to delineate their eventual correlation to biochemical and molecular aberrances previously described in other neuropathologies. Our data suggest significant dysfunctions in different pathways, critical for CNS homeostasis, occurring in Het brain. These are likely to make KD carriers more vulnerable to any other risk factor, either environmental or genetic, thus",18_21,Neurodegenerative Disorder Risk in Krabbe Disease Carriers,04 11 2022,,Krabbe_Disease
"factor, either environmental or genetic, thus exposing them to a greater likelihood of developing neuropathies. We applied a functional proteomic approach on whole brain protein extracts obtained from 33-day-old twitcher, <italic toggle=""yes"">galc</italic> <sup>+/−</sup> heterozygous, and wild-type mice. At this age, the disease is overt in Twi and GALC activity drastically lower than in the controls [<xref rid=""B27-ijms-23-13537"" ref-type=""bibr"">27</xref>]. Nonetheless, they are still viable since death",18_22,Neurodegenerative Disorder Risk in Krabbe Disease Carriers,04 11 2022,,Krabbe_Disease
"Nonetheless, they are still viable since death occurs by ~40 days after birth. Twenty-seven highly significant protein differences were detected among these sample classes (<xref rid=""ijms-23-13537-f001"" ref-type=""fig"">Figure 1</xref>) by applying 2DE and gel image analysis (on seven gels for each tested condition), rigorous statistics, and result filtering for %Vol fold change. Then, MALDI-TOF/TOF mass spectrometry successfully identified 23 of the differing protein spots, which correspond to 21 unique",18_23,Neurodegenerative Disorder Risk in Krabbe Disease Carriers,04 11 2022,,Krabbe_Disease
"protein spots, which correspond to 21 unique proteins (<xref rid=""ijms-23-13537-t001"" ref-type=""table"">Table 1</xref> and <xref rid=""ijms-23-13537-f002"" ref-type=""fig"">Figure 2</xref>). The variance-covariance analysis was performed by principal component analysis (PCA) on the %Vol values of significantly differing spots and the first three axes of variation, i.e., PC1, PC2, and PC3, explain the 27.5%, 19.8%, and 13.1% of variance, respectively. The PC1/PC2 plot (<xref rid=""ijms-23-13537-f003""",18_24,Neurodegenerative Disorder Risk in Krabbe Disease Carriers,04 11 2022,,Krabbe_Disease
"The PC1/PC2 plot (<xref rid=""ijms-23-13537-f003"" ref-type=""fig"">Figure 3</xref>) shows Het mice clustering apart from the others on the right side of PC1 and partially overlapping with the Twi and WT groups around the center of PC2 (<xref rid=""ijms-23-13537-f003"" ref-type=""fig"">Figure 3</xref>A). The WT cluster is instead interposed, on PC1/PC2 (<xref rid=""ijms-23-13537-f003"" ref-type=""fig"">Figure 3</xref>A) and PC1/PC3 (<xref rid=""ijms-23-13537-f003"" ref-type=""fig"">Figure 3</xref>B) plots, between the",18_25,Neurodegenerative Disorder Risk in Krabbe Disease Carriers,04 11 2022,,Krabbe_Disease
"3</xref>B) plots, between the other two conditions and presents a relatively low PC1 variability with a relevant clustering. Finally, Twi and Het mice widely overlap on the PC1/PC2 and partially on PC2/PC3 plots throughout PC2 and PC3 axes, respectively (<xref rid=""ijms-23-13537-f003"" ref-type=""fig"">Figure 3</xref>C). Overall, PCA evidences that Het animals, despite being apparently “normal”, present a distinct biochemical profile from Twi and WT mice, which may expose Het to an increased risk to develop",18_26,Neurodegenerative Disorder Risk in Krabbe Disease Carriers,04 11 2022,,Krabbe_Disease
"may expose Het to an increased risk to develop other disorders, including neuropathologies [<xref rid=""B28-ijms-23-13537"" ref-type=""bibr"">28</xref>]. To further the understanding of the biological implications that the protein profile outlined in Het may have, we performed a bioinformatics analysis and predicted functional interactions occurring between the 21 differentially identified abundant unique proteins by applying the shortest-path-network (SPN) building tool from the MetaCore resource. Except for",18_27,Neurodegenerative Disorder Risk in Krabbe Disease Carriers,04 11 2022,,Krabbe_Disease
"tool from the MetaCore resource. Except for tropomodulin-2, all the processed proteins entered into the SPN, resulting in being perfectly embedded in their functionality. This underlines that identified factors belong to the same or related biochemical pathways. Vimentin (VIME), protein NDRG1 (alternative name: N-myc downstream-regulated gene 1 protein), receptor of activated protein C kinase 1 (RACK1), transitional endoplasmic reticulum ATPase (alternative name: valosin-containing protein, VCP), and",18_28,Neurodegenerative Disorder Risk in Krabbe Disease Carriers,04 11 2022,,Krabbe_Disease
"name: valosin-containing protein, VCP), and myelin basic protein (MBP) emerged as central hubs, by establishing the highest number of interactions with the other proteins of the net (<xref rid=""ijms-23-13537-f004"" ref-type=""fig"">Figure 4</xref>). Furthermore, the MetaCore enrichment analysis in the “Pathways Maps” ontology, which highlights the molecular pathways related to identified differences (<xref rid=""app1-ijms-23-13537"" ref-type=""app"">Table S1</xref>), suggested the presence of cytoskeleton",18_29,Neurodegenerative Disorder Risk in Krabbe Disease Carriers,04 11 2022,,Krabbe_Disease
"suggested the presence of cytoskeleton remodeling and neuronal cell development affections and their direct correlation to VIME and MBP deregulation in Twi as well as in Het mice.  This study highlights the heterozygous <italic toggle=""yes"">galc</italic>",18_30,Neurodegenerative Disorder Risk in Krabbe Disease Carriers,04 11 2022,,Krabbe_Disease
"<sup>+/−</sup> mice showing characteristic proteomic features that clearly distinguish them from Twi and WT mice. Overall, the protein differences we described suggest molecular impairment, probably related to the occurrence of different proteoforms in cytoskeleton dynamics and related signal transduction, the proteostasis network, mitochondrion integrity and functionalities, energy supply, and lipid metabolism. In particular, the vimentin and RACK1 down-regulation in Het animals may represent a potential",18_31,Neurodegenerative Disorder Risk in Krabbe Disease Carriers,04 11 2022,,Krabbe_Disease
"in Het animals may represent a potential molecular link between the KD carrier and the risk of developing neuropathies, principally related to mechanosignaling and intracellular trafficking defects as well as to an altered myelin turnover associated with cytoskeleton dysfunctions. In addition, the dysregulation of NDRG1, besides strengthening our hypothesis on cytoskeletal rearrangement, suggests lipid metabolism defects in Het mice as also proposed for other neurodegenerative disorders, e.g., AD.",18_32,Neurodegenerative Disorder Risk in Krabbe Disease Carriers,04 11 2022,,Krabbe_Disease
"for other neurodegenerative disorders, e.g., AD. Furthermore, the overall decrease in ubiquitinated proteins that we detected in Het mice along with the dysregulation of VCP and UCHL5 strengthens the supposition of proteostasis imbalances in KD carriers that may result in a hazard to its NS, classically associated to neuron inclusions and related neurodegenerations. The altered presence of mitochondrial factors, principally ACO2, was also detected in both Twi and Het mice, hence suggesting potential",18_33,Neurodegenerative Disorder Risk in Krabbe Disease Carriers,04 11 2022,,Krabbe_Disease
"both Twi and Het mice, hence suggesting potential mitochondrion failure with increased oxidative stress and energy imbalance in both Twi and KD carriers. Nonetheless, the deregulation of some of the identified proteoforms, and especially transgelin-3, MBP and NDRG1 proteoforms, may be also considered a molecular Het mouse response to counterbalance a probable sub-pathological myelin dyshomeostasis in the normal-appearing carriers’ brain, for preserving neuron survival and function. In both cases, the Het",18_34,Neurodegenerative Disorder Risk in Krabbe Disease Carriers,04 11 2022,,Krabbe_Disease
"survival and function. In both cases, the Het proteome profile, by differing from both WT and Twi ones, suggests molecular affections reasonably related to the occurrence of a mutated <italic toggle=""yes"">galc</italic> allele that could concur over time and, bona fide, in association with stressful conditions to the onset of neurological disorders.",18_35,Neurodegenerative Disorder Risk in Krabbe Disease Carriers,04 11 2022,,Krabbe_Disease
"Adult-onset Krabbe disease presenting with progressive myoclonic epilepsy and asymmetric occipital lesions: A case report Krabbe disease (KD), also known as globoid cell leukodystrophy, is a rare autosomal recessive condition caused by mutations in the galactocerebrosidase (GALC) gene. KD is more common in infants and young children than in adults. We reported the case of an adult-onset KD presenting with progressive myoclonic epilepsy (PME) and cortical lesions mimicking mitochondrial encephalomyopathy,",19_0,Adult-onset Krabbe disease presenting with progressive myoclonic epilepsy and asymmetric occipital lesions: A case report,21 10 2022,,Krabbe_Disease
"mimicking mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) syndrome. The whole-exome sequencing (WES) identified a pathogenic homozygous missense mutation of the <italic toggle=""yes"">GALC</italic> gene. Parents of the patient were heterozygous for the mutation. The clinical, electrophysiological, and radiological data of the patient were retrospectively analyzed. The patient was a 24-year-old woman presenting with generalized seizures, progressive cognitive decline,",19_1,Adult-onset Krabbe disease presenting with progressive myoclonic epilepsy and asymmetric occipital lesions: A case report,21 10 2022,,Krabbe_Disease
"seizures, progressive cognitive decline, psychiatric symptoms, gait ataxia, and action-induced myoclonus. The brain magnetic resonance imaging (MRI) revealed a right occipital cortical ribbon sign without any other damage. This single case expands the clinical phenotypes of adult-onset KD. Krabbe disease (KD) is an autosomal recessive condition initially reported by the Danish neuropathologist Knud Krabbe (<xref rid=""B1"" ref-type=""bibr"">1</xref>). It is now classified as a sphingolipidosis, a lipid storage",19_2,Adult-onset Krabbe disease presenting with progressive myoclonic epilepsy and asymmetric occipital lesions: A case report,21 10 2022,,Krabbe_Disease
"classified as a sphingolipidosis, a lipid storage disorder caused by the deficiency of an enzyme that is required for the catabolism of lipids that contain ceramide. Mutations in the galactocerebrosidase (GALC) gene on chromosome 14q31 cause a deficiency of an enzyme called galactosylceramidase, resulting in an abnormal and toxic accumulation of psychosine in oligodendrocytes. The clinical hallmarks of KD include the demyelination and gliosis of multinuclear macrophages (globoid cells) in the white matter.",19_3,Adult-onset Krabbe disease presenting with progressive myoclonic epilepsy and asymmetric occipital lesions: A case report,21 10 2022,,Krabbe_Disease
"macrophages (globoid cells) in the white matter. The most common form of KD usually begins before the age of 1 year. Initial signs and symptoms typically include irritability, feeding difficulties, developmental delay, and seizures. Brain magnetic resonance imaging (MRI) is characterized by aberrant signals in the basal ganglia, cerebellum, corpus callosum, and demyelination of the white matter in posterior regions. Due to the severity of the condition, infants with KD rarely survive beyond the age of 2",19_4,Adult-onset Krabbe disease presenting with progressive myoclonic epilepsy and asymmetric occipital lesions: A case report,21 10 2022,,Krabbe_Disease
"with KD rarely survive beyond the age of 2 years. Less commonly, KD begins in childhood, adolescence, or adulthood (<xref rid=""B2"" ref-type=""bibr"">2</xref>). Individuals with late-onset KD may survive many years after the condition begins and are identified by progressive spastic paraplegia and gait abnormalities. In the late-onset KD, brain MRI abnormalities implicated the bilateral pyramidal tracts, the posterior ventricle, parietal-occipital white matter, and the corpus callosum (<xref rid=""B3""",19_5,Adult-onset Krabbe disease presenting with progressive myoclonic epilepsy and asymmetric occipital lesions: A case report,21 10 2022,,Krabbe_Disease
"matter, and the corpus callosum (<xref rid=""B3"" ref-type=""bibr"">3</xref>). In this study, we described a Chinese patient with adult-onset KD and a homozygous missense mutation in the <italic toggle=""yes"">GALC</italic> gene, characterized by progressive myoclonic epilepsy and an asymmetric occipital cortical ribbon sign. The patient was previously misdiagnosed as having mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) syndrome. This case report describes new clinical and",19_6,Adult-onset Krabbe disease presenting with progressive myoclonic epilepsy and asymmetric occipital lesions: A case report,21 10 2022,,Krabbe_Disease
"This case report describes new clinical and radiological manifestations of adult-onset KD. In August 2019, a 22-year-old Chinese woman born from consanguineous parents (cousins) developed generalized tonic-clonic seizures (GTCS). There was no family history of relevant disorders. In early life, her physical and intellectual growth was unremarkable. The GTCS was treated at the local hospital. At home, the patient discontinued several anti-seizure drugs, such as valproate, clonazepam, and oxcarbazepine. The",19_7,Adult-onset Krabbe disease presenting with progressive myoclonic epilepsy and asymmetric occipital lesions: A case report,21 10 2022,,Krabbe_Disease
"as valproate, clonazepam, and oxcarbazepine. The patient's family noticed limited responsiveness to external stimuli, with decreased production and fluidity of speech. The patient's behaviors became childlike with no apparent reason. The patient started to exhibit action- or posture-induced myoclonus involving the trunk and extremities, particularly the legs. She experienced difficulty in walking and intolerance to physical exercise. In January 2020, she complained several episodes of GTCS. The frequency",19_8,Adult-onset Krabbe disease presenting with progressive myoclonic epilepsy and asymmetric occipital lesions: A case report,21 10 2022,,Krabbe_Disease
"several episodes of GTCS. The frequency of seizures decreased when she started taking levetiracetam and lamotrigine. To determine the epileptic cause, she was referred to our hospital in October 2021. At the time of admission, the physical examination showed horizontal nystagmus, mild dysarthria, gait ataxia, hypotonia and hyperreflexia in all limbs, bilateral pyramidal signs, and pes cavus. The finger-to-nose and rapid alternating movement tests were abnormal. Her head and limbs showed shaking-like",19_9,Adult-onset Krabbe disease presenting with progressive myoclonic epilepsy and asymmetric occipital lesions: A case report,21 10 2022,,Krabbe_Disease
"abnormal. Her head and limbs showed shaking-like involuntary movements while walking or standing. Orientation in space and time was normal but attention, calculation, and comprehension were impaired. She did not cooperate during the sensory testing. Laboratory tests and cerebrospinal fluid evaluation were normal, including the screening for autoimmune encephalitis and paraneoplastic syndromes-related antibodies. On ultrasound examination, there was no visceromegaly or evident masses. The optical coherence",19_10,Adult-onset Krabbe disease presenting with progressive myoclonic epilepsy and asymmetric occipital lesions: A case report,21 10 2022,,Krabbe_Disease
"or evident masses. The optical coherence tomography fundus images were normal. The reduced motor nerve conduction velocity, compound muscle action potential amplitude of median nerves, and the sensory conduction velocity of peroneal and sural nerves suggested the presence of a demyelinating peripheral neuropathy. The interictal electroencephalogram (EEG) showed severe generalized slowing waves (<xref rid=""F1"" ref-type=""fig"">Figure 1</xref>). Brain MRI exhibited a right occipital cortical ribbon sign on",19_11,Adult-onset Krabbe disease presenting with progressive myoclonic epilepsy and asymmetric occipital lesions: A case report,21 10 2022,,Krabbe_Disease
"a right occipital cortical ribbon sign on T2-weighted and fluid-attenuated inversion recovery (FLAIR) sequences, with global brain atrophy and ventricular enlargement. Diffusion-weighted imaging (DWI) and susceptibility-weighted imaging (SWI) sequences revealed no other abnormalities (<xref rid=""F2"" ref-type=""fig"">Figure 2</xref>). There were other manifestations of psychiatric, cognitive, or movement disorders. Although antibodies were negative for autoimmune encephalitis, we used high-dose glucocorticoid",19_12,Adult-onset Krabbe disease presenting with progressive myoclonic epilepsy and asymmetric occipital lesions: A case report,21 10 2022,,Krabbe_Disease
"encephalitis, we used high-dose glucocorticoid therapy (500 mg/day for 5 days). The treatment, however, was ineffective. Meanwhile, we diagnosed a progressive myoclonic epilepsy (PME). Based on clinical presentations and MRI findings, we suspected probable MELAS syndrome or atypical autosomal-recessive cerebellar ataxia (ARCA). The whole-exome sequencing (WES) analysis identified pathogenic homozygous missense mutations of the <italic toggle=""yes"">GALC</italic> gene, c.1901T>C (p.Leu634Ser). The Sanger",19_13,Adult-onset Krabbe disease presenting with progressive myoclonic epilepsy and asymmetric occipital lesions: A case report,21 10 2022,,Krabbe_Disease
"gene, c.1901T>C (p.Leu634Ser). The Sanger sequencing confirmed that these mutations were inherited from her parents (<xref rid=""F3"" ref-type=""fig"">Figure 3</xref>). Then, we diagnosed an adult-onset KD. Serum GALC enzyme activity was found to be ~3.3 nmol/17 h/mg protein (normal range > 12.7 nmol/17 h/mg protein), providing additional support for the clinical diagnosis. There are currently no approved treatments for KD. Adult-onset KD might benefit from hematopoietic stem cell transplantation, as described",19_14,Adult-onset Krabbe disease presenting with progressive myoclonic epilepsy and asymmetric occipital lesions: A case report,21 10 2022,,Krabbe_Disease
"stem cell transplantation, as described in a single case report (<xref rid=""B4"" ref-type=""bibr"">4</xref>). The family refused the treatment due to the high risk of failure. A few months later, the patient experienced new GTCS with a general deterioration of neurological function, such as persistent confusion, cataphasia, and insomnia. Her family reported a transient gaze paresis of the right side, with involuntary twitch-like movements affecting her right upper limb and mouth. The EEG findings showed",19_15,Adult-onset Krabbe disease presenting with progressive myoclonic epilepsy and asymmetric occipital lesions: A case report,21 10 2022,,Krabbe_Disease
"upper limb and mouth. The EEG findings showed numerous irregular left-sided delta waves mixed with a large number of sharp waves, spikes, and wave discharges (<xref rid=""F4"" ref-type=""fig"">Figure 4</xref>). Brain MRI showed a damage to the left cerebral hemisphere (<xref rid=""F5"" ref-type=""fig"">Figure 5</xref>). Magnetic resonance spectroscopy (MRS) found an increased peak of choline, a decreased peak of N-acetylaspartate and an inverted peak of lipid-lactate in bilateral basal ganglia (<xref rid=""F6""",19_16,Adult-onset Krabbe disease presenting with progressive myoclonic epilepsy and asymmetric occipital lesions: A case report,21 10 2022,,Krabbe_Disease
"in bilateral basal ganglia (<xref rid=""F6"" ref-type=""fig"">Figure 6</xref>). She was treated with levetiracetam (1,500 mg/day) and lamotrigine (200 mg/day). She gradually returned to consciousness, the frequency of abnormal involuntary movements decreased. We described an adult case of KD with atypical clinical and neuroimaging characteristics. We reported for the first time an adult-onset KD presenting PME, a rare epileptic syndrome most commonly inherited in a recessive manner. PME usually appears in late",19_17,Adult-onset Krabbe disease presenting with progressive myoclonic epilepsy and asymmetric occipital lesions: A case report,21 10 2022,,Krabbe_Disease
"a recessive manner. PME usually appears in late childhood or adolescence with myoclonus, multiple seizure types, cerebellar symptoms, and a progressive degeneration of neurological function (<xref rid=""B5"" ref-type=""bibr"">5</xref>). The most common causes of PME are lysosomal storage disorders (e.g., neuronal ceroid-lipofuscinoses, Gaucher disease, and sialidosis), mitochondrial disorders (e.g., myoclonic epilepsy with ragged red fibers), spinocerebellar ataxia, Lafora disease, and Unverricht-Lundborg",19_18,Adult-onset Krabbe disease presenting with progressive myoclonic epilepsy and asymmetric occipital lesions: A case report,21 10 2022,,Krabbe_Disease
"ataxia, Lafora disease, and Unverricht-Lundborg disease (<xref rid=""B6"" ref-type=""bibr"">6</xref>). Delays in diagnosis are common due to the lack of disease awareness, non-specific clinical presentation, and limited access to diagnostic testing resources in some areas. Our case was early misdiagnosed as an autoimmune encephalitis and incorrectly treated with glucocorticoids. When epilepsy or autoimmune encephalitis is suspected but patients do not respond well to immunotherapies or show no radiological",19_19,Adult-onset Krabbe disease presenting with progressive myoclonic epilepsy and asymmetric occipital lesions: A case report,21 10 2022,,Krabbe_Disease
"well to immunotherapies or show no radiological improvements, there is a possibility of misdiagnosis. Only four provinces and cities in China have implemented newborn screening for lysosomal storage disorders. In addition, the test of enzyme is very common in pediatric departments, while it tends to be ignored in adult neurology, which may lead to the underestimation of the late-onset KD prevalence. Therefore, more attention should be directed to adult-onset genetic disorders, especially when common causes",19_20,Adult-onset Krabbe disease presenting with progressive myoclonic epilepsy and asymmetric occipital lesions: A case report,21 10 2022,,Krabbe_Disease
"genetic disorders, especially when common causes have been excluded. In neurological disorders, an imaging examination is an essential component in the differential diagnosis. In our patient, the MRI findings lead to diagnostic pitfalls. The main imaging feature of KD is leukoencephalopathy, but our patient revealed no widespread supra- or infratentorial white matter signals. The corticospinal tracts, regarded as the most frequent areas involved in adult-onset KD, were not damaged. On initial inspection,",19_21,Adult-onset Krabbe disease presenting with progressive myoclonic epilepsy and asymmetric occipital lesions: A case report,21 10 2022,,Krabbe_Disease
"KD, were not damaged. On initial inspection, the occipital lobe showed a unilateral cortical ribbon sign. When combined with clinical symptoms, the cortical ribbon sign is highly suggestive of mitochondrial disorders. When the cortical ribbon sign is present, multiple autoimmune or metabolic encephalitis, or sporadic Creutzfeldt-Jakob disease should be considered in the differential diagnosis. MELAS syndrome is a relatively common mitochondrial disorder characterized by stroke-like episodes involving the",19_22,Adult-onset Krabbe disease presenting with progressive myoclonic epilepsy and asymmetric occipital lesions: A case report,21 10 2022,,Krabbe_Disease
"by stroke-like episodes involving the cerebral cortex and diagnosed by genetic testing. We detected no mutations in mitochondrial or nuclear DNA, but we found a homozygous missense variant carrying a c.1901T>C (p.Leu634Ser) mutation in the <italic toggle=""yes"">GALC</italic> gene. So far, more than 300 mutations of the <italic toggle=""yes"">GALC</italic> gene have been found in patients with KD. The identified pathogenic variant indicated that thymidine at the 1901st position of the coding region of GALC",19_23,Adult-onset Krabbe disease presenting with progressive myoclonic epilepsy and asymmetric occipital lesions: A case report,21 10 2022,,Krabbe_Disease
"the 1901st position of the coding region of GALC changed to a methylated cytosine, leading to an amino acid substitution (leucine to serine, the 634th amino acid). Her parents were phenotypically normal with a heterozygous <italic toggle=""yes"">GALC</italic> gene missense variant. According to the GnomAD database, the frequency of this variant is 0.006 in the East Asian population. This variant was predicted to be “probably damaging” by PolyPhen-2 and “deleterious” by the Sorting Intolerant from Tolerant",19_24,Adult-onset Krabbe disease presenting with progressive myoclonic epilepsy and asymmetric occipital lesions: A case report,21 10 2022,,Krabbe_Disease
"by the Sorting Intolerant from Tolerant (SIFT). Previous research demonstrated that this missense mutation inhibited protein synthesis <italic toggle=""yes"">in vitro</italic>. Of interest, all patients carrying this variant were associated with a late-onset and mild form of KD. They all were Asian people, particularly from Japan (<xref rid=""B7"" ref-type=""bibr"">7</xref>), China (<xref rid=""B8"" ref-type=""bibr"">8</xref>), and Korea (<xref rid=""T1"" ref-type=""table"">Table 1</xref>). Unlike previous reported",19_25,Adult-onset Krabbe disease presenting with progressive myoclonic epilepsy and asymmetric occipital lesions: A case report,21 10 2022,,Krabbe_Disease
"1</xref>). Unlike previous reported cases with a relatively benign phenotype, our patient was associated with a more rapid course and worse outcomes (<xref rid=""B9"" ref-type=""bibr"">9</xref>). The <italic toggle=""yes"">GALC</italic> gene dysfunction lowers the activity of the GALC enzyme, which catalyzes the hydrolysis of galactose from several glycosphingolipids (<xref rid=""B10"" ref-type=""bibr"">10</xref>). Psychosine, a substrate of the GALC enzyme, is a biomarker for infant KD. In the late-onset KD, the",19_26,Adult-onset Krabbe disease presenting with progressive myoclonic epilepsy and asymmetric occipital lesions: A case report,21 10 2022,,Krabbe_Disease
"for infant KD. In the late-onset KD, the diagnosis is supported by a low activity of the GALC enzyme (0–5% of normal activity) in leukocytes. The age of onset and severity of lysosomal storage disorders are often related to the activities of enzymes involved in the disease, with individuals with some enzymatic activity having a higher age of occurrence. In KD, the loss of enzymatic activity does not always predict the development of the disease (<xref rid=""B11"" ref-type=""bibr"">11</xref>). We found a",19_27,Adult-onset Krabbe disease presenting with progressive myoclonic epilepsy and asymmetric occipital lesions: A case report,21 10 2022,,Krabbe_Disease
"rid=""B11"" ref-type=""bibr"">11</xref>). We found a relatively low activity of the GALC enzyme (about 25.98% of normal activity) in leukocytes, suggesting that KD patients with the p.Leu634Ser mutation may exhibit a broader range of GALC activities. The severity of phenotype may not be necessarily represented by very low enzymatic activity. It is possible that different activities of the GALC enzyme coexist between peripheral blood and the central nervous system. The activity measured in leukocytes may not",19_28,Adult-onset Krabbe disease presenting with progressive myoclonic epilepsy and asymmetric occipital lesions: A case report,21 10 2022,,Krabbe_Disease
"The activity measured in leukocytes may not accurately reflect the activity necessary to maintain an appropriate myelination in neural tissues. Bascou et al. suggested that vision loss could be the first indicator of late-onset KD due to a p.Leu634Ser variant (<xref rid=""B12"" ref-type=""bibr"">12</xref>). Our patient was able to see and count fingers but the visual acuity was not tested because of cognitive impairment. The loss of GALC activity can cause oligodendrocyte toxicity, demyelination, and poor",19_29,Adult-onset Krabbe disease presenting with progressive myoclonic epilepsy and asymmetric occipital lesions: A case report,21 10 2022,,Krabbe_Disease
"oligodendrocyte toxicity, demyelination, and poor remyelination in the brain and peripheral nerves (<xref rid=""B13"" ref-type=""bibr"">13</xref>). Electrophysiological findings and high arches in the feet supported the presence of a peripheral neuropathy. Previously, a restricted diffusion on DWI suggested an acute aggravation of KD in a few individuals (<xref rid=""B9"" ref-type=""bibr"">9</xref>). In our patient, we found a limited high signal on DWI in the interictal stage and a high signal in the acute",19_30,Adult-onset Krabbe disease presenting with progressive myoclonic epilepsy and asymmetric occipital lesions: A case report,21 10 2022,,Krabbe_Disease
"interictal stage and a high signal in the acute period. DWI appears to be useful in assessing disease progression in people with KD. We reported the case of a single patient with adult-onset KD, PME, and a cortical ribbon sign. At the beginning, the clinical and neuroimaging characteristics were strongly suggestive of MELAS syndrome. This study could help extending genetic and clinical aspects of adult-onset KD. We acknowledge that our study investigated only a single individual. Skin or muscle samples, if",19_31,Adult-onset Krabbe disease presenting with progressive myoclonic epilepsy and asymmetric occipital lesions: A case report,21 10 2022,,Krabbe_Disease
"a single individual. Skin or muscle samples, if available, could better inform the specificities of adult-onset KD. The datasets presented in this article are not readily available because of ethical and privacy restrictions. Requests to access the datasets should be directed to the corresponding author/s. The Medical Research Ethics Committee of the Affiliated Hospital of the Neurology Institute of Anhui University of Chinese Medicine provided the formal approval to this study. The patient and her family",19_32,Adult-onset Krabbe disease presenting with progressive myoclonic epilepsy and asymmetric occipital lesions: A case report,21 10 2022,,Krabbe_Disease
to this study. The patient and her family provided a written informed consent for the publication of this case report. YW and S-yW wrote the manuscript with input from all authors. All authors contributed to data acquisition and analysis. All authors contributed to the article and approved the submitted version. The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. All claims expressed in,19_33,Adult-onset Krabbe disease presenting with progressive myoclonic epilepsy and asymmetric occipital lesions: A case report,21 10 2022,,Krabbe_Disease
"conflict of interest. All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.",19_34,Adult-onset Krabbe disease presenting with progressive myoclonic epilepsy and asymmetric occipital lesions: A case report,21 10 2022,,Krabbe_Disease
"Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases Krabbe disease (KD) is a lysosomal storage disease (LSD) caused by mutations in the <italic toggle=""yes"">galc</italic> gene. There are over 50 monogenetic LSDs, which largely impede the normal development of children and often lead to premature death. At present, there are no cures for LSDs and the available treatments are generally insufficient, short acting, and not without",20_0,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"insufficient, short acting, and not without co-morbidities or long-term side effects. The last 30 years have seen significant advances in our understanding of LSD pathology as well as treatment options. Two gene therapy-based clinical trials, <ext-link ext-link-type=""ClinicalTrials.gov"" http://www.w3.org/1999/xlink href=""NCT04693598"" id=""intref0010"">NCT04693598</ext-link> and <ext-link ext-link-type=""ClinicalTrials.gov"" http://www.w3.org/1999/xlink href=""NCT04771416"" id=""intref0015"">NCT04771416</ext-link>,",20_1,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"id=""intref0015"">NCT04771416</ext-link>, for KD were recently started based on those advances. This review will discuss how our knowledge of KD got to where it is today, focusing on preclinical investigations, and how what was discovered may prove beneficial for the treatment of other LSDs.  The current standard-of-care treatment of Krabbe disease (hematopoietic stem cell transplantation) only moderately increases life expectancy and partially protects against symptoms. Adeno-associated virus-based gene",20_2,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"symptoms. Adeno-associated virus-based gene therapy is the most effective single-modality treatment of Krabbe disease. Combination therapies are the overall most effective treatments to increase life expectancy and protect against disease signs. Lysosomal storage diseases (LSDs) are family of over 50 diseases caused by genetic defects in lysosomal genes. While each individual LSD is rare, together they are relatively common with a combined estimated incidence rate of 1 in 2,300–7,700 live births.<xref",20_3,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"rate of 1 in 2,300–7,700 live births.<xref rid=""bib1"" ref-type=""bibr""><sup>1</sup></xref> These genetic defects, usually leading to expression of defective lysosomal enzymes, typically result in accumulation of the defective enzyme’s substrate because it cannot be catabolized. The symptoms exhibited in LSDs vary significantly depending on the specific genetic defect but there are some commonalities such as developmental delay/regression, vision loss, hepatosplenomegaly, and premature death.<xref rid=""bib1""",20_4,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"and premature death.<xref rid=""bib1"" ref-type=""bibr""><sup>1</sup></xref> At present, there are no cures for any LSD and the existing treatments mostly only delay symptom development. This is particularly true for LSDs that affect the central nervous system (CNS). Additionally, many of the current treatments, such as hematopoietic stem cell transplantation (HSCT), for LSDs pose risks of their own.<xref rid=""bib1"" ref-type=""bibr""><sup>1</sup></xref> This review will focus on Krabbe disease (KD) as an",20_5,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"review will focus on Krabbe disease (KD) as an introduction to potential therapeutics for other LSDs. KD is a leukodystrophy and LSD first described by Knud H. Krabbe in 1916.<xref rid=""bib2"" ref-type=""bibr""><sup>2</sup></xref> In the last century there have been countless breakthroughs in our understanding of the underlying pathology as well as treatment, but there is still no cure. KD is an autosomal recessive disease caused by mutations in the <italic toggle=""yes"">galc</italic> gene that result in",20_6,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"toggle=""yes"">galc</italic> gene that result in reduced activity of the lysosomal hydrolase, galactosylceramidase (GALC). KD is typically divided into three subtypes based on age of onset and severity of symptoms: (1) infantile (symptom onset before 3 years of age; some physicians and investigators further divide it into early infantile and late infantile), (2) juvenile (onset after 3 years of age), and (3) adult onset (onset after 18 years of age).<xref rid=""bib3"" ref-type=""bibr""><sup>3</sup></xref> A",20_7,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"rid=""bib3"" ref-type=""bibr""><sup>3</sup></xref> A retrospective analysis of KD cases in the United States estimates an incidence of 1 in 310,000 live births.<xref rid=""bib4"" ref-type=""bibr""><sup>4</sup></xref> Newborn screening (NBS) data from New York State estimate an incidence of 1 in 394,000 live births.<xref rid=""bib5"" ref-type=""bibr""><sup>5</sup></xref> It should be noted that these estimates are from hospitalization and NBS data, respectively, and both of these data collection methods are biased",20_8,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"both of these data collection methods are biased toward identifying infantile KD. Given that, the actual incidence may be higher because juvenile- and adult-onset patients may not have been detected in these studies. Additionally, there is some disparity between different ethnic groups; for example, the Druze population in the Middle East has an estimated incidence of 1 in 100 live births.<xref rid=""bib6"" ref-type=""bibr""><sup>6</sup></xref> GALC is responsible for the catabolic removal of galactose from",20_9,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"for the catabolic removal of galactose from sphingolipids containing galactose, such as galactosylceramides.<xref rid=""bib7"" ref-type=""bibr""><sup>7</sup></xref><sup>,</sup><xref rid=""bib8"" ref-type=""bibr""><sup>8</sup></xref> GALC deficiency renders the body unable to metabolize several galactosphingolipids, which leads to their subsequent accumulation. This process is illustrated in <xref rid=""fig1"" ref-type=""fig"">Figure 1</xref>.<xref rid=""bib7"" ref-type=""bibr""><sup>7</sup></xref><sup>,</sup><xref",20_10,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"rid=""bib9"" ref-type=""bibr""><sup>9</sup></xref> Elevated levels of galactosylceramides cause the characteristic globoid cell reaction in macrophages that gives rise to KD’s formal name, globoid cell leukodystrophy (GLD).<xref rid=""bib10"" ref-type=""bibr""><sup>10</sup></xref> However, it should be mentioned that KD is different from many other LSDs in that the main substrate of the GALC enzyme, galactosylceramides, does not reach the levels of accumulated substrate seen in other LSDs.<xref rid=""bib9""",20_11,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"substrate seen in other LSDs.<xref rid=""bib9"" ref-type=""bibr""><sup>9</sup></xref><sup>,</sup><xref rid=""bib11"" ref-type=""bibr""><sup>11</sup></xref><fig id=""fig1""><label>Figure 1</label><caption><p>Main metabolic pathways involving GALC</p><p>This figure outlines some of the relevant molecules and enzymes in KD. It is important to note that most of these reactions are normally reversible using differing enzymes; for example, ceremide galactosyltransferase (CGT) catalyzes addition of galactose to ceramides",20_12,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"catalyzes addition of galactose to ceramides to form galactosylceramides, and GALC normally catalyzes the removal of galactose from galactosylceramides. Additionally, many of these enzymes catalyze reactions with other substrates, such as sphingosine and psychosine. One exception is the irreversible catalytic removal of the fatty acid group from galactosylceramides by acid ceramidase (ACD).</p></caption><graphic http://www.w3.org/1999/xlink href=""gr1""></graphic></fig> Galactosylsphingosine (commonly",20_13,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"Galactosylsphingosine (commonly referred to as psychosine) is a sphingolipid that is catabolized by GALC, such that it is nearly undetectable in unaffected people and animals.<xref rid=""bib11"" ref-type=""bibr""><sup>11</sup></xref><sup>,</sup><xref rid=""bib12"" ref-type=""bibr""><sup>12</sup></xref><sup>,</sup><xref rid=""bib13"" ref-type=""bibr""><sup>13</sup></xref><sup>,</sup><xref rid=""bib14"" ref-type=""bibr""><sup>14</sup></xref><sup>,</sup><xref rid=""bib15"" ref-type=""bibr""><sup>15</sup></xref> High",20_14,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"ref-type=""bibr""><sup>15</sup></xref> High concentrations of psychosine are cytotoxic and trigger a cascade of pathogenic mechanisms, primarily by disrupting cell membranes as well as activating apoptotic pathways.<xref rid=""bib16"" ref-type=""bibr""><sup>16</sup></xref><sup>,</sup><xref rid=""bib17"" ref-type=""bibr""><sup>17</sup></xref><sup>,</sup><xref rid=""bib18"" ref-type=""bibr""><sup>18</sup></xref><sup>,</sup><xref rid=""bib19"" ref-type=""bibr""><sup>19</sup></xref><sup>,</sup><xref rid=""bib20""",20_15,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"rid=""bib20"" ref-type=""bibr""><sup>20</sup></xref> Psychosine accumulation has been confirmed in KD patients, the Twitcher (TWI) mouse model of KD, new gene edited mouse KD models, and the canine model of KD.<xref rid=""bib11"" ref-type=""bibr""><sup>11</sup></xref><sup>,</sup><xref rid=""bib14"" ref-type=""bibr""><sup>14</sup></xref><sup>,</sup><xref rid=""bib15"" ref-type=""bibr""><sup>15</sup></xref><sup>,</sup><xref rid=""bib21"" ref-type=""bibr""><sup>21</sup></xref> Miyatake and Suzuki first proposed what is now known",20_16,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"and Suzuki first proposed what is now known as the psychosine hypothesis in 1972 to address the relatively low levels of galactosylceramides and high levels of psychosine. This hypothesis suggests that, because of the metabolic block preventing the normal breakdown of galactosylceramides into galactose and ceramides, galactosylceramides are instead deacylated into psychosine, which cannot be catabolized due to GALC deficiency.<xref rid=""bib13"" ref-type=""bibr""><sup>13</sup></xref> Most of the psychosine",20_17,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"Most of the psychosine hypothesis has been confirmed, the one exception being that psychosine was originally thought to be generated through aberrant sphingolipid synthesis.<xref rid=""bib12"" ref-type=""bibr""><sup>12</sup></xref> However, it was recently shown that the main source of psychosine is through catabolic de-acylation of galactosylceramides by acid ceramidase with the anabolic pathway possibly playing a minor role.<xref rid=""bib22"" ref-type=""bibr""><sup>22</sup></xref> Myelinating cells,",20_18,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"Myelinating cells, oligodendrocytes, and Schwann cells generate the aforementioned sphingolipids in significantly higher quantities than other cell types, thus they are particularly vulnerable to the metabolic blockade caused by the lack of GALC.<xref rid=""bib11"" ref-type=""bibr""><sup>11</sup></xref><sup>,</sup><xref rid=""bib23"" ref-type=""bibr""><sup>23</sup></xref> The main pathological characteristics of KD are global diffuse demyelination (both CNS and peripheral nervous system [PNS]) and the appearance",20_19,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"nervous system [PNS]) and the appearance of multinucleated globoid cells.<xref rid=""bib2"" ref-type=""bibr""><sup>2</sup></xref><sup>,</sup><xref rid=""bib10"" ref-type=""bibr""><sup>10</sup></xref><sup>,</sup><xref rid=""bib24"" ref-type=""bibr""><sup>24</sup></xref> There are, however, many other pathological processes occurring in KD, such as disordered cell membrane dynamics (particularly within lipid rafts), disrupted signal transduction pathways, axonopathy, synaptic complications, overactivation of the",20_20,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"synaptic complications, overactivation of the proteosome degradation pathway, and problems regulating apoptosis.<xref rid=""bib16"" ref-type=""bibr""><sup>16</sup></xref><sup>,</sup><xref rid=""bib17"" ref-type=""bibr""><sup>17</sup></xref><sup>,</sup><xref rid=""bib18"" ref-type=""bibr""><sup>18</sup></xref><sup>,</sup><xref rid=""bib25"" ref-type=""bibr""><sup>25</sup></xref><sup>,</sup><xref rid=""bib26"" ref-type=""bibr""><sup>26</sup></xref><sup>,</sup><xref rid=""bib27""",20_21,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"rid=""bib27"" ref-type=""bibr""><sup>27</sup></xref><sup>,</sup><xref rid=""bib28"" ref-type=""bibr""><sup>28</sup></xref><sup>,</sup><xref rid=""bib29"" ref-type=""bibr""><sup>29</sup></xref><sup>,</sup><xref rid=""bib30"" ref-type=""bibr""><sup>30</sup></xref> Together, these pathologic processes give rise to the clinical signs observed in KD patients. All of the research into KD pathology, NBS, treatments, and more by numerous independent investigators has provided the foundation of two recently started phase 1/2",20_22,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"the foundation of two recently started phase 1/2 clinical trials investigating adeno-associated virus (AAV)-based gene therapy for KD: <ext-link ext-link-type=""ClinicalTrials.gov"" http://www.w3.org/1999/xlink href=""NCT04771416"" id=""intref0020"">NCT04771416</ext-link> and <ext-link ext-link-type=""ClinicalTrials.gov"" http://www.w3.org/1999/xlink href=""NCT04693598"" id=""intref0025"">NCT04693598</ext-link>. Untreated infantile KD is typically divided into an asymptomatic stage, followed by three progressively",20_23,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"stage, followed by three progressively worsening symptomatic stages. Affected infants typically have a short asymptomatic period where they seemingly develop normally. Stage 1 is characterized by mostly nonspecific symptoms such as difficulty feeding, vomiting, hypersensitivity, hyperirritability, and fever. Stiffness, developmental delay or regression, and seizures are less common but possible in this stage. The main laboratory finding at this stage is increased cerebrospinal fluid protein levels. Stage 2",20_24,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"cerebrospinal fluid protein levels. Stage 2 symptoms include severe motor and mental deterioration with hypertonicity and hyperactive reflexes. Optic atrophy and tonic/clonic seizures are less common symptoms at this stage. At stage 3, the infant has very limited mobility, is decerebrate, and is blind. Untreated infants rarely live beyond 2–3 years.<xref rid=""bib3"" ref-type=""bibr""><sup>3</sup></xref><sup>,</sup><xref rid=""bib31"" ref-type=""bibr""><sup>31</sup></xref> Later-onset subtypes of KD, including",20_25,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"Later-onset subtypes of KD, including juvenile and adult onset, have more variable presentations. Often, the patients are clinically normal prior to symptom onset. Common presenting symptoms include visual deficits, weakness, balance problems, and cognitive impairment. Not only are symptoms variable but the age of onset and disease course are also variable, even between siblings with the same mutation.<xref rid=""bib32"" ref-type=""bibr""><sup>32</sup></xref><sup>,</sup><xref rid=""bib33""",20_26,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"rid=""bib33"" ref-type=""bibr""><sup>33</sup></xref> The <italic toggle=""yes"">galc</italic> gene was localized to chromosome 14 by linkage analysis and was subsequently sequenced and cloned.<xref rid=""bib34"" ref-type=""bibr""><sup>34</sup></xref><sup>,</sup><xref rid=""bib35"" ref-type=""bibr""><sup>35</sup></xref><sup>,</sup><xref rid=""bib36"" ref-type=""bibr""><sup>36</sup></xref> Full sequencing of the <italic toggle=""yes"">galc</italic> gene led to identification of at least 147 mutations and many single-nucleotide",20_27,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"at least 147 mutations and many single-nucleotide polymorphisms.<xref rid=""bib37"" ref-type=""bibr""><sup>37</sup></xref><sup>,</sup><xref rid=""bib38"" ref-type=""bibr""><sup>38</sup></xref> Given the relatively large number of variants of unknown significance (VUSs) and the variable nature of the disease, it has been difficult to establish a clear genotype-phenotype correlation. A notable exception is a 30-kb deletion that encompasses exons 11 through 17, which correlates to a loss of the entirety of the",20_28,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"which correlates to a loss of the entirety of the smaller 30-kDa subunit and part of the larger 50- to 52-kDa subunit of the GALC protein, leading to an infantile presentation in individuals homozygous for this mutation.<xref rid=""bib38"" ref-type=""bibr""><sup>38</sup></xref><sup>,</sup><xref rid=""bib39"" ref-type=""bibr""><sup>39</sup></xref><sup>,</sup><xref rid=""bib40"" ref-type=""bibr""><sup>40</sup></xref><sup>,</sup><xref rid=""bib41"" ref-type=""bibr""><sup>41</sup></xref> Patients with juvenile- and",20_29,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"Patients with juvenile- and adult-onset KD are typically compound heterozygotes, usually possessing one copy of the <italic toggle=""yes"">galc</italic> gene containing the 30-kb deletion, and one copy with mutations that retain greater GALC functionality than mutations that more frequently lead to infantile KD.<xref rid=""bib33"" ref-type=""bibr""><sup>33</sup></xref><sup>,</sup><xref rid=""bib42"" ref-type=""bibr""><sup>42</sup></xref><sup>,</sup><xref rid=""bib43""",20_30,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"rid=""bib43"" ref-type=""bibr""><sup>43</sup></xref><sup>,</sup><xref rid=""bib44"" ref-type=""bibr""><sup>44</sup></xref> There are many animal models of KD, such as mouse, dog, and rhesus macaque.<xref rid=""bib45"" ref-type=""bibr""><sup>45</sup></xref><sup>,</sup><xref rid=""bib46"" ref-type=""bibr""><sup>46</sup></xref><sup>,</sup><xref rid=""bib47"" ref-type=""bibr""><sup>47</sup></xref><sup>,</sup><xref rid=""bib48"" ref-type=""bibr""><sup>48</sup></xref> These models have allowed research into its pathogenesis as well as",20_31,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"allowed research into its pathogenesis as well as possible treatment options.<xref rid=""bib49"" ref-type=""bibr""><sup>49</sup></xref><sup>,</sup><xref rid=""bib50"" ref-type=""bibr""><sup>50</sup></xref><sup>,</sup><xref rid=""bib51"" ref-type=""bibr""><sup>51</sup></xref><sup>,</sup><xref rid=""bib52"" ref-type=""bibr""><sup>52</sup></xref><sup>,</sup><xref rid=""bib53"" ref-type=""bibr""><sup>53</sup></xref> The most commonly used animal models include the TWI mouse and canine KD models, both of which closely model",20_32,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"and canine KD models, both of which closely model infantile KD.<xref rid=""bib49"" ref-type=""bibr""><sup>49</sup></xref><sup>,</sup><xref rid=""bib51"" ref-type=""bibr""><sup>51</sup></xref><sup>,</sup><xref rid=""bib52"" ref-type=""bibr""><sup>52</sup></xref><sup>,</sup><xref rid=""bib54"" ref-type=""bibr""><sup>54</sup></xref><sup>,</sup><xref rid=""bib55"" ref-type=""bibr""><sup>55</sup></xref><sup>,</sup><xref rid=""bib56"" ref-type=""bibr""><sup>56</sup></xref><sup>,</sup><xref rid=""bib57""",20_33,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"rid=""bib57"" ref-type=""bibr""><sup>57</sup></xref><sup>,</sup><xref rid=""bib58"" ref-type=""bibr""><sup>58</sup></xref> TWI are a naturally occurring KD model possessing a spontaneous nonsense mutation in the <italic toggle=""yes"">galc</italic> gene leading to nonsense-mediated mRNA decay and a complete lack of functional GALC enzyme.<xref rid=""bib45"" ref-type=""bibr""><sup>45</sup></xref><sup>,</sup><xref rid=""bib59"" ref-type=""bibr""><sup>59</sup></xref><sup>,</sup><xref rid=""bib60""",20_34,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"rid=""bib60"" ref-type=""bibr""><sup>60</sup></xref><sup>,</sup><xref rid=""bib61"" ref-type=""bibr""><sup>61</sup></xref> TWI exhibit psychosine accumulation analogous to KD patients. Similar to KD patients, TWI show no signs of disease for the first weeks of life. TWI reach their maximum mass of 8–12 g around postnatal day (PND) 30, then continuously decline until their death at ∼PND40, analogous to failure to thrive in KD infants. Around PND20, muscle atrophy and weakness begin to develop, particularly in the",20_35,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"weakness begin to develop, particularly in the hind limbs, ultimately leading to paralysis at approximately PND35–40. TWI begin to display the eponymous tremor or twitch around PND30. The histological features of disease in TWI include diffuse, global demyelination (both CNS and PNS), globoid cell formation, axonopathy, and neuroinflammation characterized by astrogliosis and microgliosis.<xref rid=""bib45"" ref-type=""bibr""><sup>45</sup></xref><sup>,</sup><xref rid=""bib61""",20_36,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"rid=""bib61"" ref-type=""bibr""><sup>61</sup></xref><sup>,</sup><xref rid=""bib62"" ref-type=""bibr""><sup>62</sup></xref><sup>,</sup><xref rid=""bib63"" ref-type=""bibr""><sup>63</sup></xref><sup>,</sup><xref rid=""bib64"" ref-type=""bibr""><sup>64</sup></xref> The trs mouse is another KD model; they harbor a H168C missense mutation leading to 10%–20% wildtype (WT) mouse GALC activity. trs mice accumulate psychosine slightly slower than TWI. The median survival of trs mice is approximately 50 days, and they exhibit",20_37,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"mice is approximately 50 days, and they exhibit remarkably similar disease signs to TWI but delayed by about 10 days. Finally, the trs mice display similar levels of demyelination to TWI but have fewer infiltrating macrophages.<xref rid=""bib65"" ref-type=""bibr""><sup>65</sup></xref> An inducible <italic toggle=""yes"">galc</italic> knockout (KO) mouse was developed using a <italic toggle=""yes"">galc</italic> gene flanked by loxP sites and the Cre/enzyme replacement therapy (ERT) system to examine the effect of",20_38,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"therapy (ERT) system to examine the effect of <italic toggle=""yes"">galc</italic> loss at different time points. It was found that very early (PND0) <italic toggle=""yes"">galc</italic> KO led to disease progression essentially identical to TWI, but, as <italic toggle=""yes"">galc</italic> KO was introduced later, disease onset was delayed and disease severity was reduced.<xref rid=""bib66"" ref-type=""bibr""><sup>66</sup></xref><sup>,</sup><xref rid=""bib67"" ref-type=""bibr""><sup>67</sup></xref> A lysosomal membrane",20_39,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"A lysosomal membrane tethered GALC mouse, GALCLAMP1, was created to investigate cell-autonomous expression of GALC. GALCLAMP1 mice can also be induced to delete <italic toggle=""yes"">galc</italic> to recapitulate the TWI phenotype because the <italic toggle=""yes"">galclamp1</italic> gene construct is flanked by loxP sites. Furthermore, GALCLAMP1 can be crossed with mouse lines that express Cre only in certain cell types to selectively delete <italic toggle=""yes"">galclamp1</italic> expression in specific",20_40,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"expression in specific cells and determine the unique role of <italic toggle=""yes"">galc</italic> in only those cells.<xref rid=""bib68"" ref-type=""bibr""><sup>68</sup></xref> CRISPR-based gene editing has also been used to generate a severe infantile-like murine line carrying the T513M mutation and an adult-onset model murine line carrying the G41S mutation. The T513M mice exhibit disease progression almost identically to TWI as assessed by median survival, weight, tremor, and a multitude of behavioral tests.",20_41,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"tremor, and a multitude of behavioral tests. Pathologically, T513M mice are also extremely similar to TWI in that GALC activity is severely reduced and psychosine is elevated compared with WT. Since the G41S mice model adult-onset KD, they do not present pathological abnormalities until ∼PND200 and, even then, display much milder disease signs and pathology than TWI.<xref rid=""bib21"" ref-type=""bibr""><sup>21</sup></xref> The canine model of KD is another naturally occurring model that was first reported in",20_42,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"occurring model that was first reported in 1966 in the West Highland terriers and Cairn terrier breeds.<xref rid=""bib46"" ref-type=""bibr""><sup>46</sup></xref> This model has reduced GALC activity due to a spontaneous missense mutation, Y158S, leading to elevated psychosine levels throughout the nervous system.<xref rid=""bib52"" ref-type=""bibr""><sup>52</sup></xref><sup>,</sup><xref rid=""bib58"" ref-type=""bibr""><sup>58</sup></xref><sup>,</sup><xref rid=""bib69""",20_43,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"rid=""bib69"" ref-type=""bibr""><sup>69</sup></xref><sup>,</sup><xref rid=""bib70"" ref-type=""bibr""><sup>70</sup></xref><sup>,</sup><xref rid=""bib71"" ref-type=""bibr""><sup>71</sup></xref> The KD canine phenotype typically manifests at 4–6 weeks of age, with the first disease signs being hind limb weakness, forelimb dysmetria, and tremor. The signs progressively worsen, such that, by 12 weeks of age, they display hind limb ataxia and reach humane endpoint by 16 weeks of age due to disease burden.<xref rid=""bib52""",20_44,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"of age due to disease burden.<xref rid=""bib52"" ref-type=""bibr""><sup>52</sup></xref><sup>,</sup><xref rid=""bib72"" ref-type=""bibr""><sup>72</sup></xref><sup>,</sup><xref rid=""bib73"" ref-type=""bibr""><sup>73</sup></xref> Histologically, KD canines display myelin loss, astrogliosis, microgliosis, and globoid cell accumulation similar to the human disease.<xref rid=""bib52"" ref-type=""bibr""><sup>52</sup></xref><sup>,</sup><xref rid=""bib58"" ref-type=""bibr""><sup>58</sup></xref><sup>,</sup><xref rid=""bib72""",20_45,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"rid=""bib72"" ref-type=""bibr""><sup>72</sup></xref><sup>,</sup><xref rid=""bib74"" ref-type=""bibr""><sup>74</sup></xref> Currently, the standard-of-care treatment for pre-symptomatic infants with KD is HSCT.<xref rid=""bib75"" ref-type=""bibr""><sup>75</sup></xref> HSCT can utilize either bone marrow transplantation (BMT) or umbilical cord blood transplantation (UCBT). BMT was first found to increase survival in TWI from PND40 to PND80 days in 1984 but it resulted in only a minor increase in GALC activity and a",20_46,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"in only a minor increase in GALC activity and a small decrease in psychosine accumulation within the brain.<xref rid=""bib49"" ref-type=""bibr""><sup>49</sup></xref><sup>,</sup><xref rid=""bib76"" ref-type=""bibr""><sup>76</sup></xref><sup>,</sup><xref rid=""bib77"" ref-type=""bibr""><sup>77</sup></xref> In addition to providing a source of GALC enzyme, it is thought that BMT may also play a role in reducing neuroinflammation, as shown by a significant reduction in astrogliosis and microgliosis.<xref rid=""bib78""",20_47,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"astrogliosis and microgliosis.<xref rid=""bib78"" ref-type=""bibr""><sup>78</sup></xref> BMT was first attempted in infantile- and juvenile-onset patients in 1998.<xref rid=""bib79"" ref-type=""bibr""><sup>79</sup></xref> BMT attenuated KD pathology in the juvenile-onset patients and significantly slowed the development of symptoms in infantile KD. BMT increased leukocyte GALC activity from a nearly undetectable level to approximately 3 nmol/h/mg protein (normal: >0.8 nmol/h/mg protein) within a few months of the",20_48,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"protein) within a few months of the treatment.<xref rid=""bib31"" ref-type=""bibr""><sup>31</sup></xref><sup>,</sup><xref rid=""bib79"" ref-type=""bibr""><sup>79</sup></xref> This effect was sustained for at least 3 years. Additionally, BMT reduced abnormal signal intensity on magnetic resonance imaging (MRI), indicating improved myelination.<xref rid=""bib79"" ref-type=""bibr""><sup>79</sup></xref> A subsequent study of UCBT for infantile KD examined 11 pre-symptomatic patients and 14 symptomatic patients. All",20_49,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"patients and 14 symptomatic patients. All pre-symptomatic patients and six of the 14 symptomatic patients were alive at the end of a 3-year follow-up period with a median survival of 30 months for symptomatic patients, compared with untreated early infantile KD patients with a median survival of 13–18 months.<xref rid=""bib80"" ref-type=""bibr""><sup>80</sup></xref><sup>,</sup><xref rid=""bib81"" ref-type=""bibr""><sup>81</sup></xref> UCBT had little effect on symptomatic patients. UCBT delayed the development of",20_50,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"patients. UCBT delayed the development of many standard KD symptoms in the pre-symptomatic treatment group, such that they had improved vision, cognitive skills, and peripheral nerve conduction, compared with untreated KD children. Most of the pre-symptomatic treatment group patients displayed improved language skills and gross motor skills, and ∼50% showed normal hearing.<xref rid=""bib82"" ref-type=""bibr""><sup>82</sup></xref> Long-term follow-up of 16 UCBT and two BMT early infantile KD patients treated",20_51,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"and two BMT early infantile KD patients treated prior to symptom onset showed that 13 were alive after a 15-year follow-up period with a median survival of 11 years. All patients had normalized leukocyte GALC activity ranging from 1.1–4.4 nmol/h/mg (pre-transplant levels ranged from 0–0.12 nmol/h/mg). The majority showed stable MRI findings, approximately average language skills, could walk with assistance, and slightly below-average cognitive development. However, many exhibited symptoms, including",20_52,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"However, many exhibited symptoms, including spasticity, eating difficulties, vision impairment, as well as bone and joint involvement.<xref rid=""bib75"" ref-type=""bibr""><sup>75</sup></xref> These studies show that, while HSCT provides a significant benefit to infants compared with untreated KD patients, it has limitations in preventing disease progression. While HSCT provides significant benefit for KD patients, it is associated with both acute and chronic complications that pose a risk to patients.",20_53,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"complications that pose a risk to patients. Patients must complete an immunosuppression regime for graft-versus-host disease (GVHD) prophylaxis prior to the procedure. Acute and chronic GVHD are associated with potential life-threatening complications. HSCT graft failure leads to minimal effectiveness and symptoms comparable with those of untreated KD.<xref rid=""bib75"" ref-type=""bibr""><sup>75</sup></xref><sup>,</sup><xref rid=""bib79"" ref-type=""bibr""><sup>79</sup></xref><sup>,</sup><xref rid=""bib82""",20_54,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"rid=""bib82"" ref-type=""bibr""><sup>82</sup></xref> Altogether, while HSCT is not a cure for KD, it increases survival and improves quality of life for patients, but it has the potential for procedure-related complications such as GVHD. HSCT has also been performed in other LSDs with varied levels of success. One of the most successful cases, in addition to KD, is metachromatic leukodystrophy (MLD). MLD is a demyelinating disorder similar to KD caused by mutations in arylsulfatase A (ARSA). Similar to the",20_55,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"in arylsulfatase A (ARSA). Similar to the therapeutic effect observed in KD, HSCT attenuates clinical symptoms and extends median lifespan of treated MLD patients into teenage years.<xref rid=""bib83"" ref-type=""bibr""><sup>83</sup></xref> Additionally, HSCT is the standard-of-care treatment for mucopolysaccharidosis-1 (MPS1). MPS1 is an LSD caused by mutations in the <italic toggle=""yes"">IDUA</italic> gene, which is responsible for making the α-L-iduronidase enzyme. HSCT slows MPS1 progression and",20_56,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"enzyme. HSCT slows MPS1 progression and significantly extends life expectancy beyond untreated patients.<xref rid=""bib84"" ref-type=""bibr""><sup>84</sup></xref><sup>,</sup><xref rid=""bib85"" ref-type=""bibr""><sup>85</sup></xref> Given the therapeutic efficacy of HSCT for KD and other LSDs, combined with the minimal number of currently available safe and effective treatments, HSCT will likely continue to be the standard of care for many of these diseases. As mentioned previously, HSCT is most successful when",20_57,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"previously, HSCT is most successful when performed prior to development of symptoms.<xref rid=""bib82"" ref-type=""bibr""><sup>82</sup></xref> Furthermore, HSCT has the highest chances of ameliorating KD symptoms when performed as early as possible.<xref rid=""bib86"" ref-type=""bibr""><sup>86</sup></xref> These time constraints make treatment more complicated because they necessitate the ability to identify KD patients as early as possible. Historically, patients were diagnosed with KD either through symptom",20_58,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"were diagnosed with KD either through symptom development, and thus would not benefit from HSCT, or family history.<xref rid=""bib75"" ref-type=""bibr""><sup>75</sup></xref><sup>,</sup><xref rid=""bib79"" ref-type=""bibr""><sup>79</sup></xref><sup>,</sup><xref rid=""bib82"" ref-type=""bibr""><sup>82</sup></xref> One potential way of solving this issue is through NBS programs. New York State was the first state to start testing newborns for KD in 2006; since then, seven more states have added KD to their NBS testing",20_59,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"more states have added KD to their NBS testing panel. Additionally, KD is currently undergoing evidence review to be added to the Recommended Uniform Screening Panel (RUSP), which would recommend every state add KD to their NBS testing panel.<xref rid=""bib5"" ref-type=""bibr""><sup>5</sup></xref><sup>,</sup><xref rid=""bib87"" ref-type=""bibr""><sup>87</sup></xref> NBS programs take dried blood spot (DBS) samples from infants in the first days of life and then analyze them for indications of a given disease. In",20_60,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"them for indications of a given disease. In the case of KD, the exact tests performed on the samples vary by state, but the most common first-tier test examines GALC activity. Babies that display low GALC activity are then moved onto second-tier testing, which again varies by state but is usually <italic toggle=""yes"">galc</italic> genotyping or psychosine quantification. The families are notified at this point and the diagnosis is then confirmed with additional testing, such as MRI and nerve conduction",20_61,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"testing, such as MRI and nerve conduction tests.<xref rid=""bib4"" ref-type=""bibr""><sup>4</sup></xref><sup>,</sup><xref rid=""bib5"" ref-type=""bibr""><sup>5</sup></xref><sup>,</sup><xref rid=""bib87"" ref-type=""bibr""><sup>87</sup></xref> It should be noted that the outcomes of the first KD patients identified through NBS in New York were mixed due to a multitude of factors, such as second-tier testing taking too long and patients not being promptly referred to specialty transplant centers. In the first 9 years,",20_62,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"transplant centers. In the first 9 years, five infants were diagnosed with KD and four underwent HSCT. Of these four patients, one is overall doing well with some motor deficits, one has severe disabilities (received HSCT at 2 months), and two died due to transplant-related complications.<xref rid=""bib5"" ref-type=""bibr""><sup>5</sup></xref><sup>,</sup><xref rid=""bib86"" ref-type=""bibr""><sup>86</sup></xref> Given these results, new protocols have been put in place to expedite second-tier testing and have",20_63,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"in place to expedite second-tier testing and have confirmed cases transferred to transplant centers as fast as possible. The current goal of NBS programs is to have the results back by the seventh day of life. The infant should then be moved to a specialty center for confirmation of the KD diagnosis. Finally, the infant is referred to a transplant center for final evaluations and to have the procedure performed. The goal is to have the transplant completed by the 30<sup>th</sup> day of life to ensure the",20_64,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"by the 30<sup>th</sup> day of life to ensure the highest probability of success.<xref rid=""bib86"" ref-type=""bibr""><sup>86</sup></xref> Many different therapies have been attempted for KD over the years. A notable, but not exhaustive, list includes stem cell transplantation, substrate reduction therapy (SRT), ERT, anti-inflammatory therapy, chaperone therapy, gene therapy, and various combination investigative therapies.<xref rid=""bib49"" ref-type=""bibr""><sup>49</sup></xref><sup>,</sup><xref rid=""bib50""",20_65,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"rid=""bib50"" ref-type=""bibr""><sup>50</sup></xref><sup>,</sup><xref rid=""bib51"" ref-type=""bibr""><sup>51</sup></xref><sup>,</sup><xref rid=""bib53"" ref-type=""bibr""><sup>53</sup></xref><sup>,</sup><xref rid=""bib54"" ref-type=""bibr""><sup>54</sup></xref><sup>,</sup><xref rid=""bib57"" ref-type=""bibr""><sup>57</sup></xref><sup>,</sup><xref rid=""bib62"" ref-type=""bibr""><sup>62</sup></xref><sup>,</sup><xref rid=""bib78"" ref-type=""bibr""><sup>78</sup></xref><sup>,</sup><xref rid=""bib88""",20_66,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"rid=""bib88"" ref-type=""bibr""><sup>88</sup></xref><sup>,</sup><xref rid=""bib89"" ref-type=""bibr""><sup>89</sup></xref><sup>,</sup><xref rid=""bib90"" ref-type=""bibr""><sup>90</sup></xref><sup>,</sup><xref rid=""bib91"" ref-type=""bibr""><sup>91</sup></xref><sup>,</sup><xref rid=""bib92"" ref-type=""bibr""><sup>92</sup></xref><sup>,</sup><xref rid=""bib93"" ref-type=""bibr""><sup>93</sup></xref><sup>,</sup><xref rid=""bib94"" ref-type=""bibr""><sup>94</sup></xref><sup>,</sup><xref rid=""bib95""",20_67,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"rid=""bib95"" ref-type=""bibr""><sup>95</sup></xref><sup>,</sup><xref rid=""bib96"" ref-type=""bibr""><sup>96</sup></xref><sup>,</sup><xref rid=""bib97"" ref-type=""bibr""><sup>97</sup></xref><sup>,</sup><xref rid=""bib98"" ref-type=""bibr""><sup>98</sup></xref><sup>,</sup><xref rid=""bib99"" ref-type=""bibr""><sup>99</sup></xref><sup>,</sup><xref rid=""bib100"" ref-type=""bibr""><sup>100</sup></xref> The effects of these investigative therapies on TWI survival, GALC activity, psychosine levels, phenotypic changes, and histologic",20_68,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"levels, phenotypic changes, and histologic changes are outlined in <xref rid=""tbl1"" ref-type=""table"">Table 1</xref> (single-modality treatment) and <xref rid=""tbl2"" ref-type=""table"">Table 2</xref> (combination treatments).<table-wrap position=""float"" id=""tbl1""><label>Table 1</label><caption><p>Single-modality investigative therapies in TWI</p></caption><table frame=""hsides"" rules=""groups""><thead><tr><th>Therapy</th><th>Median survival increase (days)</th><th>Brain G and P</th><th>Phenotypic",20_69,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"(days)</th><th>Brain G and P</th><th>Phenotypic change</th><th>Pathology</th></tr></thead><tbody><tr><td>1 × 10<sup>7</sup> HSC i.p. on PND10 <xref rid=""bib49"" ref-type=""bibr""><sup>49</sup></xref></td><td>40</td><td>NA</td><td>slight delay in motor problems</td><td>no change</td></tr><tr><td>4 × 10<sup>5</sup> HSC i.p. on PND10 <xref rid=""bib77"" ref-type=""bibr""><sup>77</sup></xref></td><td>10</td><td>increased G to 15% WT</td><td>improved weight gain</td><td>NA</td></tr><tr><td>75 mg/kg LCS SQ every other",20_70,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"LCS SQ every other day starting PND5 <xref rid=""bib50"" ref-type=""bibr""><sup>50</sup></xref></td><td>13</td><td>NA</td><td>delayed weight loss 2 weeks</td><td>decreased GC and AC<break></break>no change in M</td></tr><tr><td>1.9 × 10<sup>7</sup> vg Adenovirus-GALC i.c.v. on PND0 <xref rid=""bib97"" ref-type=""bibr""><sup>97</sup></xref></td><td>3</td><td>increased G to 15% WT<break></break>decreased P by 45%</td><td>delayed Twitching 3 days.<break></break>improved weight gain 30%</td><td>no",20_71,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"weight gain 30%</td><td>no change</td></tr><tr><td>6 mg/kg GALC i.p. <xref rid=""bib51"" ref-type=""bibr""><sup>51</sup></xref>every other day starting PND10</td><td>7</td><td>increased G to 7% WT<break></break>decreased P by 20%</td><td>improved weight gain and mobility</td><td>no change</td></tr><tr><td>2.6 × 10<sup>9</sup> vg AAV2-GALC i.c. or 1.4 × 10<sup>10</sup> vg AAV5-GALC i.c. on PND3 <xref rid=""bib98"" ref-type=""bibr""><sup>98</sup></xref></td><td>AAV2: 10<break></break>AAV5:",20_72,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"10<break></break>AAV5: 14</td><td>NA</td><td>improved weight gain and rotarod</td><td>decreased MP and improved M</td></tr><tr><td>1.2 × 10<sup>11</sup> vg AAV1-GALC i.c.v. on PND1 <xref rid=""bib101"" ref-type=""bibr""><sup>101</sup></xref></td><td>15</td><td>increased G to 5× WT</td><td>NA</td><td>normalized M, reduced MP, and reduced AC</td></tr><tr><td>1 × 10<sup>8</sup> vg lentivirus-GALC i.v. or i.p. on PND7. <xref rid=""bib102"" ref-type=""bibr""><sup>102</sup></xref></td><td>0</td><td>increased G to 10%",20_73,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"G to 10% WT</td><td>no change</td><td>no change</td></tr><tr><td>Single GALC injection i.c.v. on PND20 <xref rid=""bib103"" ref-type=""bibr""><sup>103</sup></xref></td><td>10</td><td>increased G to 5× WT<break></break>decreased P but 17%</td><td>NA</td><td>NA</td></tr><tr><td>Anti-inflammatory therapy <xref rid=""bib92"" ref-type=""bibr""><sup>92</sup></xref>∗</td><td>5–15</td><td>NA</td><td>NA</td><td>reduced inflammatory markers 30–50%</td></tr><tr><td>GALC-expressing neural progenitors i.c. on PND2 <xref",20_74,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"neural progenitors i.c. on PND2 <xref rid=""bib88"" ref-type=""bibr""><sup>88</sup></xref></td><td>7</td><td>qualitatively increased G</td><td>delayed tremor and hindlimb paralysis 5 days<break></break>Improved weight</td><td>reduced GC and AC<break></break>Improved M</td></tr><tr><td>2.4 × 10<sup>9</sup> vg AAV5-GALC i.c. on PND3 <xref rid=""bib104"" ref-type=""bibr""><sup>104</sup></xref></td><td>22</td><td>increased G to 4× WT<break></break>Decreased P by 50%</td><td>delayed muscle atrophy",20_75,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"P by 50%</td><td>delayed muscle atrophy 2 weeks<break></break>Improved weight gain</td><td>improved M</td></tr><tr><td>7.5 × 10<sup>5</sup> NSC i.c.v. on PND2 <xref rid=""bib89"" ref-type=""bibr""><sup>89</sup></xref></td><td>5</td><td>increased G to 33% WT</td><td>improved gait</td><td>reduced GC, MP, MG, and AC. Improved myelination</td></tr><tr><td>4 × 10<sup>5</sup> MSC i.c.v. on PND3.5 <xref rid=""bib90"" ref-type=""bibr""><sup>90</sup></xref></td><td>5</td><td>no change in G</td><td>increased weight",20_76,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"change in G</td><td>increased weight gain</td><td>decreased MP and MG</td></tr><tr><td>4 × 10<sup>5</sup> MSC i.c. on PND3.5 <xref rid=""bib105"" ref-type=""bibr""><sup>105</sup></xref></td><td>0</td><td>NA</td><td>improved rotarod performance</td><td>NA</td></tr><tr><td>2 × 10<sup>10</sup> vg i.t. + 1.6 × 10<sup>10</sup> vg i.c. AAV5-GALC on PND2.5 <xref rid=""bib106"" ref-type=""bibr""><sup>106</sup></xref></td><td>30</td><td>increased G to 5× WT</td><td>improved rotarod performance, moderately improved weight",20_77,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"rotarod performance, moderately improved weight gain, reduced tremor, and no effect on wire hang</td><td>increased CD4 and CD8 T cells and decreased AC</td></tr><tr><td>4.5 × 10<sup>9</sup> vg i.c. + 7.6e9 vg i.v. AAVrh10-GALC on PND2<xref rid=""bib99"" ref-type=""bibr""><sup>99</sup></xref></td><td>64</td><td>increased G to 4× WT</td><td>normalized motor ability</td><td>normal M<break></break>reduced GC</td></tr><tr><td>0.15 mg/kg S202 i.p. 3×/week <xref rid=""bib91""",20_78,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"S202 i.p. 3×/week <xref rid=""bib91"" ref-type=""bibr""><sup>91</sup></xref></td><td>20</td><td>decreased P by 85%</td><td>no effect on weight gain</td><td>normalized M. nonsignificant decrease in MP and AC</td></tr><tr><td>1 × 10<sup>11</sup> vg AAVhu68-GALC i.c.v. on PND0 <xref rid=""bib107"" ref-type=""bibr""><sup>107</sup></xref></td><td>90</td><td>increased G to 2,1× WT</td><td>improved rotarod performance</td><td>NA</td></tr><tr><td>∼2 × 10<sup>12</sup> vg AAVrh10 -GALC i.v. on PND10",20_79,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"vg AAVrh10 -GALC i.v. on PND10 (4 × 10<sup>14</sup>vg/kg) <xref rid=""bib108"" ref-type=""bibr""><sup>108</sup></xref></td><td>240</td><td>increased G to ∼3.4× WT</td><td>normalized weight gain, wire hang, and gait</td><td>normalized MP and AC</td></tr></tbody></table><table-wrap-foot><fn><p>HSC, hematopoetic stem cells; i.p., intraperitoneal; LCS, L-cycloserine; SQ, subcutaneous; vg, viral genomes; i.c.v, intracerebroventricular; i.c., intracerebral; MSC, mesenchymal stem cells; i.t., intrathecal; GC, globoid",20_80,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"stem cells; i.t., intrathecal; GC, globoid cells; AC, astrocytes; M, myelin; MP, macrophages; MG, microglia; NSC, neural stem cell; G, GALC activity; P, psychosine; NA, not available. ∗Study done on trs mice, not TWI.</p></fn></table-wrap-foot></table-wrap><table-wrap position=""float"" id=""tbl2""><label>Table 2</label><caption><p>Combination investigative therapies in TWI.</p></caption><table frame=""hsides"" rules=""groups""><thead><tr><th>Therapy</th><th>Median survival increase (days)</th><th>Effect on brain",20_81,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"survival increase (days)</th><th>Effect on brain G and P</th><th>Phenotypic improvement</th><th>Pathology</th></tr></thead><tbody><tr><td>HSCT PND10-20 and SQ 50 mg/kg LCS <xref rid=""bib54"" ref-type=""bibr""><sup>54</sup></xref></td><td>85</td><td>NA</td><td>improved weight gain</td><td>decreased GC and AC</td></tr><tr><td>1.4 × 10<sup>10</sup> vg AAV5-GALC i.c. and BMT on PND3 <xref rid=""bib100"" ref-type=""bibr""><sup>100</sup></xref></td><td>65</td><td>increased G to 4× WT</td><td>delayed motor",20_82,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"G to 4× WT</td><td>delayed motor problems<break></break>increased weight</td><td>reduced MP, AC, and GC<break></break>normalized M</td></tr><tr><td>BMT and 1 × 10<sup>7</sup> vg lentivirus-GALC i.v. on PND1.5 <xref rid=""bib109"" ref-type=""bibr""><sup>109</sup></xref></td><td>35</td><td>increased G to 33% of WT<break></break>reduced P</td><td>NA</td><td>reduced GC and improved M</td></tr><tr><td>BMT on PND3.5 and 2 × 10<sup>10</sup> vg i.t. + 1.6 × 10<sup>10</sup> vg i.c. AAV5-GALC on PND2.5 <xref",20_83,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"vg i.c. AAV5-GALC on PND2.5 <xref rid=""bib106"" ref-type=""bibr""><sup>106</sup></xref></td><td>82</td><td>increased G to 1.5× WT<break></break>reduced P by 66%</td><td>mostly normalized motor problems<break></break>increased weight</td><td>Decreased CD4, CD8, and MG</td></tr><tr><td>5.33 ug i.t. + 1.6 ug i.c.v. GALC on PND2 and BMT i.v. on PND3 <xref rid=""bib78"" ref-type=""bibr""><sup>78</sup></xref></td><td>19</td><td>G increased to 2× WT at 24 h but decreased over time<break></break>reduced P by",20_84,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"decreased over time<break></break>reduced P by 90%</td><td>delayed motor problems 10 days</td><td>moderate normalization of M</td></tr><tr><td>2 × 10<sup>10</sup> vg i.t. +1.5 × 10<sup>9</sup> vg i.c. AAV5-GALC on PND2<break></break>BMT on PND3<break></break>25–50 mg/kg LCS 3/week starting PND5 <xref rid=""bib110"" ref-type=""bibr""><sup>110</sup></xref></td><td>250</td><td>increased G to 6× WT but decreased to 2× over time<break></break>reduced P to WT level</td><td>delayed motor problems",20_85,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"P to WT level</td><td>delayed motor problems 15 weeks</td><td>initially normalized M but multifocal demyelination later<break></break>GC, AC, and MG reduced at p35 but elevated later</td></tr><tr><td>BMT on PND 9.5 and 2 × 10<sup>11</sup> vg AAV9-GALC i.t. on PND10.5 <xref rid=""bib56"" ref-type=""bibr""><sup>56</sup></xref></td><td>39</td><td>NA</td><td>NA</td><td>near normalization of M</td></tr><tr><td>BMT on p8/9 and 2 × 10<sup>11</sup> vg AAVrh10-GALC i.v. on PND10-12 <xref rid=""bib111""",20_86,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"AAVrh10-GALC i.v. on PND10-12 <xref rid=""bib111"" ref-type=""bibr""><sup>111</sup></xref></td><td>300</td><td>increased G to WT but declined over time</td><td>normalized gait<break></break>increased weight</td><td>normalized M<break></break>decreased AC and MG</td></tr><tr><td>2 × 10<sup>6</sup> vg lentivirus-GALC i.c. or 4 × 10<sup>5</sup> NSC i.c.v. on p2 and 5 × 10<sup><sup>6</sup></sup>BMT on PND7 <xref rid=""bib112"" ref-type=""bibr""><sup>112</sup></xref></td><td>LV + BMT: 102<break></break>NSC + BMT:",20_87,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"BMT: 102<break></break>NSC + BMT: 173</td><td>increased G to 30% WT<break></break>reduced P</td><td>increased weight</td><td>partially restored M<break></break>AC initially reduced by increased over time</td></tr><tr><td>9 × 10<sup>9</sup> vg i.c. + 8.25 × 10<sup>10</sup> vg i.t. + 3.3 × 10<sup>11</sup> vg i.v. AAV9-GALC on PND0 and BMT on PND1 <xref rid=""bib53"" ref-type=""bibr""><sup>53</sup></xref></td><td>241</td><td>increased G to 14× WT but decline over time<break></break>reduced P to WT level but",20_88,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"over time<break></break>reduced P to WT level but increased over time</td><td>delayed motor problems 20 weeks<break></break>increased weight</td><td>M normalized but focal demyelination later<break></break>reduced AC and MG</td></tr><tr><td>1.5 × 10<sup>11</sup> vg i.t. + 6 × 10<sup>10</sup> vg i.c. AAV9-GALC on PND0<break></break>BMT on PND1<break></break>25–50 mg/kg LCS 3×/week <xref rid=""bib57"" ref-type=""bibr""><sup>57</sup></xref></td><td>363</td><td>increased G to WT<break></break>normalized",20_89,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"G to WT<break></break>normalized P</td><td>normalized motor ability<break></break>increased weight</td><td>decreased MG but increased over time</td></tr><tr><td>2 × 10<sup>11</sup> vg AAVrh10-GALC i.v. on PND10<break></break>BMT on PND10 <xref rid=""bib108"" ref-type=""bibr""><sup>108</sup></xref></td><td>311</td><td>increased G to WT level</td><td>NA</td><td>NA</td></tr></tbody></table><table-wrap-foot><fn><p>LCS, L-cycloserine; SQ, subcutaneous; vg, viral genomes; i.c., intracerebral; i.v., intraventricular;",20_90,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"i.c., intracerebral; i.v., intraventricular; i.t., intrathecal; i.c.v., intracerebroventricular; NSC, neural stem cells; GC, globoid cells; AC, astrocytes; M, myelin; MG, microglia; G, GALC activity; P, psychosine; NA, not available.</p></fn></table-wrap-foot></table-wrap> One of the most important early findings from these investigations was that GALC overexpression can lead to secretion and uptake of GALC by neighboring cells; this phenomenon is known as cross-correction. Cross-correction was first",20_91,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"as cross-correction. Cross-correction was first demonstrated in 1968 when cultured fibroblasts from Hurler and Hunter disease patients were shown to attenuate the biochemical defect in the other cells when mixed together. The same held true when either Hurler or Hunter disease fibroblasts were mixed with fibroblasts from healthy patients.<xref rid=""bib113"" ref-type=""bibr""><sup>113</sup></xref> This phenomenon was then demonstrated specifically for KD after TWI nerves were grafted into healthy animals; this",20_92,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"nerves were grafted into healthy animals; this led to a reduction in pathology over time.<xref rid=""bib114"" ref-type=""bibr""><sup>114</sup></xref> It was then shown that, when GALC-overexpressing cells secreted GALC into media, neighboring cells endocytosed the secreted enzyme.<xref rid=""bib115"" ref-type=""bibr""><sup>115</sup></xref><sup>,</sup><xref rid=""bib116"" ref-type=""bibr""><sup>116</sup></xref> Finally, TWI oligodendrocyte precursor cells (OPCs) were transplanted into myelin basic protein",20_93,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"were transplanted into myelin basic protein (MBP)-deficient shiverer mice, where they migrated away from the injection site, matured into oligodendrocytes, and synthesized nearly normal levels of myelin. These transplanted TWI oligodendrocytes were shown to have functional GALC, likely endocytosed from their neighboring GALC-expressing cells.<xref rid=""bib117"" ref-type=""bibr""><sup>117</sup></xref> This was an important finding because it reinforced the concept that therapies do not need to reach every cell",20_94,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"that therapies do not need to reach every cell in the body to be effective; GALC could naturally redistribute to many cells not directly targeted by the therapy. SRT typically utilizes a small-molecule drug to inhibit the enzyme responsible for synthesis of the accumulating substrate, thus slowing the accumulation of that substrate. Up until recently, SRT for KD has primarily focused on the use of L-cycloserine, an inhibitor of serine palmitoyltransferase (previously called 3-ketodyhydrosphingosine",20_95,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"(previously called 3-ketodyhydrosphingosine synthetase/synthase), the first enzyme in the synthetic pathway of many ceramides and sphingolipids.<xref rid=""bib118"" ref-type=""bibr""><sup>118</sup></xref><sup>,</sup><xref rid=""bib119"" ref-type=""bibr""><sup>119</sup></xref><sup>,</sup><xref rid=""bib120"" ref-type=""bibr""><sup>120</sup></xref> Repeated subcutaneous injections of L-cycloserine increased median survival in TWI by 13 days, increased body weight, reduced the number of globoid cells, and decreased",20_96,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"the number of globoid cells, and decreased astrogliosis.<xref rid=""bib50"" ref-type=""bibr""><sup>50</sup></xref><sup>,</sup><xref rid=""bib54"" ref-type=""bibr""><sup>54</sup></xref> Unfortunately, L-cycloserine has a narrow therapeutic window since it leads to a reduction of many other critical lipids in addition to psychosine.<xref rid=""bib118"" ref-type=""bibr""><sup>118</sup></xref><sup>,</sup><xref rid=""bib119"" ref-type=""bibr""><sup>119</sup></xref> Recently developed SRT drugs target enzymes that are more",20_97,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"developed SRT drugs target enzymes that are more proximal to psychosine synthesis, such as ceramide galactosyltransferase (CGT) or acid ceramidase, in an attempt to limit off-target effects.<xref rid=""bib91"" ref-type=""bibr""><sup>91</sup></xref><sup>,</sup><xref rid=""bib121"" ref-type=""bibr""><sup>121</sup></xref> Intraperitoneal (i.p.) injections of the CGT inhibitor S202 in TWI increased median survival ∼20 days and improved body weight. Furthermore, S202 reduced psychosine by >70% and normalized",20_98,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"S202 reduced psychosine by >70% and normalized myelination when used at >0.15mg/kg. However, long-term treatment with such doses of S202 led to worsened nerve conduction velocity, poor performance on wire hang, and vacuolation in the CNS of WT mice. These side effects, which may be caused by collateral effects of CGT inhibition on the production of sulfatides and accumulation of ceramides, appear to be dose dependent.<xref rid=""bib91"" ref-type=""bibr""><sup>91</sup></xref> Another new SRT drug, 22m, inhibits",20_99,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"Another new SRT drug, 22m, inhibits acid ceramidase and has shown potential in reducing psychosine both <italic toggle=""yes"">in vitro</italic> and <italic toggle=""yes"">in vivo</italic>.<xref rid=""bib121"" ref-type=""bibr""><sup>121</sup></xref> An important observation from these studies is that the level of toxicity appears to correlate with the inhibitor dose. This suggests that an appropriate dose might provide treatment conditions where side effects are minimal or negligent, while still exerting",20_100,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"are minimal or negligent, while still exerting therapeutic effects on psychosine production. SRT has been investigated for a number of other LSDs.<xref rid=""bib122"" ref-type=""bibr""><sup>122</sup></xref> As with KD, finding drugs that are effective but have minimal side effects has been difficult because many of the drugs target early steps within synthetic pathways. Additionally, drug discovery for CNS disorders is further complicated by finding drugs that will cross the blood-brain barrier (BBB).<xref",20_101,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"will cross the blood-brain barrier (BBB).<xref rid=""bib123"" ref-type=""bibr""><sup>123</sup></xref> Miglustat was the first SRT drug approved in humans for type 1 Gaucher disease (GD). Miglustat improved bone density, increased hemoglobin levels, and reduced liver and spleen volume.<xref rid=""bib124"" ref-type=""bibr""><sup>124</sup></xref><sup>,</sup><xref rid=""bib125"" ref-type=""bibr""><sup>125</sup></xref><sup>,</sup><xref rid=""bib126"" ref-type=""bibr""><sup>126</sup></xref><sup>,</sup><xref rid=""bib127""",20_102,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"rid=""bib127"" ref-type=""bibr""><sup>127</sup></xref><sup>,</sup><xref rid=""bib128"" ref-type=""bibr""><sup>128</sup></xref><sup>,</sup><xref rid=""bib129"" ref-type=""bibr""><sup>129</sup></xref> Miglustat’s success in treating GD led to investigators using it to treat other LSDs with defects in common biochemical pathways, such as Niemann-Pick C (NPC). Miglustat treatment of NPC patients led to an improvement in multiple symptoms of NPC, such as supranuclear gaze palsy and dysphagia.<xref rid=""bib123""",20_103,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"gaze palsy and dysphagia.<xref rid=""bib123"" ref-type=""bibr""><sup>123</sup></xref><sup>,</sup><xref rid=""bib130"" ref-type=""bibr""><sup>130</sup></xref> Eliglustat was later found to be superior to miglustat in treating GD and is now a first-line therapy.<xref rid=""bib131"" ref-type=""bibr""><sup>131</sup></xref> Two new drugs, venglustat and lucerastat, are currently being investigated predominately for the treatment of GD and Fabry disease.<xref rid=""bib132""",20_104,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"of GD and Fabry disease.<xref rid=""bib132"" ref-type=""bibr""><sup>132</sup></xref><sup>,</sup><xref rid=""bib133"" ref-type=""bibr""><sup>133</sup></xref> Looking forward, SRT has the potential to treat many LSDs, especially as new, more specific drugs are discovered.<xref rid=""bib91"" ref-type=""bibr""><sup>91</sup></xref><sup>,</sup><xref rid=""bib121"" ref-type=""bibr""><sup>121</sup></xref> ERT involves supplementing the defective enzyme using externally synthesized replacement enzyme. ERT using recombinant GALC",20_105,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"replacement enzyme. ERT using recombinant GALC delivered via i.p. injections every other day increased median survival in TWI by ∼10 days. There was a minimal reduction of psychosine within the brain, suggesting that GALC cannot cross the BBB.<xref rid=""bib51"" ref-type=""bibr""><sup>51</sup></xref> Although a negative result, it was still an important finding since it showed that any successful therapy will need to be administered directly to the CNS or utilize technology to cross the BBB. Single dose",20_106,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"utilize technology to cross the BBB. Single dose intracerebroventricular (i.c.v.) administration of GALC enzyme increased TWI median survival by ∼10 days. The minimal effectiveness of ERT is likely due to rapid enzyme turnover as shown by there being no detectable enzyme at a terminal time point.<xref rid=""bib103"" ref-type=""bibr""><sup>103</sup></xref> KD patients would almost certainly require continuous GALC injections directly into the CNS for the duration of their life for ERT to work effectively. This",20_107,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"of their life for ERT to work effectively. This severely limits the applicability of CNS-directed, ERT-based treatment for KD. ERT has been attempted with varying levels of success in many other LSDs. Historically, as with KD, the replacement enzyme has not been able to sufficiently enter the CNS to significantly alter disease pathology or symptom development.<xref rid=""bib1"" ref-type=""bibr""><sup>1</sup></xref><sup>,</sup><xref rid=""bib125"" ref-type=""bibr""><sup>125</sup></xref><sup>,</sup><xref",20_108,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"rid=""bib131"" ref-type=""bibr""><sup>131</sup></xref><sup>,</sup><xref rid=""bib134"" ref-type=""bibr""><sup>134</sup></xref> ERT has been recommended mostly for non-neuropathic LSDs such as type 1 GD and Pompe disease; however, repeated i.c.v. administration of tripeptidyl peptidase 1 (TPP1) was recently approved for the treatment of CLN2 disease.<xref rid=""bib125"" ref-type=""bibr""><sup>125</sup></xref><sup>,</sup><xref rid=""bib135"" ref-type=""bibr""><sup>135</sup></xref><sup>,</sup><xref rid=""bib136""",20_109,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"rid=""bib136"" ref-type=""bibr""><sup>136</sup></xref><sup>,</sup><xref rid=""bib137"" ref-type=""bibr""><sup>137</sup></xref> For type 1 GD, long-term ERT normalized height, RBC counts, and bone density as well as reducing hepatosplenomegaly.<xref rid=""bib138"" ref-type=""bibr""><sup>138</sup></xref> One method that has been attempted to circumvent the BBB is administering the replacement enzyme intrathecally (i.t.) or i.c.v. In the past, this treatment route has exhibited limited efficacy. For example, a clinical",20_110,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"limited efficacy. For example, a clinical trial (<ext-link ext-link-type=""ClinicalTrials.gov"" http://www.w3.org/1999/xlink href=""NCT01510028"" id=""intref0030"">NCT01510028</ext-link>) using repeated i.t. administered ARSA to treat MLD only showed slightly reduced disease symptoms and sulfatide accumulation.<xref rid=""bib139"" ref-type=""bibr""><sup>139</sup></xref> More recently, there have been a few developments to improve ERT for CNS disorders. One system fuses the enzyme to antibodies targeting endogenous",20_111,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"the enzyme to antibodies targeting endogenous proteins (e.g., leptin, insulin, and transferrin) expressed in the lumen of brain capillary endothelial cells. Then, the enzyme-antibody-protein construct is taken into the endothelial cell via endocytosis. Finally, the enzyme-antibody-protein construct is exocytosed on the brain parenchyma side of the capillary. This process is known as transcytosis.<xref rid=""bib140"" ref-type=""bibr""><sup>140</sup></xref><sup>,</sup><xref rid=""bib141""",20_112,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"rid=""bib141"" ref-type=""bibr""><sup>141</sup></xref><sup>,</sup><xref rid=""bib142"" ref-type=""bibr""><sup>142</sup></xref><sup>,</sup><xref rid=""bib143"" ref-type=""bibr""><sup>143</sup></xref><sup>,</sup><xref rid=""bib144"" ref-type=""bibr""><sup>144</sup></xref><sup>,</sup><xref rid=""bib145"" ref-type=""bibr""><sup>145</sup></xref> An antibody-enzyme fusion protein, JR-141, containing the transferrin receptor antibody and iduronate-2-sulftase was developed to treat MPS2. Following intravenous (i.v.) administration of",20_113,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"Following intravenous (i.v.) administration of JR-141 in a MPS2 mouse model, JR-141 was detected within the brain and was shown to decrease the accumulation of glycosaminoglycans.<xref rid=""bib146"" ref-type=""bibr""><sup>146</sup></xref> Additionally, following the success of implantable CNS injection devices for ERT delivery in the canine model of neuronal ceroid lipofuscinosis (CLN2), a clinical trial indicated it significantly delayed symptom development, which led to its US Food and Drug Administration",20_114,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"which led to its US Food and Drug Administration (FDA) approval.<xref rid=""bib136"" ref-type=""bibr""><sup>136</sup></xref><sup>,</sup><xref rid=""bib137"" ref-type=""bibr""><sup>137</sup></xref><sup>,</sup><xref rid=""bib147"" ref-type=""bibr""><sup>147</sup></xref> Implantable CNS injection devices have existed for some time, but using them for ERT has been limited due to the frequent injections, as often as every 2 weeks, and long injection time required for ERT. The frequent injections and long injection time",20_115,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"The frequent injections and long injection time significantly increase the risks of adverse events such as infection. However, a recent study developed guidelines that significantly reduced the risk of these adverse events.<xref rid=""bib137"" ref-type=""bibr""><sup>137</sup></xref><sup>,</sup><xref rid=""bib148"" ref-type=""bibr""><sup>148</sup></xref> Given these recent advances in ERT for CNS LSDs, ERT could be an important component of their treatment in the future. As a monogenic loss-of-function disorder, KD",20_116,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"As a monogenic loss-of-function disorder, KD is an ideal candidate for gene therapy. A variety of viruses have been investigated for use in treating KD, including adenovirus, lentivirus, and AAV.<xref rid=""bib53"" ref-type=""bibr""><sup>53</sup></xref><sup>,</sup><xref rid=""bib55"" ref-type=""bibr""><sup>55</sup></xref><sup>,</sup><xref rid=""bib57"" ref-type=""bibr""><sup>57</sup></xref><sup>,</sup><xref rid=""bib58"" ref-type=""bibr""><sup>58</sup></xref><sup>,</sup><xref rid=""bib97""",20_117,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"rid=""bib97"" ref-type=""bibr""><sup>97</sup></xref><sup>,</sup><xref rid=""bib98"" ref-type=""bibr""><sup>98</sup></xref><sup>,</sup><xref rid=""bib102"" ref-type=""bibr""><sup>102</sup></xref><sup>,</sup><xref rid=""bib108"" ref-type=""bibr""><sup>108</sup></xref> To date, AAV appears to be the most promising viral vector for KD gene therapy.<xref rid=""bib53"" ref-type=""bibr""><sup>53</sup></xref><sup>,</sup><xref rid=""bib57"" ref-type=""bibr""><sup>57</sup></xref><sup>,</sup><xref rid=""bib58""",20_118,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"rid=""bib58"" ref-type=""bibr""><sup>58</sup></xref><sup>,</sup><xref rid=""bib108"" ref-type=""bibr""><sup>108</sup></xref> The AAV capsid determines its cellular tropism and is, therefore, an important factor in therapy efficacy.<xref rid=""bib149"" ref-type=""bibr""><sup>149</sup></xref><sup>,</sup><xref rid=""bib150"" ref-type=""bibr""><sup>150</sup></xref><sup>,</sup><xref rid=""bib151"" ref-type=""bibr""><sup>151</sup></xref><sup>,</sup><xref rid=""bib152"" ref-type=""bibr""><sup>152</sup></xref><sup>,</sup><xref",20_119,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"rid=""bib153"" ref-type=""bibr""><sup>153</sup></xref> Naturally occurring AAVs generally have a broad tropism but often still have a bias toward one specific cell type, with neuronal bias being the most common within the CNS.<xref rid=""bib154"" ref-type=""bibr""><sup>154</sup></xref><sup>,</sup><xref rid=""bib155"" ref-type=""bibr""><sup>155</sup></xref><sup>,</sup><xref rid=""bib156"" ref-type=""bibr""><sup>156</sup></xref> Each AAV’s tropism varies depending on administration route, target species, age of infusion,",20_120,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"route, target species, age of infusion, and purification methods.<xref rid=""bib154"" ref-type=""bibr""><sup>154</sup></xref><sup>,</sup><xref rid=""bib157"" ref-type=""bibr""><sup>157</sup></xref><sup>,</sup><xref rid=""bib158"" ref-type=""bibr""><sup>158</sup></xref> CNS-directed, AAV-mediated gene therapy using vectors pseudotyped with either the AAV5 or AAV1 capsids carrying a <italic toggle=""yes"">galc</italic> transgene, initiated during the neonatal period, increased the median survival of TWI by",20_121,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"period, increased the median survival of TWI by 10–15 days.<xref rid=""bib98"" ref-type=""bibr""><sup>98</sup></xref><sup>,</sup><xref rid=""bib101"" ref-type=""bibr""><sup>101</sup></xref> Addition of i.t. injections in conjunction with the intracerebral (i.c.) route further increased median survival by another ∼15 days.<xref rid=""bib106"" ref-type=""bibr""><sup>106</sup></xref> The greatest increase in lifespan, median survival of 280 days of age, in TWI attributed solely to AAV-mediated gene therapy was observed",20_122,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"solely to AAV-mediated gene therapy was observed following high-dose i.v. AAVrh10. This approach significantly increased GALC activity in both the brain and sciatic nerve, reduced neuroinflammation, improved weight gain, increased strength, and normalized gait.<xref rid=""bib108"" ref-type=""bibr""><sup>108</sup></xref> A study investigating gene therapy in the canine model of KD administered AAVrh10-GALC i.v. and i.c.v. at 3 days and 6 weeks, respectively. The therapy had a clear dose response and resulted in",20_123,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"therapy had a clear dose response and resulted in increased GALC activity, reduced psychosine, and improved myelination. However, correction was not complete, likely due to the treatment dosage being too low.<xref rid=""bib52"" ref-type=""bibr""><sup>52</sup></xref> A subsequent report from the same laboratory completed a dose-response study of AAV9-GALC delivered by intracisternal injection at pre-symptomatic (2 weeks) and post-symptomatic (6 weeks) time points. The second study found that delivery of",20_124,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"points. The second study found that delivery of high-dose AAV9-GALC extended survival over seven times that of untreated canines and corrected neurological dysfunction as shown by attenuated loss of myelin and significantly reduced psychosine.<xref rid=""bib58"" ref-type=""bibr""><sup>58</sup></xref> Gene therapy has also been investigated in many other LSDs; see Ohashi et al. 2019 for a review focusing on this topic.<xref rid=""bib159"" ref-type=""bibr""><sup>159</sup></xref> Like KD, many LSDs have shown",20_125,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"Like KD, many LSDs have shown significant improvements in median survival and disease pathology in animal models following gene therapy and are now moving into clinical trials. For example, a mouse model of GM1 gangliosidosis, displayed near-complete correction of the β-galactosidase (βgal) deficiency following therapy with an AAV2 vector administered i.c.v.<xref rid=""bib160"" ref-type=""bibr""><sup>160</sup></xref> Treating the GM1 gangliosidosis mouse model with an AAV9 vector administered i.v. increased",20_126,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"with an AAV9 vector administered i.v. increased βgal, significantly reduced GM1, improved behavioral performance on multiple assays, and increased median survival by 150 days.<xref rid=""bib161"" ref-type=""bibr""><sup>161</sup></xref> A similar therapeutic approach of i.v. AAV9 was used to treat a feline model of GM1 gangliosidosis. This treatment decreased GM1, nearly normalized βgal, reduced pathology, partially normalized myelination, and increased survival by almost 3 years.<xref rid=""bib162""",20_127,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"survival by almost 3 years.<xref rid=""bib162"" ref-type=""bibr""><sup>162</sup></xref> These results led to a phase 1/2 clinical trial using an AAV9 vector to treat GM1 gangliosidosis (<ext-link ext-link-type=""ClinicalTrials.gov"" http://www.w3.org/1999/xlink href=""NCT03952637"" id=""intref0035"">NCT03952637</ext-link>). Any information that is gained from this and other clinical trials investigating AAV therapy for LSDs, such as which AAV serotype, treatment route, or dosing strategies are most efficacious, will",20_128,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"or dosing strategies are most efficacious, will be immensely useful for future LSD studies and clinical trials. For a more complete list of AAV-based gene therapy trials for LSDs currently underway, see <ext-link ext-link-type=""uri"" http://www.w3.org/1999/xlink href=""http://clinicaltrials.gov"" id=""intref0040"">clinicaltrials.gov</ext-link>. Although each single-modality therapy has different targets and provides moderate benefit, they also each have their own limitations. The most promising therapies are",20_129,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"own limitations. The most promising therapies are those that employed combinations of previously discussed treatments.<xref rid=""bib53"" ref-type=""bibr""><sup>53</sup></xref><sup>,</sup><xref rid=""bib57"" ref-type=""bibr""><sup>57</sup></xref><sup>,</sup><xref rid=""bib106"" ref-type=""bibr""><sup>106</sup></xref><sup>,</sup><xref rid=""bib108"" ref-type=""bibr""><sup>108</sup></xref><sup>,</sup><xref rid=""bib110"" ref-type=""bibr""><sup>110</sup></xref> The first combination therapy attempted in TWI utilized BMT and",20_130,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"therapy attempted in TWI utilized BMT and L-cycloserine-mediated SRT. These therapies had a synergistic effect such that they increased median survival to 110 days, more than either achieved in isolation.<xref rid=""bib54"" ref-type=""bibr""><sup>54</sup></xref> Similarly, combining BMT with i.c. AAV5-GALC increased median survival to 100 days and improved motor function.<xref rid=""bib100"" ref-type=""bibr""><sup>100</sup></xref> Addition of an i.t. injection of AAV5-GALC further increased median survival an",20_131,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"of AAV5-GALC further increased median survival an additional 25 days. This treatment protocol also increased GALC activity to five times WT levels in the brain and reduced psychosine to nearly WT levels in the brain and spinal cord. However, there were limited improvements in the wire hang assay, which may indicate this combination therapy did not adequately treat the PNS.<xref rid=""bib100"" ref-type=""bibr""><sup>100</sup></xref><sup>,</sup><xref rid=""bib106"" ref-type=""bibr""><sup>106</sup></xref> Combining",20_132,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"ref-type=""bibr""><sup>106</sup></xref> Combining neonatal administrations of i.v., i.t., and i.c. AAV9-GALC with BMT increased median survival to 285 days. Additionally, the mice showed decreased signs of disease: increased body weight, improved locomotion, and improved performance on neurobehavioral tests. The mice exhibited improved myelination and supraphysiological GALC activity, and decreased psychosine accumulation.<xref rid=""bib53"" ref-type=""bibr""><sup>53</sup></xref> Another AAV + BMT study",20_133,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"Another AAV + BMT study administered the treatments later, BMT at PND8.5 and i.v. AAVrh10-GALC at PND11. This study found that the later treatment schedule led to better outcomes, including increasing median survival to 340 days, no tremor, normalized gait, improved weight, and near-normalized myelination.<xref rid=""bib111"" ref-type=""bibr""><sup>111</sup></xref> The later dosing schedule may also better model the age of KD children when they should receive AAV therapy; they are currently treated with HSCT",20_134,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"AAV therapy; they are currently treated with HSCT around 1 month old and potentially would be treated with AAV around the same time.<xref rid=""bib86"" ref-type=""bibr""><sup>86</sup></xref> A triple therapy combining i.c. and i.t. AAV5, BMT, and L-cycloserine SRT increased the median survival to 290 days. This approach increased GALC activity to 3.5 times WT, reduced psychosine to nearly WT levels, reduced neuroinflammation, and effectively preserved myelin. To highlight the synergistic efficacy of SRT, this",20_135,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"highlight the synergistic efficacy of SRT, this study was able to achieve a similar median survival increase as an AAV + BMT-only study using 100-fold less AAV.<xref rid=""bib110"" ref-type=""bibr""><sup>110</sup></xref><sup>,</sup><xref rid=""bib111"" ref-type=""bibr""><sup>111</sup></xref> A follow-up study of the triple therapy that changed the AAV capsid from AAV5 to AAV9 further increased median survival to 404 days.<xref rid=""bib57"" ref-type=""bibr""><sup>57</sup></xref> Looking forward, future combination",20_136,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"Looking forward, future combination therapies utilizing newer SRT drugs, more effective AAV vectors, and improved HSCT protocols may further increase survival and reduce pathology due to improved specificity.<xref rid=""bib91"" ref-type=""bibr""><sup>91</sup></xref><sup>,</sup><xref rid=""bib121"" ref-type=""bibr""><sup>121</sup></xref> As with KD, combination therapies for other LSDs have been shown to be synergistic in reducing disease pathology and increasing median survival.<xref rid=""bib163""",20_137,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"and increasing median survival.<xref rid=""bib163"" ref-type=""bibr""><sup>163</sup></xref><sup>,</sup><xref rid=""bib164"" ref-type=""bibr""><sup>164</sup></xref><sup>,</sup><xref rid=""bib165"" ref-type=""bibr""><sup>165</sup></xref><sup>,</sup><xref rid=""bib166"" ref-type=""bibr""><sup>166</sup></xref> Most of the combination therapies investigated for KD have also been studied in other LSDs, such as ERT + BMT, BMT + gene therapy, and SRT + BMT.<xref rid=""bib163"" ref-type=""bibr""><sup>163</sup></xref><sup>,</sup><xref",20_138,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"rid=""bib165"" ref-type=""bibr""><sup>165</sup></xref><sup>,</sup><xref rid=""bib166"" ref-type=""bibr""><sup>166</sup></xref> These therapies had varying levels of success, but, like combination therapies for KD, they invariably were additive, and most showed some level of synergy. One previously discussed example, Eliglustat-based SRT, has already been shown to synergize with other treatment modalities in preclinical investigations.<xref rid=""bib54"" ref-type=""bibr""><sup>54</sup></xref><sup>,</sup><xref",20_139,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"rid=""bib57"" ref-type=""bibr""><sup>57</sup></xref><sup>,</sup><xref rid=""bib110"" ref-type=""bibr""><sup>110</sup></xref><sup>,</sup><xref rid=""bib167"" ref-type=""bibr""><sup>167</sup></xref> This indicates that SRT can be used in combination with other treatment modalities, such as HSCT and gene therapy, to treat LSD patients. Combination therapies allow for each treatment to address the weaknesses of the other treatment to ensure more complete therapeutic coverage.<xref rid=""bib164""",20_140,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"complete therapeutic coverage.<xref rid=""bib164"" ref-type=""bibr""><sup>164</sup></xref> As mentioned previously, each AAV serotype has a unique tropism based on the capsid.<xref rid=""bib149"" ref-type=""bibr""><sup>149</sup></xref><sup>,</sup><xref rid=""bib150"" ref-type=""bibr""><sup>150</sup></xref><sup>,</sup><xref rid=""bib151"" ref-type=""bibr""><sup>151</sup></xref><sup>,</sup><xref rid=""bib152"" ref-type=""bibr""><sup>152</sup></xref><sup>,</sup><xref rid=""bib153""",20_141,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"rid=""bib153"" ref-type=""bibr""><sup>153</sup></xref><sup>,</sup><xref rid=""bib154"" ref-type=""bibr""><sup>154</sup></xref><sup>,</sup><xref rid=""bib155"" ref-type=""bibr""><sup>155</sup></xref><sup>,</sup><xref rid=""bib156"" ref-type=""bibr""><sup>156</sup></xref> There has been a significant amount of research into engineering AAV capsids for specific purposes, whether that be targeting specific cell types, detargeting off-target cell types, or increasing penetration through the BBB as reviewed in von Jonquieres",20_142,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"through the BBB as reviewed in von Jonquieres et al. 2021.<xref rid=""bib154"" ref-type=""bibr""><sup>154</sup></xref> One particularly relevant novel AAV capsid for KD and other LSDs that predominately affect oligodendrocytes is Olig001, which preferentially targets oligodendrocytes.<xref rid=""bib203"" ref-type=""bibr""><sup>203</sup></xref> This could potentially allow utilization of a lower total dose of AAV since a higher proportion of the virus will transduce oligodendrocytes. Alternatively, a",20_143,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"will transduce oligodendrocytes. Alternatively, a neuron-specific AAV could be used to increase transduction of neurons in LSDs that primarily affect neurons.<xref rid=""bib149"" ref-type=""bibr""><sup>149</sup></xref><sup>,</sup><xref rid=""bib150"" ref-type=""bibr""><sup>150</sup></xref><sup>,</sup><xref rid=""bib151"" ref-type=""bibr""><sup>151</sup></xref><sup>,</sup><xref rid=""bib152"" ref-type=""bibr""><sup>152</sup></xref><sup>,</sup><xref rid=""bib153"" ref-type=""bibr""><sup>153</sup></xref><sup>,</sup><xref",20_144,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"rid=""bib154"" ref-type=""bibr""><sup>154</sup></xref><sup>,</sup><xref rid=""bib155"" ref-type=""bibr""><sup>155</sup></xref><sup>,</sup><xref rid=""bib156"" ref-type=""bibr""><sup>156</sup></xref><sup>,</sup><xref rid=""bib158"" ref-type=""bibr""><sup>158</sup></xref> Additionally, transgene expression can be controlled using cell-specific promoters.<xref rid=""bib154"" ref-type=""bibr""><sup>154</sup></xref> For example, the MBP promoter has been used to limit transgene expression to oligodendrocytes.<xref rid=""bib204""",20_145,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"expression to oligodendrocytes.<xref rid=""bib204"" ref-type=""bibr""><sup>204</sup></xref> Using engineered cell-specific capsids in conjunction with cell-specific promoters allows for precise targeting of transgene expression with minimal off-target effects. All of the information acquired on KD genetics, pathology, and investigative therapies in the past 35 years have provided the foundation of two current trials. <ext-link ext-link-type=""ClinicalTrials.gov"" http://www.w3.org/1999/xlink href=""NCT04771416""",20_146,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"http://www.w3.org/1999/xlink href=""NCT04771416"" id=""intref0045"">NCT04771416</ext-link> is examining the efficacy of AAVhu68 (modified AAV9) administered into the cisterna magna and has already treated the first patient. This trial is based on work showing that the i.c.v. AAVhu68 increased median survival in TWI 3-fold, increased brain GALC activity to 200% WT, and improved rotarod latency to fall. Additionally, AAVhu68 was tested in the KD canine model; treated animals did not display any of the classical",20_147,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"animals did not display any of the classical signs of disease throughout their lives. Furthermore, the canines displayed partially normalized myelination, normal auditory evoked potential, and reduced neuroinflammation. Finally, safety and tolerability of AAVhu68 was tested in non-human primates and found to be well tolerated.<xref rid=""bib107"" ref-type=""bibr""><sup>107</sup></xref>",20_148,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"<ext-link ext-link-type=""ClinicalTrials.gov"" http://www.w3.org/1999/xlink href=""NCT04693598"" id=""intref0050"">NCT04693598</ext-link> is studying HSCT combined with AAVrh10 administered i.v. based on preclinical studies discussed earlier.<xref rid=""bib108"" ref-type=""bibr""><sup>108</sup></xref><sup>,</sup><xref rid=""bib111"" ref-type=""bibr""><sup>111</sup></xref> Since these clinical trials were only recently initiated, there are no data regarding efficacy yet. Whatever information is acquired from these trials",20_149,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"information is acquired from these trials will help not only KD patients but also those suffering from other LSDs as well by guiding the design of future clinical trials. In addition to these KD studies, there are currently ongoing AAV-based clinical trials for numerous LSDs such as GD, MLD, and GM1 gangliosidosis, as seen on <ext-link ext-link-type=""uri"" http://www.w3.org/1999/xlink href=""http://clinicaltrials.gov"" id=""intref0055"">clinicaltrials.gov</ext-link>.",20_150,Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases,04 1 2023,,Krabbe_Disease
"Galactosylceramidase deficiency and pathological abnormalities in cerebral white matter of Krabbe disease Krabbe Disease (KD) is an autosomal recessive disorder that results from loss-of-function mutations in the <italic toggle=""yes"">GALC</italic> gene, which encodes lysosomal enzyme galactosylceramidase (GALC). Functional deficiency of GALC is toxic to myelin-producing cells, which leads to progressive demyelination in both the central and peripheral nervous systems. It is hypothesized that accumulation of",21_0,Galactosylceramidase deficiency and pathological abnormalities in cerebral white matter of Krabbe disease,4 8 2023,,Krabbe_Disease
"systems. It is hypothesized that accumulation of psychosine, which can only be degraded by GALC, is a primary initiator of pathologic cascades. Despite the central role of GALC in KD pathomechanism, investigations of GALC deficiency at a protein level are largely absent, due in part, to the lack of sensitive antibodies in the field. Leveraging two custom antibodies that can detect GALC at endogenous levels, we demonstrated that GALC protein is predominantly localized to oligodendrocytes in cerebral white",21_1,Galactosylceramidase deficiency and pathological abnormalities in cerebral white matter of Krabbe disease,4 8 2023,,Krabbe_Disease
"localized to oligodendrocytes in cerebral white matter of an infant brain, consistent with its functional role in myelination. Mature GALC could also be quantitatively detected as a 26 kDa band by western blotting and correlated to enzyme activity in brain tissues. The p.Ile562Thr polymorphic variant, which is over-represented in the KD population, was associated with reduced mature GALC protein and activity. In three infantile KD cases, homozygous null mutations in <italic toggle=""yes"">GALC</italic> lead",21_2,Galactosylceramidase deficiency and pathological abnormalities in cerebral white matter of Krabbe disease,4 8 2023,,Krabbe_Disease
"in <italic toggle=""yes"">GALC</italic> lead to deficiency in total GALC protein and activity. Interestingly, although GALC activity was absent, normal levels of total GALC protein were detected by a sandwich ELISA using our custom antibodies in a later-onset KD brain, which suggests that the assay has the potential to differentiate infantile- and later-onset KD cases. Among the infantile KD cases, we quantified a 5-fold increase in psychosine levels, and observed increased levels of acid ceramidase, a key",21_3,Galactosylceramidase deficiency and pathological abnormalities in cerebral white matter of Krabbe disease,4 8 2023,,Krabbe_Disease
"increased levels of acid ceramidase, a key enzyme for psychosine production, and hyperglycosylated lysosomal-associated membrane protein 1, a marker for lysosomal activation, in periventricular white matter, a major pathological brain region, when compared with age-matched normal controls. While near complete demyelination was observed in these cases, we quantified that an early-infantile case (age of death at 10 months) had about 3-fold increases in both globoid cells, a pathological hallmark for KD, and",21_4,Galactosylceramidase deficiency and pathological abnormalities in cerebral white matter of Krabbe disease,4 8 2023,,Krabbe_Disease
"cells, a pathological hallmark for KD, and CD8-positive T lymphocytes, a pathological marker for multiple sclerosis, in the white matter when compared with a slower progressing infantile case (age of death at 21 months), which suggests a positive correlation between clinical severity and neuropathology. Taken together, our findings have advanced the understanding of GALC protein biology in the context of normal and KD brain white matter. We also revealed new neuropathological changes that may provide",21_5,Galactosylceramidase deficiency and pathological abnormalities in cerebral white matter of Krabbe disease,4 8 2023,,Krabbe_Disease
"new neuropathological changes that may provide insights to understand KD pathogenesis. Globoid cell leukodystrophy or Krabbe disease (KD) (OMIM 245200) is an inherited demyelinating disorder caused by a deficiency of galactosylceramidase (GALC; EC 3.2.1.46), which leads to the accumulation of its substrates galactosylceramide (GalCer) and galactosylsphingosine (also known as psychosine) in myelin-producing cells (<xref rid=""R47"" ref-type=""bibr"">Wenger et al., 2019</xref>). Given that GalCer is readily",21_6,Galactosylceramidase deficiency and pathological abnormalities in cerebral white matter of Krabbe disease,4 8 2023,,Krabbe_Disease
"al., 2019</xref>). Given that GalCer is readily converted into psychosine via enzymatic diacylation by acid ceramidase (ASAH1) (<xref rid=""R19"" ref-type=""bibr"">Li et al., 2019</xref>) and GalCer is abundantly produced during the active myelination phase of early brain development, the loss of GALC activity is thought to lead to toxic accumulation of psychosine, as well as dysfunction and death of oligodendrocytes and Schwann cells. This results in demyelination in both central and peripheral nervous",21_7,Galactosylceramidase deficiency and pathological abnormalities in cerebral white matter of Krabbe disease,4 8 2023,,Krabbe_Disease
"in both central and peripheral nervous systems in KD (<xref rid=""R13"" ref-type=""bibr"">Igisu and Suzuki, 1984</xref>; <xref rid=""R23"" ref-type=""bibr"">Miyatake and Suzuki, 1972</xref>; <xref rid=""R40"" ref-type=""bibr"">Svennerholm et al., 1980</xref>). Despite the central role of GALC in KD pathomechanism, investigations of GALC deficiency at a protein level are largely absent, due in part, to the lack of sensitive antibodies. Although several classifications have been proposed for KD (<xref rid=""R6""",21_8,Galactosylceramidase deficiency and pathological abnormalities in cerebral white matter of Krabbe disease,4 8 2023,,Krabbe_Disease
"have been proposed for KD (<xref rid=""R6"" ref-type=""bibr"">Duffner et al., 2011</xref>; <xref rid=""R45"" ref-type=""bibr"">Wenger et al., 1997</xref>), it can be divided into two subtypes based on the age at symptom onset (<xref rid=""R26"" ref-type=""bibr"">Orsini et al., 2000</xref>). Infantile KD (before 12 months) is the most common and fatal form of the disease, which clinically presents with irritability, feeding difficulties, loss of vision and hearing, and seizures after a few months of normal development.",21_9,Galactosylceramidase deficiency and pathological abnormalities in cerebral white matter of Krabbe disease,4 8 2023,,Krabbe_Disease
"after a few months of normal development. Later-onset KD (after 12 months) usually has a better prognosis, and its clinical presentations vary. Genetically, KD is caused by homozygous or compound heterozygous mutations in the human <italic toggle=""yes"">GALC</italic> gene (<xref rid=""R41"" ref-type=""bibr"">Tappino et al., 2010</xref>; <xref rid=""R45"" ref-type=""bibr"">Wenger et al., 1997</xref>), which lead to a dramatic reduction or complete deficit of GALC protein function. Null mutations eliminate normal",21_10,Galactosylceramidase deficiency and pathological abnormalities in cerebral white matter of Krabbe disease,4 8 2023,,Krabbe_Disease
"protein function. Null mutations eliminate normal <italic toggle=""yes"">GALC</italic> transcripts and all functional GALC protein. By contrast, missense mutations impair GALC function through mechanisms such as protein instability, misfolding, mis-trafficking and catalytic inactivation (<xref rid=""R4"" ref-type=""bibr"">Deane et al., 2011</xref>). Patients carrying the homozygous null mutation, such as a 30 kb deletion in the <italic toggle=""yes"">GALC</italic> gene, common in those of European descent (<xref",21_11,Galactosylceramidase deficiency and pathological abnormalities in cerebral white matter of Krabbe disease,4 8 2023,,Krabbe_Disease
"gene, common in those of European descent (<xref rid=""R21"" ref-type=""bibr"">Luzi et al., 1995</xref>; <xref rid=""R31"" ref-type=""bibr"">Rafi et al., 1995</xref>), are likely to develop infantile KD; while those with at least one allele, such as p.Gly286Asp mutation (<xref rid=""R8"" ref-type=""bibr"">Furuya et al., 1997</xref>), develop later-onset KD. In general, symptomatic KD patients have ≤10% of normal GALC activity as measured in dried blood spots, leukocytes or cultured skin fibroblasts (<xref rid=""R27""",21_12,Galactosylceramidase deficiency and pathological abnormalities in cerebral white matter of Krabbe disease,4 8 2023,,Krabbe_Disease
"or cultured skin fibroblasts (<xref rid=""R27"" ref-type=""bibr"">Orsini et al., 2016</xref>; <xref rid=""R45"" ref-type=""bibr"">Wenger et al., 1997</xref>). While GALC activity provides a critical index for KD diagnosis, it has also been shown to produce a relatively high false-positive rate in newborn screening. Moreover, GALC activities measured in leukocytes or fibroblasts cannot always differentiate between infantile KD and later-onset KD (<xref rid=""R48"" ref-type=""bibr"">Wenger et al., 2021</xref>).",21_13,Galactosylceramidase deficiency and pathological abnormalities in cerebral white matter of Krabbe disease,4 8 2023,,Krabbe_Disease
"ref-type=""bibr"">Wenger et al., 2021</xref>). Diagnostic tests that include measurement of psychosine levels provide a more robust index of lysosomal GALC activity (<xref rid=""R11"" ref-type=""bibr"">Guenzel et al., 2020</xref>; <xref rid=""R16"" ref-type=""bibr"">Langan et al., 2019</xref>). Understanding the relationship between KD genotype and GALC deficiency, psychosine accumulation, demyelination, globoid cell pathology and neuroinflammation is an important step in understanding pathogenesis of KD and",21_14,Galactosylceramidase deficiency and pathological abnormalities in cerebral white matter of Krabbe disease,4 8 2023,,Krabbe_Disease
"step in understanding pathogenesis of KD and eventual treatment for KD. Unfortunately, there are only a few studies that link the genetic, biochemical and neuropathological features in KD. In this study, we provide a comprehensive analyses of postmortem brain samples from infantile-KD and later-onset KD compared with age- and sex-matched normal controls.   We performed comprehensive biochemical and histopathologic analyses of postmortem brain tissues from KD with different degrees of pathologic severity.",21_15,Galactosylceramidase deficiency and pathological abnormalities in cerebral white matter of Krabbe disease,4 8 2023,,Krabbe_Disease
"KD with different degrees of pathologic severity. To our knowledge, this is the first study that examines GALC deficiency in KD compared with age-matched normal brains with respect to genetics, protein levels, enzyme activity and histology methods. As expected, we found that KD with homozygous null mutation, such as the 30 kb deletion, results in loss of GALC protein expression, with barely background levels of total GALC and Lys-GALC proteins, as well as minimal GALC activity in brain homogenates.",21_16,Galactosylceramidase deficiency and pathological abnormalities in cerebral white matter of Krabbe disease,4 8 2023,,Krabbe_Disease
"as minimal GALC activity in brain homogenates. Although no KD-related mutation was identified on one allele of case #5, the baseline total GALC protein levels strongly suggests that this patient is a homozygous null mutation carrier. On the other hand, the later-onset KD (case #8) carried a heterozygous missense mutation variant (MMV) (p.Met117Leu) that drives expression of about half GALC protein levels despite the lack of significant differences in GALC activity compared with other infantile KD. These",21_17,Galactosylceramidase deficiency and pathological abnormalities in cerebral white matter of Krabbe disease,4 8 2023,,Krabbe_Disease
"activity compared with other infantile KD. These two examples demonstrate that GALC protein ELISA provides an additional method to differentiate homozygous null-<italic toggle=""yes"">GALC</italic> mutations from <italic toggle=""yes"">GALC</italic>-MMV genotype, which separates infantile and later-onset KD. Given the time needed for molecular analysis of <italic toggle=""yes"">GALC</italic> and limited coverage of coding regions with DNA sequencing, GALC protein measurement by ELISA can hasten determination a",21_18,Galactosylceramidase deficiency and pathological abnormalities in cerebral white matter of Krabbe disease,4 8 2023,,Krabbe_Disease
"measurement by ELISA can hasten determination a clinical diagnosis. One of the important findings of genetics of KD is the role of the p. Ile562Thr pseudo-deficiency variant in <italic toggle=""yes"">GALC</italic>. It was estimated that 64% to 77% of later-onset KD patients have at least one copy of the variant in cis with a KD-related mutation (<xref rid=""R5"" ref-type=""bibr"">Debs et al., 2013</xref>). Among 348 infants in a referral group from the New York Newborn Screening program, who had equal or <12% of",21_19,Galactosylceramidase deficiency and pathological abnormalities in cerebral white matter of Krabbe disease,4 8 2023,,Krabbe_Disease
"Screening program, who had equal or <12% of control GALC activity, the carrier frequency was determined to be 87% (<xref rid=""R27"" ref-type=""bibr"">Orsini et al., 2016</xref>). Mechanistically, the inheritance of this polymorphic background on a KD-MMV allele attenuates GALC activity, leading to decreased activity sufficient to surpass the threshold needed to drive disease onset (<xref rid=""R46"" ref-type=""bibr"">Wenger et al., 2014</xref>). For example, the p.Ile562Thr background was found to reduce GALC",21_20,Galactosylceramidase deficiency and pathological abnormalities in cerebral white matter of Krabbe disease,4 8 2023,,Krabbe_Disease
"p.Ile562Thr background was found to reduce GALC activity, lysosomal localization and Lys-GALC protein levels in the p. Tyr567Ser variant when expressed in HEK293 cells (<xref rid=""R35"" ref-type=""bibr"">Shin et al., 2016</xref>). The p.Ile562Thr polymorphic background was also shown to severely reduce secretion and lysosomal localization of GALC protein in carriers of the p.Gly286Asp variant when expressed in Hela cells (<xref rid=""R38"" ref-type=""bibr"">Spratley et al., 2016</xref>). In the current study, we",21_21,Galactosylceramidase deficiency and pathological abnormalities in cerebral white matter of Krabbe disease,4 8 2023,,Krabbe_Disease
"et al., 2016</xref>). In the current study, we confirmed a gene dose-dependent effect of the p.Ile562Thr variant in brain tissue. Control cases carrying two copies of the p.Ile562Thr variant (cases #1 and #4) had significantly less Lys-GALC protein and GALC activity in brain homogenates compared to controls carrying only one copy of the variant. Given the prevalence of the p.Ile562Thr polymorphism in KD and the likelihood that this variant impairs GALC function through effects on protein misfolding,",21_22,Galactosylceramidase deficiency and pathological abnormalities in cerebral white matter of Krabbe disease,4 8 2023,,Krabbe_Disease
"function through effects on protein misfolding, development of therapeutic targets, such as pharmacological chaperones that stabilize protein is a potential direction for drug discovery in KD patients carrying the p.Ile562Thr variant. The case with later-onset KD (case #8) was a Polish patient who had progressive spastic quadriparesis. He was diagnosed with later-onset KD at 13 years of age, and he died at 40 years of age (<xref rid=""R10"" ref-type=""bibr"">Grewal et al., 1991</xref>; <xref rid=""R15""",21_23,Galactosylceramidase deficiency and pathological abnormalities in cerebral white matter of Krabbe disease,4 8 2023,,Krabbe_Disease
"et al., 1991</xref>; <xref rid=""R15"" ref-type=""bibr"">Kolodny et al., 1991</xref>). GALC variant expression was studied in COS7 cells to determine the effect of p.Met117Leu and p.Ile562Thr genotype on GALC activity (<xref rid=""R3"" ref-type=""bibr"">De Gasperi et al., 1996</xref>). The p.Met117Leu and p. Ile562Thr genotype reduced GALC activity by 90%. In the current study, we detected a comparable 94% reduction in GALC activity in brain homogenates of case #8 compared with an age-matched control (case #4).",21_24,Galactosylceramidase deficiency and pathological abnormalities in cerebral white matter of Krabbe disease,4 8 2023,,Krabbe_Disease
"compared with an age-matched control (case #4). The fact that we were unable to distinguish later-onset KD from infantile KD by GALC activity in brain homogenates is consistent with previous observations in clinical samples, such as leukocytes and skin fibroblasts (<xref rid=""R15"" ref-type=""bibr"">Kolodny et al., 1991</xref>; <xref rid=""R44"" ref-type=""bibr"">Wenger et al., 1974</xref>; <xref rid=""R51"" ref-type=""bibr"">Young et al., 1972</xref>). The failure to distinguish cases with different clinical",21_25,Galactosylceramidase deficiency and pathological abnormalities in cerebral white matter of Krabbe disease,4 8 2023,,Krabbe_Disease
"to distinguish cases with different clinical phenotypes may be due to limitations of analysis of postmortem tissue samples. As mentioned, GALC protein is highly enriched in oligodendrocytes, which are greatly decreased in end-stage KD brains. Heterogeneity of surviving cell populations in autopsy samples may increase variability in GALC activity. Analysis of non-KD control brain tissues showed age-dependent increases in psychosine in PVWM. Psychosine levels were increased from 8 to 50 pmol/mg protein in",21_26,Galactosylceramidase deficiency and pathological abnormalities in cerebral white matter of Krabbe disease,4 8 2023,,Krabbe_Disease
"were increased from 8 to 50 pmol/mg protein in samples with 0.6 and 1.6 years of age. This indicates a 6-fold increase in psychosine during the neonatal period. Consistent with our finding, a similar observation on age-related psychosine increase in white matter was reported in a neuropsychiatric brain cohort between 25 and 68 years of age (<xref rid=""R22"" ref-type=""bibr"">Marshall et al., 2018</xref>). Three KD brain samples (cases #5, #7, #8) had psychosine levels in the range of 150 to 176 pmol/mg",21_27,Galactosylceramidase deficiency and pathological abnormalities in cerebral white matter of Krabbe disease,4 8 2023,,Krabbe_Disease
"levels in the range of 150 to 176 pmol/mg despite differences in age of death. Severity-dependent increases in psychosine levels of 22×, 3.3× and 1.1× (from severe to mild) was observed when normalized to age-matched controls. Given age-dependent increases in psychosine levels in neonates, it is critical to use age-matched controls in measuring psychosine in KD. In addition to psychosine accumulation, biochemical abnormalities, including increased ASAH1 and hyperglycosylated LAMP1 protein levels, were",21_28,Galactosylceramidase deficiency and pathological abnormalities in cerebral white matter of Krabbe disease,4 8 2023,,Krabbe_Disease
"and hyperglycosylated LAMP1 protein levels, were detected in infantile KD. These increases are likely related to neuroinflammatory response since oligodendrocytes were virtually absent in end-stage KD. Consistent with this notion, hyperglycosylated LAMP1 was localizes mostly in activated microglia of a NPC1-knockout mouse model (<xref rid=""R2"" ref-type=""bibr"">Cawley et al., 2020</xref>). ASAH1 is a lysosomal cysteine amidase that converts ceramide to sphingosine and its metabolite sphingosine 1-phosphate",21_29,Galactosylceramidase deficiency and pathological abnormalities in cerebral white matter of Krabbe disease,4 8 2023,,Krabbe_Disease
"and its metabolite sphingosine 1-phosphate (<xref rid=""R29"" ref-type=""bibr"">Parveen et al., 2019</xref>). Deficiency in ASAH1 induces ceramide accumulation, which is a major cause of Farber disease (<xref rid=""R39"" ref-type=""bibr"">Sugita et al., 1972</xref>). In the context of KD, ASAH1 was recently demonstrated to be a key driver of psychosine accumulation, in part due to the abundance of its substrate, galactosylceramide. Genetic ablation of ASAH1 partially rescues the phenotype of the twitcher mouse",21_30,Galactosylceramidase deficiency and pathological abnormalities in cerebral white matter of Krabbe disease,4 8 2023,,Krabbe_Disease
"rescues the phenotype of the twitcher mouse model of KD (<xref rid=""R19"" ref-type=""bibr"">Li et al., 2019</xref>). Here we showed that ASAH1 levels were increased in infantile KD and were mostly expressed in immune cells. It is unclear how psychosine accumulation in immune cells contributes to KD pathogenesis and if ASAH1 drives psychosine accumulation in oligodendrocytes. As more is known about the role of ASAH1 in KD, it will be important to understand the mechanism and extent to which it drives",21_31,Galactosylceramidase deficiency and pathological abnormalities in cerebral white matter of Krabbe disease,4 8 2023,,Krabbe_Disease
"the mechanism and extent to which it drives progression of KD. KD is also known as globoid cell leukodystrophy and is characterized by severe demyelination in central and peripheral nervous systems. Neuroinflammation plays a key role in the pathogenesis of KD. Globoid cells are multinucleated macrophages characterized by accumulation of lipid. We found that astrogliosis paralleled globoid cells accumulation and microgliosis, which were found prior to demyelination. How neuroinflammation contributes to",21_32,Galactosylceramidase deficiency and pathological abnormalities in cerebral white matter of Krabbe disease,4 8 2023,,Krabbe_Disease
"How neuroinflammation contributes to demyelination in KD is unclear. Recently, studies of Schwann cell targeting mice (floxed GALC knockout mice) indicate that normal macrophages attenuate disease by facilitating phagocytosis, but that GALC deficient macrophages promote disease through an inflammatory mechanism (<xref rid=""R43"" ref-type=""bibr"">Weinstock et al., 2020</xref>). Suppression of astrogliosis by blocking prostaglandin D2 alleviated oligo-dendroglial apoptosis, demyelination and spasticity in",21_33,Galactosylceramidase deficiency and pathological abnormalities in cerebral white matter of Krabbe disease,4 8 2023,,Krabbe_Disease
"apoptosis, demyelination and spasticity in twitcher mice, suggesting a pathological role for astrogliosis in KD (<xref rid=""R24"" ref-type=""bibr"">Mohri et al., 2006</xref>). Our analyses showed increases in globoid cells and astrogliosis in white matter of two infantile KD brains (#5, #7) compared to an age-matched normal brain (case #2). Given the advanced disease stage of both KD cases, there was no difference in levels of demyelination assessed with LFB-PAS staining of myelin or MBP levels with Western",21_34,Galactosylceramidase deficiency and pathological abnormalities in cerebral white matter of Krabbe disease,4 8 2023,,Krabbe_Disease
"staining of myelin or MBP levels with Western blots. On the other hand, globoid cells and astrogliosis increased with disease severity. In particular, more severe pathology was detected in severe KD (case #5), with age of death of 10 months, compared with the milder KD (case #7), with age of death of 21 months. These results strongly suggest that differences in neuropathology are related to disease duration. Case #5 had a disease onset at 4 months of age, consistent with early-infantile KD. Unfortunately,",21_35,Galactosylceramidase deficiency and pathological abnormalities in cerebral white matter of Krabbe disease,4 8 2023,,Krabbe_Disease
"with early-infantile KD. Unfortunately, information on symptom-onset was unavailable for case #7. Given that the age of death was 21 months, which is near the high-end for infantile KD (i.e. 24 months), the subject is possibly a late-infantile KD case, which may explain milder neuropathology. Of note, we detected CD8+, but not CD4+ T lymphocytes in two infantile KD cases, while none were detected in the control case. Consistent with the trend observed for globoid cells and astrogliosis, the number of CD8+",21_36,Galactosylceramidase deficiency and pathological abnormalities in cerebral white matter of Krabbe disease,4 8 2023,,Krabbe_Disease
"cells and astrogliosis, the number of CD8+ T lymphocytes was three times higher in KD with more severe pathology (case #5) compared to KD with less severe pathology (case #7). Of relevance, both CD4+ and CD8+ T lymphocytes have been reported in demyelinating lesions of multiple sclerosis. CD4+ T lymphocytes are mostly found in acute lesions, whereas the CD8+ T lymphocytes are found in chronic lesions (<xref rid=""R32"" ref-type=""bibr"">Raine, 1994</xref>). CD4+ T lymphocytes are implicated in the pathogenesis",21_37,Galactosylceramidase deficiency and pathological abnormalities in cerebral white matter of Krabbe disease,4 8 2023,,Krabbe_Disease
"T lymphocytes are implicated in the pathogenesis of multiple sclerosis by a strong association of disease susceptibility with MHC class II alleles, but the mechanism is largely unclear (<xref rid=""R12"" ref-type=""bibr"">Hafler et al., 2007</xref>). Additional similarities between KD and multiple sclerosis include the presence of neuroinflammatory cells (macrophages and astrocytes) associated with demyelinating lesions in both diseases. Recently, <italic toggle=""yes"">GALC</italic> was identified as a risk",21_38,Galactosylceramidase deficiency and pathological abnormalities in cerebral white matter of Krabbe disease,4 8 2023,,Krabbe_Disease
"was identified as a risk factor gene for multiple sclerosis (<xref rid=""R20"" ref-type=""bibr"">Li et al., 2021</xref>). Immunity-modulating hematopoietic stem cell transplantation is an effective treatment for both diseases (<xref rid=""R25"" ref-type=""bibr"">Muraro et al., 2017</xref>; <xref rid=""R50"" ref-type=""bibr"">Yoon et al., 2021</xref>). Fingolimod, an FDA-approved drug for the treatment of multiple sclerosis, was efficacious in improving the phenotype and extending the lifespan of the twitcher mouse",21_39,Galactosylceramidase deficiency and pathological abnormalities in cerebral white matter of Krabbe disease,4 8 2023,,Krabbe_Disease
"and extending the lifespan of the twitcher mouse model of KD (<xref rid=""R1"" ref-type=""bibr"">Bechet et al., 2020</xref>). Because of these similarities, understanding pathogenesis and potential treatment options from studies of multiple sclerosis may translate to drug discovery in KD. Given the role of CD8+ and CD4+ T lymphocytes in immune surveillance of white matter (<xref rid=""R36"" ref-type=""bibr"">Smolders et al., 2018</xref>), one need to be a cautious in interpreting our findings in KD. Further",21_40,Galactosylceramidase deficiency and pathological abnormalities in cerebral white matter of Krabbe disease,4 8 2023,,Krabbe_Disease
"in interpreting our findings in KD. Further studies of disease progression in KD animal models may clarify the role of CD8+ T lymphocytes in KD. A limitation of our study is the small number of postmortem brain tissues for the analyses, although we obtained all available cases in public brain banks. The tissue quality also varied; therefore, we compared the immunohistochemical results in select cases. Nevertheless, we could select two infantile cases of different severity and show the correlations between",21_41,Galactosylceramidase deficiency and pathological abnormalities in cerebral white matter of Krabbe disease,4 8 2023,,Krabbe_Disease
"severity and show the correlations between age of death and pathology severity. Further statistical analyses need to be done in larger cohorts. Overall, our findings have advanced the understanding of GALC protein biology in the context of normal and KD brain white matter. We also revealed new neuropathological changes that may provide insights to understand KD pathogenesis.",21_42,Galactosylceramidase deficiency and pathological abnormalities in cerebral white matter of Krabbe disease,4 8 2023,,Krabbe_Disease
"Improved Brain Pathology and Progressive Peripheral Neuropathy in a 15 Year Old Survivor of Infantile Krabbe Disease Treated With Umbilical Cord Transplantation Krabbe disease, or globoid cell leukodystrophy, is a neurodegenerative disorder, primarily involving the white matter in the peripheral (PNS) and central nervous system (CNS). It is an autosomal recessive disease caused by various mutations in the galactocerebrosidase (<italic toggle=""yes"">GalC</italic>) gene. During myelin turnover, the decreased",22_0,Improved Brain Pathology and Progressive Peripheral Neuropathy in a 15 Year Old Survivor of Infantile Krabbe Disease Treated With Umbilical Cord Transplantation,28 7 2022,,Krabbe_Disease
"gene. During myelin turnover, the decreased or lost GALC enzyme activity leads to impaired degradation of its two main substrates, galactosylceramide (galactocerebroside) and galactosylsphingosine (psychosine) (<xref rid=""B39"" ref-type=""bibr"">Wenger et al., 2001</xref>; <xref rid=""B30"" ref-type=""bibr"">Suzuki, 2003</xref>; <xref rid=""B11"" ref-type=""bibr"">Graziano and Cardile, 2015</xref>). The accumulation of cytotoxic psychosine results in the apoptosis of myelin-forming cells and induction of inflammatory",22_1,Improved Brain Pathology and Progressive Peripheral Neuropathy in a 15 Year Old Survivor of Infantile Krabbe Disease Treated With Umbilical Cord Transplantation,28 7 2022,,Krabbe_Disease
"cells and induction of inflammatory processes, forming the basis of the “psychosine hypothesis” of Krabbe disease (<xref rid=""B21"" ref-type=""bibr"">Miyatake and Suzuki, 1972</xref>; <xref rid=""B29"" ref-type=""bibr"">Suzuki, 1998</xref>). The impaired degradation of galactosylceramide leads to the characteristic formation of enlarged, spherical and sometimes multinucleated macrophages, called globoid cells, in the white matter of the CNS (<xref rid=""B30"" ref-type=""bibr"">Suzuki, 2003</xref>; <xref rid=""B11""",22_2,Improved Brain Pathology and Progressive Peripheral Neuropathy in a 15 Year Old Survivor of Infantile Krabbe Disease Treated With Umbilical Cord Transplantation,28 7 2022,,Krabbe_Disease
"2003</xref>; <xref rid=""B11"" ref-type=""bibr"">Graziano and Cardile, 2015</xref>). More recent evidence suggests that psychosine is also detrimental to other cell types in the brain, leading to early microglial and astrocyte activation and initiation of an inflammatory cascade, which in turn may contribute to demyelination (<xref rid=""B15"" ref-type=""bibr"">Karumuthil-Melethil and Gray, 2016</xref>; <xref rid=""B23"" ref-type=""bibr"">Nicaise et al., 2016</xref>; <xref rid=""B25"" ref-type=""bibr"">Potter and",22_3,Improved Brain Pathology and Progressive Peripheral Neuropathy in a 15 Year Old Survivor of Infantile Krabbe Disease Treated With Umbilical Cord Transplantation,28 7 2022,,Krabbe_Disease
"<xref rid=""B25"" ref-type=""bibr"">Potter and Petryniak, 2016</xref>). The disease is typically subdivided into four groups based on age-of-onset of clinical symptoms (<xref rid=""B39"" ref-type=""bibr"">Wenger et al., 2001</xref>; <xref rid=""B30"" ref-type=""bibr"">Suzuki, 2003</xref>). The most common form is the early infantile presentation, with an estimated incidence of 1 in 100,000 to ∼400,000 (<xref rid=""B24"" ref-type=""bibr"">Orsini et al., 2016</xref>). Recently, our group has proposed reclassification of",22_4,Improved Brain Pathology and Progressive Peripheral Neuropathy in a 15 Year Old Survivor of Infantile Krabbe Disease Treated With Umbilical Cord Transplantation,28 7 2022,,Krabbe_Disease
"our group has proposed reclassification of Krabbe variants according to our prospective natural history studies (<xref rid=""B2"" ref-type=""bibr"">Bascou et al., 2018</xref>; <xref rid=""B3"" ref-type=""bibr"">Beltran-Quintero et al., 2019</xref>), eliminating the Early Infantile phenotype in favor of the Infantile phenotype which now encompasses patients that present between 0 and 12 months of age. The Late-Infantile phenotype now includes patients with symptom onset from 13 to 36 months. The other two",22_5,Improved Brain Pathology and Progressive Peripheral Neuropathy in a 15 Year Old Survivor of Infantile Krabbe Disease Treated With Umbilical Cord Transplantation,28 7 2022,,Krabbe_Disease
"symptom onset from 13 to 36 months. The other two phenotypes described for Krabbe disease are juvenile (onset of symptoms from 3 to 16 years) and adult forms (onset in patients > 16 years old). Pathology in Krabbe disease is characterized by a rapid and nearly complete disappearance of myelin and myelin-forming cells, i.e., the oligodendrocytes in the CNS and the Schwann cells in the PNS, associated with reactive astrocytic gliosis, and accumulation of globoid cells that contain strongly periodic",22_6,Improved Brain Pathology and Progressive Peripheral Neuropathy in a 15 Year Old Survivor of Infantile Krabbe Disease Treated With Umbilical Cord Transplantation,28 7 2022,,Krabbe_Disease
"of globoid cells that contain strongly periodic acid-Schiff (PAS)-positive inclusions, biochemically identical with galactosylceramide (<xref rid=""B30"" ref-type=""bibr"">Suzuki, 2003</xref>; <xref rid=""B32"" ref-type=""bibr"">Suzuki and Vanier, 2004</xref>; <xref rid=""B35"" ref-type=""bibr"">Walkley et al., 2015</xref>). Peripheral nerves exhibit endoneurial fibrosis and segmental demyelination with tubular inclusions in endoneurial macrophages and Schwann cells (<xref rid=""B30"" ref-type=""bibr"">Suzuki,",22_7,Improved Brain Pathology and Progressive Peripheral Neuropathy in a 15 Year Old Survivor of Infantile Krabbe Disease Treated With Umbilical Cord Transplantation,28 7 2022,,Krabbe_Disease
"cells (<xref rid=""B30"" ref-type=""bibr"">Suzuki, 2003</xref>). Hematopoietic stem cell transplantation, most commonly in the form of umbilical cord blood transplantation (UCBT), is currently the only available treatment modality that has shown to favorably alter the disease course by improving lifespan and functional abilities, but only if performed before onset of clinical symptoms (<xref rid=""B19"" ref-type=""bibr"">Krivit et al., 1998</xref>; <xref rid=""B9"" ref-type=""bibr"">Escolar et al., 2005</xref>; <xref",22_8,Improved Brain Pathology and Progressive Peripheral Neuropathy in a 15 Year Old Survivor of Infantile Krabbe Disease Treated With Umbilical Cord Transplantation,28 7 2022,,Krabbe_Disease
"et al., 2005</xref>; <xref rid=""B28"" ref-type=""bibr"">Sakai, 2009</xref>; <xref rid=""B41"" ref-type=""bibr"">Wright et al., 2017</xref>; <xref rid=""B1"" ref-type=""bibr"">Allewelt et al., 2018</xref>). Functional outcomes in pre-symptomatic or minimally symptomatic patients depend heavily on disease burden at the time of HSCT (<xref rid=""B41"" ref-type=""bibr"">Wright et al., 2017</xref>). Serial brain magnetic resonance imaging (MRI) studies of transplanted Krabbe patients revealed stabilization of CNS disease in",22_9,Improved Brain Pathology and Progressive Peripheral Neuropathy in a 15 Year Old Survivor of Infantile Krabbe Disease Treated With Umbilical Cord Transplantation,28 7 2022,,Krabbe_Disease
"patients revealed stabilization of CNS disease in the vast majority of subjects, but nerve conduction studies demonstrated only transient improvements of nerve conduction velocities (<xref rid=""B41"" ref-type=""bibr"">Wright et al., 2017</xref>). The rationale for this therapeutic approach is that bone marrow-derived macrophages secrete the missing protein, which then leads to cross-correction of the enzymatic defect in myelin-forming cells (<xref rid=""B38"" ref-type=""bibr"">Wenger et al., 2000</xref>; <xref",22_10,Improved Brain Pathology and Progressive Peripheral Neuropathy in a 15 Year Old Survivor of Infantile Krabbe Disease Treated With Umbilical Cord Transplantation,28 7 2022,,Krabbe_Disease
"ref-type=""bibr"">Wenger et al., 2000</xref>; <xref rid=""B11"" ref-type=""bibr"">Graziano and Cardile, 2015</xref>). However, this mechanism has recently been called into question by two studies failing to identify convincing enzymatic restoration in target cells in human metachromatic leukodystrophy brains (<xref rid=""B40"" ref-type=""bibr"">Wolf et al., 2020</xref>) and Krabbe disease peripheral nerves (<xref rid=""B36"" ref-type=""bibr"">Weinstock et al., 2020</xref>) despite clear evidence of donor-derived",22_11,Improved Brain Pathology and Progressive Peripheral Neuropathy in a 15 Year Old Survivor of Infantile Krabbe Disease Treated With Umbilical Cord Transplantation,28 7 2022,,Krabbe_Disease
"despite clear evidence of donor-derived macrophage engraftment and improved myelination. Both studies propose restoration of phagocytic response and modulation of neuroinflammation by donor macrophages as alternative mechanisms. Aside from the above report on peripheral nerves from a transplanted Krabbe disease case, information about neuropathologic changes following transplantation is limited to animal models of Krabbe disease. In murine models, bone marrow transplantation resulted in extended life",22_12,Improved Brain Pathology and Progressive Peripheral Neuropathy in a 15 Year Old Survivor of Infantile Krabbe Disease Treated With Umbilical Cord Transplantation,28 7 2022,,Krabbe_Disease
"marrow transplantation resulted in extended life spans, increased GalC activity and less psychosine accumulation in the nervous system (<xref rid=""B42"" ref-type=""bibr"">Yeager et al., 1984</xref>; <xref rid=""B14"" ref-type=""bibr"">Ichioka et al., 1987</xref>; <xref rid=""B12"" ref-type=""bibr"">Hoogerbrugge et al., 1988a</xref>; <xref rid=""B20"" ref-type=""bibr"">Luzi et al., 2005</xref>). This was accompanied by increased numbers of remyelinated fibers and significantly decreased numbers of the typical",22_13,Improved Brain Pathology and Progressive Peripheral Neuropathy in a 15 Year Old Survivor of Infantile Krabbe Disease Treated With Umbilical Cord Transplantation,28 7 2022,,Krabbe_Disease
"significantly decreased numbers of the typical inclusion-laden macrophages in peripheral nerves, but inclusions were still seen in some remyelinating Schwann cells (<xref rid=""B42"" ref-type=""bibr"">Yeager et al., 1984</xref>; <xref rid=""B17"" ref-type=""bibr"">Kondo et al., 1988</xref>; <xref rid=""B20"" ref-type=""bibr"">Luzi et al., 2005</xref>). In the central nervous system, improvements were only appreciated after prolonged survival and consisted of evidence of remyelination and disappearance of",22_14,Improved Brain Pathology and Progressive Peripheral Neuropathy in a 15 Year Old Survivor of Infantile Krabbe Disease Treated With Umbilical Cord Transplantation,28 7 2022,,Krabbe_Disease
"of evidence of remyelination and disappearance of inclusion-bearing macrophages (<xref rid=""B42"" ref-type=""bibr"">Yeager et al., 1984</xref>; <xref rid=""B31"" ref-type=""bibr"">Suzuki et al., 1988</xref>; <xref rid=""B20"" ref-type=""bibr"">Luzi et al., 2005</xref>). Similar to peripheral Schwann cells, inclusions were still identified in oligodendrocytes. Taken together, these studies suggest that bone marrow transplantation was beneficial, but that the metabolic defect was only partially corrected. To date there",22_15,Improved Brain Pathology and Progressive Peripheral Neuropathy in a 15 Year Old Survivor of Infantile Krabbe Disease Treated With Umbilical Cord Transplantation,28 7 2022,,Krabbe_Disease
"was only partially corrected. To date there are no pathologic studies on UBCT treated patients. This study aims to describe the neuropathological changes seen in humans, comparing a patient that progressed untreated to one that was treated with UCBT before the onset of symptoms. This study was made possible by the Program for the Study of Neurodevelopment in Rare Disorders (NDRD), which established the NDRD Brain and Tissue Bank at the University of Pittsburgh with a focus on pediatric neurodegenerative",22_16,Improved Brain Pathology and Progressive Peripheral Neuropathy in a 15 Year Old Survivor of Infantile Krabbe Disease Treated With Umbilical Cord Transplantation,28 7 2022,,Krabbe_Disease
"with a focus on pediatric neurodegenerative diseases. This report is the first histopathological characterization of the effects of UBCT treatment on the degenerative changes associated with Krabbe disease.   Hematopoietic stem cell transplantation is currently the only available treatment modality for Krabbe patients. Most survivors show durable engraftment of donor-derived cells with normalization of peripheral blood galactocerebrosidase levels. If performed in the pre-clinical stage, transplantation has",22_17,Improved Brain Pathology and Progressive Peripheral Neuropathy in a 15 Year Old Survivor of Infantile Krabbe Disease Treated With Umbilical Cord Transplantation,28 7 2022,,Krabbe_Disease
"in the pre-clinical stage, transplantation has been shown to improve lifespan and functional abilities, although some children experience delays in expressive language and gross motor skills (<xref rid=""B19"" ref-type=""bibr"">Krivit et al., 1998</xref>; <xref rid=""B9"" ref-type=""bibr"">Escolar et al., 2005</xref>; <xref rid=""B28"" ref-type=""bibr"">Sakai, 2009</xref>; <xref rid=""B41"" ref-type=""bibr"">Wright et al., 2017</xref>; <xref rid=""B1"" ref-type=""bibr"">Allewelt et al., 2018</xref>). These functional",22_18,Improved Brain Pathology and Progressive Peripheral Neuropathy in a 15 Year Old Survivor of Infantile Krabbe Disease Treated With Umbilical Cord Transplantation,28 7 2022,,Krabbe_Disease
"et al., 2018</xref>). These functional improvements are accompanied by progressive myelination on serial brain MRI scans, as also observed in our transplanted case. We now describe for the first time the neuropathological findings in a transplanted Krabbe disease case. Compared to our untreated case and other infantile cases reported in the literature (<xref rid=""B39"" ref-type=""bibr"">Wenger et al., 2001</xref>), the transplanted brain demonstrated a markedly improved degree of myelination, albeit not",22_19,Improved Brain Pathology and Progressive Peripheral Neuropathy in a 15 Year Old Survivor of Infantile Krabbe Disease Treated With Umbilical Cord Transplantation,28 7 2022,,Krabbe_Disease
"improved degree of myelination, albeit not reaching the levels expected for a normal brain. The myelination abnormalities were most prominent in centrum semiovale, cerebellar white matter and corticospinal tracts, areas typically affected early and severely in Krabbe disease. With this patient being already mildly symptomatic at birth, it is likely that these areas were already involved pre-transplant, as confirmed by early postnatal MRI findings. The decreased degree of myelination is most likely a",22_20,Improved Brain Pathology and Progressive Peripheral Neuropathy in a 15 Year Old Survivor of Infantile Krabbe Disease Treated With Umbilical Cord Transplantation,28 7 2022,,Krabbe_Disease
"decreased degree of myelination is most likely a reflection of injury that occurred early in the disease course as no evidence of post-transplant active demyelination was seen in the central nervous system. This anatomic distribution also correlated well with the patient’s severe clinical deficits in gross motor skills. Data from twitcher mice indicate that it takes several weeks after transplantation until GalC activity increases in the brain, psychosine levels reduce and pathologic features improve",22_21,Improved Brain Pathology and Progressive Peripheral Neuropathy in a 15 Year Old Survivor of Infantile Krabbe Disease Treated With Umbilical Cord Transplantation,28 7 2022,,Krabbe_Disease
"levels reduce and pathologic features improve (<xref rid=""B42"" ref-type=""bibr"">Yeager et al., 1984</xref>; <xref rid=""B14"" ref-type=""bibr"">Ichioka et al., 1987</xref>; <xref rid=""B12"" ref-type=""bibr"">Hoogerbrugge et al., 1988a</xref>, b; <xref rid=""B31"" ref-type=""bibr"">Suzuki et al., 1988</xref>). Thus, most if not all of the CNS myelin loss seen in our case likely happened before or in the early weeks after transplantation when there is a period of conditioning and cell engraftment during which the",22_22,Improved Brain Pathology and Progressive Peripheral Neuropathy in a 15 Year Old Survivor of Infantile Krabbe Disease Treated With Umbilical Cord Transplantation,28 7 2022,,Krabbe_Disease
"and cell engraftment during which the disease continues to progress. The lack of active demyelination later in life is consistent with serial imaging studies which demonstrated stable white matter abnormalities. The decrease in myelin was accompanied by concurrent axonal loss, which likely represents a major factor in limiting complete remyelination and restoration of white matter integrity. While we do not have data on brain GalC activity or psychosine levels in our autopsy cases, the absence of globoid",22_23,Improved Brain Pathology and Progressive Peripheral Neuropathy in a 15 Year Old Survivor of Infantile Krabbe Disease Treated With Umbilical Cord Transplantation,28 7 2022,,Krabbe_Disease
"in our autopsy cases, the absence of globoid cells and lack of active demyelination highly suggest that the enzymatic defect was significantly ameliorated by the transplant procedure, at least in the central nervous system. In addition to the beneficial effects of UCBT on myelination, we also noted significant preservation of neuronal cell populations. While Krabbe disease is mainly considered a white matter disease, many untreated cases show significant neuronal depletion in a stereotypical distribution",22_24,Improved Brain Pathology and Progressive Peripheral Neuropathy in a 15 Year Old Survivor of Infantile Krabbe Disease Treated With Umbilical Cord Transplantation,28 7 2022,,Krabbe_Disease
"depletion in a stereotypical distribution pattern involving primarily cerebellar cortex, dentate nucleus, inferior olives, basis pontis, thalamus, and claustrum (<xref rid=""B16"" ref-type=""bibr"">Kofler et al., 2019</xref>). While these regions showed marked neuronal loss in our untreated case, only subtle changes were present after transplantation. The mechanisms underlying neuronal loss in Krabbe disease, and in particular the selective vulnerability of certain cell populations, are poorly understood.",22_25,Improved Brain Pathology and Progressive Peripheral Neuropathy in a 15 Year Old Survivor of Infantile Krabbe Disease Treated With Umbilical Cord Transplantation,28 7 2022,,Krabbe_Disease
"certain cell populations, are poorly understood. There is some evidence from twitcher mice that neurons do accumulate psychosine, albeit less than oligodendrocytes, and that psychosine has neurotoxic effects in culture (<xref rid=""B5"" ref-type=""bibr"">Castelvetri et al., 2011</xref>). <italic toggle=""yes"">In vivo</italic>, axonopathy is observed early in twitcher mice, before the onset of demyelination, but neuronal loss is not seen until late stages (<xref rid=""B5"" ref-type=""bibr"">Castelvetri et al.,",22_26,Improved Brain Pathology and Progressive Peripheral Neuropathy in a 15 Year Old Survivor of Infantile Krabbe Disease Treated With Umbilical Cord Transplantation,28 7 2022,,Krabbe_Disease
"rid=""B5"" ref-type=""bibr"">Castelvetri et al., 2011</xref>). Our findings suggest that the time course for neuronal loss may be different in human Krabbe brains, as mild neuronal loss was present in stereotypical brain regions in the transplanted case. We assume that this neuronal injury occurred in the pre- or early post-transplantation period, similar to the white matter injury. The lack of more advanced neuronal loss suggests that transplantation was effective in halting further neurodegeneration by",22_27,Improved Brain Pathology and Progressive Peripheral Neuropathy in a 15 Year Old Survivor of Infantile Krabbe Disease Treated With Umbilical Cord Transplantation,28 7 2022,,Krabbe_Disease
"effective in halting further neurodegeneration by either cross-correcting neuronal enzyme deficits or by otherwise preventing injury cascades leading to neuronal death. Unlike the stabilization observed clinically, radiologically and pathologically for the CNS disease, many transplanted Krabbe patients experience minimal clinical benefit in the peripheral nervous system. This impression is supported by serial nerve conduction studies which demonstrated only transient improvements of nerve conduction",22_28,Improved Brain Pathology and Progressive Peripheral Neuropathy in a 15 Year Old Survivor of Infantile Krabbe Disease Treated With Umbilical Cord Transplantation,28 7 2022,,Krabbe_Disease
"only transient improvements of nerve conduction velocities after UCBT (<xref rid=""B41"" ref-type=""bibr"">Wright et al., 2017</xref>). While postmortem examination identified only minimal macrophage infiltration into peripheral nerves, less than seen in non-transplanted cases, significant nerve pathology was present and characterized by myelin loss, axon loss, endoneurial fibrosis, subperineurial, and endoneurial edema, and ultrastructural inclusions in Schwann cells. These results share many similarities",22_29,Improved Brain Pathology and Progressive Peripheral Neuropathy in a 15 Year Old Survivor of Infantile Krabbe Disease Treated With Umbilical Cord Transplantation,28 7 2022,,Krabbe_Disease
"cells. These results share many similarities with the peripheral nerve findings in transplanted twitcher mice. After a lag period of several weeks, the mice showed increased numbers of remyelinated fibers, disappearance of the typical inclusion-laden macrophages and absence of active demyelination, but persistence of inclusions in Schwann cells and continued presence of demyelinated fibers (<xref rid=""B17"" ref-type=""bibr"">Kondo et al., 1988</xref>). More recent experiments with GalC-deficient Schwann cells",22_30,Improved Brain Pathology and Progressive Peripheral Neuropathy in a 15 Year Old Survivor of Infantile Krabbe Disease Treated With Umbilical Cord Transplantation,28 7 2022,,Krabbe_Disease
"experiments with GalC-deficient Schwann cells demonstrate that these cells are inefficient in receiving GalC from surrounding cells and are not appropriately cross-corrected (<xref rid=""B36"" ref-type=""bibr"">Weinstock et al., 2020</xref>). These data suggest that GalC-competent, donor-derived macrophages may provide some benefit in peripheral nerves through immunomodulatory mechanisms (<xref rid=""B27"" ref-type=""bibr"">Reddy et al., 2011</xref>; <xref rid=""B15"" ref-type=""bibr"">Karumuthil-Melethil and Gray,",22_31,Improved Brain Pathology and Progressive Peripheral Neuropathy in a 15 Year Old Survivor of Infantile Krabbe Disease Treated With Umbilical Cord Transplantation,28 7 2022,,Krabbe_Disease
"ref-type=""bibr"">Karumuthil-Melethil and Gray, 2016</xref>; <xref rid=""B25"" ref-type=""bibr"">Potter and Petryniak, 2016</xref>; <xref rid=""B36"" ref-type=""bibr"">Weinstock et al., 2020</xref>), but are unable to correct the metabolic defect in Schwann cells leading to progressive PNS disease in transplant recipients. Like most UCBT survivors, our transplanted case showed durable engraftment of donor-derived cells with normalization of peripheral blood galactocerebrosidase levels. This was confirmed by",22_32,Improved Brain Pathology and Progressive Peripheral Neuropathy in a 15 Year Old Survivor of Infantile Krabbe Disease Treated With Umbilical Cord Transplantation,28 7 2022,,Krabbe_Disease
"levels. This was confirmed by postmortem <italic toggle=""yes"">in situ</italic> hybridization studies demonstrating an abundance of male donor-derived hematopoietic cells in spleen and gastrointestinal tract of our female recipient. Furthermore, male cells were identified in the central nervous system, comprising about 5% of the total cell population in the white matter. The cells appeared scattered throughout the parenchyma and not restricted to intra- or perivascular spaces. These findings suggest that",22_33,Improved Brain Pathology and Progressive Peripheral Neuropathy in a 15 Year Old Survivor of Infantile Krabbe Disease Treated With Umbilical Cord Transplantation,28 7 2022,,Krabbe_Disease
"perivascular spaces. These findings suggest that long-term integration of donor-derived cells into the CNS occurred. While technical limitations prevented us from further characterizing the lineage of these donor-derived cells, they most likely represent monocyte-derived microglia/macrophages, an interpretation consistent with morphological features of these cells and limited evidence in the literature. In twitcher mice, donor-derived macrophages were observed in the CNS after bone marrow transplantation,",22_34,Improved Brain Pathology and Progressive Peripheral Neuropathy in a 15 Year Old Survivor of Infantile Krabbe Disease Treated With Umbilical Cord Transplantation,28 7 2022,,Krabbe_Disease
"in the CNS after bone marrow transplantation, but not until several weeks after the procedure. These donor-derived cells were seen most frequently in areas affected by the disease, and the time course of infiltration aligned with a gradual increase in GalC activity in the brain, suggesting that the donor-derived cells were the source for the improved enzyme activity (<xref rid=""B13"" ref-type=""bibr"">Hoogerbrugge et al., 1988b</xref>). In a small case series of pediatric and young adult female patients",22_35,Improved Brain Pathology and Progressive Peripheral Neuropathy in a 15 Year Old Survivor of Infantile Krabbe Disease Treated With Umbilical Cord Transplantation,28 7 2022,,Krabbe_Disease
"of pediatric and young adult female patients receiving bone marrow transplants for hematological disorders, male donor-derived cells were identified in intravascular, perivascular, and intraparenchymal locations in postmortem brain tissue sections and corresponded in distribution to leukocyte common antigen (LCA)-positive mononuclear leukocytes (<xref rid=""B34"" ref-type=""bibr"">Unger et al., 1993</xref>). While these early studies suggested that donor-derived myeloid cells engrafted into the brain, it",22_36,Improved Brain Pathology and Progressive Peripheral Neuropathy in a 15 Year Old Survivor of Infantile Krabbe Disease Treated With Umbilical Cord Transplantation,28 7 2022,,Krabbe_Disease
"myeloid cells engrafted into the brain, it remained unclear if they truly differentiated phenotypically into microglial cells. In a mouse model of Gaucher disease, a small subset of donor-derived cells appeared consistent with parenchymal microglia and displayed ramified morphology (<xref rid=""B18"" ref-type=""bibr"">Krall et al., 1994</xref>). In a single case report of a female patient who underwent UCBT for lymphoma, donor-derived cells were identified in the brain using immunohistochemical staining",22_37,Improved Brain Pathology and Progressive Peripheral Neuropathy in a 15 Year Old Survivor of Infantile Krabbe Disease Treated With Umbilical Cord Transplantation,28 7 2022,,Krabbe_Disease
"in the brain using immunohistochemical staining against a mismatched HLA antigen. Many of the positive cells adopted a ramified morphology and co-labeled with microglial marker Iba1 but not with astrocyte marker GFAP (<xref rid=""B33"" ref-type=""bibr"">Takahashi et al., 2015</xref>). An autopsy study of two transplanted metachromatic leukodystrophy (MLD) cases found metabolically competent donor macrophages throughout the white matter expressing arylsulfatase A, the deficient enzyme in MLD (<xref rid=""B40""",22_38,Improved Brain Pathology and Progressive Peripheral Neuropathy in a 15 Year Old Survivor of Infantile Krabbe Disease Treated With Umbilical Cord Transplantation,28 7 2022,,Krabbe_Disease
"A, the deficient enzyme in MLD (<xref rid=""B40"" ref-type=""bibr"">Wolf et al., 2020</xref>). Taken together, these results suggest that donor-derived myeloid cells are capable of entering and durably engrafting into the CNS after BMT or UBCT. Moreover, they resemble microglial cells, at least morphologically, and are functionally competent in a manner to supply sufficient enzyme activity to halt disease progression in Krabbe disease. Further studies are needed, though, to determine if these donor-derived",22_39,Improved Brain Pathology and Progressive Peripheral Neuropathy in a 15 Year Old Survivor of Infantile Krabbe Disease Treated With Umbilical Cord Transplantation,28 7 2022,,Krabbe_Disease
"though, to determine if these donor-derived cells are phenotypically similar to host microglia or represent a unique phenotype. Recent evidence supports the latter, by finding that brain-engrafting macrophages have a transcriptional profile distinct from microglia (<xref rid=""B6"" ref-type=""bibr"">Cronk et al., 2018</xref>). In the brains of MLD patients, increased macrophage expression of mannose receptor was seen in transplanted compared to non-treated patients, suggestive of skewing toward an alternative",22_40,Improved Brain Pathology and Progressive Peripheral Neuropathy in a 15 Year Old Survivor of Infantile Krabbe Disease Treated With Umbilical Cord Transplantation,28 7 2022,,Krabbe_Disease
"suggestive of skewing toward an alternative activation state, which is considered to be anti-inflammatory and supportive of oligodendrocyte survival and remyelination (<xref rid=""B40"" ref-type=""bibr"">Wolf et al., 2020</xref>). In conclusion, our data provide evidence that UCBT has beneficial effects in pre-clinical Krabbe disease by leading to engraftment of donor-derived cells into the brain and halting progressive demyelination and neuronal loss. While this treatment leads to stabilization of CNS",22_41,Improved Brain Pathology and Progressive Peripheral Neuropathy in a 15 Year Old Survivor of Infantile Krabbe Disease Treated With Umbilical Cord Transplantation,28 7 2022,,Krabbe_Disease
"this treatment leads to stabilization of CNS disease, both clinical and pathological findings indicate progression of PNS disease, resulting in a markedly changed disease phenotype in long-term transplant survivors. The reasons for these differences in efficacy remain under investigation, but a leading hypothesis is the limited degree of Schwann cell cross-correction as demonstrated in a recent publication (<xref rid=""B36"" ref-type=""bibr"">Weinstock et al., 2020</xref>). Adeno-associated virus (AAV) gene",22_42,Improved Brain Pathology and Progressive Peripheral Neuropathy in a 15 Year Old Survivor of Infantile Krabbe Disease Treated With Umbilical Cord Transplantation,28 7 2022,,Krabbe_Disease
"2020</xref>). Adeno-associated virus (AAV) gene therapy, alone or in combination with transplantation, has led to improved outcomes in murine and canine Krabbe disease models (<xref rid=""B27"" ref-type=""bibr"">Reddy et al., 2011</xref>; <xref rid=""B26"" ref-type=""bibr"">Rafi et al., 2015</xref>; <xref rid=""B4"" ref-type=""bibr"">Bradbury et al., 2018</xref>). Combination of UCBT with gene therapy has been shown to have a synergistic effect with better outcomes than each therapy alone. This combination approach is",22_43,Improved Brain Pathology and Progressive Peripheral Neuropathy in a 15 Year Old Survivor of Infantile Krabbe Disease Treated With Umbilical Cord Transplantation,28 7 2022,,Krabbe_Disease
"each therapy alone. This combination approach is now in human phase I/II clinical trials, in the hope that this two-pronged approach can overcome the limitations of stand-alone UCBT/BMT. The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation. The studies involving human participants were reviewed and approved by the Human Research Protection Office at the University of Pittsburgh and the Office of Human Research Ethics at the University of",22_44,Improved Brain Pathology and Progressive Peripheral Neuropathy in a 15 Year Old Survivor of Infantile Krabbe Disease Treated With Umbilical Cord Transplantation,28 7 2022,,Krabbe_Disease
"of Human Research Ethics at the University of North Carolina - Chapel Hill. Written informed consent was obtained from the minor(s)’ legal guardian/next of kin for the publication of any potentially identifiable images or data included in this article. JK: conceived, designed and performed the pathology analyses, and drafted the manuscript. MB-Q: collected the clinical data and drafted the clinical section. AR: contributed to the clinical data and coordinated the NDRD autopsy program. GZ: contributed to",22_45,Improved Brain Pathology and Progressive Peripheral Neuropathy in a 15 Year Old Survivor of Infantile Krabbe Disease Treated With Umbilical Cord Transplantation,28 7 2022,,Krabbe_Disease
"the NDRD autopsy program. GZ: contributed to the radiology data. SK: collected the clinical data. ME: conceived and designed the study, managed the patients, and performed the clinical examinations. All authors reviewed and revised the manuscript and approved the final version. ME had financial equity and employment at Forge Biologics. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of",22_46,Improved Brain Pathology and Progressive Peripheral Neuropathy in a 15 Year Old Survivor of Infantile Krabbe Disease Treated With Umbilical Cord Transplantation,28 7 2022,,Krabbe_Disease
"could be construed as a potential conflict of interest. All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.",22_47,Improved Brain Pathology and Progressive Peripheral Neuropathy in a 15 Year Old Survivor of Infantile Krabbe Disease Treated With Umbilical Cord Transplantation,28 7 2022,,Krabbe_Disease
"Neurons contribute to pathology in a mouse model of Krabbe disease in a cell-autonomous manner In this issue of <italic toggle=""yes"">PLOS Biology</italic>, Kreher and colleagues show in a mouse model that in vivo, neurons and not only myelinating glia are primary effectors of disease progression in Krabbe disease. The neuron-specific model generated allows the unprecedented capacity to investigate the neuronal autonomous component of this disorder. This Primer explores the implications of a PLOS Biology",23_0,Neurons contribute to pathology in a mouse model of Krabbe disease in a cell-autonomous manner,6 7 2022,,Krabbe_Disease
"explores the implications of a PLOS Biology showing that in vivo, neurons (not only myelinating glia) are primary effectors of disease progression in Krabbe disease; the neuron-specific animal model described allows an unprecedented opportunity to investigate the neuronal-autonomous component of this disorder. Full text not available in PMC",23_1,Neurons contribute to pathology in a mouse model of Krabbe disease in a cell-autonomous manner,6 7 2022,,Krabbe_Disease
"Neuron-specific ablation of the Krabbe disease gene galactosylceramidase in mice results in neurodegeneration Krabbe disease is caused by a deficiency of the lysosomal galactosylceramidase (GALC) enzyme, which results in the accumulation of galactosylceramide (GalCer) and psychosine. In Krabbe disease, the brunt of demyelination and neurodegeneration is believed to result from the dysfunction of myelinating glia. Recent studies have shown that neuronal axons are both structurally and functionally",24_0,Neuron-specific ablation of the Krabbe disease gene galactosylceramidase in mice results in neurodegeneration,5 7 2022,,Krabbe_Disease
"axons are both structurally and functionally compromised in Krabbe disease, even before demyelination, suggesting a possible neuron-autonomous role of GALC. Using a novel neuron-specific <italic toggle=""yes"">Galc</italic> knockout (CKO) model, we show that neuronal <italic toggle=""yes"">Galc</italic> deletion is sufficient to cause growth and motor coordination defects and inflammatory gliosis in mice. Furthermore, psychosine accumulates significantly in the nervous system of neuron-specific <italic",24_1,Neuron-specific ablation of the Krabbe disease gene galactosylceramidase in mice results in neurodegeneration,5 7 2022,,Krabbe_Disease
"in the nervous system of neuron-specific <italic toggle=""yes"">Galc</italic>-CKO. Confocal and electron microscopic analyses show profound neuro-axonal degeneration with a mild effect on myelin structure. Thus, we prove for the first time that neuronal GALC is essential to maintain and protect neuronal function independently of myelin and may directly contribute to the pathogenesis of Krabbe disease. Krabbe disease is a demyelinating neurodegenerative disorder caused by a deficiency of the enzyme lysosomal",24_2,Neuron-specific ablation of the Krabbe disease gene galactosylceramidase in mice results in neurodegeneration,5 7 2022,,Krabbe_Disease
"caused by a deficiency of the enzyme lysosomal galactosylceramidase (GALC), which results in the accumulation of galactosylceramide and psychosine. This study uses a novel neuron-specific knockout model in the first in vivo attempt to investigate the role of neuronal GALC in neuronal function and the etiology of Krabbe disease. Krabbe disease is caused by a deficiency of galactosylceramidase (GALC) [<xref rid=""pbio.3001661.ref001"" ref-type=""bibr"">1</xref>], a lysosomal acid hydrolase that catabolizes the",24_3,Neuron-specific ablation of the Krabbe disease gene galactosylceramidase in mice results in neurodegeneration,5 7 2022,,Krabbe_Disease
"a lysosomal acid hydrolase that catabolizes the lipids galactosylceramide (GalCer) and galactosylsphingosine (= psychosine). A recent study suggests that acid ceramidase can deacylate GalCer into psychosine [<xref rid=""pbio.3001661.ref002"" ref-type=""bibr"">2</xref>,<xref rid=""pbio.3001661.ref003"" ref-type=""bibr"">3</xref>]. In Krabbe tissues, especially within the brain [<xref rid=""pbio.3001661.ref004"" ref-type=""bibr"">4</xref>], psychosine accumulates to high levels, triggering membrane destabilization and",24_4,Neuron-specific ablation of the Krabbe disease gene galactosylceramidase in mice results in neurodegeneration,5 7 2022,,Krabbe_Disease
"levels, triggering membrane destabilization and cell death [<xref rid=""pbio.3001661.ref005"" ref-type=""bibr"">5</xref>–<xref rid=""pbio.3001661.ref009"" ref-type=""bibr"">9</xref>]. Other pathologic hallmarks of Krabbe disease include rapid and progressive demyelination of the central and peripheral nervous systems (CNS and PNS, respectively) with diffuse Periodic Acid–Schiff positive multinucleated macrophage infiltration [<xref rid=""pbio.3001661.ref010"" ref-type=""bibr"">10</xref>] and reactive astrogliosis",24_5,Neuron-specific ablation of the Krabbe disease gene galactosylceramidase in mice results in neurodegeneration,5 7 2022,,Krabbe_Disease
"and reactive astrogliosis [<xref rid=""pbio.3001661.ref011"" ref-type=""bibr"">11</xref>–<xref rid=""pbio.3001661.ref013"" ref-type=""bibr"">13</xref>]. Since Krabbe disease begins during active myelination and is characterized by extensive demyelination with relative sparing of the gray matter [<xref rid=""pbio.3001661.ref014"" ref-type=""bibr"">14</xref>], oligodendrocytes (OLs) have been regarded as the first and primary cells targeted by the pathology (reviewed in [<xref rid=""pbio.3001661.ref015""",24_6,Neuron-specific ablation of the Krabbe disease gene galactosylceramidase in mice results in neurodegeneration,5 7 2022,,Krabbe_Disease
"(reviewed in [<xref rid=""pbio.3001661.ref015"" ref-type=""bibr"">15</xref>]). This demyelination should secondarily affect neurons, whose degeneration likely contributes significantly to major symptoms of the disease. While myelinating glia have traditionally been considered as primary drivers of Krabbe pathogenesis and the cause for most neurological symptoms in Krabbe patients, the extent and contribution for other cell types including neurons remain unknown. In fact, GALC is expressed ubiquitously and",24_7,Neuron-specific ablation of the Krabbe disease gene galactosylceramidase in mice results in neurodegeneration,5 7 2022,,Krabbe_Disease
"In fact, GALC is expressed ubiquitously and peaks at an early developmental period in the brains of postnatal mice [<xref rid=""pbio.3001661.ref016"" ref-type=""bibr"">16</xref>–<xref rid=""pbio.3001661.ref019"" ref-type=""bibr"">19</xref>], indicating a possibility that other brain cells could contribute to the disease. Indeed, evidence suggests that cell types other than OLs could contribute to Krabbe disease. For example, in an in vitro system, cultured axons become primarily and progressively dysfunctional in",24_8,Neuron-specific ablation of the Krabbe disease gene galactosylceramidase in mice results in neurodegeneration,5 7 2022,,Krabbe_Disease
"primarily and progressively dysfunctional in response to psychosine, causing lipid raft clustering and finally generating a dying-back neuropathy [<xref rid=""pbio.3001661.ref016"" ref-type=""bibr"">16</xref>,<xref rid=""pbio.3001661.ref020"" ref-type=""bibr"">20</xref>]. Induced neurons from Krabbe patient’s fibroblasts had axonal defects that might be caused by neuron-autonomous psychosine accumulation [<xref rid=""pbio.3001661.ref021"" ref-type=""bibr"">21</xref>], yet whether the neuroaxonal pathology was",24_9,Neuron-specific ablation of the Krabbe disease gene galactosylceramidase in mice results in neurodegeneration,5 7 2022,,Krabbe_Disease
"yet whether the neuroaxonal pathology was neuron-autonomous remains unclear due to the ubiquitous nature of GALC. It was possible cultured neurons were already conditioned by toxicities from other cell types. Therefore, we previously used <italic toggle=""yes"">Thy1Cre/ER</italic><sup><italic toggle=""yes"">T2</italic></sup>-mediated neuron-specific <italic toggle=""yes"">Galc</italic> knockout (KO) mouse model, to study the neuron-autonomous function of GALC without other cells’ effects [<xref",24_10,Neuron-specific ablation of the Krabbe disease gene galactosylceramidase in mice results in neurodegeneration,5 7 2022,,Krabbe_Disease
"of GALC without other cells’ effects [<xref rid=""pbio.3001661.ref017"" ref-type=""bibr"">17</xref>]. Interestingly, we found that immature neurons are increased in the brain of neuron-specific mutants when GALC is depleted before developmental myelination starts in mice. However, this induced neuron-specific <italic toggle=""yes"">Galc</italic> KO mouse did not show any pathological symptoms including psychosine accumulation. We hypothesized that this might be due to the inability of <italic",24_11,Neuron-specific ablation of the Krabbe disease gene galactosylceramidase in mice results in neurodegeneration,5 7 2022,,Krabbe_Disease
"this might be due to the inability of <italic toggle=""yes"">Thy1Cre/ER</italic><sup><italic toggle=""yes"">T2</italic></sup> mice to have sufficient neuronal expression. To this end, to maximize the ablation effect of <italic toggle=""yes"">Galc</italic> in neurons at all times, in this study, we generated pan-neuronal <italic toggle=""yes"">Galc</italic> KO mice using a <italic toggle=""yes"">Galc-flox</italic> allele [<xref rid=""pbio.3001661.ref017"" ref-type=""bibr"">17</xref>] crossed with <italic",24_12,Neuron-specific ablation of the Krabbe disease gene galactosylceramidase in mice results in neurodegeneration,5 7 2022,,Krabbe_Disease
"ref-type=""bibr"">17</xref>] crossed with <italic toggle=""yes"">Syn1Cre</italic> substrain that deletes <italic toggle=""yes"">Galc</italic> gene constitutively [<xref rid=""pbio.3001661.ref022"" ref-type=""bibr"">22</xref>,<xref rid=""pbio.3001661.ref023"" ref-type=""bibr"">23</xref>]. As expected, the Cre activity was quite robust in most neurons and had a neuropathological phenotype that was not seen in the previous <italic toggle=""yes"">Thy1Cre/ER</italic><sup><italic toggle=""yes"">T2</italic></sup>-mediated <italic",24_13,Neuron-specific ablation of the Krabbe disease gene galactosylceramidase in mice results in neurodegeneration,5 7 2022,,Krabbe_Disease
"toggle=""yes"">T2</italic></sup>-mediated <italic toggle=""yes"">Galc</italic> KO mouse. This model allowed us for the first time in an in vivo system to investigate the neuron-autonomous role of GALC and, furthermore, the effects of neuronal GALC ablation on motor function, biochemical changes, and morphological abnormalities in Krabbe disease. Notably, we showed a distinct neuro-axonal degeneration with a marginal effect on myelin structure, implying a neuron-autonomous GALC function.  We previously",24_14,Neuron-specific ablation of the Krabbe disease gene galactosylceramidase in mice results in neurodegeneration,5 7 2022,,Krabbe_Disease
"a neuron-autonomous GALC function.  We previously identified a critical perinatal period of vulnerability to GALC depletion in mice by inducing ubiquitous <italic toggle=""yes"">Galc</italic> ablation at various postnatal time points. During this vulnerable period, neuron-specific GALC influenced neuronal differentiation without affecting the OLs population. These data led to the discovery of a novel neuronal cell-autonomous role for GALC, which is sufficient to delay neuronal maturation. However, the",24_15,Neuron-specific ablation of the Krabbe disease gene galactosylceramidase in mice results in neurodegeneration,5 7 2022,,Krabbe_Disease
"to delay neuronal maturation. However, the induced neuron-specific <italic toggle=""yes"">Galc</italic> KO mouse did not show any pathological symptoms such as psychosine accumulation [<xref rid=""pbio.3001661.ref017"" ref-type=""bibr"">17</xref>] or gliosis (<bold><xref rid=""pbio.3001661.s004"" ref-type=""supplementary-material"">S4 Fig</xref></bold>). We suspected that this was because <italic toggle=""yes"">Thy1Cre/ER</italic><sup><italic toggle=""yes"">T2</italic></sup>, while specific, was expressed in only a",24_16,Neuron-specific ablation of the Krabbe disease gene galactosylceramidase in mice results in neurodegeneration,5 7 2022,,Krabbe_Disease
"while specific, was expressed in only a small subset of neurons, as many ER<sup>T</sup>-mediated Cre drivers are specific but lack robust and widespread Cre expression. Here, we decided to use the <italic toggle=""yes"">Syn1Cre</italic> mouse as a robust Cre driver among most neurons. In this study, we showed that GALC has a neuron-autonomous role, and its absence in neurons triggers neuro-axonal degeneration and subsequent inflammatory demyelination by affecting other brain cells. Considering the more",24_17,Neuron-specific ablation of the Krabbe disease gene galactosylceramidase in mice results in neurodegeneration,5 7 2022,,Krabbe_Disease
"affecting other brain cells. Considering the more severe phenotype of the <italic toggle=""yes"">Syn1Cre; Galc flox/−</italic> mice compared to the previous <italic toggle=""yes"">Thy1Cre/ER</italic><sup><italic toggle=""yes"">T2</italic></sup><italic toggle=""yes"">; Galc flox/−</italic> model, the depletion of neuronal GALC is likely multifactorial wherein the constitutively active <italic toggle=""yes"">Syn1Cre</italic> is able to elicit further pathological consequences beyond the delayed neuronal maturation",24_18,Neuron-specific ablation of the Krabbe disease gene galactosylceramidase in mice results in neurodegeneration,5 7 2022,,Krabbe_Disease
"beyond the delayed neuronal maturation phenotype of the critical perinatal period observed in both models. (<bold><xref rid=""pbio.3001661.g005"" ref-type=""fig"">Fig 5E and 5F</xref></bold>). It is possible that a specific type of CNS neuron is crucial for the phenotype of <italic toggle=""yes"">Syn1Cre; Galc flox/−</italic>. Since MN-specific <italic toggle=""yes"">HB9Cre; Galc flox/−</italic> mice had no abnormal phenotype (<bold>Figs <xref rid=""pbio.3001661.g006"" ref-type=""fig"">6</xref> and <xref",24_19,Neuron-specific ablation of the Krabbe disease gene galactosylceramidase in mice results in neurodegeneration,5 7 2022,,Krabbe_Disease
"ref-type=""fig"">6</xref> and <xref rid=""pbio.3001661.g007"" ref-type=""fig"">7</xref></bold>), the critical neurons in the <italic toggle=""yes"">Syn1Cre; Galc flox/−</italic> pathology are likely non-MNs based in the CNS. Our prior study [<xref rid=""pbio.3001661.ref017"" ref-type=""bibr"">17</xref>] revealed a subregion of the brainstem in which perinatal GALC is important. Therefore, our findings suggest that neuronal GALC has a primary role in neuronal homeostasis. Disruption of neuronal homeostasis (<bold><xref",24_20,Neuron-specific ablation of the Krabbe disease gene galactosylceramidase in mice results in neurodegeneration,5 7 2022,,Krabbe_Disease
"Disruption of neuronal homeostasis (<bold><xref rid=""pbio.3001661.g004"" ref-type=""fig"">Fig 4</xref></bold>), caused by the ablation of neuronal GALC, influences myelin thickness and myelin protein levels (<bold><xref rid=""pbio.3001661.g007"" ref-type=""fig"">Fig 7</xref></bold>). This happens, at least in part, independently of GALC absence in myelinating cells. No change in the number of OL lineage cells in the perinatal brains of <italic toggle=""yes"">Syn1Cre; Galc flox/−</italic> indicates that the myelin",24_21,Neuron-specific ablation of the Krabbe disease gene galactosylceramidase in mice results in neurodegeneration,5 7 2022,,Krabbe_Disease
"Galc flox/−</italic> indicates that the myelin phenotype in <italic toggle=""yes"">Syn1Cre; Galc flox/−</italic> may not be due to loss of gliogenesis but presumably toxicity from GALC-deficient neurons such as psychosine (<bold><xref rid=""pbio.3001661.g007"" ref-type=""fig"">Fig 7H</xref></bold>). A recent publication from Reiter and colleagues [<xref rid=""pbio.3001661.ref042"" ref-type=""bibr"">42</xref>] demonstrated appreciable levels of psychosine in extracellular vesicles of the <italic",24_22,Neuron-specific ablation of the Krabbe disease gene galactosylceramidase in mice results in neurodegeneration,5 7 2022,,Krabbe_Disease
"in extracellular vesicles of the <italic toggle=""yes"">twitcher</italic> mouse, providing proof of concept to the idea that psychosine of neuronal origin may influence the health of neighboring cells. Alternatively, in line with recent studies showing that electrically active neurons can signal nearby OPCs to initiate proliferation and/or differentiation to mature OLs in response to environmental cues [<xref rid=""pbio.3001661.ref043"" ref-type=""bibr"">43</xref>], it is possible that deletion of <italic",24_23,Neuron-specific ablation of the Krabbe disease gene galactosylceramidase in mice results in neurodegeneration,5 7 2022,,Krabbe_Disease
"it is possible that deletion of <italic toggle=""yes"">Galc</italic> in neurons alters neuronal activity and its effect on myelination. Moreover, it is possible that the survival of OLs may be dependent on the presence of healthy axons as shown by the death of approximately 50% of OLs in the optic nerve due to loss of axonal substrate [<xref rid=""pbio.3001661.ref044"" ref-type=""bibr"">44</xref>]. Furthermore, the signals from axons that promote myelination must also be considered. Neuronal signals, such as",24_24,Neuron-specific ablation of the Krabbe disease gene galactosylceramidase in mice results in neurodegeneration,5 7 2022,,Krabbe_Disease
"also be considered. Neuronal signals, such as neuregulins, Notch-1, neurotrophins, and polysialylated-neural cell adhesion molecules, from the axonal membrane regulate myelination, integrating signals from multiple axons, with different caliber and electrical activity (reviewed in [<xref rid=""pbio.3001661.ref045"" ref-type=""bibr"">45</xref>]). In addition, neurons and glia interact via extracellular vesicles called exosomes that carry a variety of metabolites, proteins, lipids, mRNAs, and miRNAs [<xref",24_25,Neuron-specific ablation of the Krabbe disease gene galactosylceramidase in mice results in neurodegeneration,5 7 2022,,Krabbe_Disease
"proteins, lipids, mRNAs, and miRNAs [<xref rid=""pbio.3001661.ref046"" ref-type=""bibr"">46</xref>]. Since these secretory organelles share the common lysosomal pathway, it is conceivable that dysfunctional lysosomal secretory pathways in neurons caused by <italic toggle=""yes"">Galc</italic> deletion may trigger aberrant communication between neurons and OLs, eventually affecting myelination. We are the first to show that psychosine is accumulated in vivo in the <italic toggle=""yes"">Galc</italic>-deleted",24_26,Neuron-specific ablation of the Krabbe disease gene galactosylceramidase in mice results in neurodegeneration,5 7 2022,,Krabbe_Disease
"in the <italic toggle=""yes"">Galc</italic>-deleted neurons (<bold><xref rid=""pbio.3001661.g006"" ref-type=""fig"">Fig 6F</xref></bold>) and is accompanied by axonal degeneration and mild myelin loss, proving that neurons could be one of the primary cell types targeted by the pathology independently from other cell type contributions. The psychosine accumulation was not seen in our previous study using <italic toggle=""yes"">Thy1Cre/ER</italic><sup><italic toggle=""yes"">T2</italic></sup>-mediated <italic",24_27,Neuron-specific ablation of the Krabbe disease gene galactosylceramidase in mice results in neurodegeneration,5 7 2022,,Krabbe_Disease
"toggle=""yes"">T2</italic></sup>-mediated <italic toggle=""yes"">Galc</italic> ablation [<xref rid=""pbio.3001661.ref017"" ref-type=""bibr"">17</xref>]. This discrepancy might be due to the fact that <italic toggle=""yes"">Thy1Cre/ER</italic><sup><italic toggle=""yes"">T2</italic></sup> only mediates temporal GALC depletion with tamoxifen whereas <italic toggle=""yes"">Syn1Cre</italic> is constitutively active. It may be the case that a majority of neuronal psychosine is generated early in neurogenesis when neurite",24_28,Neuron-specific ablation of the Krabbe disease gene galactosylceramidase in mice results in neurodegeneration,5 7 2022,,Krabbe_Disease
"is generated early in neurogenesis when neurite extension and membrane synthesis is at its height. If that is the case, then the <italic toggle=""yes"">Thy1Cre/ER</italic><sup><italic toggle=""yes"">T2</italic></sup> model would miss the window of peak neuronal psychosine formation whereas <italic toggle=""yes"">Syn1Cre</italic> would permit psychosine generation prenatally. Furthermore, considering the transient persistence of tamoxifen, while many neurons would be subject to recombination, the effects of this",24_29,Neuron-specific ablation of the Krabbe disease gene galactosylceramidase in mice results in neurodegeneration,5 7 2022,,Krabbe_Disease
"be subject to recombination, the effects of this could be diluted out by neurons differentiated past this window. The accumulation of psychosine is proposed to be responsible for significant pathology found in Krabbe disease. Psychosine can intercalate into membrane microdomains in the brain of Krabbe patients, disrupting the lipid raft structure [<xref rid=""pbio.3001661.ref005"" ref-type=""bibr"">5</xref>], which is highly enriched in signal-transducing proteins and thus affects multiple signaling pathways",24_30,Neuron-specific ablation of the Krabbe disease gene galactosylceramidase in mice results in neurodegeneration,5 7 2022,,Krabbe_Disease
"and thus affects multiple signaling pathways critical to neuronal development, function, and axonal guidance [<xref rid=""pbio.3001661.ref047"" ref-type=""bibr"">47</xref>, <xref rid=""pbio.3001661.ref048"" ref-type=""bibr"">48</xref>]. Specifically, psychosine abolishes the protein kinase C signal pathway [<xref rid=""pbio.3001661.ref005"" ref-type=""bibr"">5</xref>], which is critical for synaptic plasticity as well as myelination in OLs [<xref rid=""pbio.3001661.ref049"" ref-type=""bibr"">49</xref>,<xref",24_31,Neuron-specific ablation of the Krabbe disease gene galactosylceramidase in mice results in neurodegeneration,5 7 2022,,Krabbe_Disease
"ref-type=""bibr"">49</xref>,<xref rid=""pbio.3001661.ref050"" ref-type=""bibr"">50</xref>]. Psychosine also impairs the axonal transport and synaptic structures by dephosphorylating neurofilaments [<xref rid=""pbio.3001661.ref051"" ref-type=""bibr"">51</xref>,<xref rid=""pbio.3001661.ref052"" ref-type=""bibr"">52</xref>]. Since synaptic terminals are most exposed to astrocytic and microglial processes, accumulation of psychosine at the synapse would trigger a cascade of responses leading to exacerbated neuroinflammation",24_32,Neuron-specific ablation of the Krabbe disease gene galactosylceramidase in mice results in neurodegeneration,5 7 2022,,Krabbe_Disease
"leading to exacerbated neuroinflammation [<xref rid=""pbio.3001661.ref053"" ref-type=""bibr"">53</xref>,<xref rid=""pbio.3001661.ref054"" ref-type=""bibr"">54</xref>] and neurodegeneration as seen in the neuron-specific <italic toggle=""yes"">Galc</italic>-CKO brain (<bold>Figs <xref rid=""pbio.3001661.g004"" ref-type=""fig"">4</xref></bold> and <bold><xref rid=""pbio.3001661.g006"" ref-type=""fig"">6</xref></bold>). This possibility is also supported by a recent finding that GALC-deficient immature neurons are more",24_33,Neuron-specific ablation of the Krabbe disease gene galactosylceramidase in mice results in neurodegeneration,5 7 2022,,Krabbe_Disease
"that GALC-deficient immature neurons are more vulnerable to accumulated psychosine, less responsive to external signals, and eventually eliminated [<xref rid=""pbio.3001661.ref017"" ref-type=""bibr"">17</xref>,<xref rid=""pbio.3001661.ref055"" ref-type=""bibr"">55</xref>]. Last, it is possible that psychosine may alkalize the lysosomal pH in GALC-deficient neurons, as shown in <italic toggle=""yes"">Galc</italic>-KO OPCs [<xref rid=""pbio.3001661.ref008"" ref-type=""bibr"">8</xref>]. It is likely that the lysosomal",24_34,Neuron-specific ablation of the Krabbe disease gene galactosylceramidase in mice results in neurodegeneration,5 7 2022,,Krabbe_Disease
"It is likely that the lysosomal reacidification that rescued OPC proliferation would be beneficial to neuronal health as well. However, despite a significantly reduced body weight along with the neurological phenotype, neuron-specific <italic toggle=""yes"">Galc</italic>-CKO mice did not show a reduced life span as with the global <italic toggle=""yes"">Galc-</italic>KO [<xref rid=""pbio.3001661.ref017"" ref-type=""bibr"">17</xref>] (<bold><xref rid=""pbio.3001661.g003"" ref-type=""fig"">Fig 3</xref></bold>),",24_35,Neuron-specific ablation of the Krabbe disease gene galactosylceramidase in mice results in neurodegeneration,5 7 2022,,Krabbe_Disease
"ref-type=""fig"">Fig 3</xref></bold>), indicating that the nonneuronal autonomous process is critical to make a full Krabbe disease phenotype. Psychosine is known to be formed in at least 2 different ways: by ceramide galactosyltransferase (UGT8) via galactosylation of sphingosine [<xref rid=""pbio.3001661.ref014"" ref-type=""bibr"">14</xref>], or by acid-ceramidase with deacylation of GalCer [<xref rid=""pbio.3001661.ref002"" ref-type=""bibr"">2</xref>]. While it is true that UGT8 is highly enriched in OLs and",24_36,Neuron-specific ablation of the Krabbe disease gene galactosylceramidase in mice results in neurodegeneration,5 7 2022,,Krabbe_Disease
"is true that UGT8 is highly enriched in OLs and Schwann cells, there is evidence via in situ hybridization that the <italic toggle=""yes"">UGT8</italic> transcript exists at low levels in particular subsets of neurons including in the deep cerebellar nuclei, lateral cerebellar nuclei, and lateral vestibular nuclei [<xref rid=""pbio.3001661.ref056"" ref-type=""bibr"">56</xref>]. These neurons should therefore have the capability for de novo (and autonomous) synthesis of psychosine from galactose and sphingosine.",24_37,Neuron-specific ablation of the Krabbe disease gene galactosylceramidase in mice results in neurodegeneration,5 7 2022,,Krabbe_Disease
"of psychosine from galactose and sphingosine. Alternatively, it is possible that psychosine can be generated from neuronal GalCer. Our preliminary colocalization study of GalCer (O1 antibody) with Npas4 (neuronal marker) in the murine brain shows the presence of neuronal GalCer (<bold><xref rid=""pbio.3001661.s005"" ref-type=""supplementary-material"">S5 Fig</xref></bold>), suggesting GalCer is a component of neuronal cell membranes. A number of studies highlight the importance of GalCer in neurons. In",24_38,Neuron-specific ablation of the Krabbe disease gene galactosylceramidase in mice results in neurodegeneration,5 7 2022,,Krabbe_Disease
"highlight the importance of GalCer in neurons. In juvenile neuronal ceroid lipofuscinosis, which is caused by mutations in the <italic toggle=""yes"">CLN3</italic> gene, neuronal GalCer expression and transport is important and thus a defect in the anterograde transport of GalCer from the trans-Golgi to lipid rafts of plasma membrane affects the proper composition, structure, and function of plasma membranes, which, in turn, leads to deregulation of ceramide levels with an end effect of increased neuronal",24_39,Neuron-specific ablation of the Krabbe disease gene galactosylceramidase in mice results in neurodegeneration,5 7 2022,,Krabbe_Disease
"levels with an end effect of increased neuronal apoptosis [<xref rid=""pbio.3001661.ref057"" ref-type=""bibr"">57</xref>]. Since acid ceramidase is expressed ubiquitously, it is conceivable that psychosine can be generated from the deacylation of neuronal GalCer [<xref rid=""pbio.3001661.ref002"" ref-type=""bibr"">2</xref>]. Last, recent evidence indicating the presence of OL-derived exosomes that traverse the periaxonal space to be internalized by axons could provide a source of extra-neuronal GalCer [<xref",24_40,Neuron-specific ablation of the Krabbe disease gene galactosylceramidase in mice results in neurodegeneration,5 7 2022,,Krabbe_Disease
"provide a source of extra-neuronal GalCer [<xref rid=""pbio.3001661.ref058"" ref-type=""bibr"">58</xref>]. These exosomes have been shown to deliver the NAD-dependent deacetylase SIRT2 to promote local ATP production. The import of these transcellular exosomes can provide a route for GalCer to be ushered into neurons, which could be exacerbated in the case of axonal dysfunction. Although <italic toggle=""yes"">Syn1Cre; Galc flox/−</italic> mice had neuronal pathology with central myelination defects, they did",24_41,Neuron-specific ablation of the Krabbe disease gene galactosylceramidase in mice results in neurodegeneration,5 7 2022,,Krabbe_Disease
"with central myelination defects, they did not show overt signs of demyelination or other pathological hallmarks in the PNS. These mice had largely unchanged nerve morphology including normal axonal numbers and density, as well as normal myelin thickness and appearance. This is surprising, as <italic toggle=""yes"">Syn1Cre</italic> was efficiently expressed in the PNS (<bold>Figs <xref rid=""pbio.3001661.g008"" ref-type=""fig"">8</xref> and</bold>",24_42,Neuron-specific ablation of the Krabbe disease gene galactosylceramidase in mice results in neurodegeneration,5 7 2022,,Krabbe_Disease
"<xref rid=""pbio.3001661.s003"" ref-type=""supplementary-material"">S3</xref>). Widespread demyelination and edema are prevalent in the peripheral nerves of Krabbe models and patients [<xref rid=""pbio.3001661.ref020"" ref-type=""bibr"">20</xref>,<xref rid=""pbio.3001661.ref040"" ref-type=""bibr"">40</xref>,<xref rid=""pbio.3001661.ref041"" ref-type=""bibr"">41</xref>]. Of note, Teixeira and colleagues [<xref rid=""pbio.3001661.ref020"" ref-type=""bibr"">20</xref>] showed that the sciatic nerves of <italic",24_43,Neuron-specific ablation of the Krabbe disease gene galactosylceramidase in mice results in neurodegeneration,5 7 2022,,Krabbe_Disease
"showed that the sciatic nerves of <italic toggle=""yes"">twitcher</italic> mice had fewer axonal numbers before demyelination and endoneurial edema was evident, which seems not caused by a developmental impairment since the axonal density was not changed at birth. Our prior work [<xref rid=""pbio.3001661.ref040"" ref-type=""bibr"">40</xref>] also showed that axonal reduction of global <italic toggle=""yes"">Galc</italic> KO nerves was quantified to approximately 10% in the entire nerve cross-section. The",24_44,Neuron-specific ablation of the Krabbe disease gene galactosylceramidase in mice results in neurodegeneration,5 7 2022,,Krabbe_Disease
"10% in the entire nerve cross-section. The discrepancy between the current study and other previous studies may imply that the reduced myelinated axons in the <italic toggle=""yes"">twitcher</italic> model is caused not only by neuron-autonomous GALC but also by other cells’ effects and interplay including myelinating cells. Lipofuscin pigment granules, which reflect lipid-containing residues of lysosomal digestion, are found in the cytoplasm of neurons in patients with neurodegenerative diseases like",24_45,Neuron-specific ablation of the Krabbe disease gene galactosylceramidase in mice results in neurodegeneration,5 7 2022,,Krabbe_Disease
"in patients with neurodegenerative diseases like Alzheimer, Parkinson, and some lysosomal storage diseases [<xref rid=""pbio.3001661.ref032"" ref-type=""bibr"">32</xref>,<xref rid=""pbio.3001661.ref059"" ref-type=""bibr"">59</xref>]. We found increased levels of lipofuscin in the brains of <italic toggle=""yes"">Syn1Cre; Galc flox/−</italic> mice (<bold><xref rid=""pbio.3001661.g004"" ref-type=""fig"">Fig 4F</xref></bold>), suggesting an underlying similarity between this mouse model and other neurodegenerative",24_46,Neuron-specific ablation of the Krabbe disease gene galactosylceramidase in mice results in neurodegeneration,5 7 2022,,Krabbe_Disease
"this mouse model and other neurodegenerative diseases. In line with this, the <italic toggle=""yes"">GALC</italic> gene was found to be a disease risk locus for Parkinson disease, along with other lysosomal genes such as glucocerebrosidase (<italic toggle=""yes"">GBA</italic>) [<xref rid=""pbio.3001661.ref060"" ref-type=""bibr"">60</xref>]. Therefore, lysosomal dysfunction is likely involved in the underlying pathogenesis of Parkinson disease. Furthermore, the role of lysosomal biology in the degradation of",24_47,Neuron-specific ablation of the Krabbe disease gene galactosylceramidase in mice results in neurodegeneration,5 7 2022,,Krabbe_Disease
"role of lysosomal biology in the degradation of protein aggregates has recently emerged in the risk of developing Parkinson disease. The most common Parkinson disease–related mutation is <italic toggle=""yes"">GBA</italic>, the enzyme defunct in Gaucher disease, with many patients and carriers of Gaucher disease develop Parkinsonian symptoms in later life (reviewed in [<xref rid=""pbio.3001661.ref061"" ref-type=""bibr"">61</xref>]). It is therefore reasonable to suspect that perturbed lysosomal function of",24_48,Neuron-specific ablation of the Krabbe disease gene galactosylceramidase in mice results in neurodegeneration,5 7 2022,,Krabbe_Disease
"to suspect that perturbed lysosomal function of dopaminergic neurons may be related to the pathology and symptoms of <italic toggle=""yes"">Syn1Cre; Galc flox/−</italic> mice. These data would also correlate with a number of recent studies that show GALC deficiency is associated with other pathologic signs of Parkinson disease [<xref rid=""pbio.3001661.ref062"" ref-type=""bibr"">62</xref>–<xref rid=""pbio.3001661.ref064"" ref-type=""bibr"">64</xref>]. The aggregated forms of alpha-synuclein and ubiquitin, which are",24_49,Neuron-specific ablation of the Krabbe disease gene galactosylceramidase in mice results in neurodegeneration,5 7 2022,,Krabbe_Disease
"forms of alpha-synuclein and ubiquitin, which are involved in the formation of Lewy bodies in Parkinson disease, are accumulated in the brains of both Krabbe patients and the <italic toggle=""yes"">twitcher</italic> mouse model. Therefore, our findings of the increased lipofuscin and lysosomal inclusions in the brains of <italic toggle=""yes"">Syn1Cre; Galc flox/−</italic> mice suggest a potential role of neuronal GALC in age-related neurodegenerative diseases. Using Thy1.1-YFP reporter mice that can visualize",24_50,Neuron-specific ablation of the Krabbe disease gene galactosylceramidase in mice results in neurodegeneration,5 7 2022,,Krabbe_Disease
"Using Thy1.1-YFP reporter mice that can visualize neuro-axonal structures [<xref rid=""pbio.3001661.ref034"" ref-type=""bibr"">34</xref>], we found a dramatic reduction of YFP signals in the neuron-specific <italic toggle=""yes"">Galc</italic>-CKO brain (<bold><xref rid=""pbio.3001661.g005"" ref-type=""fig"">Fig 5A and 5B</xref></bold>), similar to the phenotype seen in global <italic toggle=""yes"">Galc</italic>-KO animal models [<xref rid=""pbio.3001661.ref017"" ref-type=""bibr"">17</xref>]. The parallel finding of",24_51,Neuron-specific ablation of the Krabbe disease gene galactosylceramidase in mice results in neurodegeneration,5 7 2022,,Krabbe_Disease
"The parallel finding of decreased presynaptic SPH in the mutant brain (<bold><xref rid=""pbio.3001661.g005"" ref-type=""fig"">Fig 5C and 5D</xref></bold>) suggests diminished synaptic structures due to <italic toggle=""yes"">Galc</italic> deficiency. In fact, it has been reported that neuronal lysosomes regulate synaptic structures and activity [<xref rid=""pbio.3001661.ref065"" ref-type=""bibr"">65</xref>,<xref rid=""pbio.3001661.ref066"" ref-type=""bibr"">66</xref>]. For example, they dynamically modulate dendritic",24_52,Neuron-specific ablation of the Krabbe disease gene galactosylceramidase in mice results in neurodegeneration,5 7 2022,,Krabbe_Disease
"For example, they dynamically modulate dendritic spine numbers in an activity-dependent manner [<xref rid=""pbio.3001661.ref067"" ref-type=""bibr"">67</xref>,<xref rid=""pbio.3001661.ref068"" ref-type=""bibr"">68</xref>]. Moreover, neuronal lysosomes undergo regulated exocytosis to aid in the membrane expansion during dendrite formation, ultimately aiding in the plasticity of dendritic spines [<xref rid=""pbio.3001661.ref069"" ref-type=""bibr"">69</xref>]. Neuronal lysosomes also regulate the fate of the",24_53,Neuron-specific ablation of the Krabbe disease gene galactosylceramidase in mice results in neurodegeneration,5 7 2022,,Krabbe_Disease
"Neuronal lysosomes also regulate the fate of the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors to control the excitatory synaptic signal strength [<xref rid=""pbio.3001661.ref070"" ref-type=""bibr"">70</xref>]. Finally, postmitotic neurons require constant membrane remodeling, in which lysosomes are imperative to release and uptake synaptic vesicles [<xref rid=""pbio.3001661.ref071"" ref-type=""bibr"">71</xref>,<xref rid=""pbio.3001661.ref072"" ref-type=""bibr"">72</xref>]. Therefore, it is",24_54,Neuron-specific ablation of the Krabbe disease gene galactosylceramidase in mice results in neurodegeneration,5 7 2022,,Krabbe_Disease
"ref-type=""bibr"">72</xref>]. Therefore, it is highly likely that GALC-deficient lysosomes may be dysfunctional, which results in the aberrant synapse and dendritic spines leading to neuronal degeneration and abnormalities. A prominent feature of Krabbe disease is neuroinflammation that includes widespread gliosis and exponential increase of proinflammatory chemokines [<xref rid=""pbio.3001661.ref073"" ref-type=""bibr"">73</xref>]. Our neuronal <italic toggle=""yes"">Galc</italic> deletion also induces",24_55,Neuron-specific ablation of the Krabbe disease gene galactosylceramidase in mice results in neurodegeneration,5 7 2022,,Krabbe_Disease
"toggle=""yes"">Galc</italic> deletion also induces inflammatory gliosis with increased proinflammatory cytokines in the brain (<bold><xref rid=""pbio.3001661.g006"" ref-type=""fig"">Fig 6</xref></bold>), akin to the phenotype seen in genuine Krabbe animal models and patients [<xref rid=""pbio.3001661.ref017"" ref-type=""bibr"">17</xref>,<xref rid=""pbio.3001661.ref040"" ref-type=""bibr"">40</xref>]. Although immune surveillance and protection via the propagation of inflammatory responses are the main functions,",24_56,Neuron-specific ablation of the Krabbe disease gene galactosylceramidase in mice results in neurodegeneration,5 7 2022,,Krabbe_Disease
"of inflammatory responses are the main functions, microglia also modulate synaptic pruning and learning, demonstrating their benefit and necessity to normal brain function [<xref rid=""pbio.3001661.ref074"" ref-type=""bibr"">74</xref>]. However, there is a downside as these cells can increase the permeability of the blood–brain barrier, and thus, their overrecruitment can be destructive, causing a loss of myelin and neuronal death [<xref rid=""pbio.3001661.ref075"" ref-type=""bibr"">75</xref>,<xref",24_57,Neuron-specific ablation of the Krabbe disease gene galactosylceramidase in mice results in neurodegeneration,5 7 2022,,Krabbe_Disease
"ref-type=""bibr"">75</xref>,<xref rid=""pbio.3001661.ref076"" ref-type=""bibr"">76</xref>]. Our previous finding in which inflammation is elicited by myelin debris in <italic toggle=""yes"">Galc</italic>-deficient macrophages [<xref rid=""pbio.3001661.ref040"" ref-type=""bibr"">40</xref>] allows us to speculate that the inflammation seen in the neuronal <italic toggle=""yes"">Galc</italic>-CKO model may be mediated by degenerated neurons and axons. In summary, our findings highlight that GALC-deficient neurons can",24_58,Neuron-specific ablation of the Krabbe disease gene galactosylceramidase in mice results in neurodegeneration,5 7 2022,,Krabbe_Disease
"highlight that GALC-deficient neurons can generate psychosine in vivo, which may, in turn, induce neuronal death, inflammation, and myelin loss. We confirmed that OLs are not the sole cell type responsible for initiating Krabbe pathogenesis, as <italic toggle=""yes"">Galc</italic>-ablated neurons contribute in a cell-autonomous manner to disease progression and are sufficient to cause some component of the disease. This may indicate the presence of specific cellular mechanisms of GALC function in neurons",24_59,Neuron-specific ablation of the Krabbe disease gene galactosylceramidase in mice results in neurodegeneration,5 7 2022,,Krabbe_Disease
"cellular mechanisms of GALC function in neurons that need to be corrected to cure the disease. Furthermore, Parkinson disease–like pathology in the neuron-specific <italic toggle=""yes"">Galc</italic> KO such as lipofuscin accumulation may provide evidence of the connection between GALC dysfunction and the pathogenic mechanism of other neurodegenerative diseases. Further studies will elaborate on the specific molecular mechanisms in which neuronal <italic toggle=""yes"">Galc</italic> deletion triggers cellular",24_60,Neuron-specific ablation of the Krabbe disease gene galactosylceramidase in mice results in neurodegeneration,5 7 2022,,Krabbe_Disease
deletion triggers cellular and lysosomal pathogenesis in Krabbe disease and if similar processes occur in other lysosomal storage diseases.,24_61,Neuron-specific ablation of the Krabbe disease gene galactosylceramidase in mice results in neurodegeneration,5 7 2022,,Krabbe_Disease
"“Atypical” Krabbe disease in two siblings harboring biallelic <italic toggle=""yes"">GALC</italic> mutations including a deep intronic variant Krabbe disease (KD) is a rare lysosomal storage disorder caused by biallelic pathogenic variants in <italic toggle=""yes"">GALC</italic>. Most patients manifest the severe classic early-infantile form, while a small percentage of cases have later-onset types. We present two siblings with atypical clinical and neuroimaging phenotypes, compared to the classification of KD,",25_0,"“Atypical” Krabbe disease in two siblings harboring biallelic <italic toggle=""yes"">GALC</italic> mutations including a deep intronic variant",17 5 2022,,Krabbe_Disease
"phenotypes, compared to the classification of KD, who were found to carry biallelic loss-of-function <italic toggle=""yes"">GALC</italic> variants, including a recurrent 30 kb deletion and a previously unreported deep intronic variant that was identified by mRNA sequencing. This family represents a unique description in the KD literature and contributes to expanding the clinical and molecular spectra of this rare disorder. Full text not available in PMC",25_1,"“Atypical” Krabbe disease in two siblings harboring biallelic <italic toggle=""yes"">GALC</italic> mutations including a deep intronic variant",17 5 2022,,Krabbe_Disease
"Efficacy and Safety of a Krabbe Disease Gene Therapy Krabbe disease is a lysosomal storage disease caused by mutations in the gene that encodes galactosylceramidase, in which galactosylsphingosine (psychosine) accumulation drives demyelination in the central and peripheral nervous systems, ultimately progressing to death in early childhood. Gene therapy, alone or in combination with transplant, has been developed for almost two decades in mouse models, with increasing therapeutic benefit paralleling the",26_0,Efficacy and Safety of a Krabbe Disease Gene Therapy,01 5 2022 May 2022,,Krabbe_Disease
"increasing therapeutic benefit paralleling the improvement of next-generation adeno-associated virus (AAV) vectors. This effort has recently shown remarkable efficacy in the canine model of the disease by two different groups that used either systemic or cerebrospinal fluid (CSF) administration of AAVrh10 or AAV9. Building on our experience developing CSF-delivered, AAV-based drug products for a variety of neurodegenerative disorders, we conducted efficacy, pharmacology, and safety studies of AAVhu68",26_1,Efficacy and Safety of a Krabbe Disease Gene Therapy,01 5 2022 May 2022,,Krabbe_Disease
"pharmacology, and safety studies of AAVhu68 delivered to the CSF in two relevant natural Krabbe animal models, and in nonhuman primates. In newborn Twitcher mice, the highest dose (1 × 10<sup>11</sup> genome copies [GC]) of AAVhu68.hGALC injected into the lateral ventricle led to a median survival of 130 days compared to 40.5 days in vehicle-treated mice. When this dose was administered intravenously, the median survival was 49 days. A single intracisterna magna injection of AAVhu68.cGALC at",26_2,Efficacy and Safety of a Krabbe Disease Gene Therapy,01 5 2022 May 2022,,Krabbe_Disease
"intracisterna magna injection of AAVhu68.cGALC at 3 × 10<sup>13</sup> GC into presymptomatic Krabbe dogs increased survival for up to 85 weeks compared to 12 weeks in controls. It prevented psychosine accumulation in the CSF, preserved peripheral nerve myelination, ambulation, and decreased brain neuroinflammation and demyelination, although some regions remained abnormal. In a Good Laboratory Practice-compliant toxicology study, we administered the clinical candidate into the cisterna magna of 18 juvenile",26_3,Efficacy and Safety of a Krabbe Disease Gene Therapy,01 5 2022 May 2022,,Krabbe_Disease
"candidate into the cisterna magna of 18 juvenile rhesus macaques at 3 doses that displayed efficacy in mice. We observed no dose-limiting toxicity and sporadic minimal degeneration of dorsal root ganglia (DRG) neurons. Our studies demonstrate the efficacy, scalability, and safety of a single cisterna magna AAVhu68 administration to treat Krabbe disease. <uri http://www.w3.org/1999/xlink href=""http://ClinicalTrials.Gov"">ClinicalTrials.Gov</uri> ID: NCT04771416. Krabbe disease (globoid cell leukodystrophy)",26_4,Efficacy and Safety of a Krabbe Disease Gene Therapy,01 5 2022 May 2022,,Krabbe_Disease
"Krabbe disease (globoid cell leukodystrophy) is an autosomal recessive lysosomal storage disease caused by mutations in the gene encoding the hydrolytic enzyme galactosylceramidase (GALC).<sup><xref rid=""B1"" ref-type=""bibr"">1</xref></sup> This enzyme is responsible for the degradation of galactosylceramide (GalCer; a type of ceramide) and galactosylsphingosine (psychosine). GALC deficiency causes toxic accumulation of psychosine in the plasma membrane of cells throughout the nervous system.<sup><xref",26_5,Efficacy and Safety of a Krabbe Disease Gene Therapy,01 5 2022 May 2022,,Krabbe_Disease
"of cells throughout the nervous system.<sup><xref rid=""B2"" ref-type=""bibr"">2</xref>,<xref rid=""B3"" ref-type=""bibr"">3</xref></sup> The myelin-producing oligodendrocytes in the central nervous system (CNS) and Schwann cells in the peripheral nervous system (PNS) are sensitive to psychosine accumulation, which can cause death of these cell populations.<sup><xref rid=""B4"" ref-type=""bibr"">4</xref></sup> However, recent work suggests that other cell-autonomous defects in neurons and macrophages also contribute",26_6,Efficacy and Safety of a Krabbe Disease Gene Therapy,01 5 2022 May 2022,,Krabbe_Disease
"in neurons and macrophages also contribute to the pathophysiology of Krabbe disease.<sup><xref rid=""B5"" ref-type=""bibr"">5–8</xref></sup> The breakdown of myelin in the CNS and PNS is accompanied by reactive astrocytic gliosis, microgliosis, and the infiltration of macrophages that cannot digest the myelin debris due to their enzymatic deficit. The phagocytic cells adopt a giant multinucleated morphology (“globoid cells”) that is characteristic of the progressive severe neuroinflammation associated with",26_7,Efficacy and Safety of a Krabbe Disease Gene Therapy,01 5 2022 May 2022,,Krabbe_Disease
"severe neuroinflammation associated with Krabbe disease.<sup><xref rid=""B8"" ref-type=""bibr"">8–10</xref></sup> Clinically, Krabbe disease is divided into four forms, depending on age at symptom-onset: early infantile; late infantile; juvenile; and adolescent or adult Krabbe disease. The most severe early infantile form manifests before 6 months of age and is fatal by 2 years of age in most patients.<sup><xref rid=""B11"" ref-type=""bibr"">11–13</xref></sup> Demyelination and globoid cell infiltration affects",26_8,Efficacy and Safety of a Krabbe Disease Gene Therapy,01 5 2022 May 2022,,Krabbe_Disease
"and globoid cell infiltration affects both the peripheral nerves and CNS. Disease progression in peripheral nerves can be monitored via nerve conduction velocity testing, while CNS white matter demyelination can be visualized on magnetic resonance imaging (MRI),<sup><xref rid=""B14"" ref-type=""bibr"">14</xref></sup> and manifest as abnormal brainstem auditory evoked responses.<sup><xref rid=""B11"" ref-type=""bibr"">11</xref>,<xref rid=""B15"" ref-type=""bibr"">15</xref>,<xref rid=""B16""",26_9,Efficacy and Safety of a Krabbe Disease Gene Therapy,01 5 2022 May 2022,,Krabbe_Disease
"ref-type=""bibr"">15</xref>,<xref rid=""B16"" ref-type=""bibr"">16</xref></sup> The only disease-modifying treatment—hematopoietic stem cell transplantation (HSCT)—shows significant survival benefit when performed in presymptomatic newborns.<sup><xref rid=""B17"" ref-type=""bibr"">17</xref></sup> However, the therapeutic window is narrow due to the competition between rapid disease progression and slow cell engraftment in the CNS. Transplant is only efficacious when performed within the first month of life; even",26_10,Efficacy and Safety of a Krabbe Disease Gene Therapy,01 5 2022 May 2022,,Krabbe_Disease
"performed within the first month of life; even then, motor outcomes are poor and peripheral neuropathy remains unaffected.<sup><xref rid=""B13"" ref-type=""bibr"">13</xref>,<xref rid=""B17"" ref-type=""bibr"">17–19</xref></sup> Development of experimental treatments for Krabbe disease benefits from the availability of multiple relevant animal models from mouse and dog to nonhuman primates.<sup><xref rid=""B20"" ref-type=""bibr"">20–22</xref></sup> Early work using recombinant enzyme replacement therapy administered",26_11,Efficacy and Safety of a Krabbe Disease Gene Therapy,01 5 2022 May 2022,,Krabbe_Disease
"enzyme replacement therapy administered weekly into the peritoneal cavity or once into the lateral ventricle of Twitcher mice demonstrated a modest survival benefit and reduction of psychosine levels, paving the way for other therapies that rely on cross correction.<sup><xref rid=""B23"" ref-type=""bibr"">23</xref>,<xref rid=""B24"" ref-type=""bibr"">24</xref></sup> Rafi <italic toggle=""yes"">et al.</italic> demonstrated that direct administration of AAV1.mGALC into the cerebral ventricles of neonatal mice achieved",26_12,Efficacy and Safety of a Krabbe Disease Gene Therapy,01 5 2022 May 2022,,Krabbe_Disease
"the cerebral ventricles of neonatal mice achieved neuronal transduction, cross-correction of glial cells, prevention of psychosine accumulation, and mild extension of the lifespan from 42 to up to 66 days.<sup><xref rid=""B25"" ref-type=""bibr"">25</xref></sup> Lin <italic toggle=""yes"">et al.</italic> demonstrated the synergy of intracerebral AAV5 combined with bone marrow transplant (BMT) to extend survival beyond 150 days.<sup><xref rid=""B26"" ref-type=""bibr"">26</xref></sup> The following decade saw multiple",26_13,Efficacy and Safety of a Krabbe Disease Gene Therapy,01 5 2022 May 2022,,Krabbe_Disease
"The following decade saw multiple teams push the limit of disease prevention in the mouse model through the use of next-generation capsids, dose optimization, and/or combination therapies. Using AAVrh10, Rafi <italic toggle=""yes"">et al.</italic> achieved greater efficacy in mice by either increasing the dose via combined route of administration,<sup><xref rid=""B27"" ref-type=""bibr"">27</xref></sup> combination of systemic AAVrh10 with BMT,<sup><xref rid=""B28"" ref-type=""bibr"">28</xref></sup> or more recently",26_14,Efficacy and Safety of a Krabbe Disease Gene Therapy,01 5 2022 May 2022,,Krabbe_Disease
"ref-type=""bibr"">28</xref></sup> or more recently using systemic AAVrh10 at a very high dose, the latter of which led to a maximal survival of 430 days (median 280 days).<sup><xref rid=""B29"" ref-type=""bibr"">29</xref></sup> Karumuthil-Melethil <italic toggle=""yes"">et al.</italic> compared AAV9, AAVrh10, or AAVolig001 via lumbar administration with or without BMT, and found the best outcomes with an ssAAV9 construct when combined with BMT.<sup><xref rid=""B30"" ref-type=""bibr"">30</xref></sup> Both groups",26_15,Efficacy and Safety of a Krabbe Disease Gene Therapy,01 5 2022 May 2022,,Krabbe_Disease
"ref-type=""bibr"">30</xref></sup> Both groups translated their studies to the clinically relevant dog model and obtained remarkable dose-dependent disease mitigation with AAVrh10<sup>31</sup> or AAV9.<sup><xref rid=""B32"" ref-type=""bibr"">32</xref></sup> Finally, combination therapy using intracerebroventricular (ICV) AAV9, substrate reduction, and BMT in newborn Twitcher mice achieved complete disease prevention, although long-term survivors developed hepatocellular carcinoma.<sup><xref rid=""B33""",26_16,Efficacy and Safety of a Krabbe Disease Gene Therapy,01 5 2022 May 2022,,Krabbe_Disease
"hepatocellular carcinoma.<sup><xref rid=""B33"" ref-type=""bibr"">33</xref></sup> We and others have demonstrated the remarkable translational efficacy of cerebrospinal fluid (CSF)-delivered adeno-associated virus (AAV) as a monotherapy for the treatment of neuropathic lysosomal storage disorders in large animal models.<sup><xref rid=""B32"" ref-type=""bibr"">32</xref>,<xref rid=""B34"" ref-type=""bibr"">34–41</xref></sup> Robust transduction of lower motor neurons in the spinal cord and dorsal root ganglia (DRG)",26_17,Efficacy and Safety of a Krabbe Disease Gene Therapy,01 5 2022 May 2022,,Krabbe_Disease
"in the spinal cord and dorsal root ganglia (DRG) neurons, as well as scattered transduction of cortical neurons, cerebellar Purkinje cells, and medulla motor neurons, can provide a broad source of replacement enzyme that can support cross-correction of peripheral nerves and CNS cells.<sup><xref rid=""B36"" ref-type=""bibr"">36</xref>,<xref rid=""B38"" ref-type=""bibr"">38</xref>,<xref rid=""B42"" ref-type=""bibr"">42–45</xref></sup> Compared to systemic administration of neurotropic vectors at high doses, the",26_18,Efficacy and Safety of a Krabbe Disease Gene Therapy,01 5 2022 May 2022,,Krabbe_Disease
"of neurotropic vectors at high doses, the CSF-directed approach appears to be safer.<sup><xref rid=""B46"" ref-type=""bibr"">46–52</xref></sup> This approach also consumes less vector and is not limited by preexisting neutralizing antibodies (NAbs).<sup><xref rid=""B42"" ref-type=""bibr"">42</xref>,<xref rid=""B50"" ref-type=""bibr"">50</xref></sup> Good Laboratory Practice (GLP)-compliant studies in nonhuman primates demonstrated the safety of the intracisterna magna (ICM) AAV-mediated approach with several drug",26_19,Efficacy and Safety of a Krabbe Disease Gene Therapy,01 5 2022 May 2022,,Krabbe_Disease
"(ICM) AAV-mediated approach with several drug candidates that are being evaluated in clinical trials.<sup><xref rid=""B50"" ref-type=""bibr"">50</xref>,<xref rid=""B51"" ref-type=""bibr"">51</xref></sup> We performed nonclinical studies supporting an investigational new drug (IND) application for the treatment of infantile Krabbe disease using an AAVhu68 vector expressing a codon-optimized <italic toggle=""yes"">GALC</italic> administered into the cisterna magna (NCT04771416). In this study, we report the findings",26_20,Efficacy and Safety of a Krabbe Disease Gene Therapy,01 5 2022 May 2022,,Krabbe_Disease
"In this study, we report the findings from three preclinical studies. The first entailed route-of-administration (ROA) and dose-finding studies in neonatal and juvenile Twitcher mice using the ICV or intravenous (IV) routes. The second is a pilot efficacy study in Krabbe dogs using the intended clinical route (<italic toggle=""yes"">i.e</italic>., ICM). The third is a GLP-compliant toxicology study in juvenile rhesus macaques using clinically comparable fluoroscopy-guided ICM administration. Our results",26_21,Efficacy and Safety of a Krabbe Disease Gene Therapy,01 5 2022 May 2022,,Krabbe_Disease
"ICM administration. Our results demonstrate a translationally feasible and efficacious approach to treat Krabbe disease using a single ICM administration of AAVhu68.hGALC without concomitant transplant or immune suppression.   Our aim was to develop an AAV-based drug product for the treatment of infantile Krabbe disease. We selected AAVhu68 capsid, a natural clade F variant, close to AAV9, that presents widespread diffusion and neurotropism after CSF administration.<sup><xref rid=""B39""",26_22,Efficacy and Safety of a Krabbe Disease Gene Therapy,01 5 2022 May 2022,,Krabbe_Disease
"after CSF administration.<sup><xref rid=""B39"" ref-type=""bibr"">39</xref>,<xref rid=""B46"" ref-type=""bibr"">46</xref>,<xref rid=""B63"" ref-type=""bibr"">63</xref></sup> Dose-finding and route of administration studies in newborn Twitcher mice demonstrated that AAVhu68.hGALC administration leads to dose-dependent survival up to 165 days after ICV injection of 1 × 10<sup>11</sup> GC, outperforming IV administration at the same dose with our study conditions. We elected for CSF administration and used the juvenile",26_23,Efficacy and Safety of a Krabbe Disease Gene Therapy,01 5 2022 May 2022,,Krabbe_Disease
"for CSF administration and used the juvenile Twitcher mice as our model for formal pharmacology IND-enabling study, demonstrating a minimum effective dose (MED) of 2.0 × 10<sup>10</sup> GC. A GLP toxicology study using the intended clinical route in juvenile rhesus macaques tested a dose range starting at the MED (scaled by brain weight) up to 10-fold the MED with no dose-limiting toxicity. Almost two decades of work using AAV in Twitcher mice demonstrated improved lifespan with a variety of approaches.",26_24,Efficacy and Safety of a Krabbe Disease Gene Therapy,01 5 2022 May 2022,,Krabbe_Disease
"improved lifespan with a variety of approaches. With CSF administration, Rafi <italic toggle=""yes"">et al.</italic> reported a maximal lifespan of 66 days in newborn Twitcher mice treated ICV with 6 × 10<sup>10</sup> GC of AAV1.mGALC.<sup><xref rid=""B25"" ref-type=""bibr"">25</xref></sup> Karumuthil-Melethil <italic toggle=""yes"">et al.</italic> obtained a median lifespan of 55.5 days when dosing 2 × 10<sup>11</sup> GC of AAV9.mGALC in PND10–11 mice via the lumbar route.<sup><xref rid=""B30""",26_25,Efficacy and Safety of a Krabbe Disease Gene Therapy,01 5 2022 May 2022,,Krabbe_Disease
"mice via the lumbar route.<sup><xref rid=""B30"" ref-type=""bibr"">30</xref></sup> When comparing similar doses (with the caveat of titering method variability between different laboratories) and injection ages, 5 × 10<sup>10</sup> GC of AAVhu68.hGALC ICV in newborns achieved up to 147 days survival, while 2 × 10<sup>11</sup> GC ICV to juvenile PND12 mice achieved a median survival of 70 days. Notably, using systemic administration of AAVrh10 at a very high dose (4 × 10<sup>14</sup> GC/kg IV), Rafi <italic",26_26,Efficacy and Safety of a Krabbe Disease Gene Therapy,01 5 2022 May 2022,,Krabbe_Disease
"dose (4 × 10<sup>14</sup> GC/kg IV), Rafi <italic toggle=""yes"">et al.</italic> recently obtained an unprecedented survival of up to 430 days.<sup><xref rid=""B29"" ref-type=""bibr"">29</xref></sup> Such a result was previously only achieved by the same team when combining lower doses of AAVrh10-GALC with BMT,<sup><xref rid=""B29"" ref-type=""bibr"">29</xref></sup> or by another group that combined AAV9 ICV administration with BMT and substrate reduction.<sup><xref rid=""B33"" ref-type=""bibr"">33</xref></sup> This",26_27,Efficacy and Safety of a Krabbe Disease Gene Therapy,01 5 2022 May 2022,,Krabbe_Disease
"rid=""B33"" ref-type=""bibr"">33</xref></sup> This suggests that increasing the dose and using a neurotropic capsid may be sufficient for achieving maximal <italic toggle=""yes"">GALC</italic> expression in the CNS and full disease prevention in the mouse model, although safety needs to be carefully explored in nonrodent species when using very high doses or combination therapies. The observation that high-dose AAV may be sufficient without BMT is consistent with recent reports of successful gene therapy in the",26_28,Efficacy and Safety of a Krabbe Disease Gene Therapy,01 5 2022 May 2022,,Krabbe_Disease
"recent reports of successful gene therapy in the dog model of Krabbe disease. Using AAVrh10 administered IV at postnatal day 3 followed by ICV at 6 weeks, Bradbury <italic toggle=""yes"">et al.</italic> obtained a modest dose-dependent increase in survival from 18–22 weeks at 1.2 × 10<sup>12</sup> GC to 30–43 weeks at 3.8 × 10<sup>13</sup> GC.<sup><xref rid=""B31"" ref-type=""bibr"">31</xref></sup> However, these dogs eventually developed the classical Krabbe phenotype, indicating that the optimal dose was",26_29,Efficacy and Safety of a Krabbe Disease Gene Therapy,01 5 2022 May 2022,,Krabbe_Disease
"phenotype, indicating that the optimal dose was likely not reached and that treatment only delayed disease progression. In agreement with the hypothesis that a higher dose could fully prevent disease in the absence of any other intervention, Bradbury <italic toggle=""yes"">et al.</italic> reported disease prevention in dogs for at least 2.5 years after ICM administration of AAV9.cGALC at 1 × 10<sup>14</sup> GC using a dose 3.3-fold higher than the present study.<sup><xref rid=""B32""",26_30,Efficacy and Safety of a Krabbe Disease Gene Therapy,01 5 2022 May 2022,,Krabbe_Disease
"than the present study.<sup><xref rid=""B32"" ref-type=""bibr"">32</xref></sup> A fivefold lower dose of 2 × 10<sup>13</sup> GC, close to our dose of 3 × 10<sup>13</sup> GC, attenuated the disease with survival up to 35 weeks, similar to the previous work using AAVrh10 at 3.8 × 10<sup>13</sup> GC (IV+ICV). Although our dog study is limited by a low number of treated dogs (<italic toggle=""yes"">n</italic> = 4), our results of survival and lack of classical disease signs for up to 85 weeks with AAVhu68.cGALC at",26_31,Efficacy and Safety of a Krabbe Disease Gene Therapy,01 5 2022 May 2022,,Krabbe_Disease
"signs for up to 85 weeks with AAVhu68.cGALC at 3 × 10<sup>13</sup> GC ICM suggests the potential for transformative therapeutic benefits at a dose that was safe in two nonrodent species and also highlighted its translationally feasibility. In addition, ICM administration has not been associated with any serious adverse events thus far (NCT03580083, NCT04408625, and NCT04127578). Furthermore, the potential risk of sensory neuronal degeneration in DRG seems low based on the minimal and sporadic findings from",26_32,Efficacy and Safety of a Krabbe Disease Gene Therapy,01 5 2022 May 2022,,Krabbe_Disease
"based on the minimal and sporadic findings from our toxicology study, and the absence of DRG pathology from the dog study using an equivalent construct expressing canine <italic toggle=""yes"">GALC</italic>. The lack of AAV-related pathology in the DRG in dog models of genetic diseases following intrathecal gene therapy encoding canine transgenes aligns with published work and suggests that dog is less sensitive than NHP.<sup><xref rid=""B32"" ref-type=""bibr"">32</xref>,<xref rid=""B64""",26_33,Efficacy and Safety of a Krabbe Disease Gene Therapy,01 5 2022 May 2022,,Krabbe_Disease
"ref-type=""bibr"">32</xref>,<xref rid=""B64"" ref-type=""bibr"">64</xref></sup> The normalization of peripheral nerve function and histology in our dog study is noteworthy as this result was never achieved with hematopoietic stem cell transplant.<sup><xref rid=""B15"" ref-type=""bibr"">15</xref>,<xref rid=""B16"" ref-type=""bibr"">16</xref>,<xref rid=""B18"" ref-type=""bibr"">18</xref>,<xref rid=""B19"" ref-type=""bibr"">19</xref>,<xref rid=""B65"" ref-type=""bibr"">65</xref></sup> We believe that peripheral nerve correction after",26_34,Efficacy and Safety of a Krabbe Disease Gene Therapy,01 5 2022 May 2022,,Krabbe_Disease
"We believe that peripheral nerve correction after ICM AAV administration results from robust transduction of DRG sensory neurons and spinal cord lower motor neurons, the axons of which collectively make up peripheral nerves. Full normalization of peripheral nerve function and myelination suggests that neuronal transduction is therapeutic. One possible explanation is that the resultant presence of supraphysiological enzyme levels in axons can cross-correct Schwann cells and endoneurial macrophages to",26_35,Efficacy and Safety of a Krabbe Disease Gene Therapy,01 5 2022 May 2022,,Krabbe_Disease
"Schwann cells and endoneurial macrophages to restore normal nerve morphology and function. Alternatively, GALC enzyme secreted into the CSF could gain access to the endoneurial fluid due to the continuity between the subarachnoid space and the endoneurium of the nerve roots.<sup><xref rid=""B66"" ref-type=""bibr"">66</xref></sup> Finally, continual resorption of CSF into the systemic circulation may lead to peripheral organ transduction after CSF AAV administration (mainly liver and heart) to provide a",26_36,Efficacy and Safety of a Krabbe Disease Gene Therapy,01 5 2022 May 2022,,Krabbe_Disease
"(mainly liver and heart) to provide a peripheral source of secreted enzyme (which manifested as increased serum enzyme levels in the NHP study). Recent reports questioned the possibility of cross-correction in the PNS of Twitcher mice<sup><xref rid=""B8"" ref-type=""bibr"">8</xref></sup> or in the CNS of metachromatic leukodystrophy.<sup><xref rid=""B67"" ref-type=""bibr"">67</xref></sup> In both articles, the authors investigated whether WT macrophages expressing natural levels of enzyme could support",26_37,Efficacy and Safety of a Krabbe Disease Gene Therapy,01 5 2022 May 2022,,Krabbe_Disease
"expressing natural levels of enzyme could support cross-correction; they failed to detect either GALC or arylsulfatase A in Schwann cells or oligodendrocytes when normal WT macrophages were present. The method of detection in both cases may not have been sensitive enough to detect low levels of enzyme uptake, which is expected when the source does not overexpress the protein. Gene therapy likely leads to overexpression by a subset of transduced cells, which then secrete supraphysiological levels of",26_38,Efficacy and Safety of a Krabbe Disease Gene Therapy,01 5 2022 May 2022,,Krabbe_Disease
"which then secrete supraphysiological levels of transgene that can support tissue cross-correction but is undetectable in nontransduced cells. This hypothesis is consistent with the remarkable therapeutic benefit of <italic toggle=""yes"">ex vivo</italic> gene therapy observed in presymptomatic metachromatic leukodystrophy patients.<sup><xref rid=""B68"" ref-type=""bibr"">68</xref></sup> If macrophages/microglia only acted as a cell-autonomous anti-inflammatory population, the trial's outcome should not be",26_39,Efficacy and Safety of a Krabbe Disease Gene Therapy,01 5 2022 May 2022,,Krabbe_Disease
"population, the trial's outcome should not be better than traditional HSCT. Similarly, Rafi <italic toggle=""yes"">et al.</italic> elegantly demonstrated the role of <italic toggle=""yes"">GALC</italic> expression in donor cells by demonstrating increased survival after BMT when the donors are WT compared to heterozygous mice, and by showing that high-dose AAV-treated mice overexpressed <italic toggle=""yes"">GALC</italic> in their bone marrow, suggesting transduction of hematopoietic cells <italic",26_40,Efficacy and Safety of a Krabbe Disease Gene Therapy,01 5 2022 May 2022,,Krabbe_Disease
"transduction of hematopoietic cells <italic toggle=""yes"">in vivo</italic>.<sup><xref rid=""B69"" ref-type=""bibr"">69</xref></sup> Finally, macrophages appear to be the most readily cross-corrected cell type via both M6PR and M6PR-independent pathways.<sup><xref rid=""B70"" ref-type=""bibr"">70</xref></sup> This suggests that macrophages, which migrate to the CNS and PNS, could be cross corrected locally in a context of robust neuronal or astrocytic enzyme expression after ICM gene therapy. Notably, we achieved",26_41,Efficacy and Safety of a Krabbe Disease Gene Therapy,01 5 2022 May 2022,,Krabbe_Disease
"after ICM gene therapy. Notably, we achieved less disease prevention and lifespan extension in the ICV-treated newborn or juvenile mice than the ICM-treated dogs. Treated mice developed sciatic nerve demyelination and hindleg weakness, whereas the dogs remained ambulatory until scheduled or unscheduled euthanasia. Twitcher mice exhibit a disproportionate vulnerability to PNS degeneration compared to CNS,<sup><xref rid=""B20"" ref-type=""bibr"">20</xref></sup> whereas Krabbe dogs recapitulate the combined CNS",26_42,Efficacy and Safety of a Krabbe Disease Gene Therapy,01 5 2022 May 2022,,Krabbe_Disease
"whereas Krabbe dogs recapitulate the combined CNS and PNS demyelination pattern seen in patients.<sup><xref rid=""B62"" ref-type=""bibr"">62</xref>,<xref rid=""B71"" ref-type=""bibr"">71</xref></sup> The small size and early phenotype in Twitcher mice limit route and dose options. ICV treatment in newborn and juvenile mice does not achieve as much spinal cord and DRG transduction by AAV compared to ICM or intrathecal administration in large-animal models.<sup><xref rid=""B39"" ref-type=""bibr"">39</xref></sup>",26_43,Efficacy and Safety of a Krabbe Disease Gene Therapy,01 5 2022 May 2022,,Krabbe_Disease
"rid=""B39"" ref-type=""bibr"">39</xref></sup> Peripheral nerve correction after ICV in mice is therefore suboptimal, thus enabling disease progression in Twitcher mice. When delivering a sufficient AAV dose with an optimal ICM ROA in the translationally relevant dog model, we and others have shown the remarkable therapeutic benefit of gene therapy as a monotherapy, without the need for HSCT. We report that a translationally feasible single administration of AAVhu68 expressing GALC into the CSF—without BMT or",26_44,Efficacy and Safety of a Krabbe Disease Gene Therapy,01 5 2022 May 2022,,Krabbe_Disease
"expressing GALC into the CSF—without BMT or immune suppression—can mitigate most signs of Krabbe disease in the mouse and canine models. A GLP toxicology study in NHPs confirmed the safety of our approach and paved the way for a first-in-human trial of AAVhu68.hGALC-administered ICM to infantile Krabbe disease patients. In agreement with previously published work, we observed that early intervention, as well as achieving high CNS and PNS transduction, is key to achieving maximal therapeutic benefit. ICM",26_45,Efficacy and Safety of a Krabbe Disease Gene Therapy,01 5 2022 May 2022,,Krabbe_Disease
key to achieving maximal therapeutic benefit. ICM seems to be the most practical route for safely achieving these effects in patients.,26_46,Efficacy and Safety of a Krabbe Disease Gene Therapy,01 5 2022 May 2022,,Krabbe_Disease
"CRISPR-Cas9 Knock-In of T513M and G41S Mutations in the Murine β–Galactosyl-Ceramidase Gene Re-capitulates Early-Onset and Adult-Onset Forms of Krabbe Disease Krabbe Disease (KD) is a lysosomal storage disorder characterized by the genetic deficiency of the lysosomal enzyme β-galactosyl-ceramidase (GALC). Deficit or a reduction in the activity of the GALC enzyme has been correlated with the progressive accumulation of the sphingolipid metabolite psychosine, which leads to local disruption in lipid raft",27_0,CRISPR-Cas9 Knock-In of T513M and G41S Mutations in the Murine β–Galactosyl-Ceramidase Gene Re-capitulates Early-Onset and Adult-Onset Forms of Krabbe Disease,10 5 2022,,Krabbe_Disease
"which leads to local disruption in lipid raft architecture, diffuse demyelination, astrogliosis, and globoid cell formation. The <italic toggle=""yes"">twitcher</italic> mouse, the most used animal model, has a nonsense mutation, which limits the study of how different mutations impact the processing and activity of GALC enzyme. To partially address this, we generated two new transgenic mouse models carrying point mutations frequently found in infantile and adult forms of KD. Using CRISPR-Cas9 gene editing,",27_1,CRISPR-Cas9 Knock-In of T513M and G41S Mutations in the Murine β–Galactosyl-Ceramidase Gene Re-capitulates Early-Onset and Adult-Onset Forms of Krabbe Disease,10 5 2022,,Krabbe_Disease
"forms of KD. Using CRISPR-Cas9 gene editing, point mutations T513M (infantile) and G41S (adult) were introduced in the murine GALC gene and stable founders were generated. We show that <italic toggle=""yes"">GALC</italic><sup><italic toggle=""yes"">T</italic>513<italic toggle=""yes"">M</italic>/<italic toggle=""yes"">T</italic>513<italic toggle=""yes"">M</italic></sup> mice are short lived, have the greatest decrease in GALC activity, have sharp increases of psychosine, and rapidly progress into a severe and lethal",27_2,CRISPR-Cas9 Knock-In of T513M and G41S Mutations in the Murine β–Galactosyl-Ceramidase Gene Re-capitulates Early-Onset and Adult-Onset Forms of Krabbe Disease,10 5 2022,,Krabbe_Disease
"and rapidly progress into a severe and lethal neurological phenotype. In contrast, <italic toggle=""yes"">GALC</italic><sup><italic toggle=""yes"">G</italic>41<italic toggle=""yes"">S</italic>/G41<italic toggle=""yes"">S</italic></sup> mice have normal lifespan, modest decreases of GALC, and minimal psychosine accumulation, but develop adult mild inflammatory demyelination and slight declines in coordination, motor skills, and memory. These two novel transgenic lines offer the possibility to study the mechanisms",27_3,CRISPR-Cas9 Knock-In of T513M and G41S Mutations in the Murine β–Galactosyl-Ceramidase Gene Re-capitulates Early-Onset and Adult-Onset Forms of Krabbe Disease,10 5 2022,,Krabbe_Disease
"offer the possibility to study the mechanisms by which two distinct GALC mutations affect the trafficking of mutated GALC and modify phenotypic manifestations in early- vs adult-onset KD. Krabbe disease (KD) is a neuropathic lysosomal storage disease caused by deficiency of the enzyme β-galactosyl-ceramidase (GALC) (<xref rid=""B75"" ref-type=""bibr"">Suzuki and Suzuki, 1970</xref>). Loss-of-function of GALC blocks the lysosomal hydrolysis of galactosylceramides (GalCer) and galactosylsphingosine (psychosine)",27_4,CRISPR-Cas9 Knock-In of T513M and G41S Mutations in the Murine β–Galactosyl-Ceramidase Gene Re-capitulates Early-Onset and Adult-Onset Forms of Krabbe Disease,10 5 2022,,Krabbe_Disease
"(GalCer) and galactosylsphingosine (psychosine) (<xref rid=""B75"" ref-type=""bibr"">Suzuki and Suzuki, 1970</xref>; <xref rid=""B35"" ref-type=""bibr"">Igisu and Suzuki, 1984</xref>; <xref rid=""B40"" ref-type=""bibr"">Kobayashi et al., 1987</xref>; <xref rid=""B30"" ref-type=""bibr"">Greiner-Tollersrud and Berg, 2000/2013</xref>; <xref rid=""B80"" ref-type=""bibr"">Wenger, 2001</xref>). KD is primarily a childhood disease with most patients presenting neurological symptoms soon after birth. Krabbe infants can develop",27_5,CRISPR-Cas9 Knock-In of T513M and G41S Mutations in the Murine β–Galactosyl-Ceramidase Gene Re-capitulates Early-Onset and Adult-Onset Forms of Krabbe Disease,10 5 2022,,Krabbe_Disease
"soon after birth. Krabbe infants can develop irritability, spasticity, seizures, muscle weakness, and a progressive loss of motor and cognitive functions (<xref rid=""B23"" ref-type=""bibr"">Escolar et al., 2016</xref>). Late-onset forms of the disease develop usually beyond 7–10 years of age, are less frequent, and characterized by vision problems, walking difficulties, and cognitive deterioration (<xref rid=""B29"" ref-type=""bibr"">Graziano and Cardile, 2015</xref>). The abnormal buildup of psychosine in the",27_6,CRISPR-Cas9 Knock-In of T513M and G41S Mutations in the Murine β–Galactosyl-Ceramidase Gene Re-capitulates Early-Onset and Adult-Onset Forms of Krabbe Disease,10 5 2022,,Krabbe_Disease
"The abnormal buildup of psychosine in the central and peripheral nervous systems is considered the main contributor to neuropathology in infantile severe forms of KD. Psychosine promotes demyelination (<xref rid=""B77"" ref-type=""bibr"">Taniike and Suzuki, 1994</xref>; <xref rid=""B76"" ref-type=""bibr"">Suzuki and Taniike, 1995</xref>; <xref rid=""B57"" ref-type=""bibr"">O’Sullivan and Dev, 2015</xref>), gliosis and inflammation (<xref rid=""B25"" ref-type=""bibr"">Giri et al., 2002</xref>), disruption of lipid rafts",27_7,CRISPR-Cas9 Knock-In of T513M and G41S Mutations in the Murine β–Galactosyl-Ceramidase Gene Re-capitulates Early-Onset and Adult-Onset Forms of Krabbe Disease,10 5 2022,,Krabbe_Disease
"et al., 2002</xref>), disruption of lipid rafts (<xref rid=""B82"" ref-type=""bibr"">White et al., 2009</xref>; <xref rid=""B32"" ref-type=""bibr"">Hawkins-Salsbury et al., 2013</xref>), neuropathy (<xref rid=""B10"" ref-type=""bibr"">Castelvetri et al., 2011</xref>, <xref rid=""B9"" ref-type=""bibr"">2013</xref>; <xref rid=""B71"" ref-type=""bibr"">Smith et al., 2011</xref>; <xref rid=""B8"" ref-type=""bibr"">Cantuti-Castelvetri et al., 2012</xref>, <xref rid=""B7"" ref-type=""bibr"">2015</xref>), and alterations in many signal",27_8,CRISPR-Cas9 Knock-In of T513M and G41S Mutations in the Murine β–Galactosyl-Ceramidase Gene Re-capitulates Early-Onset and Adult-Onset Forms of Krabbe Disease,10 5 2022,,Krabbe_Disease
"and alterations in many signal transduction pathways (<xref rid=""B26"" ref-type=""bibr"">Giri et al., 2008</xref>; <xref rid=""B9"" ref-type=""bibr"">Castelvetri et al., 2013</xref>; <xref rid=""B74"" ref-type=""bibr"">Sural-Fehr et al., 2019</xref>). While the pathogenic role of psychosine in infantile KD is well documented, its contribution to neuropathology in adult forms of KD is poorly understood, primarily due to the lack of adult-onset KD animal models and mechanistic studies in patients with this form of the",27_9,CRISPR-Cas9 Knock-In of T513M and G41S Mutations in the Murine β–Galactosyl-Ceramidase Gene Re-capitulates Early-Onset and Adult-Onset Forms of Krabbe Disease,10 5 2022,,Krabbe_Disease
"studies in patients with this form of the disease. The most widely used KD animal model is the Twitcher (TWI) mouse, in which a naturally occurring mutation leads to degradation of GALC mRNA and absence of functional GALC protein (<xref rid=""B22"" ref-type=""bibr"">Duchen et al., 1980</xref>; <xref rid=""B44"" ref-type=""bibr"">Lee et al., 2006</xref>). The TWI mouse is a surrogate model of KD, with many hallmarks observed in human patients with infantile KD. These include toxic accumulation of psychosine, ataxic",27_10,CRISPR-Cas9 Knock-In of T513M and G41S Mutations in the Murine β–Galactosyl-Ceramidase Gene Re-capitulates Early-Onset and Adult-Onset Forms of Krabbe Disease,10 5 2022,,Krabbe_Disease
"include toxic accumulation of psychosine, ataxic gait deficits, muscular weakness, hind limb paralysis, and are short life span. Other animal models, including the globoid cell leukodystrophy (GLD) dog, the non-human primate, and various murine lines (<xref rid=""B3"" ref-type=""bibr"">Bradbury et al., 2020</xref>), also largely model severe forms of KD. There are no described animal models of adult-onset KD. To contribute to the study of neuropathic mechanisms of disease in KD, particularly those at play in",27_11,CRISPR-Cas9 Knock-In of T513M and G41S Mutations in the Murine β–Galactosyl-Ceramidase Gene Re-capitulates Early-Onset and Adult-Onset Forms of Krabbe Disease,10 5 2022,,Krabbe_Disease
"of disease in KD, particularly those at play in adult-onset forms, we used CRISPR-Cas9 gene editing to introduce early infantile and adult-onset KD point mutations in the GALC gene. Over 140 mutations and polymorphisms in the GALC gene have been described (<xref rid=""B81"" ref-type=""bibr"">Wenger et al., 1997</xref>; <xref rid=""B78"" ref-type=""bibr"">Tappino et al., 2010</xref>; <xref rid=""B29"" ref-type=""bibr"">Graziano and Cardile, 2015</xref>) with the 30 kb deletion of exons 10–17 being frequently found in",27_12,CRISPR-Cas9 Knock-In of T513M and G41S Mutations in the Murine β–Galactosyl-Ceramidase Gene Re-capitulates Early-Onset and Adult-Onset Forms of Krabbe Disease,10 5 2022,,Krabbe_Disease
"deletion of exons 10–17 being frequently found in severe infantile forms. Previous <italic toggle=""yes"">in vitro</italic> studies showed how several point mutations in the GALC gene, found in homozygous as well as in compound heterozygous patients, can affect not only GALC activity but also its trafficking to the lysosomes (<xref rid=""B43"" ref-type=""bibr"">Lee et al., 2010</xref>; <xref rid=""B69"" ref-type=""bibr"">Shin et al., 2016</xref>; <xref rid=""B36"" ref-type=""bibr"">Irahara-Miyana et al., 2018</xref>).",27_13,CRISPR-Cas9 Knock-In of T513M and G41S Mutations in the Murine β–Galactosyl-Ceramidase Gene Re-capitulates Early-Onset and Adult-Onset Forms of Krabbe Disease,10 5 2022,,Krabbe_Disease
"et al., 2018</xref>). Based on this, we have selected point mutations T513M, present in many infantile patients (<xref rid=""B81"" ref-type=""bibr"">Wenger et al., 1997</xref>) and G41S, present in many adult patients (<xref rid=""B46"" ref-type=""bibr"">Lissens et al., 2007</xref>), to generate knock in mouse models. This report presents the characterization of <italic toggle=""yes"">GALC</italic><sup><italic toggle=""yes"">T</italic>513<italic toggle=""yes"">M/T</italic>513<italic toggle=""yes"">M</italic></sup> and",27_14,CRISPR-Cas9 Knock-In of T513M and G41S Mutations in the Murine β–Galactosyl-Ceramidase Gene Re-capitulates Early-Onset and Adult-Onset Forms of Krabbe Disease,10 5 2022,,Krabbe_Disease
"toggle=""yes"">M</italic></sup> and <italic toggle=""yes"">GALC</italic><sup><italic toggle=""yes"">G</italic>41<italic toggle=""yes"">S</italic>/G41<italic toggle=""yes"">S</italic></sup> transgenic mice, which recapitulate early-onset (<italic toggle=""yes"">GALC</italic><sup><italic toggle=""yes"">T</italic>513<italic toggle=""yes"">M/T</italic>513<italic toggle=""yes"">M</italic></sup>) and late-onset (<italic toggle=""yes"">GALC</italic><sup><italic toggle=""yes"">G</italic>41<italic toggle=""yes"">S</italic>/G41<italic",27_15,CRISPR-Cas9 Knock-In of T513M and G41S Mutations in the Murine β–Galactosyl-Ceramidase Gene Re-capitulates Early-Onset and Adult-Onset Forms of Krabbe Disease,10 5 2022,,Krabbe_Disease
"toggle=""yes"">S</italic>/G41<italic toggle=""yes"">S</italic></sup>) KD forms.   This study presents two new murine KD models carrying point mutations T513M, frequent in human patients with infantile forms of KD (<xref rid=""B81"" ref-type=""bibr"">Wenger et al., 1997</xref>), and G41S, found in many adult forms of KD (<xref rid=""B46"" ref-type=""bibr"">Lissens et al., 2007</xref>). The new mutants were generated using CRISPR-Cas9 gene editing and show remarkably reproducible phenotypes, with viable carrier",27_16,CRISPR-Cas9 Knock-In of T513M and G41S Mutations in the Murine β–Galactosyl-Ceramidase Gene Re-capitulates Early-Onset and Adult-Onset Forms of Krabbe Disease,10 5 2022,,Krabbe_Disease
"reproducible phenotypes, with viable carrier breeders. <italic toggle=""yes"">GALC</italic><sup><italic toggle=""yes"">T</italic>513<italic toggle=""yes"">M/T</italic>513<italic toggle=""yes"">M</italic></sup> mice show clinical signs of an early neurological condition, with onset of motor and behavioral declines at ∼P24. Mutant mice rapidly progress into stereotypic manifestations of a severe leukodystrophy, with body weight loss, twitching, tremor, and eventually death by the 7th week of life. This mutation is",27_17,CRISPR-Cas9 Knock-In of T513M and G41S Mutations in the Murine β–Galactosyl-Ceramidase Gene Re-capitulates Early-Onset and Adult-Onset Forms of Krabbe Disease,10 5 2022,,Krabbe_Disease
"death by the 7th week of life. This mutation is present in many infant patients of European ancestry, contributing to ∼10% of infant forms of KD (<xref rid=""B39"" ref-type=""bibr"">Kleijer et al., 1997</xref>). These patients show early-onset motor declines and premature death. Homozygous mice for <italic toggle=""yes"">GALC</italic><sup><italic toggle=""yes"">T</italic>513<italic toggle=""yes"">M/T</italic>513<italic toggle=""yes"">M</italic></sup> displayed the expected progression, and thus, constitute a newly",27_18,CRISPR-Cas9 Knock-In of T513M and G41S Mutations in the Murine β–Galactosyl-Ceramidase Gene Re-capitulates Early-Onset and Adult-Onset Forms of Krabbe Disease,10 5 2022,,Krabbe_Disease
"progression, and thus, constitute a newly engineered but genuine model for infantile KD, matching a severe mutation found in human patients. While the TWI mouse has been historically used as a model for infantile KD, it is more of a surrogate model for the 30 kb deletion found in infantile patients (<xref rid=""B39"" ref-type=""bibr"">Kleijer et al., 1997</xref>), because the deficiency of GALC activity in TWI mice is due to the absence of detectable GALC protein. In contrast, the new <italic",27_19,CRISPR-Cas9 Knock-In of T513M and G41S Mutations in the Murine β–Galactosyl-Ceramidase Gene Re-capitulates Early-Onset and Adult-Onset Forms of Krabbe Disease,10 5 2022,,Krabbe_Disease
"GALC protein. In contrast, the new <italic toggle=""yes"">GALC</italic><sup><italic toggle=""yes"">T</italic>513<italic toggle=""yes"">M/T</italic>513<italic toggle=""yes"">M</italic></sup> mouse presents with a clinical disease that recapitulates that of the TWI but with detectable protein both by western blotting and immunohistochemistry. Mice with the <italic toggle=""yes"">GALC</italic><sup><italic toggle=""yes"">G</italic>41<italic toggle=""yes"">S</italic></sup> mutation showed normal postnatal development, with",27_20,CRISPR-Cas9 Knock-In of T513M and G41S Mutations in the Murine β–Galactosyl-Ceramidase Gene Re-capitulates Early-Onset and Adult-Onset Forms of Krabbe Disease,10 5 2022,,Krabbe_Disease
"showed normal postnatal development, with no apparent compromise in survival, minimal changes in motor skills, and some alterations in anxiety-type behaviors measurable in aged (>P250) mutants. Patients with this mutation usually present with adult onset manifestations, with less neurological compromise, at least during the first several years of life (<xref rid=""B46"" ref-type=""bibr"">Lissens et al., 2007</xref>). Thus, the <italic toggle=""yes"">GALC</italic><sup><italic toggle=""yes"">G</italic>41<italic",27_21,CRISPR-Cas9 Knock-In of T513M and G41S Mutations in the Murine β–Galactosyl-Ceramidase Gene Re-capitulates Early-Onset and Adult-Onset Forms of Krabbe Disease,10 5 2022,,Krabbe_Disease
"toggle=""yes"">G</italic>41<italic toggle=""yes"">S/G</italic>41<italic toggle=""yes"">S</italic></sup> mutant represents a genuine genetic model recapitulating many aspects of adult-onset KD. The effects of each mutation on enzymatic activity and lysosomal translocation were remarkably different. <italic toggle=""yes"">In vitro</italic> studies have reported how different point mutations in the GALC gene can affect not only the activity, but also its trafficking to the lysosome (<xref rid=""B69""",27_22,CRISPR-Cas9 Knock-In of T513M and G41S Mutations in the Murine β–Galactosyl-Ceramidase Gene Re-capitulates Early-Onset and Adult-Onset Forms of Krabbe Disease,10 5 2022,,Krabbe_Disease
"its trafficking to the lysosome (<xref rid=""B69"" ref-type=""bibr"">Shin et al., 2016</xref>; <xref rid=""B36"" ref-type=""bibr"">Irahara-Miyana et al., 2018</xref>). The <italic toggle=""yes"">GALC</italic><sup><italic toggle=""yes"">T</italic>513<italic toggle=""yes"">M</italic></sup> mutation changes a polar side chain to a hydrophobic side chain with loss of stabilizing hydrogen bond and steric hindrance (<xref rid=""B18"" ref-type=""bibr"">Deane et al., 2011</xref>). <italic toggle=""yes"">In vitro</italic> studies have",27_23,CRISPR-Cas9 Knock-In of T513M and G41S Mutations in the Murine β–Galactosyl-Ceramidase Gene Re-capitulates Early-Onset and Adult-Onset Forms of Krabbe Disease,10 5 2022,,Krabbe_Disease
"toggle=""yes"">In vitro</italic> studies have shown that this change not only effectively abolishes GALC activity but also largely blocks the mutated protein from reaching the lysosomal compartment (<xref rid=""B69"" ref-type=""bibr"">Shin et al., 2016</xref>). Aligned with this, enzyme activity and localization analyses in our study show that the <italic toggle=""yes"">GALC</italic><sup><italic toggle=""yes"">T</italic>513<italic toggle=""yes"">M/T</italic>513<italic toggle=""yes"">M</italic></sup> mutated protein",27_24,CRISPR-Cas9 Knock-In of T513M and G41S Mutations in the Murine β–Galactosyl-Ceramidase Gene Re-capitulates Early-Onset and Adult-Onset Forms of Krabbe Disease,10 5 2022,,Krabbe_Disease
"toggle=""yes"">M</italic></sup> mutated protein lacks detectable enzyme activity, and a large fraction of the protein remains outside of the lysosomal compartment. The <italic toggle=""yes"">GALC</italic><sup><italic toggle=""yes"">G</italic>41<italic toggle=""yes"">S</italic></sup> mutation introduces a polar side chain in the TIM barrel domain of the 50 kDa GALC subunit (<xref rid=""B46"" ref-type=""bibr"">Lissens et al., 2007</xref>; <xref rid=""B18"" ref-type=""bibr"">Deane et al., 2011</xref>; <xref rid=""B73""",27_25,CRISPR-Cas9 Knock-In of T513M and G41S Mutations in the Murine β–Galactosyl-Ceramidase Gene Re-capitulates Early-Onset and Adult-Onset Forms of Krabbe Disease,10 5 2022,,Krabbe_Disease
"et al., 2011</xref>; <xref rid=""B73"" ref-type=""bibr"">Spratley et al., 2016</xref>; <xref rid=""B33"" ref-type=""bibr"">Hill et al., 2018</xref>), and thus should have minimal effect on the catalytic site or to induce major protein misfolding impairing transport to lysosomes (<xref rid=""B69"" ref-type=""bibr"">Shin et al., 2016</xref>). In fact, our <italic toggle=""yes"">in vivo</italic> studies show that >80% of GALC<sup><italic toggle=""yes"">G</italic>41<italic toggle=""yes"">S</italic></sup> immunodetectable",27_26,CRISPR-Cas9 Knock-In of T513M and G41S Mutations in the Murine β–Galactosyl-Ceramidase Gene Re-capitulates Early-Onset and Adult-Onset Forms of Krabbe Disease,10 5 2022,,Krabbe_Disease
"toggle=""yes"">S</italic></sup> immunodetectable protein co-localized with Lamp2+ puncta, retaining significant residual enzyme activity. Likely, the translocation of GALC<sup><italic toggle=""yes"">G</italic>41<italic toggle=""yes"">S</italic></sup> enzyme residual activity to lysosomes explains the lower accumulation of psychosine in this mutant. In contrast, the <italic toggle=""yes"">GALC</italic><sup><italic toggle=""yes"">T</italic>513<italic toggle=""yes"">M/T</italic>513<italic toggle=""yes"">M</italic></sup>",27_27,CRISPR-Cas9 Knock-In of T513M and G41S Mutations in the Murine β–Galactosyl-Ceramidase Gene Re-capitulates Early-Onset and Adult-Onset Forms of Krabbe Disease,10 5 2022,,Krabbe_Disease
"toggle=""yes"">M</italic></sup> mutants, which have poor lysosomal translocation of a mutated protein without residual enzyme activity, accumulated high levels of psychosine, comparable with levels measured in TWI mice. The new KD mutants show interesting and chronologically different neuropathological changes. A direct correlation between toxic accumulations of psychosine and levels of demyelination, astrogliosis, and microglial dysfunction in the nervous system of the TWI mouse is well established (<xref",27_28,CRISPR-Cas9 Knock-In of T513M and G41S Mutations in the Murine β–Galactosyl-Ceramidase Gene Re-capitulates Early-Onset and Adult-Onset Forms of Krabbe Disease,10 5 2022,,Krabbe_Disease
"of the TWI mouse is well established (<xref rid=""B55"" ref-type=""bibr"">Ohno et al., 1993</xref>; <xref rid=""B77"" ref-type=""bibr"">Taniike and Suzuki, 1994</xref>; <xref rid=""B26"" ref-type=""bibr"">Giri et al., 2008</xref>; <xref rid=""B42"" ref-type=""bibr"">Kondo et al., 2011</xref>; <xref rid=""B14"" ref-type=""bibr"">Claycomb et al., 2014</xref>; <xref rid=""B57"" ref-type=""bibr"">O’Sullivan and Dev, 2015</xref>). As expected, these three neuropathological responses started at onset of clinical signs in <italic",27_29,CRISPR-Cas9 Knock-In of T513M and G41S Mutations in the Murine β–Galactosyl-Ceramidase Gene Re-capitulates Early-Onset and Adult-Onset Forms of Krabbe Disease,10 5 2022,,Krabbe_Disease
"started at onset of clinical signs in <italic toggle=""yes"">GALC</italic><sup><italic toggle=""yes"">T</italic>513<italic toggle=""yes"">M/T</italic>513<italic toggle=""yes"">M</italic></sup> mutants and worsened as disease progressed. Demyelination, while impacting all levels of white matter in the nervous system of <italic toggle=""yes"">GALC</italic><sup><italic toggle=""yes"">T</italic>513<italic toggle=""yes"">M/T</italic>513<italic toggle=""yes"">M</italic></sup> mutants, appeared patchy and less diffuse than that",27_30,CRISPR-Cas9 Knock-In of T513M and G41S Mutations in the Murine β–Galactosyl-Ceramidase Gene Re-capitulates Early-Onset and Adult-Onset Forms of Krabbe Disease,10 5 2022,,Krabbe_Disease
"appeared patchy and less diffuse than that observed in TWI mice, which may indicate undergoing segmental demyelination. Whether there is remyelination ongoing to repair demyelination is currently one area of study in our laboratory. In contrast, central demyelination and gliosis in <italic toggle=""yes"">GALC</italic><sup><italic toggle=""yes"">G</italic>41<italic toggle=""yes"">S</italic>/G41<italic toggle=""yes"">S</italic></sup> mutants were evident only in older mutants, consistent with late-onset",27_31,CRISPR-Cas9 Knock-In of T513M and G41S Mutations in the Murine β–Galactosyl-Ceramidase Gene Re-capitulates Early-Onset and Adult-Onset Forms of Krabbe Disease,10 5 2022,,Krabbe_Disease
"only in older mutants, consistent with late-onset neuropathology of adult forms of KD. Peripherally, both mutants also show different patterns of demyelination, which was clearly detected in sciatic nerves from <italic toggle=""yes"">GALC</italic><sup><italic toggle=""yes"">T</italic>513<italic toggle=""yes"">M/T</italic>513<italic toggle=""yes"">M</italic></sup> mutants but absent in <italic toggle=""yes"">GALC</italic><sup><italic toggle=""yes"">G</italic>41<italic toggle=""yes"">S</italic>/G41<italic",27_32,CRISPR-Cas9 Knock-In of T513M and G41S Mutations in the Murine β–Galactosyl-Ceramidase Gene Re-capitulates Early-Onset and Adult-Onset Forms of Krabbe Disease,10 5 2022,,Krabbe_Disease
"toggle=""yes"">S</italic>/G41<italic toggle=""yes"">S</italic></sup> nerves. The different involvement of central and peripheral nerve damage in these mutants clearly and quantifiably place the two models into the early-onset (<italic toggle=""yes"">GALC</italic><sup><italic toggle=""yes"">T</italic>513<italic toggle=""yes"">M/T</italic>513<italic toggle=""yes"">M</italic></sup>) and late-onset (<italic toggle=""yes"">GALC</italic><sup><italic toggle=""yes"">G</italic>41<italic toggle=""yes"">S/G</italic>41<italic",27_33,CRISPR-Cas9 Knock-In of T513M and G41S Mutations in the Murine β–Galactosyl-Ceramidase Gene Re-capitulates Early-Onset and Adult-Onset Forms of Krabbe Disease,10 5 2022,,Krabbe_Disease
"toggle=""yes"">S/G</italic>41<italic toggle=""yes"">S</italic></sup>) categories. Behavioral examination of both mutants showed clear indications of early (<italic toggle=""yes"">GALC</italic><sup><italic toggle=""yes"">T</italic>513<italic toggle=""yes"">M/T</italic>513<italic toggle=""yes"">M</italic></sup>) vs late (<italic toggle=""yes"">GALC</italic><sup><italic toggle=""yes"">G</italic>41<italic toggle=""yes"">S</italic>/G41<italic toggle=""yes"">S</italic></sup>) motor involvement. <italic",27_34,CRISPR-Cas9 Knock-In of T513M and G41S Mutations in the Murine β–Galactosyl-Ceramidase Gene Re-capitulates Early-Onset and Adult-Onset Forms of Krabbe Disease,10 5 2022,,Krabbe_Disease
"motor involvement. <italic toggle=""yes"">GALC</italic><sup><italic toggle=""yes"">T</italic>513<italic toggle=""yes"">M/T</italic>513<italic toggle=""yes"">M</italic></sup> mutants showed stereotypic motor declines comparable to those measured in TWI mice (<xref rid=""B56"" ref-type=""bibr"">Olmstead, 1987</xref>). All motor readouts, including grip strength, ledge walking, rotarod, and open field tests indicated a progressive neurological involvement of motor pathways, leading to severe and rapid paralysis. On the",27_35,CRISPR-Cas9 Knock-In of T513M and G41S Mutations in the Murine β–Galactosyl-Ceramidase Gene Re-capitulates Early-Onset and Adult-Onset Forms of Krabbe Disease,10 5 2022,,Krabbe_Disease
"leading to severe and rapid paralysis. On the other hand, <italic toggle=""yes"">GALC</italic><sup><italic toggle=""yes"">G</italic>41<italic toggle=""yes"">S</italic>/G41<italic toggle=""yes"">S</italic></sup> mutants showed mild and late onset deficits in some of the motor tests measured in our study. Interestingly, <italic toggle=""yes"">GALC</italic><sup><italic toggle=""yes"">G</italic>41<italic toggle=""yes"">S/G</italic>41<italic toggle=""yes"">S</italic></sup> mutants showed alterations in behavioral aspects",27_36,CRISPR-Cas9 Knock-In of T513M and G41S Mutations in the Murine β–Galactosyl-Ceramidase Gene Re-capitulates Early-Onset and Adult-Onset Forms of Krabbe Disease,10 5 2022,,Krabbe_Disease
"mutants showed alterations in behavioral aspects involving exploratory activities and anxiety-related responses. Particularly, <italic toggle=""yes"">GALC</italic><sup><italic toggle=""yes"">G</italic>41<italic toggle=""yes"">S/G</italic>41<italic toggle=""yes"">S</italic></sup> mutants showed increased times involving exploratory activities in the open field, light/dark box, and the Barnes maze tests. This may suggest that <italic toggle=""yes"">GALC</italic><sup><italic toggle=""yes"">G</italic>41<italic",27_37,CRISPR-Cas9 Knock-In of T513M and G41S Mutations in the Murine β–Galactosyl-Ceramidase Gene Re-capitulates Early-Onset and Adult-Onset Forms of Krabbe Disease,10 5 2022,,Krabbe_Disease
"toggle=""yes"">G</italic>41<italic toggle=""yes"">S/G</italic>41<italic toggle=""yes"">S</italic></sup> mutants are less anxious, and/or more curious. There are very few studies that have studied cognitive aspects on in KD, with most research focused on infantile cases and fewer on adult-onset cases (<xref rid=""B60"" ref-type=""bibr"">Patrick and Wilson, 1972</xref>; <xref rid=""B17"" ref-type=""bibr"">Crome et al., 1973</xref>; <xref rid=""B47"" ref-type=""bibr"">Loonen et al., 1985</xref>; <xref rid=""B56""",27_38,CRISPR-Cas9 Knock-In of T513M and G41S Mutations in the Murine β–Galactosyl-Ceramidase Gene Re-capitulates Early-Onset and Adult-Onset Forms of Krabbe Disease,10 5 2022,,Krabbe_Disease
"et al., 1985</xref>; <xref rid=""B56"" ref-type=""bibr"">Olmstead, 1987</xref>; <xref rid=""B41"" ref-type=""bibr"">Kolodny et al., 1991</xref>; <xref rid=""B37"" ref-type=""bibr"">Jardim et al., 1999</xref>; <xref rid=""B19"" ref-type=""bibr"">Debs et al., 2013</xref>; <xref rid=""B83"" ref-type=""bibr"">Xia et al., 2020</xref>; <xref rid=""B84"" ref-type=""bibr"">Yoon et al., 2021</xref>). In general, most neurodevelopmental deficits in KD have been associated with the loss of myelin and motor skills, which undoubtedly impacts",27_39,CRISPR-Cas9 Knock-In of T513M and G41S Mutations in the Murine β–Galactosyl-Ceramidase Gene Re-capitulates Early-Onset and Adult-Onset Forms of Krabbe Disease,10 5 2022,,Krabbe_Disease
"and motor skills, which undoubtedly impacts on the capacity of the patient to reach neurodevelopmental milestones. The <italic toggle=""yes"">GALC</italic><sup><italic toggle=""yes"">G</italic>41<italic toggle=""yes"">S</italic></sup> mutation, which appears to trigger mild and later onset demyelination (<xref rid=""B64"" ref-type=""bibr"">Saavedra-Matiz et al., 2016</xref>), with minimal involvement of motor and learning skills, shows unexpected anxiolytic effects, at least in some exploratory tasks. Interestingly,",27_40,CRISPR-Cas9 Knock-In of T513M and G41S Mutations in the Murine β–Galactosyl-Ceramidase Gene Re-capitulates Early-Onset and Adult-Onset Forms of Krabbe Disease,10 5 2022,,Krabbe_Disease
"least in some exploratory tasks. Interestingly, changes in social behavior have been described occasionally in KD carriers (<xref rid=""B12"" ref-type=""bibr"">Christomanou et al., 1981</xref>). Considering that KD is a recessive trait, manifested only in homozygosis, the presence of subtle behavior changes in carriers of the <italic toggle=""yes"">GALC</italic><sup><italic toggle=""yes"">G</italic>41<italic toggle=""yes"">S</italic></sup> mutation may suggest some level of phenotypic variation in adult-onset KD, at",27_41,CRISPR-Cas9 Knock-In of T513M and G41S Mutations in the Murine β–Galactosyl-Ceramidase Gene Re-capitulates Early-Onset and Adult-Onset Forms of Krabbe Disease,10 5 2022,,Krabbe_Disease
"of phenotypic variation in adult-onset KD, at least with some mutations. Defects in remyelination in heterozygous carriers of the twitcher mutation have been described (<xref rid=""B67"" ref-type=""bibr"">Scott-Hewitt et al., 2017</xref>, <xref rid=""B66"" ref-type=""bibr"">2020</xref>), but nothing is known about the effects of GALC haploinsufficiency on cognition. Understanding the cause for these behavioral alterations is an exciting field of study which is under further examination in our laboratory, as it may",27_42,CRISPR-Cas9 Knock-In of T513M and G41S Mutations in the Murine β–Galactosyl-Ceramidase Gene Re-capitulates Early-Onset and Adult-Onset Forms of Krabbe Disease,10 5 2022,,Krabbe_Disease
"further examination in our laboratory, as it may be relevant to understand phenotypic manifestations reported in carriers for this and other rare conditions (<xref rid=""B13"" ref-type=""bibr"">Christomanou et al., 1980</xref>, <xref rid=""B12"" ref-type=""bibr"">1981</xref>; <xref rid=""B11"" ref-type=""bibr"">Cheung and Ewens, 2006</xref>). Impairment in lysosomal activity has been previously reported in several LSDs, with responses involving the proliferation of lysosomes (<xref rid=""B52"" ref-type=""bibr"">Napolitano",27_43,CRISPR-Cas9 Knock-In of T513M and G41S Mutations in the Murine β–Galactosyl-Ceramidase Gene Re-capitulates Early-Onset and Adult-Onset Forms of Krabbe Disease,10 5 2022,,Krabbe_Disease
"(<xref rid=""B52"" ref-type=""bibr"">Napolitano et al., 2015</xref>; <xref rid=""B65"" ref-type=""bibr"">Sambri et al., 2017</xref>). Indeed, the TWI nervous system is characterized by an increased accumulation of lysosomes, detected by their high expression of LAMP-2 (<xref rid=""B50"" ref-type=""bibr"">Marshall et al., 2018</xref>) and by defective autophagy (<xref rid=""B63"" ref-type=""bibr"">Ribbens et al., 2014</xref>; <xref rid=""B20"" ref-type=""bibr"">Del Grosso et al., 2019</xref>, <xref rid=""B21""",27_44,CRISPR-Cas9 Knock-In of T513M and G41S Mutations in the Murine β–Galactosyl-Ceramidase Gene Re-capitulates Early-Onset and Adult-Onset Forms of Krabbe Disease,10 5 2022,,Krabbe_Disease
"Grosso et al., 2019</xref>, <xref rid=""B21"" ref-type=""bibr"">2022</xref>). Both new mutants showed increased expression of lysosomal markers in the brain, although with marked differences. Expression of LAMP-1 is robustly upregulated in white matter in the brain of the <italic toggle=""yes"">GALC</italic><sup><italic toggle=""yes"">T</italic>513<italic toggle=""yes"">M</italic>/T513<italic toggle=""yes"">M</italic></sup> mutant since the onset of disease. In contrast, lysosomal responses in the <italic",27_45,CRISPR-Cas9 Knock-In of T513M and G41S Mutations in the Murine β–Galactosyl-Ceramidase Gene Re-capitulates Early-Onset and Adult-Onset Forms of Krabbe Disease,10 5 2022,,Krabbe_Disease
"In contrast, lysosomal responses in the <italic toggle=""yes"">GALC</italic><sup><italic toggle=""yes"">G</italic>41<italic toggle=""yes"">S/G</italic>41<italic toggle=""yes"">S</italic></sup> mutant in white matter areas are low and only detected in aged mutants. Aligned with results measured in TWI cells (<xref rid=""B63"" ref-type=""bibr"">Ribbens et al., 2014</xref>; <xref rid=""B20"" ref-type=""bibr"">Del Grosso et al., 2019</xref>, <xref rid=""B21"" ref-type=""bibr"">2022</xref>), <italic",27_46,CRISPR-Cas9 Knock-In of T513M and G41S Mutations in the Murine β–Galactosyl-Ceramidase Gene Re-capitulates Early-Onset and Adult-Onset Forms of Krabbe Disease,10 5 2022,,Krabbe_Disease
"rid=""B21"" ref-type=""bibr"">2022</xref>), <italic toggle=""yes"">GALC</italic><sup><italic toggle=""yes"">T</italic>513<italic toggle=""yes"">M/T</italic>513<italic toggle=""yes"">M</italic></sup> and <italic toggle=""yes"">GALC</italic><sup><italic toggle=""yes"">G</italic>41<italic toggle=""yes"">S/G</italic>41<italic toggle=""yes"">S</italic></sup> cells also showed severe (<italic toggle=""yes"">GALC</italic><sup><italic toggle=""yes"">T</italic>513<italic toggle=""yes"">M/T</italic>513<italic toggle=""yes"">M</italic></sup>)",27_47,CRISPR-Cas9 Knock-In of T513M and G41S Mutations in the Murine β–Galactosyl-Ceramidase Gene Re-capitulates Early-Onset and Adult-Onset Forms of Krabbe Disease,10 5 2022,,Krabbe_Disease
"toggle=""yes"">M</italic></sup>) and mild (<italic toggle=""yes"">GALC</italic><sup><italic toggle=""yes"">G</italic>41<italic toggle=""yes"">S/G</italic>41<italic toggle=""yes"">S</italic></sup>) defects in autophagic responses to starvation. Interestingly, aged <italic toggle=""yes"">GALC</italic><sup><italic toggle=""yes"">G</italic>41<italic toggle=""yes"">S</italic>/G41<italic toggle=""yes"">S</italic></sup> mutant neurons showed larger LAMP-1+ puncta, indicative of a late-onset lysosomal dysfunction in this mutant.",27_48,CRISPR-Cas9 Knock-In of T513M and G41S Mutations in the Murine β–Galactosyl-Ceramidase Gene Re-capitulates Early-Onset and Adult-Onset Forms of Krabbe Disease,10 5 2022,,Krabbe_Disease
"late-onset lysosomal dysfunction in this mutant. This late-onset lysosomal response may undermine cellular functions in <italic toggle=""yes"">GALC</italic><sup><italic toggle=""yes"">G</italic>41<italic toggle=""yes"">S/G</italic>41<italic toggle=""yes"">S</italic></sup> mutant neurons and lead to -some- of the observed alterations in exploratory behavior in these mice. Clinical manifestations affecting behavior and cognition have been described in several inborn errors of the metabolism (<xref rid=""B31""",27_49,CRISPR-Cas9 Knock-In of T513M and G41S Mutations in the Murine β–Galactosyl-Ceramidase Gene Re-capitulates Early-Onset and Adult-Onset Forms of Krabbe Disease,10 5 2022,,Krabbe_Disease
"inborn errors of the metabolism (<xref rid=""B31"" ref-type=""bibr"">Gutschalk et al., 2004</xref>; <xref rid=""B16"" ref-type=""bibr"">Cox, 2020</xref>). Whether the <italic toggle=""yes"">GALC</italic><sup><italic toggle=""yes"">G</italic>41<italic toggle=""yes"">S</italic></sup> mutation, and perhaps others, affecting the GALC gene directly or indirectly impact the structure and/or activity of synapses of neural networks involved in higher cognitive functions remains an open question (<xref rid=""B10""",27_50,CRISPR-Cas9 Knock-In of T513M and G41S Mutations in the Murine β–Galactosyl-Ceramidase Gene Re-capitulates Early-Onset and Adult-Onset Forms of Krabbe Disease,10 5 2022,,Krabbe_Disease
"remains an open question (<xref rid=""B10"" ref-type=""bibr"">Castelvetri et al., 2011</xref>; <xref rid=""B5"" ref-type=""bibr"">Cantuti Castelvetri et al., 2013</xref>; <xref rid=""B6"" ref-type=""bibr"">Cantuti-Castelvetri and Bongarzone, 2016</xref>; <xref rid=""B49"" ref-type=""bibr"">Marshall and Bongarzone, 2016</xref>; <xref rid=""B28"" ref-type=""bibr"">Gowrishankar et al., 2020</xref>; <xref rid=""B62"" ref-type=""bibr"">Rebiai et al., 2021</xref>) and is the subject of a follow up study in our laboratories. In addition",27_51,CRISPR-Cas9 Knock-In of T513M and G41S Mutations in the Murine β–Galactosyl-Ceramidase Gene Re-capitulates Early-Onset and Adult-Onset Forms of Krabbe Disease,10 5 2022,,Krabbe_Disease
"follow up study in our laboratories. In addition to changes in the metabolism of psychosine, other factors such as accumulation of additional metabolites like lactosylceramide (<xref rid=""B58"" ref-type=""bibr"">Papini et al., 2022</xref>), alteration of other signaling pathways following lipid raft rearrangements in membranes (<xref rid=""B82"" ref-type=""bibr"">White et al., 2009</xref>; <xref rid=""B74"" ref-type=""bibr"">Sural-Fehr et al., 2019</xref>; <xref rid=""B1"" ref-type=""bibr"">Belleri and Presta,",27_52,CRISPR-Cas9 Knock-In of T513M and G41S Mutations in the Murine β–Galactosyl-Ceramidase Gene Re-capitulates Early-Onset and Adult-Onset Forms of Krabbe Disease,10 5 2022,,Krabbe_Disease
"rid=""B1"" ref-type=""bibr"">Belleri and Presta, 2022</xref>), abnormal microglia-mediated synaptic pruning (<xref rid=""B68"" ref-type=""bibr"">Sellgren et al., 2019</xref>), could be also contributors to changes in behavioral responses. The new <italic toggle=""yes"">GALC</italic><sup><italic toggle=""yes"">T</italic>513<italic toggle=""yes"">M/T</italic>513<italic toggle=""yes"">M</italic></sup> and GALC<sup><italic toggle=""yes"">G</italic>41<italic toggle=""yes"">S/G</italic>41<italic toggle=""yes"">S</italic></sup> murine",27_53,CRISPR-Cas9 Knock-In of T513M and G41S Mutations in the Murine β–Galactosyl-Ceramidase Gene Re-capitulates Early-Onset and Adult-Onset Forms of Krabbe Disease,10 5 2022,,Krabbe_Disease
"toggle=""yes"">S</italic></sup> murine models described in this study offer contrasting yet unique opportunities to study pathogenic mechanisms affecting synaptic and myelin function and their contribution to the spectrum of phenotypes observed in KD. These new transgenic lines appear as bona fide models of infantile and adult-onset KD, with evident advantages for their use in pre-clinical therapeutic studies. Importantly, this study shows the potential of using CRISPR-Cas9 gene editing to introduce and",27_54,CRISPR-Cas9 Knock-In of T513M and G41S Mutations in the Murine β–Galactosyl-Ceramidase Gene Re-capitulates Early-Onset and Adult-Onset Forms of Krabbe Disease,10 5 2022,,Krabbe_Disease
"using CRISPR-Cas9 gene editing to introduce and study functional effects of other pathogenic mutations in cis or trans with specific single nucleotide polymorphisms (SNPs) described in the <italic toggle=""yes"">GALC</italic> gene (<xref rid=""B64"" ref-type=""bibr"">Saavedra-Matiz et al., 2016</xref>). For example some SNPs such as p.I546T, while not pathogenic <italic toggle=""yes"">per se</italic>, are known to modify the overall GALC activity when segregated with point mutations such as T513M. This gene",27_55,CRISPR-Cas9 Knock-In of T513M and G41S Mutations in the Murine β–Galactosyl-Ceramidase Gene Re-capitulates Early-Onset and Adult-Onset Forms of Krabbe Disease,10 5 2022,,Krabbe_Disease
"with point mutations such as T513M. This gene editing approach will likely be crucial to help understand genotype-phenotype correlations and mechanisms defining an early vs a late manifestation of Krabbe disease. The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding author. The animal study was reviewed and approved by Animal Care and Use Committee at the University of Illinois at Chicago. RR performed",27_56,CRISPR-Cas9 Knock-In of T513M and G41S Mutations in the Murine β–Galactosyl-Ceramidase Gene Re-capitulates Early-Onset and Adult-Onset Forms of Krabbe Disease,10 5 2022,,Krabbe_Disease
"University of Illinois at Chicago. RR performed histology, immunocytochemistry, and wrote manuscript. ER and RB performed quantitative LC-MS-MS of psychosine. SZ and LT performed Morris water maze and wrote dedicated sections. DN established founders. GS and MJ performed cell culture experiments. RF performed motor behaviors. BW and SB performed monoclonal production and wrote dedicated sections. XJ and MS performed isobaric LC-MS-MS and wrote dedicated sections. MG performed histology and wrote dedicated",27_57,CRISPR-Cas9 Knock-In of T513M and G41S Mutations in the Murine β–Galactosyl-Ceramidase Gene Re-capitulates Early-Onset and Adult-Onset Forms of Krabbe Disease,10 5 2022,,Krabbe_Disease
"MG performed histology and wrote dedicated sections. EB designed the study, performed confocal microscopy, and wrote, edited, and proofedited the manuscript. All authors contributed to the article and approved the submitted version. The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. All claims expressed in this article are solely those of the authors and do not necessarily represent",27_58,CRISPR-Cas9 Knock-In of T513M and G41S Mutations in the Murine β–Galactosyl-Ceramidase Gene Re-capitulates Early-Onset and Adult-Onset Forms of Krabbe Disease,10 5 2022,,Krabbe_Disease
"of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.",27_59,CRISPR-Cas9 Knock-In of T513M and G41S Mutations in the Murine β–Galactosyl-Ceramidase Gene Re-capitulates Early-Onset and Adult-Onset Forms of Krabbe Disease,10 5 2022,,Krabbe_Disease
"Benefits of newborn screening and hematopoietic cell transplant in infantile Krabbe disease 
<list list-type=""bullet""><list-item><p>Expanded newborn screening identified 6 infants with infantile Krabbe disease, all of whom underwent transplant before 6 weeks of age.</p></list-item><list-item><p>All infants engrafted and survived HCT. Now 30 to 58 months old, neurodevelopmental gains continue slowly with prominent gross motor delays.</p></list-item></list>",28_0,Benefits of newborn screening and hematopoietic cell transplant in infantile Krabbe disease,10 5 2022,,Krabbe_Disease
"<fig position=""float"" id=""absf1"" fig-type=""featured""><graphic http://www.w3.org/1999/xlink href=""advancesADV2021006094absf1"" position=""float""></graphic></fig> Infantile Krabbe disease (IKD) can be treated with hematopoietic cell transplantation (HCT) if done during the first weeks of life before symptoms develop. To facilitate this, newborn screening (NBS) has been instituted in 8 US states. An application to add IKD to the recommended NBS panel is currently under review. In this report, the outcomes of",28_1,Benefits of newborn screening and hematopoietic cell transplant in infantile Krabbe disease,10 5 2022,,Krabbe_Disease
"under review. In this report, the outcomes of newborns with IKD diagnosed through NBS and treated with HCT are presented. The unique challenges associated with NBS for this disease are discussed, including opportunities for earlier diagnosis and streamlining treatment referrals. This is a retrospective review of six infants with IKD detected by NBS who were referred for HCT. The timing from diagnosis to HCT was examined, and both HCT and neurodevelopmental outcomes are described. Neurologic testing before",28_2,Benefits of newborn screening and hematopoietic cell transplant in infantile Krabbe disease,10 5 2022,,Krabbe_Disease
"outcomes are described. Neurologic testing before HCT revealed evidence of active IKD in all infants. All underwent HCT between 24 and 40 days of age, were successfully engrafted, and are alive 30 to 58 months later (median, 47.5 months). All are gaining developmental milestones albeit at a slower pace than unaffected age-matched peers. Gross motor function is most notably affected. NBS for these patients enabled early access to HCT, the only currently available treatment of infants with IKD. All children",28_3,Benefits of newborn screening and hematopoietic cell transplant in infantile Krabbe disease,10 5 2022,,Krabbe_Disease
"treatment of infants with IKD. All children are alive and have derived developmental and neurologic benefits from timely HCT. Long-term follow up is ongoing. Optimization of HCT and further development of emerging therapies, all of which must be delivered early in life, are expected to further improve outcomes of infants with IKD. This retrospective study represents a collaboration between 4 experienced pediatric HCT centers: Duke Children’s Hospital (coordinating center; Durham, North Carolina), Ann &",28_4,Benefits of newborn screening and hematopoietic cell transplant in infantile Krabbe disease,10 5 2022,,Krabbe_Disease
"center; Durham, North Carolina), Ann & Robert H. Lurie Children’s Hospital (Chicago, Illinois), Nationwide Children’s Hospital (Columbus, Ohio), and St. Louis Children’s Hospital (St. Louis, Missouri). All centers had prior experience in performing transplants in children with metabolic diseases, and 1 center (Duke) had previously performed transplantation in infants with IKD. Infants included here were born between January 2016 and February 2019. To our knowledge, this report includes all infants",28_5,Benefits of newborn screening and hematopoietic cell transplant in infantile Krabbe disease,10 5 2022,,Krabbe_Disease
"our knowledge, this report includes all infants diagnosed with IKD by NBS programs outside of New York State. Infants born in New York have been previously reported.<sup><xref rid=""B3"" ref-type=""bibr"">3,8,9</xref></sup> Following Institutional Review Board approval, data were retrospectively collected from electronic medical records and entered into a secure, HIPAA-compliant Research Electronic Data Capture database (REDCap)<sup><xref rid=""B11"" ref-type=""bibr"">11</xref></sup> hosted at Duke University. The",28_6,Benefits of newborn screening and hematopoietic cell transplant in infantile Krabbe disease,10 5 2022,,Krabbe_Disease
"hosted at Duke University. The study was conducted in accordance with the Declaration of Helsinki. The primary study endpoint was the evaluation performed 1 year after HCT. Descriptive endpoints including clinical, neurodiagnostic, and neurodevelopmental outcomes were included, with follow-up ranging from 30 to 58 months. Descriptive statistics were calculated for clinical and neurodevelopmental outcomes. BSID-III standardized and growth scores allowed for comparison with age-based norms and following",28_7,Benefits of newborn screening and hematopoietic cell transplant in infantile Krabbe disease,10 5 2022,,Krabbe_Disease
"for comparison with age-based norms and following longitudinal development, respectively.<sup><xref rid=""B14"" ref-type=""bibr"">14</xref></sup> Standard definitions were used for neutrophil and platelet engraftment.<sup><xref rid=""B24"" ref-type=""bibr"">24</xref></sup> Full donor chimerism was defined as >95% donor cells in both myeloid and lymphoid lineages.<sup><xref rid=""B24"" ref-type=""bibr"">24</xref></sup> Acute and chronic graft versus host disease was graded according to consensus criteria.<sup><xref",28_8,Benefits of newborn screening and hematopoietic cell transplant in infantile Krabbe disease,10 5 2022,,Krabbe_Disease
"graded according to consensus criteria.<sup><xref rid=""B25"" ref-type=""bibr"">25,26</xref></sup>  In this report, we present the outcomes of 6 newborns diagnosed with IKD through expanded NBS in their states. Early diagnosis of IKD enabled access to emergency HCT, the only currently available treatment for infants with this disease. The newborns appeared healthy, yet all demonstrated evidence of active IKD on neurodiagnostic and neuroimaging studies performed before transplant (at 1-3 weeks of age),",28_9,Benefits of newborn screening and hematopoietic cell transplant in infantile Krabbe disease,10 5 2022,,Krabbe_Disease
"before transplant (at 1-3 weeks of age), highlighting the rapid disease course. The newborns tolerated myeloablative chemotherapy well, engrafted donor cells, and established normal GALC levels. The children, now 30 to 58 months old, are all alive, and all but 1 patient no longer receive immunosuppressive therapy. One child has intermittent transplant-related autoimmune hemolytic anemia treated with low-dose immunosuppression.<sup><xref rid=""B28"" ref-type=""bibr"">28</xref></sup> Notably, all children are",28_10,Benefits of newborn screening and hematopoietic cell transplant in infantile Krabbe disease,10 5 2022,,Krabbe_Disease
"Notably, all children are continuing to achieve developmental milestones, albeit more slowly than unaffected peers. HCT itself has been associated with developmental delays in pediatric patients,<sup><xref rid=""B29"" ref-type=""bibr"">29</xref></sup> but the impact of HCT here is not quantifiable. In contrast, untreated infants develop quadriparesis, severe motor delay (equivalent to 1 month old), autonomic instability by 1 year of age, and early death.<sup><xref rid=""B1"" ref-type=""bibr"">1,30</xref></sup>",28_11,Benefits of newborn screening and hematopoietic cell transplant in infantile Krabbe disease,10 5 2022,,Krabbe_Disease
"rid=""B1"" ref-type=""bibr"">1,30</xref></sup> This report highlights that children with IKD can benefit from early HCT with improved survival and improved neurological function although varying degrees of neurologic impairments remain. Testing newborns for IKD presents unique challenges compared with other diseases diagnosed by NBS. For infants to access HCT or other future treatments, complex care coordination is immediately needed; for 2 of 6 infants, this included referral to an out-of-state transplant",28_12,Benefits of newborn screening and hematopoietic cell transplant in infantile Krabbe disease,10 5 2022,,Krabbe_Disease
"included referral to an out-of-state transplant center. Prior reports established HCT before 30 days old as a benchmark among presymptomatic infants.<sup><xref rid=""B5"" ref-type=""bibr"">5</xref></sup> Only 1 infant achieved that goal here. The family was integrally involved in hastening the referral, thereby enabling early evaluation (7 days old) and transplant (24 days old). Comparatively, the other babies were 31 to 40 days of age at HCT. Due to the small numbers, we cannot comment on whether this timing",28_13,Benefits of newborn screening and hematopoietic cell transplant in infantile Krabbe disease,10 5 2022,,Krabbe_Disease
"numbers, we cannot comment on whether this timing impacted the outcomes. Taken together, our experience reflects real-world practice. NBS programs in this series encountered reflex testing delays (eg, need for extra blood draw), difficulties contacting the family, and delays communicating results. Kwon et al found that sources of delays in the New York series included using genotyping as a confirmatory test and consulting local specialists rather than referring directly to a transplant center.<sup><xref",28_14,Benefits of newborn screening and hematopoietic cell transplant in infantile Krabbe disease,10 5 2022,,Krabbe_Disease
"directly to a transplant center.<sup><xref rid=""B3"" ref-type=""bibr"">3</xref></sup> These steps were eliminated in this patient cohort. Possible remedies include (1) rapid reflex testing using psychosine per recent consensus recommendations,<sup><xref rid=""B3"" ref-type=""bibr"">3</xref></sup> (2) established referral pathways triggered by reflex testing, and (3) concurrent pathways to rapidly inform the pediatrician and initiate the referral. When NBS is implemented, relationships with transplant centers",28_15,Benefits of newborn screening and hematopoietic cell transplant in infantile Krabbe disease,10 5 2022,,Krabbe_Disease
"relationships with transplant centers should be firmly established. Strategies for transplant centers to mitigate delays include (1) performing transplant-related processes and disease evaluations in parallel, (2) partnering with Medicaid and private health care payers to minimize third-party payer approval time, and (3) initiating chemotherapy before final donor selection, assuming that candidate donors have been selected (not customary for HCT centers). It is unknown whether gene therapy, which is still",28_16,Benefits of newborn screening and hematopoietic cell transplant in infantile Krabbe disease,10 5 2022,,Krabbe_Disease
"is unknown whether gene therapy, which is still in developmental stages, can reverse or prevent further neurologic damage in these patients, but preclinical animal data also demonstrate a need for treatment in the first few weeks of life to optimize outcomes. Presently, HCT continues to be an emergent option for patients with IKD. Clearly, opportunities for improvement still exist for both NBS programs and treating centers to maximize efficiency. Transplant after onset of clinical symptoms yields poor",28_17,Benefits of newborn screening and hematopoietic cell transplant in infantile Krabbe disease,10 5 2022,,Krabbe_Disease
"after onset of clinical symptoms yields poor outcomes.<sup><xref rid=""B7"" ref-type=""bibr"">7</xref></sup> In presymptomatic infants, early and long-term neurologic and transplant outcomes have been published.<sup><xref rid=""B5"" ref-type=""bibr"">5-8</xref></sup> Escolar et al described 11 infants diagnosed by family history within a larger cohort of 25 infants.<sup><xref rid=""B7"" ref-type=""bibr"">7</xref></sup> To facilitate early HCT, most mothers delivered at the transplant center and often were induced 2 to",28_18,Benefits of newborn screening and hematopoietic cell transplant in infantile Krabbe disease,10 5 2022,,Krabbe_Disease
"the transplant center and often were induced 2 to 4 weeks early. Nine of the 11 children are alive with varying degrees of motor disability after a median of 18 years.<sup><xref rid=""B5"" ref-type=""bibr"">5</xref></sup> One died after an anesthesia reaction and another died of progressive IKD (at 5 and 15 years, respectively). One decade later, the New York State NBS program published its experience.<sup><xref rid=""B8"" ref-type=""bibr"">8</xref></sup> Four infants underwent HCT between 24 and 41 days old using",28_19,Benefits of newborn screening and hematopoietic cell transplant in infantile Krabbe disease,10 5 2022,,Krabbe_Disease
"underwent HCT between 24 and 41 days old using similar chemotherapy as reported here. Of note, supportive care measures have since improved. Two infants died shortly after HCT. Two are long-term survivors (14 and 10 years): 1 has moderate impairment (attends school with educational supports, converses, uses a wheelchair, HCT at 32 days old) and 1 has severe neurologic impairment (full care, HCT at 41 days old),<sup><xref rid=""B8"" ref-type=""bibr"">8</xref></sup> with Ehmann and Lantos<sup><xref rid=""B31""",28_20,Benefits of newborn screening and hematopoietic cell transplant in infantile Krabbe disease,10 5 2022,,Krabbe_Disease
"with Ehmann and Lantos<sup><xref rid=""B31"" ref-type=""bibr"">31</xref></sup> raising concerns of HCT efficacy. Comparatively, infants diagnosed by family history experienced more favorable outcomes although this result should be interpreted cautiously given the small numbers. Ehmann and Lantos postulated that many of these infants were “false positives” (ie, healthy), but, as noted by Orsini et al, this is unlikely based on long-term outcomes.<sup><xref rid=""B6"" ref-type=""bibr"">6,32</xref></sup> Most were",28_21,Benefits of newborn screening and hematopoietic cell transplant in infantile Krabbe disease,10 5 2022,,Krabbe_Disease
"ref-type=""bibr"">6,32</xref></sup> Most were diagnosed prenatally and delivered at the HCT center, thereby allowing evaluations to quickly begin. Logistics such as housing, sibling childcare, and financial approvals were arranged ahead of time. With their prior experiences, affected families may have found the decision to proceed to transplant easier. One challenge has been distinguishing true- from false-positive newborn screening results (ie, low GALC). While GALC enzyme activity has merits as a screening",28_22,Benefits of newborn screening and hematopoietic cell transplant in infantile Krabbe disease,10 5 2022,,Krabbe_Disease
"GALC enzyme activity has merits as a screening test, it lacks the sensitivity needed to differentiate affected from unaffected babies, a concern raised by Ehmann and Lantos.<sup><xref rid=""B31"" ref-type=""bibr"">31</xref></sup> Polymerase chain reaction–based deletion analysis and <italic toggle=""yes"">GALC</italic> sequencing was previously used as a second-tier test<sup><xref rid=""B9"" ref-type=""bibr"">9,33</xref></sup> although is labor intensive and expensive and can potentially miss novel pathogenic",28_23,Benefits of newborn screening and hematopoietic cell transplant in infantile Krabbe disease,10 5 2022,,Krabbe_Disease
"and can potentially miss novel pathogenic variants (eg, Patient 2) or provide indeterminate results (variants of uncertain significance). As such, the biomarker psychosine has become the reflex test of choice. It can rapidly discriminate between IKD (≥10 nmol/L), late-onset forms (>2 and <10 nmol/L), pseudodeficiencies, and carriers (<2 nmol/L).<sup><xref rid=""B2"" ref-type=""bibr"">2</xref></sup> Providing further evidence for psychosine-based confirmatory testing, all 6 infants had markedly elevated",28_24,Benefits of newborn screening and hematopoietic cell transplant in infantile Krabbe disease,10 5 2022,,Krabbe_Disease
"testing, all 6 infants had markedly elevated psychosine levels on their newborn dried blood spots. Most states’ screening for KD have now incorporated psychosine into reflex testing algorithms, but this was only partially implemented when the infants in this study were identified. Several programs now perform psychosine testing in house, and others have since arranged for faster sample turnaround. Going forward, samples could ideally be screened, undergo reflex psychosine testing, and have results between",28_25,Benefits of newborn screening and hematopoietic cell transplant in infantile Krabbe disease,10 5 2022,,Krabbe_Disease
"psychosine testing, and have results between days 2 and 4 of life (depending on in-house vs referral laboratory). We have demonstrated that with established referral protocols, it is feasible to begin evaluations even the next day (days 3-5 of life). Once the diagnosis and disease activity are confirmed, chemotherapy can start shortly thereafter, assuming that donor selection is nearly complete. This timeline, enabled by psychosine reflex testing and other strategies outlined above, could allow for HCT to",28_26,Benefits of newborn screening and hematopoietic cell transplant in infantile Krabbe disease,10 5 2022,,Krabbe_Disease
"strategies outlined above, could allow for HCT to occur when the infant is 17 to 20 days old. This report represents the largest series of infants with IKD diagnosed through NBS. Rapid diagnosis using psychosine levels on newborn blood spots enabled early referrals and transplantation before 6 weeks of age. The children in this series are alive and have derived neurologic benefits from HCT compared with untreated children. Nevertheless, all have ongoing developmental delays and motor disabilities. This",28_27,Benefits of newborn screening and hematopoietic cell transplant in infantile Krabbe disease,10 5 2022,,Krabbe_Disease
"developmental delays and motor disabilities. This report adds considerably to what is known about modern outcomes after HCT in newborn infants with IKD and will inform ongoing conversations about widespread NBS for KD. It also demonstrates the feasibility of treatment at centers closer to the families’ homes, but the urgent timeline does introduce challenges. Beyond the HCT recovery period, children generally receive their long-term care locally and are seen at larger pediatric centers 1 to 2 times per",28_28,Benefits of newborn screening and hematopoietic cell transplant in infantile Krabbe disease,10 5 2022,,Krabbe_Disease
"seen at larger pediatric centers 1 to 2 times per year. NBS enabled early access to HCT for these patients, but as new therapies emerge, it is likely that early treatment (as neonates) will need to optimize outcomes. Thus, in combination with expanded NBS to identify affected infants, efforts to optimize HCT and develop new treatments are ultimately needed. The full-text version of this article contains a data supplement.",28_29,Benefits of newborn screening and hematopoietic cell transplant in infantile Krabbe disease,10 5 2022,,Krabbe_Disease
"The Pathogenic Sphingolipid Psychosine is Secreted in Extracellular Vesicles in the Brain of a Mouse Model of Krabbe Disease Psychosine exerts most of its toxic effects by altering membrane dynamics with increased shedding of extracellular vesicles (EVs). In this study, we discovered that a fraction of psychosine produced in the brain of the Twitcher mouse, a model for Krabbe disease, is associated with secreted EVs. We evaluated the effects of attenuating EV secretion in the Twitcher brain by depleting",29_0,The Pathogenic Sphingolipid Psychosine is Secreted in Extracellular Vesicles in the Brain of a Mouse Model of Krabbe Disease,18 3 2022,,Krabbe_Disease
"EV secretion in the Twitcher brain by depleting ceramide production with an inhibitor of neutral sphingomyelinase 2, GW4869. Twitcher mice treated with GW4869 had decreased overall EV levels, reduced EV-associated psychosine and unexpectedly, correlated with increased disease severity. Notably, characterization of well-established, neuroanatomic hallmarks of disease pathology, such as demyelination and inflammatory gliosis, remained essentially unaltered in the brains of GW4869-treated Twitcher mice",29_1,The Pathogenic Sphingolipid Psychosine is Secreted in Extracellular Vesicles in the Brain of a Mouse Model of Krabbe Disease,18 3 2022,,Krabbe_Disease
in the brains of GW4869-treated Twitcher mice compared to vehicle-treated Twitcher controls. Further analysis of Twitcher brain pathophysiology is required to understand the mechanism behind early-onset disease severity in GW4869-treated mice. The results herein demonstrate that some pathogenic lipids like psychosine may be secreted using EV pathways. Our results highlight the relevance of this secretory mechanism as a possible contributor to spreading pathogenic lipids in neurological lipidoses. Krabbe,29_2,The Pathogenic Sphingolipid Psychosine is Secreted in Extracellular Vesicles in the Brain of a Mouse Model of Krabbe Disease,18 3 2022,,Krabbe_Disease
"lipids in neurological lipidoses. Krabbe disease is a genetic leukodystrophy caused by mutations in the <italic toggle=""yes"">GALC</italic> gene, which encodes the lysosomal enzyme galactosylceramidase (GALC) (<xref rid=""bibr30-17590914221087817"" ref-type=""bibr"">Krabbe, 1916</xref>; <xref rid=""bibr54-17590914221087817"" ref-type=""bibr"">Suzuki and Suzuki, 1970</xref>, <xref rid=""bibr55-17590914221087817"" ref-type=""bibr"">1971</xref>; <xref rid=""bibr72-17590914221087817"" ref-type=""bibr"">Zlotogora et al.,",29_3,The Pathogenic Sphingolipid Psychosine is Secreted in Extracellular Vesicles in the Brain of a Mouse Model of Krabbe Disease,18 3 2022,,Krabbe_Disease
"ref-type=""bibr"">Zlotogora et al., 1990</xref>). GALC deficiency blocks the catabolism of galactosylceramides (GalCer) and leads to the toxic accumulation of the lysosphingolipid galactosylsphingosine or psychosine. Endogenous levels of psychosine are low in healthy conditions but its toxic accumulation correlates with disease progression and development of CNS and PNS pathology in Krabbe patients (<xref rid=""bibr53-17590914221087817"" ref-type=""bibr"">Suzuki, 1998</xref>). Psychosine is primarily synthesized",29_4,The Pathogenic Sphingolipid Psychosine is Secreted in Extracellular Vesicles in the Brain of a Mouse Model of Krabbe Disease,18 3 2022,,Krabbe_Disease
"1998</xref>). Psychosine is primarily synthesized via deacylation of GalCer by acid ceramidase (<xref rid=""bibr33-17590914221087817"" ref-type=""bibr"">Li et al., 2019</xref>) and is considered the molecular trigger in this disease (<xref rid=""bibr40-17590914221087817"" ref-type=""bibr"">Miyatake and Suzuki, 1972</xref>). Twitcher mice represent an authentic model of infantile forms of Krabbe disease with diffuse central and peripheral demyelination, microgliosis, astrogliosis and progressive neurodegeneration",29_5,The Pathogenic Sphingolipid Psychosine is Secreted in Extracellular Vesicles in the Brain of a Mouse Model of Krabbe Disease,18 3 2022,,Krabbe_Disease
"astrogliosis and progressive neurodegeneration (<xref rid=""bibr6-17590914221087817"" ref-type=""bibr"">Austin, 1962</xref>; <xref rid=""bibr67-17590914221087817"" ref-type=""bibr"">Wallace et al., 1964</xref>; <xref rid=""bibr29-17590914221087817"" ref-type=""bibr"">Kobayashi et al., 1980</xref>; <xref rid=""bibr12-17590914221087817"" ref-type=""bibr"">Castelvetri et al., 2011</xref>; <xref rid=""bibr11-17590914221087817"" ref-type=""bibr"">Cantuti-Castelvetri et al., 2012</xref>; <xref rid=""bibr9-17590914221087817""",29_6,The Pathogenic Sphingolipid Psychosine is Secreted in Extracellular Vesicles in the Brain of a Mouse Model of Krabbe Disease,18 3 2022,,Krabbe_Disease
"2012</xref>; <xref rid=""bibr9-17590914221087817"" ref-type=""bibr"">Cantuti Castelvetri et al., 2013</xref>; <xref rid=""bibr13-17590914221087817"" ref-type=""bibr"">Claycomb et al., 2014</xref>; <xref rid=""bibr48-17590914221087817"" ref-type=""bibr"">Smith et al., 2014</xref>; <xref rid=""bibr1-17590914221087817"" ref-type=""bibr"">Abdelkarim et al., 2018</xref>; <xref rid=""bibr34-17590914221087817"" ref-type=""bibr"">Marshall et al., 2018</xref>). How psychosine triggers pathogenic mechanisms has remained incompletely",29_7,The Pathogenic Sphingolipid Psychosine is Secreted in Extracellular Vesicles in the Brain of a Mouse Model of Krabbe Disease,18 3 2022,,Krabbe_Disease
"pathogenic mechanisms has remained incompletely understood. Our laboratory discovered that psychosine accumulates in membrane lipid rafts, disrupting their architecture (<xref rid=""bibr69-17590914221087817"" ref-type=""bibr"">White et al., 2009</xref>; <xref rid=""bibr68-17590914221087817"" ref-type=""bibr"">White et al., 2011</xref>). It is believed that raft dysfunction plays a major role in modifying downstream signaling pathways such as IGF-receptor (<xref rid=""bibr52-17590914221087817""",29_8,The Pathogenic Sphingolipid Psychosine is Secreted in Extracellular Vesicles in the Brain of a Mouse Model of Krabbe Disease,18 3 2022,,Krabbe_Disease
"(<xref rid=""bibr52-17590914221087817"" ref-type=""bibr"">Sural-Fehr et al., 2019</xref>), Akt (<xref rid=""bibr10-17590914221087817"" ref-type=""bibr"">Cantuti-Castelvetri et al., 2015</xref>; <xref rid=""bibr52-17590914221087817"" ref-type=""bibr"">Sural-Fehr et al., 2019</xref>), PKC (<xref rid=""bibr69-17590914221087817"" ref-type=""bibr"">White et al., 2009</xref>; <xref rid=""bibr68-17590914221087817"" ref-type=""bibr"">White et al., 2011</xref>; <xref rid=""bibr23-17590914221087817"" ref-type=""bibr"">Hawkins-Salsbury et",29_9,The Pathogenic Sphingolipid Psychosine is Secreted in Extracellular Vesicles in the Brain of a Mouse Model of Krabbe Disease,18 3 2022,,Krabbe_Disease
"ref-type=""bibr"">Hawkins-Salsbury et al., 2013</xref>) and phosphatases (<xref rid=""bibr12-17590914221087817"" ref-type=""bibr"">Castelvetri et al., 2011</xref>; <xref rid=""bibr11-17590914221087817"" ref-type=""bibr"">Cantuti-Castelvetri et al., 2012</xref>; <xref rid=""bibr9-17590914221087817"" ref-type=""bibr"">Cantuti Castelvetri et al., 2013</xref>). Psychosine introduces steric hindrance impacting on lateral mobility and fluidity of cellular and myelin membranes (<xref rid=""bibr16-17590914221087817""",29_10,The Pathogenic Sphingolipid Psychosine is Secreted in Extracellular Vesicles in the Brain of a Mouse Model of Krabbe Disease,18 3 2022,,Krabbe_Disease
"membranes (<xref rid=""bibr16-17590914221087817"" ref-type=""bibr"">D'Auria and Bongarzone, 2016</xref>; <xref rid=""bibr7-17590914221087817"" ref-type=""bibr"">Batta et al., 2018</xref>). In fact, we recently demonstrated that psychosine decreases membrane fluidity and facilitates the shedding and secretion of extracellular vesicles (EVs) (<xref rid=""bibr17-17590914221087817"" ref-type=""bibr"">D'Auria et al., 2017</xref>). These findings and early imaging evidence of vesiculation of brain membranes in Twitcher",29_11,The Pathogenic Sphingolipid Psychosine is Secreted in Extracellular Vesicles in the Brain of a Mouse Model of Krabbe Disease,18 3 2022,,Krabbe_Disease
"of vesiculation of brain membranes in Twitcher mice, led us to question whether psychosine associates with secreted EVs. EVs are highly heterogenous secreted membrane vesicles, participating in inter-cellular communication and propagation of signals (<xref rid=""bibr62-17590914221087817"" ref-type=""bibr"">Trams et al., 1981</xref>; <xref rid=""bibr27-17590914221087817"" ref-type=""bibr"">Johnstone et al., 1987</xref>; <xref rid=""bibr14-17590914221087817"" ref-type=""bibr"">Colombo et al., 2014</xref>; <xref",29_12,The Pathogenic Sphingolipid Psychosine is Secreted in Extracellular Vesicles in the Brain of a Mouse Model of Krabbe Disease,18 3 2022,,Krabbe_Disease
"et al., 2014</xref>; <xref rid=""bibr63-17590914221087817"" ref-type=""bibr"">Tricarico et al., 2017</xref>; <xref rid=""bibr35-17590914221087817"" ref-type=""bibr"">Mathieu et al., 2019</xref>). The lipid composition of EVs is influenced by cell type, differentiation stage, age, metabolic status, and by disease state (<xref rid=""bibr14-17590914221087817"" ref-type=""bibr"">Colombo et al., 2014</xref>; <xref rid=""bibr71-17590914221087817"" ref-type=""bibr"">Willms et al., 2016</xref>; <xref",29_13,The Pathogenic Sphingolipid Psychosine is Secreted in Extracellular Vesicles in the Brain of a Mouse Model of Krabbe Disease,18 3 2022,,Krabbe_Disease
"ref-type=""bibr"">Willms et al., 2016</xref>; <xref rid=""bibr44-17590914221087817"" ref-type=""bibr"">Reiter and Bongarzone, 2019</xref>; <xref rid=""bibr70-17590914221087817"" ref-type=""bibr"">Willis et al., 2020</xref>). Once vesicles are formed, their targeting mechanism for cargo delivery is still uncertain. The lipid layer that protects the transported cargo facilitates mobilization over significant distances while evading degradative processes (<xref rid=""bibr60-17590914221087817"" ref-type=""bibr"">Thery et",29_14,The Pathogenic Sphingolipid Psychosine is Secreted in Extracellular Vesicles in the Brain of a Mouse Model of Krabbe Disease,18 3 2022,,Krabbe_Disease
"ref-type=""bibr"">Thery et al., 2006</xref>; <xref rid=""bibr50-17590914221087817"" ref-type=""bibr"">Street et al., 2012</xref>; <xref rid=""bibr64-17590914221087817"" ref-type=""bibr"">van Niel et al., 2018</xref>). These aspects are relevant when considering the implications for the propagation of pathogenic molecules such as psychosine. For example, EVs can carry pathogenic proteins such as amyloid and alpha-synuclein, likely contributing to seed formation of plaques in Alzheimer disease models and other",29_15,The Pathogenic Sphingolipid Psychosine is Secreted in Extracellular Vesicles in the Brain of a Mouse Model of Krabbe Disease,18 3 2022,,Krabbe_Disease
"of plaques in Alzheimer disease models and other proteopathic models (<xref rid=""bibr15-17590914221087817"" ref-type=""bibr"">Danzer et al., 2012</xref>; <xref rid=""bibr46-17590914221087817"" ref-type=""bibr"">Shi et al., 2014</xref>; <xref rid=""bibr39-17590914221087817"" ref-type=""bibr"">Minakaki et al., 2018</xref>). While most studies of lipids involved in EV biology have characterized compositional changes contributing to EV formation (<xref rid=""bibr47-17590914221087817"" ref-type=""bibr"">Skotland et al.,",29_16,The Pathogenic Sphingolipid Psychosine is Secreted in Extracellular Vesicles in the Brain of a Mouse Model of Krabbe Disease,18 3 2022,,Krabbe_Disease
"ref-type=""bibr"">Skotland et al., 2017</xref>), little has been done to study whether EVs can also transport pathogenic lipids in genetic lipidoses. Here we have addressed this question in EVs of the Twitcher mouse brain.   This is the first investigation to our knowledge that identifies psychosine as a lipid cargo secreted by EVs in the brain of an animal model of Krabbe disease. Our results show that a significant fraction of psychosine is present in total EVs isolated from the mutant brain, paralleling",29_17,The Pathogenic Sphingolipid Psychosine is Secreted in Extracellular Vesicles in the Brain of a Mouse Model of Krabbe Disease,18 3 2022,,Krabbe_Disease
"EVs isolated from the mutant brain, paralleling the development of disease. At early-stages, we found that TWI brains yielded greater numbers of EVs in fractions 2–4 as measured by NTA tracking. By late-stage disease EV quantities were reduced. Since this was consistent across both genotypes, this decrease is less likely to represent a pathologic process, but rather indicates that EV production and secretion are involved in normal neurodevelopmental physiology within the brain. The significance of this",29_18,The Pathogenic Sphingolipid Psychosine is Secreted in Extracellular Vesicles in the Brain of a Mouse Model of Krabbe Disease,18 3 2022,,Krabbe_Disease
"within the brain. The significance of this shift is difficult to interpret without further understanding the mechanisms that regulate EV release, which is beyond the scope of this study. EVs have been implicated in several neurodevelopmental and migratory processes within the central and peripheral nervous systems. Better understanding the course and fluctuations of EV release based on developmental processes is another interesting aspect to consider in future investigations of the CNS secretome.",29_19,The Pathogenic Sphingolipid Psychosine is Secreted in Extracellular Vesicles in the Brain of a Mouse Model of Krabbe Disease,18 3 2022,,Krabbe_Disease
"in future investigations of the CNS secretome. Psychosine accumulation is inevitable in the Twitcher mouse model and Krabbe disease owing to catabolic enzyme insufficiency without redundant mechanisms for lipid breakdown. As such, psychosine degradative capacity within lysosomes and autophagosomes is limited, with toxic levels eventually leading to cell dysfunction and apoptosis. Accumulation of psychosine occurs in both neuronal and glial cell types, as well as in the myelin membranes themselves (<xref",29_20,The Pathogenic Sphingolipid Psychosine is Secreted in Extracellular Vesicles in the Brain of a Mouse Model of Krabbe Disease,18 3 2022,,Krabbe_Disease
"well as in the myelin membranes themselves (<xref rid=""bibr17-17590914221087817"" ref-type=""bibr"">D'Auria et al., 2017</xref>). Therefore, myelin sheaths act as another source of psychosine accretion, ultimately leading to their instability and degradation. EVs may serve as an mechanism for cells to escape or reduce toxic levels of psychosine, though recipient cells would become likewise burdened. To better understand the role of EVs in psychosine accumulation and distribution within the Twitcher mouse",29_21,The Pathogenic Sphingolipid Psychosine is Secreted in Extracellular Vesicles in the Brain of a Mouse Model of Krabbe Disease,18 3 2022,,Krabbe_Disease
"and distribution within the Twitcher mouse model, we aimed to disrupt EV release with the pharmacologic inhibitor GW4869. The number of EVs isolated from brains of mice treated with the GW4869 inhibitor of nSMase2 was reduced, with decreased quantities of EVs across multiple fractions of vesicle subpopulations. This reduction was more pronounced in early-stage disease but persisted into late-stage disease as well. We speculate that the diminished reduction of EVs in late-stage disease could be due to: 1)",29_22,The Pathogenic Sphingolipid Psychosine is Secreted in Extracellular Vesicles in the Brain of a Mouse Model of Krabbe Disease,18 3 2022,,Krabbe_Disease
"of EVs in late-stage disease could be due to: 1) the efficacy of GW4869 to inhibit EV release requires a higher baseline level of EV release, therefore its inhibitory effect was decreased as EV release reduced with age in the TWI mice; 2) the mechanism of vesicle release in early disease has greater dependence on ceramide and diminishes with age; 3) the specific cell populations that contribute to secretion and/or clearance of EVs decrease EV-related functions over time. Importantly, the total levels of",29_23,The Pathogenic Sphingolipid Psychosine is Secreted in Extracellular Vesicles in the Brain of a Mouse Model of Krabbe Disease,18 3 2022,,Krabbe_Disease
"over time. Importantly, the total levels of psychosine within the brain and the psychosine content per EV remained unchanged by GW4869 treatment. The total content of psychosine released in EVs was only marginally reduced in summated EV populations following GW4869 treatment, but was significantly reduced in fractions 2 and 3 at P20, and in fraction 3 at P40.This suggests that the reduction of secreted psychosine in specific EV fractions is possibly due to an overall reduction of the secretion of EVs after",29_24,The Pathogenic Sphingolipid Psychosine is Secreted in Extracellular Vesicles in the Brain of a Mouse Model of Krabbe Disease,18 3 2022,,Krabbe_Disease
"overall reduction of the secretion of EVs after GW4869 treatment, rather than a decreased association of psychosine with EVs. Importantly, our findings that a significant amount of psychosine was secreted regardless of GW4869 treatment suggest that psychosine is released using additional secretory pathways (<xref rid=""bibr8-17590914221087817"" ref-type=""bibr"">Bobrie et al., 2011</xref>). Interestingly, the reduced secretion of psychosine in EVs in GW4869-treated mice paralleled an increased disease severity",29_25,The Pathogenic Sphingolipid Psychosine is Secreted in Extracellular Vesicles in the Brain of a Mouse Model of Krabbe Disease,18 3 2022,,Krabbe_Disease
"mice paralleled an increased disease severity in treated TWI mice, primarily during the early phase of the disease. While the use of GW4869 successfully reduced pathology in other studies (<xref rid=""bibr18-17590914221087817"" ref-type=""bibr"">Dinkins et al., 2014</xref>) there are also reports showing the opposite effect (<xref rid=""bibr26-17590914221087817"" ref-type=""bibr"">Iguchi et al., 2016</xref>). An additional aspect to note is that EVs play an important role in cell-to-cell communication (<xref",29_26,The Pathogenic Sphingolipid Psychosine is Secreted in Extracellular Vesicles in the Brain of a Mouse Model of Krabbe Disease,18 3 2022,,Krabbe_Disease
"role in cell-to-cell communication (<xref rid=""bibr14-17590914221087817"" ref-type=""bibr"">Colombo et al., 2014</xref>; <xref rid=""bibr64-17590914221087817"" ref-type=""bibr"">van Niel et al., 2018</xref>; <xref rid=""bibr35-17590914221087817"" ref-type=""bibr"">Mathieu et al., 2019</xref>; <xref rid=""bibr44-17590914221087817"" ref-type=""bibr"">Reiter and Bongarzone, 2019</xref>; <xref rid=""bibr70-17590914221087817"" ref-type=""bibr"">Willis et al., 2020</xref>). Decreasing the secretion of EVs, as done in our study,",29_27,The Pathogenic Sphingolipid Psychosine is Secreted in Extracellular Vesicles in the Brain of a Mouse Model of Krabbe Disease,18 3 2022,,Krabbe_Disease
"the secretion of EVs, as done in our study, may have affected the transfer of relevant/key information possibly contributing to the worsened clinical phenotype in GW4869-treated Twitcher mice. While we have not observed signs of neurological disease in GW4869-treated WT mice, suggesting the absence of GW4869-related side effects, there are reports where some level of toxicity has been found following administration of GW4869 (<xref rid=""bibr56-17590914221087817"" ref-type=""bibr"">Tabatadze et al.,",29_28,The Pathogenic Sphingolipid Psychosine is Secreted in Extracellular Vesicles in the Brain of a Mouse Model of Krabbe Disease,18 3 2022,,Krabbe_Disease
"ref-type=""bibr"">Tabatadze et al., 2010</xref>; <xref rid=""bibr21-17590914221087817"" ref-type=""bibr"">Essandoh et al., 2015</xref>; <xref rid=""bibr57-17590914221087817"" ref-type=""bibr"">Tan et al., 2018</xref>). Thus, being that TWI mice are intrinsically vulnerable, potential GW4869-related toxicity may have also contributed to the worsening of treated TWI mice. The apparent worsening of diffuse demyelination in TWI mice treated with GW4869 may explain the measurable increase of disease severity in these",29_29,The Pathogenic Sphingolipid Psychosine is Secreted in Extracellular Vesicles in the Brain of a Mouse Model of Krabbe Disease,18 3 2022,,Krabbe_Disease
"measurable increase of disease severity in these mice before reaching terminal neurological deterioration. One possibility is that in the naïve TWI brain, the secretion of psychosine in EVs aids to reduce cellular levels of psychosine in myelinating cells such as oligodendrocytes, acting as a defense mechanism to decrease cellular stress. When this secretory pathway is repressed with GW4869, TWI oligodendrocytes may have less opportunity to reduce their psychosine levels, eventually increasing cellular and",29_30,The Pathogenic Sphingolipid Psychosine is Secreted in Extracellular Vesicles in the Brain of a Mouse Model of Krabbe Disease,18 3 2022,,Krabbe_Disease
"levels, eventually increasing cellular and myelin stress. In this context, our histological analyses showed regional reductions of MBP staining, suggesting loss or disruption of myelin membranes, albeit in non-significant levels with respect to the already demyelinated naïve TWI brain with an intact EV secretory pathway. The lack of power in detecting significant decreases of myelin after GW4869 treatment may also represent the contribution of the asynchronic pattern of differentiation and myelination of",29_31,The Pathogenic Sphingolipid Psychosine is Secreted in Extracellular Vesicles in the Brain of a Mouse Model of Krabbe Disease,18 3 2022,,Krabbe_Disease
"pattern of differentiation and myelination of oligodendrocytes during the duration of our experiment, hence masking regional losses by the already highly demyelinating environment of the TWI brain. Ceramide is a metabolite in the same synthetic pathway as psychosine, however its depletion did not cause changes in the total levels of psychosine within treated brain tissues. This is likely because <italic toggle=""yes"">de novo</italic> synthesis (<xref rid=""bibr33-17590914221087817"" ref-type=""bibr"">Li et al.,",29_32,The Pathogenic Sphingolipid Psychosine is Secreted in Extracellular Vesicles in the Brain of a Mouse Model of Krabbe Disease,18 3 2022,,Krabbe_Disease
"ref-type=""bibr"">Li et al., 2019</xref>) and alternative catabolic enzymes were not affected by GW4869 treatment. This pharmacologic inhibitor is specific to neutral sphingomyelinase 2, and as such should lead to ceramide depletion at specific subcellular sites without total reduction of ceramide lipid species (<xref rid=""bibr18-17590914221087817"" ref-type=""bibr"">Dinkins et al., 2014</xref>; <xref rid=""bibr21-17590914221087817"" ref-type=""bibr"">Essandoh et al., 2015</xref>; <xref",29_33,The Pathogenic Sphingolipid Psychosine is Secreted in Extracellular Vesicles in the Brain of a Mouse Model of Krabbe Disease,18 3 2022,,Krabbe_Disease
"et al., 2015</xref>; <xref rid=""bibr37-17590914221087817"" ref-type=""bibr"">Menck et al., 2017</xref>). This was also demonstrated with MALDI-TOF analysis which showed region-specific reductions unique to different ceramide lipid species. Areas with notably decreased levels of ceramide included the corpus callosum and striatum. These areas, which are normally heavily myelinated, showed to have reduced myelin staining in the treated TWI brain, although not reaching significance when compared to the untreated",29_34,The Pathogenic Sphingolipid Psychosine is Secreted in Extracellular Vesicles in the Brain of a Mouse Model of Krabbe Disease,18 3 2022,,Krabbe_Disease
"significance when compared to the untreated TWI brain. The GW4869 inhibitor used in this study likely impacts only a subpopulation of highly heterogenous vesicles in the secretome. EVs have traditionally been classified based on their biogenesis, including the 3 main subgroups of exosomes, ectosomes and apoptotic bodies, though new mechanisms of EV release are continually being established (<xref rid=""bibr63-17590914221087817"" ref-type=""bibr"">Tricarico et al., 2017</xref>; <xref",29_35,The Pathogenic Sphingolipid Psychosine is Secreted in Extracellular Vesicles in the Brain of a Mouse Model of Krabbe Disease,18 3 2022,,Krabbe_Disease
"et al., 2017</xref>; <xref rid=""bibr64-17590914221087817"" ref-type=""bibr"">van Niel et al., 2018</xref>). The size ranges and biomarkers associated with each of these classifications often overlap, making the heterogeneity of EVs even more difficult to address when considering experimental design and data interpretation. Research to characterize and understand the function of EVs has expanded greatly over the last decade, including the development of established nomenclature and methods to improve the",29_36,The Pathogenic Sphingolipid Psychosine is Secreted in Extracellular Vesicles in the Brain of a Mouse Model of Krabbe Disease,18 3 2022,,Krabbe_Disease
"nomenclature and methods to improve the generalizability and reproducibility of EV data. However, most studies have been conducted using cell culture systems or small sample cohorts from patient data owing to the technical difficulties of conducting rigorous <italic toggle=""yes"">in vivo</italic> analysis of EVs. Despite these challenges, the field has identified crucial roles of EVs in both normal homeostasis and pathogenesis of numerous disease states, including neurodegenerative disorders and cancer. EVs",29_37,The Pathogenic Sphingolipid Psychosine is Secreted in Extracellular Vesicles in the Brain of a Mouse Model of Krabbe Disease,18 3 2022,,Krabbe_Disease
"neurodegenerative disorders and cancer. EVs have been shown to contribute to normal brain physiology in cortical development through Shh signaling (<xref rid=""bibr58-17590914221087817"" ref-type=""bibr"">Tanaka et al., 2005</xref>), synapse maintenance (<xref rid=""bibr32-17590914221087817"" ref-type=""bibr"">Lachenal et al., 2011</xref>), activity-dependent pruning (<xref rid=""bibr41-17590914221087817"" ref-type=""bibr"">Paolicelli and Ferretti, 2017</xref>), and clearance of neuronal debris following trauma (<xref",29_38,The Pathogenic Sphingolipid Psychosine is Secreted in Extracellular Vesicles in the Brain of a Mouse Model of Krabbe Disease,18 3 2022,,Krabbe_Disease
"of neuronal debris following trauma (<xref rid=""bibr49-17590914221087817"" ref-type=""bibr"">Sokolowski et al., 2014</xref>). However, EVs have also been implicated in a number of traumatic or neurodegenerative diseases. Microglia have been shown to have increased EV release following TBI and leading to pro-inflammatory signaling in the secondary phase of injury (<xref rid=""bibr31-17590914221087817"" ref-type=""bibr"">Kumar et al., 2017</xref>). Increased circulating EVs have been identified in the MS patients",29_39,The Pathogenic Sphingolipid Psychosine is Secreted in Extracellular Vesicles in the Brain of a Mouse Model of Krabbe Disease,18 3 2022,,Krabbe_Disease
"EVs have been identified in the MS patients (<xref rid=""bibr38-17590914221087817"" ref-type=""bibr"">Minagar et al., 2001</xref>), and have been suggested as a strong marker of neuroinflammation derived from patient CSF (<xref rid=""bibr66-17590914221087817"" ref-type=""bibr"">Verderio et al., 2012</xref>). Just as in our study which identified propagation of a toxic lipid, EVs have also been implicated in the spread of misfolded protein aggregates such as tau in Alzheimer's disease (<xref",29_40,The Pathogenic Sphingolipid Psychosine is Secreted in Extracellular Vesicles in the Brain of a Mouse Model of Krabbe Disease,18 3 2022,,Krabbe_Disease
"such as tau in Alzheimer's disease (<xref rid=""bibr25-17590914221087817"" ref-type=""bibr"">Iba et al., 2013</xref>; <xref rid=""bibr5-17590914221087817"" ref-type=""bibr"">Aulston et al., 2019</xref>) and alpha-synuclein in Parkinson's disease (<xref rid=""bibr3-17590914221087817"" ref-type=""bibr"">Alvarez-Erviti et al., 2011</xref>; <xref rid=""bibr51-17590914221087817"" ref-type=""bibr"">Stuendl et al., 2016</xref>). We are only just beginning to comprehend the propensity for EVs to serve as important molecular",29_41,The Pathogenic Sphingolipid Psychosine is Secreted in Extracellular Vesicles in the Brain of a Mouse Model of Krabbe Disease,18 3 2022,,Krabbe_Disease
"for EVs to serve as important molecular signaling mechanisms. The ability of EVs to transmit intracellular communication across long distances, evade immune detection, maintain relative stability, and cross stringent barriers make them lucrative candidates to improve our understanding of cell function in health and disease.",29_42,The Pathogenic Sphingolipid Psychosine is Secreted in Extracellular Vesicles in the Brain of a Mouse Model of Krabbe Disease,18 3 2022,,Krabbe_Disease
